PRINCIPLES MEDICINE
OF
GENDER-SPECIFIC
PRINCIPLES OF GENDER-SPECIFIC MEDICINE Second Edition Edited by
Marianne J. Legato, MD Section Editors:
William Byne, MD, PhD Nancy E. Davidson, MD Adrian Dobs, MD, MHS Marilyn K. Glassberg, MD Paula A. Johnson, MD Robert G. Lahita, MD, PhD, FACP, FACR, FRCP George M. Lazarus, MD Linda A. Lee, MD Michael Rendel, MD Lauri J. Romanzi, MD, FACOG
AMSTERDAM • BOSTON • HEIDELBERG • LONDON • NEW YORK • OXFORD PARIS • SAN DIEGO • SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier
Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA First edition 2004 Second edition 2010 Copyright © 2004, 2010, Elsevier Inc. All rights reserved No part of this publication may be reproduced, or stored in retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (44) (0) 1865 843830; fax (44) (0) 1865 853333; e-mail:
[email protected]. Alternatively, visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
Medicine is an ever-changing field. Standard safety precautions must be followed, but as new research and clinical experience broaden our knowledge, changes in treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current product information provided by the manufacturer of each drug to be administered to verify the recommended dose, the method and duration of administrations, and contraindications. It is the responsibility of the treating physician, relying on experience and knowledge of the patient, to determine dosages and the best treatment for each individual patient. Neither the publisher nor the authors assume any liability for any injury and/or damage to persons or property arising from this publication.
British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress ISBN: 978-0-12-374271-1 For information on all Academic Press publications visit our website at www.elsevierdirect.com Typeset by Macmillan Publishing Solutions www.macmillansolutions.com Printed and bound in the United States of America 10 11 12 13 10 9 8 7 6 5 4 3 2 1
To Isobel and Marvin Slomowitz, with gratitude for their generosity and support for the science of gender-specific medicine.
Contributors
NABIH I. ABDOU, MD, PhD, Clinical Professor of Medicine, University of Missouri School of Medicine and Center for Rheumatic Disease and Center for Allergy and Immunology, Kansas City, MO, USA
ELIZABETH BARBIERI, MD, FACOG, Weill Cornell Medical College, Center for Reproductive Medicine and Infertility, New York, NY, USA BARBARA D. BARTLIK, MD, Assistant Professor of Psychiatry and Psychiatry in Obstetrics and Gynecology, Weill Cornell Medical College, Department of Psychiatry, New York, NY, USA
NAZIA AHMAD, BA, CUNY Hunter College, New York, NY, USA
SHARI S. BASSUK, ScD, Epidemiologist, Brigham and Women’s Hospital, Division of Preventive Medicine, Boston, MA, USA
MUDDASSIR ALINIAZEE, MD, University of Miami, Miller School of Medicine, Pulmonary and Critical Care Medicine, Miami, FL, USA
DAVID BATEMAN, MD, Associate Professor of Clinical Pediatrics, Columbia University Medical Center, Department of Pediatrics, New York, NY, USA
SARAH ALVI, BS, University of Massachusetts, Amherst, MA, USA
KRISTY A. BAUMAN, MD, Assistant Professor, University of Michigan, Division of Pulmonary and Critical Care Medicine, Ann Arbor, MI, USA
JOAN AMATNIEK, MD, MSc, Director, Clinical Development, Ortho McNeil–Janssen Scientific Affairs, Titusville, NJ; Associate Visiting Research Scientist, Columbia University, Gertrude H. Sergievsky Center, Graduate School of Public Health, New York, NY, USA
JENNIFER J. BELL, MD, Special Lecturer in Pediatrics, Columbia University College of Physicians and Surgeons, Department of Pediatrics, New York, NY, USA
DAVID E. ANDERSON, PhD, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
KATHRYN BILELLO, MD, Central California Faculty Medical Group and Associate Clinical Professor of Medicine, University of California San Francisco–Fresno Program, Fresno, CA, USA
GAYA S. ARANOFF, MD, Professor of Clinical Pediatrics, Columbia University College of Physicians and Surgeons, Department of Pediatrics, New York, NY, USA
JUSTIN D. BLASBERG, MD, Resident, St Luke’s–Roosevelt Hospital Center, Department of Surgery, New York, NY, USA
GLORIA BACHMANN, MD, Associate Dean for Women’s Health, University of Medicine and Dentistry of New Jersey– Robert Wood Johnson Medical School, New Brunswick, NJ, USA
ROGER S. BLUMENTHAL, MD, FACC, FAHA, Professor of Medicine, The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA TAMARA BOCKOW, BS, Medical Student, University of Pennsylvania Medical School, Philadelphia, PA, USA
SANDHYA K. BALARAM, MD, PhD, FACS, Attending Surgeon, St Luke’s–Roosevelt Hospital Center, Division of Cardiothoracic Surgery; Assistant Professor of Clinical Surgery, Columbia University College of Physicians and Surgeons, New York, NY, USA
KAREN ELIZABETH BOYLE, MD, Director, Reproductive Medicine and Surgery, Sexuality & Aesthetics Chesapeake Urology Associates, Baltimore, MD, USA
xi
xii
Contributors
ARTHUR L. BURNETT, MD, Professor of Urology, The Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, MD, USA
DIALA EL-MAOUCHE, MD, MS, Post-doctoral Fellow, Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
LARA J. BURROWS, MD, The Center for Vulvovaginal Disorders, Washington, DC, USA
KAREN FEISULLIN, MD, Community Health Services, Department of Women’s Health; Department of Obstetrics and Gynecology, Hartford Hospital, Hartford, CT, USA
WILLIAM BYNE, MD, PhD, Staff Physician, Mental Illness Research, Education and Clinical Center, J.J. Peters Veterans Affairs Medical Center, Bronx, NY; Associate Professor of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA KENNETH R. CHAPMAN, MD, MSc, FRCPC, FCCP, Director, Asthma and Airway Centre, University Health Network, Toronto Western Hospital; Professor of Medicine, University of Toronto; GSK-CIHR Research Chair in Respiratory Health Care Delivery; Toronto, Ontario, Canada MARGARET A. CHESNEY, PhD, Professor of Medicine, University of Maryland School of Medicine, Center for Integrative Medicine, Baltimore, MD, USA
LAUREN FREY, MD, Assistant Professor, Department of Neurology, University of Colorado Denver, Denver, CO, USA JAMES H. GARVIN, Jr, MD, PhD, Professor of Clinical Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY, USA KATYA GAYNOR, BA, Research Coordinator, Mount Sinai School of Medicine, Department of Psychiatry, New York, NY, USA SUSAN L. GEARHART, MD, Assistant Professor of Colorectal Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA
DEBRA CHEW, MD, Clinical Assistant Professor, New Jersey Medical School of the University of Medicine and Dentistry of New Jersey, Department of Medicine, Newark, NJ, USA
KHALIL G. GHANEM, MD, PhD, Assistant Professor of Medicine, The Johns Hopkins University School of Medicine, Department of Infectious Diseases, Baltimore, MD, USA
DOREEN E. CHUNG, MD, FRCSC, Weill Cornell Medical College, Department of Urology, New York, NY, USA
MARILYN K. GLASSBERG, MD, Associate Professor, University of Miami Miller School of Medicine, Department of Medicine/Pulmonary and Critical Care Division, Director, Rare and Interstitial Lung Disease Program, Miami, FL, USA
PAK H. CHUNG, MD, Reproductive Endocrinologist and Infertility Specialist, Weill Cornell Medical College, The Center for Reproductive Medicine and Infertility, New York, NY, USA WENDY K. CHUNG, MD, PhD, Herbert Irving Assistant Professor of Pediatrics and Medicine, Director of Clinical Genetics, Columbia University, New York, NY, USA CHRISTINE A. CLARK, PhD Candidate, Mount Sinai Hospital, University of Toronto, LifeQuest Centre for Reproductive Medicine, Toronto, Ontario, Canada MAURIZIO CUTOLO, MD, University of Genoa, Research Laboratories and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, Genoa, Italy
SHERITA HILL GOLDEN, MD, MHS, Associate Professor of Medicine and Epidemiology, The Johns Hopkins University School of Medicine, Division of Endocrinology and Metabolism, Welch Center for Prevention, Epidemiology, and Clinical Research; The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA ANDREW T. GOLDSTEIN, MD, Johns Hopkins Medicine, Division of Gynecologic Specialties, Department of Gynecology and Obstetrics, Baltimore, MD, USA
SERKAN DEVECI, MD, Memorial Sloan Kettering Cancer Center, Department of Urology, New York, NY, USA
MARC GOLDSTEIN, MD, Matthew P. Hardy Distinguished Professor of Reproductive Medicine and Urology, Surgeon-inChief, Male Reproductive Medicine and Surgery, Cornell Institute for Reproductive Medicine, New York-Presbyterian Hospital/ Weill Cornell Medical Center, Weill Cornell Medical College; Senior Scientist, The Population Council, Center for Biomedical Research, New York, NY, USA
ADRIAN DOBS, MD, MHS, Professor of Medicine and Oncology, The Johns Hopkins University School of Medicine, Department of Medicine and Oncology, Baltimore, MD, USA
REBECCA F. GOTTESMAN, MD, PhD, Assistant Professor of Neurology, The Johns Hopkins University School of Medicine, Department of Neurology, Baltimore, MD, USA
NORA J. DOTY, Research Assistant, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick, NJ, USA
RAQUEL E. GUR, MD, PhD, Professor of Psychiatry, Neurology, and Radiology, University of Pennsylvania Medical Center, Pennsylvania, PA, USA
CATHERINE E. DUBEAU, MD, Professor of Medicine, University of Massachusetts Medical Center, Departments of Internal Medicine, Family and Community Health, and Obstetrics & Gynecology, Worcester, MA, USA
RUBEN C. GUR, PhD, Professor of Psychology, University of Pennsylvania Medical Center, Department of Psychiatry, Radiology and Neurology, and the Philadelphia Veterans Administration Medical Center, Philadelphia, Pennsylvania, PA, USA
NANCY E. DAVIDSON, MD, Hillman Professor of Oncology, Director, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Contributors MEILAN K. HAN, MD, MS, Medical Director, Women’s Respiratory Health Program and Pulmonary Rehabilitation, University of Michigan, Division of Pulmonary and Critical Care, Ann Arbor, MI, USA MARY L. HARRIS, MD, Medical Director, The Center for Inflammatory Bowel and Colorectal Diseases, Mercy Medical Center, Baltimore, MD, USA W. ALLEN HAUSER, MD, Professor of Neurology and Epidemiology, Columbia University College of Physicians and Surgeons and Mailman School of Public Health, New York, NY, USA ARGYE E. HILLIS, MD, Professor of Neurology and Physical Medicine and Rehabilitation, The Johns Hopkins University School of Medicine, Department of Neurology, Baltimore, MD, USA SALLY L. HODDER, MD, Professor of Medicine, New Jersey Medical School of the University of Medicine and Dentistry of New Jersey, Department of Medicine, Newark, NJ, USA AARON HOLLEY, MD, Walter Reed Army Medical Center, Division of Pulmonary/Critical Care and Sleep Medicine, Department of Internal Medicine, Washington, DC, USA DIANE JACOBS, PhD, Consulting Neuropsychologist, San Diego, CA, USA SUZANNE M. JAN DE BEUR, MD, Associate Professor of Medicine, The Johns Hopkins University School of Medicine, Director, Division of Endocrinology, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA PAULA A. JOHNSON, MD, Executive Director, Connors Center for Women’s Health and Gender Biology and Chief of the Division of Women’s Health, Brigham and Women’s Hospital, Boston, MA, USA SONYA KASHYAP, MD, Reproductive Endocrinologist, University of California at San Francisco, Center for Reproductive Health and Women’s Health Research Center, San Francisco, CA, USA DAVID M. KAUFMAN, MD, Assistant Clinical Professor of Pediatrics and Neurology, Mount Sinai School of Medicine, Department of Pediatric Neurology, New York, NY, USA HOWARD H. KIM, MD, Fellow in Male Reproductive Medicine and Microsurgery, Department of Urology and Cornell Institute for Reproductive Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, Weill Cornell Medical College; Research Fellow, The Population Council, Center for Biomedical Research, New York, NY, USA
xiii
JULIE A. KOLZET, MA, Weill Cornell Medical College, Department of Psychiatry, New York, NY, USA AYMAN KOTEISH, MD, The Johns Hopkins University School of Medicine, Department of Gastroenterology and Hepatology, Baltimore, MD, USA KAREN KROK, MD, The Johns Hopkins University School of Medicine, Department of Gastroenterology and Hepatology, Baltimore, MD, USA ROBERT G. LAHITA, MD, PhD, FACP, FACR, FRCP, Chairman of the Department of Medicine, Newark Beth Israel Medical Center, Newark, NJ; Professor of Medicine, New Jersey Medical School, Newark, NJ, USA NICOLE LANATRA, MD, New York University School of Medicine, Division of Oncology, New York, NY, USA CARL A. LASKIN MD, FRCPC, LifeQuest Centre for Reproductive Medicine; Departments of Medicine (Rheumatology), Obstetrics & Gynecology and Immunology, University of Toronto, Toronto, ON, Canada GEORGE M. LAZARUS, MD, Associate Clinical Professor of Pediatrics, Columbia University Medical Center, Morgan Stanley Children’s Hospital, Department of Pediatrics, New York, NY, USA LINDA A. LEE, MD, Assistant Professor, The Johns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology, Baltimore, MD, USA MARIANNE J. LEGATO, MD, Professor Emerita of Clinical Medicine, Columbia University College of Medicine, New York, NY; Adjunct Professor of Medicine, Johns Hopkins, Department of Medicine, Baltimore, USA JASWINDER K. LEGHE, MD, MPH, Clinical Instructor, NYU School of Medicine, Department of Medicine, New York, NY, USA SHARON LEWIN, MD, Fellow, Royal College of Physicians, Canada; Attending Physician, St. Luke’s–Roosevelt Hospital Center, Division of Infectious Disease, New York, NY; Attending Physician, New York Presbyterian Hospital Center, Division of Internal Medicine, New York, NY; Assistant Clinical Professor of Medicine, Columbia University School of Medicine, New York, NY, USA ROBERT H. LIM, MD, Research Associate, Harvard School of Public Health, Department of Environmental Health, and Instructor in Pediatrics Children’s Hospital Boston, Division of Respiratory Diseases, Boston, MA, USA
MATTHEW KIM, MD, Assistant Professor of Medicine, The Johns Hopkins Hospital, Division of Endocrinology, Baltimore, MD, USA
JOANN E. MANSON, MD, DrPH, Professor of Medicine and the Elizabeth F. Brigham Professor of Women’s Health, Harvard Medical School, Brigham and Women’s Hospital, Division of Preventive Medicine, Boston, MA, USA
LESTER KOBZIK, MD Harvard School of Public Health, Department of Environmental Health, and Brigham & Women’s Hospital, Department of Pathology, Boston, MA USA
MARGARET MCCARTHY, PhD, Professor of Physiology, University of Maryland Baltimore School of Medicine, Department of Physiology, Baltimore, MD, USA
xiv
Contributors
TARANEH MEHRANI, Baltimore, MD, USA
MD,
Union
Memorial
Hospital,
JORDAN D. METZL, MD, Co-Founder, The Sports Medicine Institute for Young Athletes, Hospital for Special Surgery, New York, NY LISA MOORES, MD, Assistant Dean for Clinical Sciences, Professor of Medicine, The Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, MD, USA KENDALL F. MOSELEY, MD, Clinical Fellow, Division of Endocrinology, The Johns Hopkins Hospital, Baltimore, MD, USA JOHN P. MULHALL, MD, Director Male Sexual and Reproductive Medicine Program Memorial Sloan Kettering Cancer Center, Department of Surgery/Urology Service, New York, NY, USA GERALD MULLIN, MD, The Johns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology, Baltimore, MD, USA MELISSA MUNSELL, MD, Clinical Fellow, The Johns Hopkins University School of Medicine, Department of Medicine and Gastroenterology, Baltimore, MD, USA SUSAN MURIN, MD, MSc, Professor, Division of Pulmonary, Critical Care, and Sleep Medicine, and Vice-Chair for Clinical Affairs, University of California Davis School of Medicine, Department of Internal Medicine, Sacramento, CA, USA
MICHAEL RENDEL, MD, Senior Attending Physician, St Luke’sRoosevelt Hospital Center, New York; Attending Physician, New York-Presbyterian Hospital/Weill Cornell Medical Center, Weill Cornell Medical College, New York; Associate Professor, Columbia University School of Medicine, New York, NY, USA VIRGINIA RIDER, PhD, Professor of Biology, Pittsburg State University, Department of Biology, Pittsburg, KS, USA LAURI J. ROMANZI, MD, FACOG, Reconstructive Surgery and Urogynecology, Clinical Associate Professor of Gynecology, New York-Presbyterian Hospital/Weill Cornell Medical Center, Weill Cornell Medical College, New York, NY, USA ANNE M. ROMPALO, MD, ScM, Professor of Medicine, The Johns Hopkins University School of Medicine, Department of Infectious Diseases, Baltimore, MD, USA TOVE S. ROSEN, MD, Professor of Clinical Pediatrics/ Neonatology, Columbia University Medical Center, Department of Pediatrics, New York, NY, USA HILARY SANFEY, MB BCh, FACS, Professor of Surgery and Vice-Chair for Education, Southern Illinois School of Medicine Department of Surgery, Springfield, IL, USA MARY SANO, PhD, Director, Alzheimer Disease Research Center; Professor, Department of Psychiatry, Mount Sinai School of Medicine; Director of Research and Development; James J Peters VAMC, New York, NY, USA
CHRISTIAN D. NAGY, MD, Fellow, The Johns Hopkins Hospital, Department of Internal Medicine and Pediatrics, Divisions of Cardiology and Pediatric Cardiology, Baltimore, MD, USA
PETER N. SCHLEGEL, MD, FACS, Professor and Chairman, Department of Urology, New York-Presbyterian Hospital/Weill Cornell Medical Center, Weill Cornell Medical College, New York; Senior Scientist, The Population Council, Center for Biomedical Research, New York, NY, USA
CORAL OMENE, MD, PhD, New York University Langone Medical Center, Department of Medicine, Division of Oncology, New York, NY, USA
MARY V. SEEMAN, MD, Professor Emerita of Psychiatry, University of Toronto, Department of Psychiatry, Toronto, Ontario, Canada
HENRY P. PARKMAN, MD, Associate Professor of Medicine and Physiology, Temple University, Department of Physiology, Philadelphia, PA, USA
SHIRIN SHAFAZAND, MD, MS, Assistant Professor of Medicine, University of Miami Miller School of Medicine, Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Miami, FL, USA
TAHMINA PARVEEN, BA, CUNY Hunter College, New York, NY, USA
KAVITA SHARMA, MD, The Johns Hopkins Hospital, Department of Internal Medicine, Baltimore, MD, USA
MICHELLE PETRI, MD, MPH, Professor, The Johns Hopkins University School of Medicine, Department of Medicine, and Director, Johns Hopkins Lupus Center, Baltimore, MD, USA
BEVERLEY J. SHEARES, MD, MS, Associate Professor of Clinical Pediatrics, Columbia University, Pulmonary Division, Department of Pediatrics, New York, NY, USA
OCTAVIA PICKETT-BLAKELY, MD, The Johns Hopkins University School of Medicine, Department of Gastroenterology and Hepatology, Baltimore, MD, USA
DEBORAH SHURE, MD, Master FCCP, Consultant Medical Reviewer, Center for Devices and Radiological Health, Miami, FL, USA
BRUCE POLSKY, MD, Interim Chairman, St Luke’s–Roosevelt Hospital Center, Department of Medicine, and Chief, Division of Infectious Diseases, New York, NY, USA
MARC SONENSHINE, MD, The Johns Hopkins University School of Medicine, Department of Internal Medicine, Baltimore, MD, USA
CHARLES A. POWELL, MD, Associate Professor of Medicine, Columbia University, Division of Pulmonary, Allergy, and Critical Care Medicine, New York, NY, USA
EMILIA MIA SORDILLO, MD, PhD, Sr, Attending, Medicine and Pathology, Medical Director, Microbiology, and Molecular Diagnostics, St Luke’s–Roosevelt Hospital Center, Department of
Contributors
xv
Clinical Pathology; Associate Professor of Clinical Medicine and Clinical Pathology and Cell Biology. College of Physicians and Surgeons, Columbia University, New York, NY, USA
REBECCA L. TOONKEL, MD, Postdoctoral Research Fellow, Columbia University, Division of Pulmonary, Allergy, and Critical Care Medicine, New York, NY, USA
KARIN SORRA, PhD, President and Chief Scientific Officer, Arroscience Inc., Toronto, Ontario, Canada
RENUKA TYAGI, MD, Assistant Professor of Urology in Obstetrics and Gynecology, Weill Cornell Medical College, Department of Urology, New York, NY, USA
KAREN A. SPITZER, MSc, University of Toronto, LifeQuest Centre for Reproductive Medicine, Toronto, Ontario, Canada SHOBHA SWAMINATHAN, MD, Assistant Professor, New Jersey Medical School of the University of Medicine and Dentistry of New Jersey, Department of Medicine, Newark, NJ, USA ALEXIS E. TE, MD, Associate Professor of Urology, Weill Cornell Medical College, Department of Urology, New York, NY, USA AMY TIERSTEN, MD, Associate Professor of Medicine (Oncology), New York University Langone Medical Center, Department of Medicine, Division of Oncology, New York, NY, USA
SARA E. WALKER, MD, MACP, Emeritus Professor of Medicine, University of Missouri School of Medicine, Department of Internal Medicine, Columbia, MO, USA CAROLYN WESTHOFF, MD, Columbia University, Department of Obstetrics and Gynecology, Division of Family Planning and Preventive Services, New York, NY, USA
Foreword: Gender-Specific Medicine – Environment and Biology Marek Glezerman, MD Professor and Chairman, Hospital for Women, Rabin Medical Center and Sackler Medical School, Tel Aviv University; Chairman, The Israel Society for Gender Medicine
adults, and no one would doubt that specific expertise is needed for diagnosing and treating children. Equally, it is unquestionable today that research performed in adults is not necessarily applicable to infants, children and adolescents. It is all the more astonishing that the parallel to gender differences is still not sufficiently appreciated and that even a basic understanding of the profound physiological and pathophysiological differences between men and women is still widely missing. Amazingly, not unlike the prevailing attitude towards children 150 to 200 years ago, women are typically regarded as smaller men. The common perception of the main difference between the sexes is usually confined to their different genital organs and to the fact that women are capable of delivering babies, while men are not. The differences are, alas, far more profound. In fact, these differences pertain to virtually all bodily systems, covering the entire life cycle from the antenatal period through infancy and adulthood. In intra-uterine life, fetal gender is independently associated with increased risks for prematurity, operative and cesarean delivery and fetal growth abnormalities. After birth, female and male infants differ in their development, in mortality and morbidity rates and are affected differently by different diseases. Female infants have a substantially higher prevalence of vesicoureteral reflux and persistent ductus arteriosus, while male infants have a higher incidence of transposition of large vessels, aortic stenosis, pylorus stenosis and hernia. Girls have
I vividly recall my first reaction when reading Eve’s Rib by Marianne Legato, about two years ago. It was a strange amalgam between asking myself ‘Where have I been during the past 30 years of my career?’ and a fair amount of skepticism. In the aftermath of an in-depth journey into the vast and largely unexplored realm of gender-related differences in medicine, I encountered very similar reactions with many peers. Subsequently, an interest group for Gender Medicine was created which included 27 department heads from different disciplines and several months later, the Israel Society for Gender Medicine was born. In less than two years, this organization has attracted 110 active members and is conducting dozens of ongoing research projects, some of which are currently in press. Such is the genesis of my personal involvement with gender medicine. As recently as two centuries ago, children were regarded as diminutive adults and were treated accordingly, both in social and in medical terms. Demands on their capacity to provide labor were restricted only by realizing their actual physical limitations and not by understanding the special needs of the growing juvenile body. In fact, the notion of physical health and particular medical treatment of children was virtually non-existent until the early eighteenth century and it required several more decades until pediatrics emerged as a distinct medical discipline. Today, no reasonable person would dare to question the profound differences in physiology and pathophysiology between children and xvii
xviii
Foreword: Gender-Specific Medicine – Environment and Biology
more auto immune diseases, such as systemic lupus and thyroiditis, and have more often precocious puberty. Boys suffer more often from autism, growth hormone deficiency and nephrotic syndrome. In adults, observational studies that indicated the preponderance of many pathologies in women have been available for many years and clinicians observe these differences constantly. For example, the gastrointestinal system functions differently in men and women. Compared to men, women have twice the incidence of colitis or Crohn’s disease, four times the incidence of gallbladder stones, suffer five times more often from irritable bowel syndrome, and 20 times more often from functional bowel disease. Female lungs are more vulnerable to disease than lungs of men. Pulmonary hypertension, asthma, and chronic obstructive lung disease are usually more severe in women than in men. Lung cancer in women is on a steady rise and is currently their most fatal cancer, accounting for 25% of all cancer deaths, with a higher incidence rate than breast cancer. In Europe there are currently about 400 000 new lung cancer cases diagnosed annually, 30% of which occur in women. Alarmingly, 80 000 out of 400 000 new lung cancer patients never smoked and most of those affected are women. Currently, in the United States more women die annually from cardiovascular disease than from all cancers combined. Data from 2005 reveal that 143 000 women died from stroke and 650 000 from cardiovascular disease, while the death toll from all cancers combined amounted to 560 000. The female heart responds differently to continuous stress such as hypertension than the male heart, and diagnostic tools, like the customary stress test, are substantially less significant and less specific in women than in men. Women with myocardial infarction are typically under-diagnosed and under-treated. Yet, until the 1990s almost all research on the cardiovascular system, and indeed on most other bodily systems, was performed exclusively in men and the majority of currently available medications have been evaluated in men only. Moreover, in terms of pharmacokinetics, the large variability of the physiological changes in cyclic women is usually neglected. The roots of this apparent discrimination date back to the mid-twentieth century, when both the treatment of pregnant women for threatened abortion with the synthetic estrogen diethylstilbestrol (DES) and the use of thalidomide for nausea during the pregnancy lead to catastrophic consequences in their offspring, including genital cancer and phocomelia, respectively. Consequently, and mainly in order to protect women, women were excluded from clinical trials. The need for gender-specific medicine emerged when it could no longer be denied that diagnosis and treatment of diseases in men and women may not be identical, and that women and men need to be represented equally in clinical trials. Efforts by the NIH in the mid-1980s to correct this unbalanced state of affairs by declining funding of research projects that did not include both sexes, were ill-fated.
As late as the mid-1990s less than one-third of published research included women, and even those data were often incomplete. Out of 120 randomized controlled trials published in the New England Journal of Medicine between 1994 and 1999, only 14% provided gender-specific analysis. This situation is now slowly but gradually changing. It is now well accepted that clinical and basic research needs to be stratified also by gender and that the gender aspect of medicine needs to be introduced in the training of students and residents. Based on this understanding, gender-specific medicine emerged and developed in the past two decades. Semantics often lag behind the development of new technologies and new scientific endeavors. Sometimes we develop the narrative and terminology before the technology catches up, and sometimes novel approaches are in search of the appropriate terms to explain them. This is also true for gender medicine. So, what is ‘gender medicine’? It is a giant step from the ‘one-size-fits-all’ approach to the direction of personalized medicine, when diagnosis and treatment will become individualized according to the genomics of each individual. This may happen sometime in the future, but first steps are already visible. In breast cancer, for example, genetic testing permits prediction of the efficiency of various medications and is helpful in rendering evidence-based and individualized decisions, concerning the optimal treatment. So, in a sense, gender medicine bridges the gap between past and future medicine. It is based on the understanding that male and female gender is much more than the chromosomal difference between the sexes and requires an in-depth understanding of the profound physiological and pathophysiological differences that have developed as a result of long-term adaptations to environmental effects and the social roles of individuals in their societies. Some of these changes are hard-wired and resulting from millions of years of physiological adaptation and some are the results of short-term expressions of the different roles and lifestyles men and women play in various societies. Being male or female is not synonymous to being masculine or feminine. Both pairs of terms are often but erroneously interchangeably used as synonyms. Yet, they present fundamentally different categories. Maleness or femaleness are chromosomally determined and thus unchangeable. This definition is to some extent a simplification, but is generally accepted in humans. To be feminine or to be masculine are characteristics that are defined by the sociological fabric of our environment, the roles we play in a given society, the functions and habits assigned by the society on us, and the expectations which a given society has set for its members. These roles can change in the course of time and are different in different societies. Whatever is required from us in terms of being feminine or masculine has obviously a strong impact on our health, and may pose gender-specific health risks that are not based on a different biology of men and women, but on the environment in which we live. This immediate impact of our social
Foreword: Gender-Specific Medicine – Environment and Biology
environment on our health is what I would call ‘environmental gender medicine’ (EGM). If the environment affects our day-to-day life long enough, eventually irreversible biological changes will ensue and even our anatomy will adapt. This aspect of gender medicine would then be reflected in the term ‘biological gender medicine’ (BGM). Both are summarized in the general term gender (specific) medicine. While talking to various audiences on gender medicine, one encounters sometimes enthusiastic support and sometimes a rather reserved reaction to what is perceived as the promotion of affirmative action, aimed at improving women’s health. Clearly, gender medicine aims to rectify a longstanding neglect of gender differences, which are mostly related to the physiology and pathophysiology of women. But gender medicine is not an advanced form of gynecology, extended to bodily systems beyond the genital organs. Gender medicine aims also at men’s health: from the onset, men are at a health disadvantage and are more susceptible to disease than women throughout their life cycle. Even their life expectancy is shorter. Male gender is independently associated with adverse pregnancy outcome and male neonates are twice more likely to die at birth. In the first trimester of pregnancy the male : female ratio is 170 : 100, but since male fetuses are spontaneously aborted three times more often than female fetuses, at delivery the male : female prevalence decreases to about 51% to 49%. Actually, all catastrophes that can affect the unborn fetus are more common in males than in females, including brain damage, premature deliveries, skeletal anomalies and stillbirth. Mortality is 20% higher in male than in female newborns and remains higher also throughout infancy and childhood. Morbidity, developmental deficiencies, susceptibility to congenital and acquired diseases are also more common in boys than in girls. As the life cycle continues, male adolescents are more likely to die from accidents or suicide than girls. Recent figures from Romania indicate that 74% out of 11 000 suicides that occurred in 2000 were committed by men. Throughout life, male adults are more susceptible to infectious diseases than women. Because male breast cancer is 100 times rarer in men than in women, this form of deadly cancer has hardly been studied in men. Men are also at a general disadvantage in cancer survival. Osteoporosis is regarded as a female disease with a lifetime risk of 1 : 2 in women but men also suffer from osteoporosis, with a lifetime risk of 1 : 5. Again, research on osteoporosis has been focused almost exclusively on women. So, gender medicine needs to deal with health issues of men and women alike. It is not a new and distinct medical discipline, but rather a new perspective and nexus between existing disciplines. Modern medicine should therefore not only be evidence-based but also gender-based. To accomplish this objective there is a dire need in extensive basic and clinical research, and also in changes in the curriculum of medical studies and of residencies.
xix
Some universities, such as Georgetown University in the United States, Monash University in Australia and Tel Aviv University in Israel, have already incorporated the gender aspect in their medical curricula, and some residency programs already include explicit gender aspects in their training. The essential prerequisite for these actions is the awareness of the necessity and the willingness to question existing paradigms. Some of these preliminary, but crucial goals are already being met. The World Health Organization has established the ‘Department of Gender, Women and Health’ and NASA has done pioneering work in studying the physiological differences between men and women as related to space travel. Fellowships in women’s health are offered by various universities, such as Columbia in New York, MacNeall in Illinois, East Carolina University, Brigham and Women’s Hospital in Boston, amongst others. Dozens of books dealing with gender medicine are available today and there are scientific journals devoted to women’s health (Gender Medicine, Elsevier), and men’s health (Men’s Health and Gender, Elsevier). An International Society for Gender Medicine has been established, and national societies in Sweden, Germany, Italy, Austria, and Israel are actively involved in the promotion of awareness of gender medicine and research. Gender-medicineoriented national and international congresses are being held worldwide. The number of research projects conducted and published is mushrooming. Obviously, this development increases the demand for scholarly texts. One of the most vocal and effective pioneers who has brought gender medicine to the place it occupies today is undoubtedly Professor Marianne Legato. Having devoted the past two decades of her professional life to the promotion of gender medicine, she has contributed tremendously to the worldwide awakening of awareness to this critically important angle from which medicine should be approached. Besides her scientific contributions, the greatest impact on public awareness of the gender differences in medicine has probably derived from her many books that have addressed the educated general public. Marianne Legato, a cardiologist by training, is founder and editor in chief of the first medical journal devoted to gender medicine, and the editor of this textbook. Now, only five years after the publication of the first edition, this second edition is to be made available to an everincreasing body of readers. As in the first edition, Dr Legato has succeeded in assembling a formidable group of scholars and pioneers in their respective fields. The book is organized in sections, with section editors who have also provided insightful introductions to the respective chapters. Reading through the table of contents is like browsing through all aspects of medicine. Paradoxically, and on first thought, this may seem to be a disadvantage. Why would I, as an obstetrician and gynecologist, choose to divert precious reading time from my own overwhelming and demanding discipline, to topics like immunology, rheumatology, pulmonology or
xx
Foreword: Gender-Specific Medicine – Environment and Biology
the nervous system, which are all beyond the areas of my professional expertise? The answer to this question materialized during my extensive reading of gender-based texts for the past two years. It was then that I became fond of peeking into other fields of medicine and began to appreciate the vastness of the unexplored grounds of gender differences. Thus, like an explorer, I was and still am experiencing the privilege of witnessing the re-writing of virtually all chapters of medicine from the gender perspective. This precisely is what is so exciting about gender medicine in general and about this textbook in particular. This textbook serves up to the reader the essence of contemporary gender medicine on a silver platter. It is in a sense a primary teaching instrument for students, residents, and specialists. It is also a reference
text, aimed to provide specific answers to specific questions. But most of all, it is an eye-opener, raising scientific curiosity and confronting the reader with a wealth of questions that cover virtually every field of medicine while challenging all of us to embark on the relevant research. The silent revolution of gender medicine has broken through the first great wall on its path, namely to be accepted as an undeniable and necessary shift of paradigms. But this is still only the beginning. Now it is time to embark on a truly inter-disciplinary journey and to invest academic and clinical efforts in order to establish gender medicine as an integral part of how we teach and apply modern medicine for the benefit of women and men alike. This textbook is a major tool in this formidable quest.
Preface
Over the arc of the last twenty years, the realization that men and women are significantly different in every system of the body has expanded to inform and refocus all the disciplines of medicine. When we published the first edition of The Principles of Gender-Specific Medicine it was axiomatic that the words ‘gender-specific’ were new and, as my then chairman of internal medicine at Columbia University, Doctor Myron Weisfeldt, pointed out in 1997, very few of us knew what ‘gender-specific’ meant. Indeed, most people who heard the term for the first time assumed it meant women’s medicine. It is still a common misperception. In fact, genderspecific medicine is the study of how the normal function and the experience of disease differs between men and women. It is as dedicated to the study of the unique aspects of men’s biology as it is to that of women; indeed, it is the comparison between the two sexes that has prompted some of the most interesting and novel questions in medicine. Medicine is a reflection of the society in which it is embedded; how we understand the human condition and tend to its ills is impacted by how society views the roles, competencies, and relative importance of men and women. The revolution called ‘gender-specific medicine’ has its roots in the social fabric of the United States in the wake of the Second World War. The events of that world-wide, all-engrossing effort to preserve our institutions and political systems resulted in two new developments: the emerging awareness of the competence of women to do men’s work and an abiding faith in the power of science to solve the problems of the human condition. On the battlefield, for example, we learned to expand the efficacy and safety of anesthesia, to understand the pathophysiology of shock, that hepatitis was caused by a virus, and that antibiotics could save countless lives that would have been lost without them. Americans came out of the war convinced that
science held a virtually limitless ability to improve and preserve human life. That conviction prompted the expansion of the nascent National Institutes of Health, which in the early 1950s was no more than a modest collection of eight buildings in Bethesda that housed the United States Department of Health, Education and Welfare (now renamed the Department of Health and Human Services). Gender-specific medicine began as an uniquely American concept. It was conceptualized and expanded first in this country simply because most of the other areas of the world were so devastated by the ravages of war that rebuilding functioning societies was their only and allconsuming goal. Miraculously, our own country had escaped the direct destruction that most of the rest of the civilized world had experienced and so the fabric of postwar society here was unique. The American feminist movement was an inevitable outgrowth of the experience women had had in filling the positions men had traditionally – and exclusively – occupied until the war left those positions empty. In this country, gender-specific medicine had its roots in the growing confidence of women in their own power, unique needs, and importance in society. During the war, whole units of male subspecialists left the academic medical centers they had dominated for the battlefield. Women filled the vacancies created with enthusiasm and confidence: the first woman chief resident in internal medicine in the history of Columbia University, Doctor M. Irene Ferrer, was appointed in 1943. She went on to create a spectacular career in investigative medicine that included developing the cardiac catheter as an instrument that defined the fundamental dynamics and the pathophysiology of disease of the cardiovascular system. By 1985, laywomen had prompted the formation of a governmental Task Force on Women’s Health, which after xxi
xxii
Preface
three years of study concluded that aside from reproductive biology, we knew nothing about the physiology of women but had always assumed that, beyond the pelvis, the physiology of the two sexes was identical.1 The traditional subjects of scientific investigation at all levels were males and it was assumed that the results of those investigations could be extrapolated to women without direct testing or modification. The 1990s saw an increasing effort by the National Institutes of Health, academic medical centers, the American Congress, and the Federal Drug Administration to study women as well as men and to compare the results of scientific research in both sexes. It has been a slow, painful progression: many – and perhaps unanticipated – obstacles that have been only partially overcome limited our understanding of the sex-specific differences in human structure and function. One of our thorniest problems is how to safely include the premenopausal woman in clinical trials: the fear of harming women’s reproductive capacity and/or the development of a fetus conceived during the conduct of an investigatory protocol remains largely unsolved. It is no surprise that the largest investigative effort mounted on behalf of women, The Women’s Health Initiative, focused on the postmenopausal female.2 Another profoundly important difference between the sexes is the frequently different age of onset and incidence of specific disease entities that make comparison difficult. The spectrum of co-morbidities that affect the two sexes with that disease may also be entirely different. Nevertheless, the results of gender-specific investigations, often completely unanticipated, have yielded an unexpectedly rich harvest and have prompted questions we never would otherwise even have asked. The value of sex-specific research is now so obvious that we are beginning to turn a sex-specific lens on the unique features of male biology. The reasons for men’s shorter lifespan compared with that of women and the two-decade earlier onset of coronary artery disease in men, for example, are subjects of particular interest and deserve intensive investigation.
In a very real sense, we have used men as clinical subjects in an effort to protect women from the risk of harm. But as a matter of justice, women should bear some of the risks of direct investigation, since they benefit from the results of those studies. Gender-specific medicine has expanded over the past 15 years from this country to other capitals of the world; among others, there are centers for the pursuit of this discipline now in Sweden, Japan, Austria, Germany, Korea, Holland and, most recently, Israel. We have formed the International Society for Gender Specific Medicine and I have established two scientific journals devoted to the new science. Both are included in MEDLINE (Medical Literature Analysis and Retrieval System Online), compiled by the US National Library of Medicine. The first was the The Journal of Gender Specific Medicine, and the second, which supplanted the first, Gender Medicine, published by Elsevier, continues to present new information about the sex-specific characteristics of human physiology and the experience of disease. Few developments in medicine have been more rewarding than the realization that the study – and comparison – of men and women has and will continue to produce a stunning flood of unexpected, novel information. Hopefully this second edition of The Principles of Gender-Specific Medicine will help to correct and expand our understanding of the enormously important impact of biological sex on human biology. Marianne J. Legato 2009
References 1. USPHS (US Public Health Service). Report of the public health service task force on women’s health issues. Public Health Rep 1985;100(1):73–106. 2. The Woman’s Health Initiative, National Institutes of Health, Bethesda, MD, 1991.
Section 1
Gender and Normal Development
s e c t i o n 1 Gender and Normal Development l
Introduction
George M. Lazarus On a summer Sunday afternoon, my wife and I attended an outdoor concert in Saint Stephen’s Green in Dublin, Ireland. As the band played music from children’s television programs and popular movies, twenty or thirty young children from about 2 to 4 years of age romped on the grass. The girls danced, ballet-style, to the music. The boys chased and tackled each other like little football players. No one told the children how to play. They just did what came naturally and there was no cross-over behavior between the boys and girls. As I enjoyed watching the children, I was impressed by how different boys and girls are from a young age. Two-year-old children know their sex. A child that age doesn’t know much, but a boy knows he is a boy, a girl knows she is a girl. Young children don’t know exactly how or why boys and girls are different, but they know that they are. In that respect, they are exactly like medical scientists! Pediatricians are well aware of the differences between the sexes that appear from the time of conception. We are learning more and more about gender differences, as will become apparent from reading the chapters in the pediatric section. We can explain the biological reasons for some differences and we can describe many more differences whose etiologies remain obscure.
Sexual differentiation in utero affects more than the external and internal sex organs. The brain is a sexual organ and some of the behavioral differences observed between boys and girls (and men and women) are likely due to the effects of androgens on the male brain before birth. Baby boys are bigger from the time they are only a small bunch of cells. More of them are born. Boys are more susceptible to nearly every disease that affects newborns, so more of them die. Many diseases present differently in boys and girls. For example, attention deficit hyperactivity disorder (ADHD) is readily apparent in a hyperactive boy but is more easily overlooked in a well-behaved but inattentive girl. Treatment of disease also may vary with sex. Boys and girls with cancer respond differently to chemotherapy and radiation, and ideal therapeutic regimens may be sexspecific. Prognosis, too, can vary by sex. Boys with cystic fibrosis tend to live longer. These are just a few examples of the importance of gender in pediatric medicine. Many more examples are to be found in the chapters that follow. I thank the pediatric authors for a job well done. They have all looked at their specialties from a new, genderspecific perspective and have gathered and clearly presented a great deal of information. Better understanding of gender differences in health and disease already has led to improved medical care for our patients, and the field is still young.
Chapter
1
The Effects of Gender in Neonatal Medicine Tove S. Rosen1, and David Bateman2 1
Professor of Clinical Pediatrics/Neonatology, Columbia University Medical Center, Department of Pediatrics, New York, NY, USA 2 Associate Professor of Clinical Pediatrics, Columbia University Medical Center, Department of Pediatrics, New York, NY, USA
Introduction
Males also face a higher incidence of neurobehavioral and developmental difficulties during childhood. In epidemiologic surveys, attention deficit hyperactivity disorder (ADHD), characterized by poor concentration ability, motoric hyperactivity, impulsivity, and frequently learning difficulties, is four times more common in boys than in girls. The increased male susceptibility to disease depends upon the interplay of environmental risk factors with fundamental genetic, endocrinologic, immunologic, and metabolic differences between the sexes.11–17
Differences between male and female infants in mortality, growth, and the susceptibility to specific diseases exist during the perinatal period (fetal and neonatal), as is shown by numerous embryologic, physiologic, epidemiologic, and anthropologic observations in humans and by laboratory studies and field observations in animals. For a cohort of individuals at a given point in life, the sex ratio (simple ratio of males to females) depends not only on the different rates of mortality between the sexes but also on the relative numbers of males and females present at birth. In humans, as in most mammalian species, slightly more males are born than females. At birth the sex ratio is approximately 1.05, representing a proportion of male births of about 51.3%. After birth the mortality of males is higher, and the sex ratio declines progressively. By the end of the first year of life, 120 males have died for every 100 females. Males continue to die at a higher rate throughout childhood and adulthood.1–4 Males are not only more numerous and more likely to die at birth, they are also larger. Differences in the rates of growth and metabolism between males and females have been reported from the earliest embryologic period onward and may influence sexual organogenesis, the sex ratio during gestation, and relative male–female survival rates during intra-uterine and extra-uterine life.5–10 Males are more likely to experience stillbirth, premature birth, congenital malformations, pulmonary hemorrhage, intracranial hemorrhage, respiratory distress, perinatal asphyxia, perinatal infection, cerebral palsy, and developmental delay. Sudden Infant Death Syndrome (SIDS) is more common in males. Infants are at highest risk for SIDS during the first 2–4 months of life. Besides male sex, other risk factors include maternal smoking, exposure to a suboptimal uterine environment, poor fetal growth, and prematurity. Principles of Gender-Specific Medicine
The sex ratio during fetal life Sex Ratio at Conception Phenotypic sexual differentiation in mammals consists of a sequence of genetic and hormonal components referred to as the Jost paradigm. The genetic component, consisting of either the XX or XY chromosome complement, is determined at conception. Gonadal differentiation occurs at 6–7 weeks gestation in humans with expression of the Y chromosome-borne SRY gene, resulting in the formation of either male or female gonads. The development of male sex organs and secondary characteristics is an active process controlled by three hormones produced by the testis: Müllerian inhibiting substance (also called anti-Müllerian hormone), testosterone, and insulin-like factor 3 (INSL3). Phenotypic female characteristics develop in the absence of these three testicular hormones.18,19 Evidence of a preponderance of male fetal losses suggests that the sex ratio is even higher around the time of conception than at birth. By assuming a constant male– female ratio of fetal loss during pregnancy, the sex ratio from the earliest point in embryonic life has been estimated to be approximately 1.1 to 1.2. However, the precise
Copyright 2010 20 , Elsevier Inc. All rights reserved.
s e c t i o n 1 Gender and Normal Development l
point at which male numerical predominance develops is unknown. Several studies have shown that the ratio of Y- to X-bearing spermatozoa in humans is approximately equal; thus, the elevated sex ratio may reflect differences in rates of fertilization, implantation or early survival. The classical explanation for the sex ratio of more rapid arrival to the ovum of lighter, faster-swimming Y-bearing spermatozoa has been discounted, and postulates involving an immuno logic or hormonal preference of the ovum for Y-bearing spermatozoa remain unsupported.3,12,20–24 An alternative explanation for male predominance is that it occurs after fertilization, at the time of implantation. Two days after fertilization the average number of male embryos exceeds that of female embryos. At the same time the metabolic rate, as measured by glucose and pyruvate uptake and lactate production, is higher in male embryos than female embryos. The higher metabolic rate and larger size of male embryos may confer a survival advantage (albeit temporary) on male embryos at the time of implantation. The enhanced metabolic rate of male embryos may be the result of the action of Y-chromosome-derived transcription factors acting on maternally-derived mitochondria. Higher metabolic rate (and increased temperature) may also play an epigenetic role in male sex differentiation.6,7,19,24–26
Sex Ratios and Periconceptional Influences Male and female fetuses and infants respond differently to biological, environmental, and cultural influences. Environmental stresses including crowding, heat, and nat ural catastrophes have been found to alter the birth sex ratio in human populations. A sharp decline in the sex ratio at birth was reported 9 months following the 1995 Kobe earthquake and 320 days after both the 1952 London smog and the 1965 Brisbane flood. Similarly, a drop in the sex ratio to 1 was seen in New York City in 2002 following the terrorist attack on September 11, 2001. Using combined Danish registries, Hansen et al. found that severe periconceptional life events (development of cancer or myocardial infarction in her partner or older children) experienced by the mother during the first trimester result in a smaller proportion of male births. Deviations in monthly environmental temperature above the overall mean were associated with a higher birth sex ratio. Data from California support the hypothesis that the fetal death sex ratio varies positively over time with the unemployment rate. Temporary decreases in the sex ratio such as these might be due to alterations of parental hormones, altered quality of semen or an increased rate of early spontaneous abortion of males. It is notable that the peak drop of the sex ratio in New York City occurred 5 months after the September 11 attacks, making increased male fetal loss, rather than altered conception, the likely mechanism. Interestingly, the sex ratio did not change following the severe Dutch famine during the winter of 1944–45.
In contrast, the proportion of males born increased sharply after both world wars in combatant countries.13,27–37 Lower birth rank, increased parental age, and decreased frequency of coitus have been associated with a lower sex ratio. Psychological stress in one parent has been shown to favor the production of offspring of the opposite sex. Parental social status may alter the sex ratio. Parents engaged in stereotypical ‘masculine’ occupations (law, politics, natural science, medicine, business, etc.) and ‘dominant women’ were more likely to produce sons than daughters.38 James has assessed the numerous, often conflicting studies relating the sex ratio in animals and humans to various environmental, social, and disease-related circumstances and has concluded that the relative parental levels of estrogen, testosterone, and gonadotropin at the time of conception contribute to the determination of fetal sex. Others have argued that the birth sex ratio is influenced by the quality of the ovum at different times in the menstrual cycle.1,24,26,39–44
Sex Ratio and Fetal Loss The results of chromosomal analyses to determine the sex ratio in spontaneous abortions have varied. Several of these studies have found a predominance of female tissue. After carefully excluding maternal contamination of tissue and androgenetic 46,XX hydatidiform moles, Hassold et al. estimated the sex ratio for genetically normal spontaneous abortions to be approximately 1.30. The study also noted an overall male predominance among spontaneously aborted fetuses with various trisomies, with the sex ratio lowest for trisomy 9 and highest for trisomy 21.45
Manipulation of the Sex Ratio Attempts at selecting the sex of an infant by controlling the frequency, timing or position of coitus or insemination in relation to ovulation have a long history of use but have never been shown to be effective. Modern laboratory techniques have been applied to the question of sex selection in an effort to control the expression of serious X-linked diseases. These techniques have attempted to take advantage of potentially differing physical, antigenic, and electrochemical properties that might allow separation of X- and Y-containing spermatozoa. Flow cytometry cell sorting uses fluorescence in-situ hybridization (FISH) to label X- and Y-containing chromosomes, which are then separated by flow cytometry. The technique is advertised to be a highly effective method of sex selection; but several commentators have worried about potential damage to genetic material subjected to fluorochrome staining, laser, and a high voltage electromagnetic field.46–49 Pre-conceptional sex selection for reasons of parental choice (as opposed to the elimination of genetic disease) is ethically controversial. Nevertheless, post-conceptional
C h a p t e r 1 The Effects of Gender in Neonatal Medicine l
sex selection has been a long-standing practice in some cultures, where infanticide or, more recently, selective abortion based on prenatal ultrasonographic determination of fetal sex are the methods of selection. In Korea, the sex ratio climbs with each pregnancy, exceeding 2.0 for the fourth child. In India, where a large gap exists between the expected and actual number of females, the sex ratio for urban births is 1.1–1.2. Similar findings have been described in China where, in census data, the births of girls have not been reported because of early deaths, most likely due to infanticide. The trend toward fewer than expected females in China is now increasingly due to selective abortion after ultrasonographic sex determination. The concept of ‘missing women’ has been advanced to focus attention on the impact of such practices. It has been estimated that there are now 40–50 million missing women in India alone, and perhaps 100 million missing women worldwide.50–54
Sex Ratio and Length of Gestation Male infants are more likely to deliver prematurely. In an analysis involving more than 1.8 million births in six New England states, Cooperstock and Campbell found a 7.2% excess of males among white singleton preterm births (20–37 weeks gestation). Beyond 36 weeks, the proportion of males declined sharply, falling below the mean proportion of all white singleton births (51.3%) by 40 weeks gestation. Among preterm singleton black infants, the male excess was significantly smaller (2.3%). Male excess has also been reported in the birth of preterm twins less than 33 weeks gestation. Female twin pairs have a significantly longer gestation period than either male twin pairs or discordant female/male twin pairs. Mortality also has been reported to be lower in female pair twins than in either male pair or discordant twins. A ‘masculinizing’ effect of the male twin on respiratory morbidity in the female twin partner in very low birthweight (VLBW) male–female twins has been observed.55–58
Sex differences in fetal and neonatal growth Fetal Growth Differences The earliest attempts to assess the rate and range of fetal growth used cross-sectional data from live born infants to construct percentile charts for growth during the third trimester. In these charts gestational age was calculated from the last menstrual period. Lubchenco et al. provided separ ate growth charts for male and female newborns. In these the weight of males born at the 50th percentile exceeds that of females born at the 50th percentile by approximately 50 g at 28 weeks gestation and 100 g at term. These percentile charts have been used arbitrarily to define categorical indices
of fetal growth such as small-, appropriate- and large-forgestational age (10th, 10th–90th, 90th percentiles, respectively). By such measures female fetuses have about a 20% greater risk for intra-uterine growth retardation (IUGR) than male fetuses.59,60 Fetal ultrasonography provides a potentially direct, longitudinal measure of fetal growth; however, standard algorithms usually have been constructed from cross-sectional data and are not adjusted for different growth rates of the sexes. In a prospective longitudinal study through the second and third trimester, Moore et al. found significantly different trajectories for male and female head growth, such that the mean biparietal diameter (BPD) for males at 28 weeks gestation was approximately equal to the mean BPD for females at 29 weeks. Pedersen et al. found that male fetuses were larger than female fetuses as early as 8 weeks of gestation. The male–female difference, expressed as the time needed for the female fetus to attain male size, ranged from 1 day at 8–12 weeks gestation to 6–7 days at term.5,61–63 Data on early fetal male–female size difference are supported by animal studies, in which evidence for size differences is present from very early in intra-uterine life, prior to gonadal differentiation. Tsunoda et al. found a size difference in mouse embryos at the blastocyst stage. Prior to implantation into foster mothers, they classified cultured embryos as ‘fast-cleaving’, ‘intermediate-cleaving’ or ‘slow-cleaving’ according to the time between fertilization and blastocyst formation. Fast-cleaving embryos were much more likely to produce males than slow-cleaving embryos. Similar results were found with bovine embryos. In human in vitro fertilization studies, larger embryos at the time of implantation were found to be much more likely to result in male births. These studies suggest that the male– female size difference is genetically rather than hormonally determined. In an article titled ‘Blastocysts prepare for the race to be male’, Mittwoch reviewed evidence in support of the hypothesis that the faster male growth rate is one of the major conditions influencing male anatomic sexual expression; slower growing embryos result in the development of an ovatestis or ovary.7–9,26,64
Neonatal Growth Differences At birth, males are slightly larger than females. In the United States the median birthweight of term males (3530 g) exceeds that of females (3399 g) by 131 g. The respective values for recumbent length and head circumference are 49.98 cm and 35.81 cm for males and 49.23 cm and 34.71 cm for females. Revised postnatal percentile growth charts based on combined cross-sectional and longitudinal data from diverse sources have recently been published by the Centers for Disease Control. These charts show that by one year of life the male–female size difference increases, with the median weight of males exceeding that of females by almost 800 g.10
s e c t i o n 1 Gender and Normal Development
l
Body composition also differs during the first year of life and into childhood. Males demonstrate larger body dimensions (chest circumference, upper arm circumference, calf circumference) but females have larger measures of body fat (skinfold thickness). In VLBW premature infants the intra-uterine sex difference in growth rate carries over into extra-uterine life, with males growing larger and leaner than females. In one study of VLBW infants fed diets in which nutrient content and density were systematic ally varied, the growth rate of male infants exceeded that of female infants by approximately 1 g/kg/day. Subscapular skinfold thickness was measured and was greater in females than males but the difference narrowed as the daily caloric intake increased.10,65
Excess male mortality The ‘Male Disadvantage’ In 1971 Naeye et al. analyzed 2735 consecutive autopsies involving both neonatal deaths and stillbirths and found an excessive risk of neonatal death in males. The ratio of male to female deaths overall was 1.28, which differed significantly from the sex ratio at birth for the general population (1.05). The male to female ratio in stillbirths without congenital anomalies was similar to that of the general birth population. However, among neonatal deaths the ratio of males to females was much higher (1.32). Higher male mortality was seen consistently over a wide range of causes of death, including major congenital malformations, hyaline membrane disease, pulmonary hemorrhage, intracran ial hemorrhage, aspiration pneumonia, pre- and post-natal infection, and the effects of maternal diabetes and toxemia. The study also examined the effects of socioeconomic status and race on mortality and found that the highest sex ratio occurred among non-poor whites. The authors postulated that while the stillbirths were due to a failure of the maternal environment and therefore affected sexes equally, there existed an inherent ‘male disadvantage’ for survival in the neonatal period that was not related to a specific disease
process. A recent study confirms the presence of a male disadvantage among VLBW infants. Other evidence has pointed to an interaction between male gender and poorer pregnancy outcomes, perhaps due in part to the larger size of male fetuses at a given gestational age. Women carrying male fetuses had higher rates of gestational diabetes mellitus, fetal macrosomia, failure to progress during the first and second stages of labor, cord prolapse, nuchal cord, and true umbilical cord knots. Cesarean sections also were found more frequently with male newborns.11,13,66–68
Sex Ratio, Infant Mortality, and Race In the United States the difference in survival between the sexes is modified by a survival difference between the races. Although infant mortality rates for both black and white infants continue to decline, the infant mortality rate of black infants remains more than double that of white infants, and the relative gap between the races appears to be growing. In 1980 the infant mortality rates for black and white males were 25.9 (per 1000) and 12.3, respectively, a ratio of 2.1. By 2004 the rate for black males had fallen to 13.8 compared to 5.7 for white males, a ratio of 2.4. Infant mortality rates for white and black males are about 23% higher than for white and black females, but the trend toward higher relative mortality in black females compared to white females over time is similar. The excess overall mortality for black infants is related largely to a downward shift in the birthweight distribution and the much greater risk of death for lower birthweight infants regardless of race and sex (see Table 1.1)4,69 Within a given birthweight category the effect of birthweight on survival is contrary to the overall effect: that is, the group with the lowest mean birthweight (black females) has historically had the highest survival rate, while the group with highest mean birthweight (white males) has had the lowest. However, it appears that this hierarchy of birthweight-specific survival may be changing, perhaps due to improved care of extremely low birthweight infants. In New York City white females now have birthweightspecific survival rates which exceed those of black females
Table 1.1 United States Birthweight-specific Survival Rates by Gender for Newborns with Birthweight 1500 g During The First 28 Days of Life, 200469 Females
Males
Birthweight (g)
Deaths
Births
% survival
Deaths
Births
% survival
499 or less 500–749 750–999 1000–1249 1250–1499 Total 1500
2729 2003 537 314 225 5807
3382 5762 5904 6981 8346 30375
19.3 65.2 90.9 95.5 97.3 80.9
3019 2781 895 383 300 7379
3571 5897 6417 7264 8459 31608
15.5 52.8 86.1 94.7 96.5 76.7
C h a p t e r 1 The Effects of Gender in Neonatal Medicine l
in essentially all categories (see Table 1.2). These changing relationships raise complex and disturbing questions about differential access to healthcare and the influence of a host of socioeconomic factors and toxic exposures on neonatal and infant mortality.70
Interaction of Growth and Mortality An intriguing hypothesis discussed by Clarke and Mittwoch postulates a connection between the increased rates of growth, metabolism, and mortality in males compared to females. In vitro populations of fibroblasts cannot divide indefinitely; a so-called species-specific ‘growth crisis’ related to the rate of chromosomal alterations occurs when the number of generations reaches a critical threshold. The authors also note that within a species, lower caloric intake and lower metabolic rates have been associated with increased longevity. Thus, decreased longevity and increased susceptibility to disease from embryonic life onward may be the price males pay for enjoying a higher basal metabolic rate and a faster rate of growth that, initially, may have provided a survival advantage at the time of implantation and contributed to male phenotypic expression 6,7–9,18,19,25
The effect of gender on the incidence and severity of diseases in infancy and childhood Early Metabolic Programming There has been a lot of interest recently in the developmental origins of adult disease, or ‘metabolic programming’. Nutritional and metabolic exposures at critical times during
early development may have long-term effects on the health of the adult. Experience during early life may be predictive of different health outcomes such as body size, body composition, and risk of diseases such as obesity, diabetes, hypertension, stroke, and cardiovascular disease. (For example, infants born to mothers with type 2 diabetes have a higher risk of developing diabetes in later life.) Two factors that appear to be implicated are fetal and postnatal growth rate. As stated previously, there are differences in the allocation of energy between male and female infants. Male newborns are heavier at birth than females at the same gestational age, with greater lean mass in males and greater fat mass in females. Skinfold thickness to birthweight and tricipital skinfold thickness to body weight ratios increase significantly with increased maternal weight gain in 1st and 2nd trimesters of gestation in the female fetus but not in the male fetus.71–74 Chronic hypertension has become an increasing problem because of the rising incidence of obesity, diabetes, and renal disease. Reports have shown an association with low birthweight and the development of adult hypertension. A recent meta-analysis found no significant gender differences in the association between low birthweight and high blood pressure. However, in a rabbit model of maternal hypertension the female offspring exhibited increased risk for the development of hypertension. This finding was thought to be related to changes in the growth and development of renal sympathetic nerves during fetal life which may contribute to the development of hypertension in the adult animal. In another study using a rat model with placental insufficiency and growth restricted offspring, both male and female offspring were hypertensive for the first 10 weeks of life. The male offspring remained hypertensive after puberty. This may be related to the interaction of the sex
Table 1.2 Neonatal Birthweight-Specific Mortality Rates by Ethnicity and Gender, New York City, 2000 Birthweight (g)
Black non-Hispanic
White non-Hispanic
Puerto Rican
Other Hispanic
Asian or Pacific Islander
Total
0–499 500–749 750–999 1000–1499 1500–2499 2500 Females
952.4 500.0 111.1 37.7 5.7 8.3
777.8 571.4 155.6 60.6 14.1 3.6
1000.0 437.5 280.0 12.8 6.9 4.7
866.7 529.4 214.3 28.3 8.7 3.8
1000.0 700.0 200.0 68.2 5.0 2.8
901.2 519.8 164.0 40.5 8.6 4.9
0–499 500–749 750–999 1000–1499 1500–2499 2500
931.0 398.2 142.9 13.3 5.9 7.0
666.7 281.3 28.6 17.5 3.6 2.0
1000.0 310.3 117.6 37.0 12.7 5.0
875.0 321.4 46.5 34.1 5.0 2.6
1000.0 687.5 76.9 87.0 4.2 3.2
884.1 381.8 95.0 26.4 5.7 3.9
Males
Rates are per 1000 live births. Number of births 125 563. Data compiled by NYC Department of Health.
s e c t i o n 1 Gender and Normal Development l
hormones with other regulatory pathways such as the reninangiotensin system during fetal and postnatal life. After puberty estrogen may provide protection in the female from the hypertension. Adverse effects can be passed transgenerationally from mother to daughter and then to her offspring. In rat studies, exposure to maternal protein restriction during pregnancy and postnatally produced female offspring (F1 generation) with increased insulin sensitivity. Her offspring, the F2 generation, showed altered glucose and insulin metabolism in both males and females.75–81
Postnatal Effects of Changes in the Intra-Uterine Environment Maternal Diabetes Abnormal intra-uterine environments have been found to affect male and female fetuses and newborn infants differently. In a retrospective review of singleton term births born to mothers with pregnancies complicated by diabetes, male infants had a higher incidence of hypoglycemia. This observation may be explained by higher levels of human chorionic gonadotropins (HCG) found in the fetuses of mothers with diabetes. Elevated HCG levels cause Leydig cell hyperplasia, resulting in higher levels of testosterone, which in turn produce hyperplasia of the pancreatic beta islet cells and increased insulin secretion. With the abrupt cessation of the transplacental glucose supply at birth, increased insulin in males raises the probability of hypoglycemia.82 A similar explanation may account for the higher incidence of respiratory distress syndrome (RDS) in male offspring of diabetic compared to non-diabetic mothers of comparable gestational ages. Higher levels of androgens have been described in both cord blood and amniotic fluid in such infants. This increased level of testosterone may in turn block the production of surfactant, exposing the male infant to a higher risk for RDS. Studies in the chick show that androgens block glucocorticoid regulation of lung maturation.83,84 Susceptibility and Response to Acidemia and Hypoxia In a Swedish study, male fetuses demonstrated more frequent and more severe episodes of acidemia following a protracted course of abnormal fetal heart tracings indicative of fetal distress. On follow-up evaluations at 4 years of age, these same male children had a higher incidence of neurodevelopmental problems. An in vitro study of the effect of hypoxia on hippocampal neuronal cells demonstrated increased vulnerability of male cells and of female cells primed with testosterone. This finding was postulated to account for some of the gender differences in neuropsychiatric diseases related to hippocampal integrity. Studies in the hypoxic-ischemic neonatal rat model have shown gender-specific differences in caspase-dependent apoptosis that may also help explain gender differences in outcome following hypoxic-ischemic insults in the human neonate.85–87
Alloimmunization, Hyperbilirubinemia Male fetuses have been shown to be more severely affected by alloimmunization of fetal red blood cells to D antigen. Male fetuses required a greater number of intra-uterine transfusions and these were performed at a lower gestational age. The odds ratio for the male developing hydrops fetalis was 13.1. Male newborns also may have higher levels of hyperbilirubinemia: in a study of 840 low birthweight infants, mean peak bilirubin was significantly higher (by 0.8 mg/dl) in males in a regression model controlling for race, birthweight, gestational age, intraventricular hemorrhage, and sepsis.88,89 Effects of Maternal Smoking Maternal smoking during pregnancy reduces fetal growth for both sexes but affects male infants disproportionately. At birth, males born to mothers with a history of heavy cigarette smoking had an 8.2% reduction in weight and a 12% reduction in fat accretion compared to 4.8% and 2%, respectively, in females. In males, head circumference was also significantly smaller, with fall-off in head growth noted as early as the second trimester. Since male fetuses have a higher rate of growth than females, factors limiting growth may have a greater impact on males. Male fetuses may be more sensitive to the direct effect of the toxic byproducts of cigarette smoke in regard to cell replication, changes in the hormonal milieu, and fetoplacental circulation.90 Effects of Drugs of Abuse Drugs of abuse such as heroin and cocaine have been shown to interfere with fetal growth. Significant decreases in birth size have been observed in infants with in utero cocaine exposure as measured by urine toxicology at birth or by analysis of cocaine content in hair or meconium. Several of these studies, using regression models to control for the effects of demographic and other risk factors, found an independent effect of sex on birth size. Although no gender specific effect of cocaine was reported, a re-examination of the original data shows that relatively larger decrements in birth size, particularly of head circumference, are observed in cocaine exposed males (D.A. Bateman, unpublished data). Similar findings of interference with growth have been described in infants born to mothers with heroin addiction. Many of these infants are premature and also exhibit growth retardation. Cell size and cell number have been found to be decreased in autopsy studies compared to infants of mothers with similar socioeconomic status and nutrition.1,91–93 Several studies have been reported on the neurobehavioral development of children exposed to drugs of abuse in utero. Children exposed in utero to cocaine demonstrated a higher incidence of neurobehavioral difficulties such as hyperactivity and language and developmental delays. When the effects were stratified by sex, male children showed a significantly higher incidence of developmental difficulties. The male
C h a p t e r 1 The Effects of Gender in Neonatal Medicine
l
children also scored significantly lower on the Bayley Scales of Infant Development. In one study, school age behavior was altered in males but not in females. Boys with persistent intra-uterine cocaine exposure had more problems with central processing, motor skills, and handling abstract concepts than controls or exposed girls. Similar neurodevelopmental and behavioral difficulties were described in children who were born to mothers on methadone maintenance during pregnancy, with male children affected more than female children. These findings correlated with the exposure to methadone, the quality of mothering and the rearing environment. Male children appeared to be more vulnerable to the interaction of adverse effects of intra-uterine exposure to drugs of abuse, opioids, and environmental factors.94–98
Congenital Anomalies and Gender The incidence of certain congenital anomalies varies with the sex of the infant and survival. The incidence of trisomy 18, for example, is higher among male than female stillbirths, but among live born infants with trisomy 18, females outnumber males three to one. Down syndrome, on the other hand, is more common in males among both live born and stillborn infants. Isolated anomalies of multi factorial inheritance that have an unequal sex distribution include pyloric stenosis, clubfoot, and cleft lip (more common in males) and cleft palate alone, meningomyelocele, anencephaly, and congenital hip dislocation (more common in females). Isolated diaphragmatic hernias, especially posterolateral types, occur more frequently in male infants. Congenital diaphragmatic hernias that occur in conjunction with chromosomal anomalies are more common in female infants. A treatment choice for infants with congenital diaphragmatic hernias with severe respiratory decompensation is extracorporeal membrane oxygenation (ECMO). A group of infants treated with ECMO were evaluated for neurocognitive development at 31 months of age. These infants exhibited an increased incidence of developmental difficulties, especially the male children, again illustrating the increased long-term vulnerability of the male child.45,99–102
Congenital Heart Disease and Outcomes of Cardiac Surgery Gender based differences have been documented in the incidence of congenital heart disease, with pulmonary atresia, tricuspid atresia, double outlet right ventricle, transposition of the great arteries, and left-sided lesions (aortic stenosis, coarctation of the aorta, hypoplastic left heart) more common in male infants. Atrial and ventricular septal defects, Ebstein’s anomaly, and patent ductus arteriosus were more common in females (see Table 1.3).103–107 A sex-related disparity in pediatric cardiac surgical mortality was noted in the California statewide hospital discharge database: although there was no crude mortality rate difference between males
Table 1.3 The Gender Ratio Observed for Specific Types of CHD, Described as Male/Female Ratio of Incidence Diagnosis
Samánek105
Calzolari et al.106
Samánek et al.107
All PDA ASD, secundum VSD Aortic stenosis CoA HLHS Pulmonary atresia Tricuspid atresia Ebstein anomaly TOF DORV TGA Truncus arteriosus
1.09:1 1:1.17
1:1
1.28:1
1:1.4 1:1.11
1:1.5 1:1 1.6:1 1.6:1 1.4:1 1.7:1
1.95:1 1.3:1 2.6:1 1.55:1 1.45:1 1:1.6 1:1.1 2.7:1 2.11:1 1:1.2
1.14:1
1.04:1 2.23:1 1:1.11
1.4:1 1.7:1 2.1:1 1.3:1
PDA, Patent ductus arteriosus; ASD, atrial septal defect; VSD, ventricular septal defect; CoA, coarctation of the aorta; HLHS, hypoplastic left heart syndrome; TOF, tetralogy of Fallot; DORV, double-outlet right ventricle; TGA, transposition of the great arteries. From Miller-Hance and Tacy, 2004103; used by permission
and females, the adjusted rate by procedure for females was 18% higher. Animal models, however, suggest that female cardiac tissue may be more resistant than that of males to the effects of hypoxia-ischemia.103,108,109
Asthma and Gender in Children Asthma is nearly twice as common in male children (11.4% vs. 6.9%) and male asthmatic children suffer more frequent attacks during the preschool period. Predictors of childhood asthma have included male gender, low birthweight, and neonatal respiratory distress due to various etiologies. When controlled for birthweight, prematurity, and neonatal respiratory distress, a significant association was found between male gender and preschool asthma. Possible etiologies entertained for the higher incidence of asthma in the male child have been the presence of smaller airways relative to lung size and diminished lung function.110
Gender and Diseases of Premature Birth Effects on Mortality Infants with birthweight less than 1000 g and gestational age less than 28 weeks continue to contribute disproportionately to infant morbidity and mortality. This is compounded by the recent increase in the incidence of multiple births (by 20%) as a result of in vitro fertilization. Mortality is on the decline for extremely premature infants, but major morbidity, especially in those with birthweights 750 g, remains unchanged. The incidence of neonatal complications such
10
s e c t i o n 1 Gender and Normal Development l
as chronic lung disease, necrotizing enterocolitis, intraventricular hemorrhages, and poor postnatal growth may even have risen.111 Table 1.1 displays the neonatal survival rate (during the first 28 days of life) according to birthweight category and gender for all VLBW babies (1500 g) born in the United States in 2004. Both gender and race-ethnicity play significant roles in mortality, morbidity, and neurodevelopmental outcome. The white premature male has the highest rate of mortality (see Table 1.2). Significant predictors of mortality in premature infants are low gestational age (28 weeks, especially 23–26 weeks), intraventricular hemorrhage, Apgar score 3, and male gender. Recently, the National Institute of Child Health and Human Development Neonatal Research Network has published separate graphic estimates for risk of mortality stratified by gender and birthweight (see Figure 1.1). Tyson and co-workers have used the NICHD data set to construct predictive equations for mortality prior to NICU discharge and disability at 18–22 months corrected age, based on expected birthweight, gestational age, gender, plurality, and maternal receipt of antenatal corticosteroids. For example, a 24-week singleton male infant with an expected birthweight of 650 g whose mother received antenatal corticosteroids has a predicted mortality of 45% with a 77% probability of death or severe disability. For females with similar characteristics, the probability of mortality and
death or severe disability are 34% and 62%, respectively. It should be emphasized that these equations are still in the investigational stage and have not been verified with broad population-based data.66,69,111–113 Apgar Score The Apgar score, a tool used to assess well-being at 1 and 5 minutes after birth, incorporates five elements: respiratory effort, heart rate, reflex irritability, muscle tone, and color. In the preterm infant, the Apgar score is directly related to birthweight and gestational age. Among premature infants, Apgar scores are significantly higher at 1 and 5 minutes in females. In addition, male premature infants frequently require more vigorous resuscitation. Higher Apgar scores in the preterm female infant may be related to the higher catecholamine levels found in female infants at birth, resulting in a more normal pressor response and improved cardiovascular stability.114 Cerebral Blood Flow Cerebral blood flow is lower in preterm female infants. This is of particular interest in that it may contribute to the better survival and neurodevelopmental outcome seen in premature females. The reason for these differences is unknown, but may be related to differences in mean arterial blood pressure, cardiac output, and/or sex hormonal influences. Males (n = 1453) 1500
1400
1400
1300
1300
1200
1200
1100
1100
Birthweight (g)
Birthweight (g)
Females (n = 1327) 1500
1000 900 0.1
1000
0.1
900 0.2
800
800
0.3
0.2
0.5 0.6 0.7
600 500
0.4
0.3
700
700
0.4
0.6 0.7
600
0.8
22
0.5
0.8
500 23
24 25 26 27 28 Gestational age (wk)
29
30
22
23
24 25 26 27 28 Gestational age (wk)
29
30
Figure 1.1 Estimated mortality risk by birth weight and gestational age based on singleton VLBW infants born in NICHD Neonatal Research Network Centers between January 1, 1995 and December 31, 1996.111 Reproduced with permission from: Lemons, Bauer, Oh et al. Pediatrics 2001;107: URL:http://www.pediatrics.org/cgi/content/full/107/e1 From: Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Research Network, January 1995 through December 1996. Pediatrics 2001;107: URL:http://www.pediatrics.org/cgi/content/full/107/e1. Used by permission.
C h a p t e r 1 The Effects of Gender in Neonatal Medicine l
Gender-related differences in cerebral blood flow distribution persist through childhood and adulthood, although the patterns change and the significance of the differences is unknown. Improved developmental outcome in males treated in the early perinatal period with indomethacin, which results in decreased cerebral blood flow, has been noted.115–117 Respiratory Distress Syndrome Respiratory distress syndrome (RDS), or respiratory insufficiency of prematurity, is one of the major complications seen in premature low birthweight infants. The incidence of RDS in premature infants between 500–1500 g ranges from 50 to 80%. Infants with lower birthweights and gestational ages have a higher incidence of RDS. The relative risk for developing RDS and its complications is 1.7 for male premature infants compared to female infants of the same gestational age. Gender differences in specific measures of airway function have been demonstrated.118–120 Antenatal steroid administration to women in premature labor has been shown to induce fetal lung maturation and decrease the incidence and severity of RDS in the premature newborn. Usually, either bethamethasone or dexamethasone is administered within 24 hours of delivery to women who are in premature labor at less than 32 weeks gestation. The administration of antenatal steroids was found to be more effective in preventing or ameliorating RDS in the female premature infant than in the male. After steroid administration, the incidence of RDS in the male was 29.1% and in the female 8.6%. In premature sheep, pulmonary function measured by compliance, conductance, lung volume and PaO2 showed greater improvement in females than in males after antenatal steroid administration. The pharmacologic and physiologic response to antenatal steroids may be related to the presence of an endogenous inhibitor of surfactant production in the lung in the male infant. Dehydrotestosterone has been shown to inhibit fetal pulmonary surfactant production. A lag in the production of surfactant has been demonstrated in the male rabbit fetus. An increase in the incidence of RDS has been described in preterm male twin pairs compared to preterm female twin pairs; male twins, although heavier, showed the same blunted response to antenatal administration of betamethasone. An increased incidence of RDS also has been noted in girls of unlike-sex preterm twins compared to girl-girl twins. A transchorionic paracrine effect on the female twin has been proposed to account for this observation.58,118,119,121–125 Surfactant production, reflecting the maturity of the fetal lung, can be evaluated by measuring the L/S (lecithin/sphingomyelin) ratio in amniotic fluid. The L/S ratio for white male fetuses is the lowest (most immature) when compared with white female, black female or black male fetuses. The data suggest a relative delay in surfactant production, which may be genetically determined in white males.
11
The response of the fetal lung to various hormones such as glucocorticoids and androgens may be influenced by genetic factors controlling development.83 Chronic lung disease (CLD) is a complication seen in small premature infants in association with RDS and its treatment modalities (especially mechanical ventilation and supplemental oxygen) and with other complications of prematurity including infection and the presence of a patent ductus arteriosus (PDA). The incidence of CLD varies with gestational age, birthweight, and length of ventilatory therapy. Male gender is also a risk factor for the development of CLD. This is consistent with the increased incidence and severity of RDS in male infants. Male preterm infants also are more likely to experience episodes of apnea and bradycardia and to develop anemia and electrolyte disturbances during the neonatal period. Interestingly, a prospective cohort study from Holland of prematurely born infants with and without CLD found a higher prevalence of asthma and respiratory symptoms in young adult women compared to men.126,127 Septicemia Septicemia is another common complication in low birthweight premature infants. Its incidence is inversely proportional to gestational age and birthweight. The risk of septicemia is 48% higher in male premature infants. Septicemia is associated with increased mortality as well as serious morbidity including severe intraventricular hemorrhage, CLD, and prolonged ventilatory treatment. The reason for the greater male susceptibility to infection is not known.128 Neurobehavior and Pain Perception Gender differences in socio-emotional behavior, well documented in human adults, may have antecedents in the earliest days of life. Neonatal imitation, considered the earliest form of communicative exchange, differed between male and female infants at 3–96 hours of life. In response to an index finger gesture, female infants had a higher number of fine motor movements and specific imitative gestures, faster response, and higher heart rate response than male infants. Early neurobehavioral gender differences on the Newborn Behavioral Assessment Scale (Brazelton Exam) also have been documented. In one study, female infants scored higher than male infants in areas of auditory orientation, alertness, and state regulation. Males had higher irritability scores. In serial assessments of predominant mood during the first two years of life, boys were reported more often to be in happy-excited moods, whereas girls were more often in a quiet-calm mood. Analysis of cord blood sex hormones including androstenedione, estrone, and progesterone showed small but significant associations and interactions between mood and cord hormone levels.129–131 Multiple adult studies have shown gender differences in pain perception but little information is available on
12
s e c t i o n 1 Gender and Normal Development l
whether or not these differences are present in the neonatal period. Interpretation of neonatal studies has been made more difficult because of the use of different instruments to evaluate pain. Biological differences have been described in responses to pain in males and females. Pain thresholds and tolerance are lower in women. Shorter latency time to cry and facial reactions have been described in male newborn infants. In addition, female infants of all gestational ages expressed more facial features of pain than males during capillary stick and 1 minute post procedure. These findings may reflect early developmental differences in pain perception among male and female infants.132
Prognosis The long-term prognosis of low birthweight premature infants is guarded. The smaller, sicker, and more premature the infant is, the higher the incidence of long-term morbidity. A 2–year follow up of low birthweight infants demonstrated that cerebral palsy, sensorineural hearing loss, visual disorders, and developmental delays were related to the severity of illness during the neonatal period. In the same study, male children showed poorer development of language and personal skills than female children, irrespective of neonatal morbidity. In another study from Holland the prevalence of handicaps at 5 years of age was three times greater in boys than girls (21% vs. 7%, odds ratio 3.2). This did not change when adjusted for gestational age and birthweight. A critical review of follow-up studies in school-aged children born at less than 1500 g demonstrated age-appropriate IQ scores but with a large variability. There was a greater need for special education for these children for learning difficulties, motor incoordination, and behavior problems. In studies where gender was examined, the outcome for females was generally better than that of males.14,15,133–136 The results of several multi-center follow-up studies of extremely low birthweight (ELBW, 1000 m) infants have been published recently, showing that approximately onethird to one-half of surviving ELBW infants demonstrate major developmental handicaps by 18–22 months corrected age. Data from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, involving at least 12 centers and collected over an 8-year period, showed that more than half of surviving ELBW children had neurodevelopmental impairment (NDI), consisting of one or more of the following: cerebral palsy, Bayley Mental Developmental Index score (MDI) 70, Bayley Physical Developmental Index Score (PDI) 70, blindness or deafness. Only 21% of infants tested were considered to be unimpaired. Disability occurred in males 1.5–2 times more frequently than in females. In studies out of Cleveland, rates of NDI in ELBW and VLBW cohorts examined over two decades were approximately 30%. Intact survival was noted in half of the infants
examined at 20 months corrected age; however, males were half as likely as females to survive intact. Table 1.4 summarizes the gender-specific outcome differences observed in several large follow-up studies.137–143 Hack et al. have pointed out the poor predictive validity of Bayley scores for cognitive function of ELBW infants at school age. Nevertheless, neurodevelopmental problems persist through early school age and even into young adulthood. The EPICure study used a battery of standardized tests to identify neurologic and developmental disability at 6 years of age in infants born 25 weeks gestational age. Overall, 41% of infants tested had serious impairment (2 SD below comparison mean score); the rates in boys and girls were 49% and 32% respectively. Hack et al. followed a cohort of VLBW survivors born in 1977–9 into young adulthood and found higher rates of neurosensory impairment, lower IQ, and lower academic achievement scores and subnormal height compared to controls. Although many of the male–female differences seen in younger cohorts were not observed, VLBW men (but not women) were significantly less likely than normal-birthweight controls to be enrolled in educational programs after high school. A follow-up study of 8-year-old Finnish children of normal and low birthweight demonstrated that the boys had poorer linguistic and motor skills than the girls. Multivariate logistic regression analyses showed that lower birthweight, young maternal age, more than four children in a family, reconstructed family, hearing impairment, and male gender were the most important determinants of poor speech and language abilities with and without adjustment for neonatal risk factors.79,137,141,143–147 Several studies have examined whether or not data gathered during the perinatal period might be predictive of long-term outcome, in order to identify at-risk children with special needs. In addition to gestational age and birthweight, significant perinatal predictors of poor neurodevelopmental outcome include neonatal sepsis, non-white race, and male gender. Low socioeconomic status and male gender were predictors of educational handicaps. The strongest child-related risk factor in all models tested was male gender. Male children were more than twice as likely to make use of special education services for learning problems. A male child was six times more likely to be referred for services for emotional disorders. The NICHD neonatal network is currently evaluating the validity of a predictive model for survival and survival without profound neurodevelopmental impairment, using risk factors at or before birth for infants born at 23–25 weeks gestation.112,113,148,149
Summary In the fetal and neonatal periods and during infancy, males and females differ in at least three fundamental ways. First,
C h a p t e r 1 The Effects of Gender in Neonatal Medicine
13
l
Table 1.4 Selected Neurodevelopmental Outcomes from Studies in which Differential Gender Outcomes are Explicitly Defined Cohort/year born
Birthweight/ Subset gestation
No. tested/ Age tested Outcome No. enrolled
M/F odds 95% CI ratio
NICHD, 1995–8139
401–1000 g
2755/3782
18–22 mth
NDI
1.6
1.4–1.9
NICHD, 1995–9137
401–1000 g
1427/1749 1278/1749
18–22 mth
CP MDI 70
1.8 2.0
1.2–2.6 1.5–2.6
NICHD, 1993–9138
25 wk GA
839/992
18–22 mth
CP MDI 70 PDI 70 NDI
1.5 1.8 1.6 1.5
1.0–2.3 1.3–2.5 1.1–2.3 1.1–2.1
650/982
20 mth
Intact survival
0.45
0.34–0.62
242
20 yr
Educational, cognitive, academic achievement
Normal Head U/S
Hack et al., 500–999 g 1990–2002141 Survival to young adulthood
Hack et al., 1977–9140
1500 g
EPIPAGE, 1997142
33 wk GA
1662/2382
5 yr
MND-2
EPICure, 1995143
25wk GA
241/308
6 yr
Composite cognitive score
Other measure
M:F half as likely to be enrolled in 4 yr college. IQ scores and rates of chronic conditions similar between M–F. 3.1
1.5–6.4 Males score mean 10 (5–15) points lower than females
NICHD: National Institute of Child Health and Human Development, Neonatal Research Network. EPIPAGE: Etude Epidémiologique sur les Petits Ages Gestationales. EPICure: Extremely Preterm Infants Cure study group. M/F: Male/Female. U/S: Ultrasonogram. MDI: Mental Developmental Index, Bayley Scale of Infant Development-II. PDI: Physical Developmental Index, Bayley Scale of Infant Development-II. CP: Cerebral palsy. NDI: Neurodevelopmental impairment: at least one of the following: CP, MDI 70, PDI 70, blindness or deafness. MND-2: moderate minor neuromotor dysfunctions.
males are more numerous; and their numerical superiority appears to be derived at conception or shortly thereafter. Second, males are larger than females and have higher metabolic rates. This difference also is apparent from very early fetal life, from the blastocyst stage, when the increased cell number and metabolism in males may, in fact, influence phenotypic sexual expression. Third, males have a higher mortality rate than females, are more susceptible to most diseases of infancy, and suffer disproportionately from their long-term consequences. This has been termed the ‘male disadvantage’. Each of these three major differences appears to involve the interplay of genetic, hormonal, metabolic, and perhaps evolutionary influences that are not yet well understood.
References 1. Clutton-Brock T, Iason G. Sex ratio variation in mammals. Quart Rev Biol 1986;61:339–74. 2. Martin J, Hamilton B, Ventura S, Menacke R, Park N. Births: Final data for 2000. National vital statistics reports, National Center for Health Statistics 2002;50:7–18.
3. Clarke C, Mittwoch U. Puzzles in longevity. Perspect Biol Med 1994;37:327–36. 4. US Bureau of the Census. Statistical Abstract of the United States 2000, 120th edn. Washington, DC: Department of Commerce, US Bureau of the Census; 2000. 5. Pedersen J. Ultrasound evidence of sexual difference in fetal size in first trimester. BMJ 1980;281:1253. 6. Ray P, Conaghan J, Winston R, et al. Increased number of cells and metabolic activity in male human preimplantation embryos following in vitro fertilization. J Reprod Fertil 1995;104:65–171. 7. Pergament E, Fiddler M, Cho N, et al. Sex differentiation and preimplantation cell growth. Hum Reprod 1994;9:1730–32. 8. Clarke C, Mittwoch U. Changes in the male to female ratio at different stages of life. Br J Obstet Gynaecol 1995;102:677–79. 9. Mittwoch U. Blastocysts prepare for the race to be male. Hum Reprod 1993;8:1550–55. 10. National Center for Health Statistics, Division of Data Services. CDC Growth Charts, United States. US Department of Health and Human Services, Centers for Disease Control and Prevention 5/30/2000 (modified 4/20/01). 11. Naeye R, Burt L, Wright D, et al. Neonatal mortality, the male disadvantage. Pediatrics 1971;48:902–6.
14
s e c t i o n 1 Gender and Normal Development l
12. Whitfield A, Bayliss R, Clarke C. Deaths in the first 20 years and problems of the sex ratio at birth. J R Coll Phys Lond 1987;21:270–74. 13. Kraemer S. The fragile male. BMJ 2000;321:1609–12. 14. Verllove-Vanhorick S, Veen S, ens-Dokkum M, et al. Sex difference in disability and handicap at five years of age in children born at very short gestation. Pediatrics 1994;93:576–79. 15. Ornstein M, Ohlsson A, Edmonds J, et al. Neonatal follow-up of very low birth weight/extremely low birth weight infants to school age: a critical overview. Acta Paediatr Scand 1991;80:741–48. 16. Hunt C. Sudden infant death syndrome. In: RE Behrman, RM Kleigman, HB Jenson, eds. Nelson Textbook of Pediatrics, 16th edn. Philadelphia, PA: WB Saunders; 2000:2139–43. 17. Daruna J, Dalton R, Forman M. Attention deficit hyperactivity disorder. In: RE Behrman, RM Kleigman, HB Jenson, eds. Nelson Textbook of Pediatrics, 16th edn.. Philadelphia, PA: WB Saunders; 2000:100–3. 18. Mittwoch U. Sex determination in mythology and history. Arq Bras Endocrinol Metabol 2005;49:7–13. 19. Viger RS, Silversides DW, Tremblay JJ. New insights into the regulation of mammalian sex determination and male sex differentiation. Vitam Horm 2005;70:387–413. 20. Graffelman J, Fugger E, Keyvanfar K, et al. Human live birth and sperm-sex ratios compared. Hum Reprod 1999;14:2917–20. 21. Martin R. Sex ratio among sperm cells. Am J Hum Genet 1990;47:349–51. 22. Bowman M, De Boer K, Cullinan R, et al. Do alterations in the sex ratio occur at fertilization? A case report using fluorescent in situ hybridization. J Assist Reprod Genet 1998;15:320–22. 23. Adinolfi M, Polani P, Crolla J. Is the sex ratio at birth affected by immune selection? Exp Clin Immunogenet 1985;2:54–64. 24. Mittwoch U. Differential implantation rates and variations in the sex ratio. Hum Reprod 1996;11:8–9. 25. Mittwoch U. The elusive action of sex-determining genes: mitochondria to the rescue? J Theor Biol 2004;228:359–65. 26. Boklage C. The epigenetic environment: secondary sex ratio depends on differential survival in embryogenesis. Hum Reprod 2005;20:2662–63. 27. Fukuda M, Fukuda K, Shimizu T, et al. Decline in sex ratio at birth after Kobe earthquake. Hum Reprod 1998;13:2321–22. 28. Lyster W. Altered sex ratio after the London smog of 1952 and the Brisbane flood of 1965. J Obstet Gynaecol Br Comm 1974;81:626–31. 29. Hansen D, Moller H, Olsen J. Severe periconceptional life events and the sex ratio in offspring follow up study based on five national registers. BMJ 1999;319:548–49. 30. MacMahon B, Pugh T. Sex ratio of white births in the United States during the Second World War. Am J Hum Genet 1954;6:284–92. 31. Bromen K, Jockel K. Change in male proportion among newborn infants. Lancet 1997;349:804–5. 32. Van den Broek J. Change in male proportion among newborn infants. Lancet 1997;349:805. 33. Lerchl A. Sex ratios at birth and environmental temperatures. Naturwissenschaften 1999;86:340–42. 34. Catalano R, Bruckner T, Gould J, et al. Sex ratios in California following the terrorist attacks of September 11, 2001. Hum Reprod 2005;20:1221–27. 35. Catalano R, Bruckner T, Marks AR, et al. Exogenous shocks to the human sex ratio: the case of September 11, 2001 in New York City. Hum Reprod 2006;21:3127–31.
36. Catalano R, Bruckner T, Anderson E, et al. Fetal death sex ratios: a test of the economic stress hypothesis. Int J Epidemiol 2005;34:944–48. 37. Stein AD, Zybert PA, Lumey LH. Acute undernutrition is not associated with excess of females at birth in humans: the Dutch hunger winter. Proc Biol Sci 2004;271:S138–41. 38. Grant VJ. Sex determination and the maternal dominance hypothesis. Hum Reprod 1996;11:2371–75. 39. James W. Evidence that mammalian sex ratios at birth are partially controlled by parental hormone levels at the time of conception. J Theor Biol 1996;180:271–86. 40. Jongbloet P, Groenewoud J, Zielhuis G. Non-optimal maturation of oocytes and the sex ratio. Hum Reprod 1996;11:2–7. 41. James W. Interpregnancy intervals, high maternal age and seasonal effects on the human sex ratio. Hum Reprod 1996; 11:7–8. 42. Evangelos AC, Yannis A. Secondary sex ratio in Greece: evidence of an influence by father’s occupational exposure. Hum Reprod 2007, dem309. 43. James W. Offspring sex ratios at birth as markers of paternal endocrine disruption. Environ Res 2006;100:77–85. 44. Cameron EZ, Linklater W. Extreme sex ratio variation in relation to change in condition around conception. Biol Lett 2007;3:395–97. 45. Hassold T, Quillen S, Yamane J. Sex ratio in spontaneous abortions. Ann Hum Genet 1983;47:39–47. 46. Simpson J. Pregnancy and the timing of intercourse. N Engl J Med 1995;333:1563–65. 47. Benagiano G, Bianchi P. Sex preselection: an aid to couples or a threat to humanity? Hum Reprod 1999;14:867–70. 48. Simpson J, Carson S. The reproductive option of sex selection. Hum Reprod 1999;14:870–72. 49. Sills E, Kirman I, Thatcher S, et al. Sex-selection of human spermatozoa evolution of current techniques and applications. Arch Gynecol Obstet 1998;261:109–15. 50. Jha P, Kumar R, Vasa P, et al. Low male-to-female sex ratio of children born in India: national survey of 1.1 million households. Lancet 2006;367:211–18. 51. Benagiano G, Bianchi P. Sex preselection: an aid to couples or a threat to humanity? Hum Reprod 1999;14:868–70. 52. Coale A, Banister J. Five decades of missing females in China. Demography 1994;31:459–79. 53. Goodkind D. Do parents prefer sons in North Korea?. Stud Fam Plann 1999;30:212–18. 54. Sharma BR, Gupta N, Relhan N. Misuse of prenatal diagnostic technology for sex-selected abortions and its consequences in India. Public Health 2007;121:854–60. 55. Cooperstock M, Campbell J. Excess males in preterm birth: interactions with gestational age, race and multiple birth. Obstet Gynecol 1996;88:189–93. 56. McGregor J, Leff M, Orleans M, et al. Fetal gender differences in preterm birth findings in a North American cohort. Am J Perinatol 1992;9:43–48. 57. Chen S, Vohr B, Oh W. Effects of birth order, gender, and intrauterine growth retardation on the outcome of very low birth weight in twins. J Pediatr 1993;123:132–36. 58. Shinwell ES, Reichman B, Lerner-Geva L, et al. ‘Masculinizing’ effect on respiratory morbidity in girls from unlike-sex preterm twins: a possible transchorionic paracrine effect. Pediatrics 2007;120:e447–53.
C h a p t e r 1 The Effects of Gender in Neonatal Medicine l
59. Lubchenco L, Hansman C, Dressler M, et al. Intrauterine growth as estimated from liveborn birth-weight data at 24 to 42 weeks of gestation. Pediatrics 1963;32:793–800. 60. Usher R, McLean F. Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 1969;74:901–10. 61. Westerway S, Davison A, Cowell S. Ultrasonic fetal measurements: new Australian standards for the new millennium. Aust NZ Obstet Gynaecol 2000;40:297–302. 62. Moore W, Ward B, Jones V, et al. Sex difference and fetal head growth. Br J Obstet Gynecol 1988;95:238–42. 63. Schild RL, Sachs C, Fimmerst R, et al. Sex-specific fetal weight prediction by ultrasound. Ultrasound Obstet Gynecol 2004;23:30–35. 64. Tsunoda Y, Tokunaga T, Sugie T. Altered sex ratio of live young after transfer of fast- and slow-moving mouse embryos. Gamete Res 1985;12:301–4. 65. Karlberg P, Taranger J. The somatic development of children in a Swedish urban community: a prospective study. Acta Paediatr Scand 1976;57:1–148. 66. Stevenson D, Verter J, Fanaroff A, et al. Sex differences in outcomes of very low birth weight infants the newborn male disadvantage. Arch Dis Child Fetal Neonatal Ed 2000;83:F182–F1855. 67. Drevenstedt GL, Crimmins EM, Vasunilashorn S, et al. The rise and fall of excess male infant mortality. Proc Natl Acad Sci USA 2008;105:5016–21. 68. Di Renzo GC, Rosati A, Sarti RD, et al. Does fetal sex affect pregnancy outcome? Gend Med 2007;4:19–30. 69. United States Department of Health and Human Services (US DHHS), Centers of Disease Control and Prevention (CDC). Linked birth/infant death records 2003–2004 on CDC WONDER on-line database: National Center for Health Statistics (NCHS), Office of Analysis and Epidemiology (OAE), Division of Vital Statistics (DVS). 70. Centers for Disease Control and Prevention. Infant mortality and low birth weight among black and white infants, United States, 1980–2000. MMWR 2002:589–92. 71. Demmelmair H, von Rosen J, Koletzko B. Long-term consequences of early nutrition. Early Hum Dev 2006;82:567–74. 72. Wells JC, Chomtho S, Fewtrell MS. Programming of body composition by early growth and nutrition. Proc Nutr Soc 2007;66:423–34. 73. Pineau J-C, Guihard-Costa A-M, Droullé P. Only two-phase models, computed independently for males and females, are appropriate to describe fetal head growth. Fetal Diagn Ther 2003;18:207–16. 74. Pineau J-C, Thiebaugeorges O, Guihard-Costa AM. Optimal standards for fetal biometry: to each measurement its fitting model. Fetal Diagn Ther 2006;21:396–99. 75. Maduwegedera D, Kett MM, Flower RL, et al. Sex differences in postnatal growth and renal development in offspring of rabbit mothers with chronic secondary hypertension. Am J Physiol Regul Integr Comp Physiol 2007;292:R706–14. 76. Maric C. Mechanisms of fetal programming of adult hypertension: role of sex hormones. Hypertension 2007;50:605–6. 77. Ojeda NB, Grigore D, Yanes LL, et al. Testosterone contributes to marked elevations in mean arterial pressure in adult male intrauterine growth restricted offspring. Am J Physiol Regul Integr Comp Physiol 2007;292:R758–63.
15
78. Ojeda NB, Grigore D, Robertson EB, et al. Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring. Hypertension 2007;50:679–85. 79. Zambrano E, Martinez-Samayoa PM, Bautista CJ, et al. Sex differences in transgenerational alterations of growth and metabolism in progeny (F2) of female offspring (F1) of rats fed a low protein diet during pregnancy and lactation. J Physiol 2005;566:225–36. 80. Lawlor DA, Ebrahim S, Davey Smith G. Is there a sex difference in the association between birth weight and systolic blood pressure in later life? Findings from a meta-regression analysis. Am J Epidemiol 2002;156:1100–14. 81. Matthews F, Johnson P, Neil A. You are what your mother eats: evidence for maternal preconception diet influencing foetal sex in humans. Proc Biol Sci 2008;275:1661–68. 82. Bracero L, Cassidy S, Byrne D. Effect of gender on perinatal outcome in pregnancies complicated by diabetes. Gynecol Obstet Invest 1996;41:10–14. 83. Torday J, Nielsen H. The sex difference in fetal lung surfactant production. Exper Lung Res 1987;12:11–19. 84. Bourbon J, Farrel P. Fetal lung development in the diabetic pregnancy. Pediatr Res 1985;19:253–67. 85. Ingemarsson I, Herbst A, Thorngren-Jerneck K. Long-term outcome after umbilical artery acidaemia at term birth: influence of gender and duration of fetal heart rate abnormalities. Br J Obstet Gynaecol 1997;104:1123–27. 86. Heyer A, Hasselblatt M, von Ahsen N, et al. In vitro gender differences in neuronal survival on hypoxia and in 17[beta]estradiol-mediated neuroprotection. J Cereb Blood Flow Metabol 2005;25:427–30. 87. Nijboer CHA, Kavelaars A, van Bel F, et al. Gender-dependent pathways of hypoxia-ischemia-induced cell death and neuroprotection in the immature p3 rat. Dev Neurosci 2007;29:385–92. 88. Ulm B, Svolba G, Ulm M, et al. Male fetuses are particularly affected by maternal alloimmunization to D antigen. Transfusion 1999;39:169–73. 89. Tioseco JA, Aly H, Milner J, et al. Does gender effect neonatal hyperbilirubinemia in low-birth-weight infants? Pediatr Crit Care Med 2005;6:171–74. 90. Zaren B, Lindmark G, Bakketeig L. Maternal smoking affects fetal growth more in the male fetus. Paediat Perinatal Epidemiol 2000;14:118–26. 91. Bateman D, Ng S, Hansen C, et al. The effects of intrauterine cocaine exposure in newborns. Am J Public Health 1993;83:190–93. 92. Bateman D, Chiriboga C. Dose-response effect of cocaine on newborn head circumference. Pediatrics 2000;106:e33. 93. Naeye R, Blanc W, Leblanc W, et al. Fetal complications of maternal heroin addiction: abnormal growth, infections and episodes of stress. J Pediatr 1973;83:1055–61. 94. Arendt R, Angelopoulos J, Salvator A, et al. Motor development of cocaine-exposed children at age two years. Pediatrics 1999;103:86–92. 95. Koren G, Nulman I, Rovet J, et al. Long-term neurodevelopmental risks in children exposed in utero to cocaine. The Toronto adoption study. Ann NY Acad Sci 1998;846:306–13. 96. Richardson G. Prenatal cocaine exposure. A longitudinal study of development. Ann NY Acad Sci 1998;846:144–52. 97. Jones K, ed. Fetal Alcohol Syndrome, 6th edn.. Philadelphia, PA: WB Saunders; 2006.
16
s e c t i o n 1 Gender and Normal Development l
98. Delaney-Black V, Covington C, Nordstrom B, et al. Prenatal cocaine: quantity of exposure and gender moderation. J Dev Behav Pediatr 2004;25:254–63. 99. Robert E, Kallen B, Harris J. The epidemiology of diaphragmatic hernia. Eur J Epidemiol 1997;13:665–73. 100. Torfs C, Curry C, Bateson T. A population-based study of congenital diaphragmatic hernia. Teratology 1992;46:555–65. 101. Stolar C, Crisafi M, Driscoll Y. Neurocognitive outcome for neonates treated with extracorporeal membrane oxygenation: are infants with congenital diaphragmatic hernia different? J Pediatric Surg 1995;30:366–71. 102. Jones K. Genetics, genetic counseling, and prevention. Smith’s Recognizable Patterns of Human Malformation, 6th edn. Philadelphia, PA: WB Saunders; 2006:796–816. 103. Miller-Hance W, Tacy T. Gender differences in pediatric cardiac surgery: the cardiologist’s perspective. J Thorac Cardiovasc Surg 2004;128:7–10. 104. Klitzner T, Lee M, Rodriguez S, et al. Sex-related disparity in surgical mortality among pediatric patients. Congenital Heart Dis 2006;1:77–88. 105. Samánek M. Boy:girl ratio in children born with different forms of cardiac malformation: a population-based study. Pediatr Cardiol 1994;15:53–57. 106. Calzolari E, Garani G, Cocchi G, et al. Congenital heart defects: 15 years of experience of the Emilia-Romagna registry (Italy). Eur J Epidemiol 2003;18:773–80. 107. Samánek M, Goetzová J, Benesová D. Distribution of congenital heart malformations in an autopsied child population. Int J Cardiol 1985;8:235–50. 108. Klitzner TS, Lee M, Rodriguez S, et al. Sex-related disparity in surgical mortality among pediatric patients. Congenital Heart Dis 2006;1:77–88. 109. Ostadal B, Ostadalova I, Dhalla NS. Development of cardiac sensitivity to oxygen deficiency: comparative and ontogenetic aspects. Physiol Rev 1999;79:635–59. 110. Schaubel D, Johansen H, Dutta M, et al. Neonatal characteristics as risk factors for preschool asthma. J Asthma 1996;33:255–64. 111. Lemons J, Bauer C, Oh W, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Research Network, January 1995 through December 1996. Pediatrics 2001;107:e1. 112. Extremely preterm birth outcome data. (Accessed 06/25/2008 at www.nichd.nih.gov/about/org/cdbpm/pp/prog_epbo/.) 113. Tyson J, Parikh N, Langer J, et al. Intensive care for extreme prematurity: moving beyond gestational age. N Engl J Med 2008;358:1672–81. 114. Hegyi T, Carbone T, Anwar M, et al. The Apgar score and its components in preterm infants. Pediatrics 1998;101:77–81. 115. Baenziger O, Jaggi J, Mueller A, et al. Cerebral blood flow in preterm infants affected by sex, mechanical ventilation, and intrauterine growth. Pediatric Neurol 1994;11:319–24. 116. Tontisirin N, Muangman SL, Suz P, et al. Early childhood gender differences in anterior and posterior cerebral blood flow velocity and autoregulation. Pediatrics 2007;119:e610–15. 117. Arne O, Robin SR, Barbara S, et al. Male/female differences in indomethacin effects in preterm infants. J Pediatrics 2005;147:860–62. 118. Malloy M, Freeman D. Respiratory distress syndrome mortality in the United States, 1987-95. J Perinatol 2000;20:414–20.
119. Pollak A, Birnbacher R. Preterm male infants need more initial respiratory support than female infants. Acta Paediatrica 2004;93:447–48. 120. Stocks J, Henschen M, Hoo A-F, et al. Influence of ethnicity and gender on airway function in preterm infants. Am J Respir Crit Care Med 1997;156:1855–62. 121. Papageorgiou A, Colle E, Farri-Kotopoulos E, et al. Incidence of respiratory distress syndrome following antenatal betamethasone: role of sex, type of delivery, and prolonged rupture of membranes. Pediatrics 1981;67:614–17. 122. Schwartz R, Luby A, Scanlon J, et al. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med 1994;330:1476–80. 123. Webb R, Shaw N. Respiratory distress in heavier versus lighter twins. J Perinat Med 2000;29:60–63. 124. Ardila J, Le Guennec J, Papageorgiou A. Influence of antenatal betamethasone and gender cohabitation on outcome of twin pregnancies 24–34 weeks gestation. Semin Perinatol 1994;18:151–58. 125. Willet K, Jobe A, Ikegami M, et al. Postnatal lung function after prenatal steroid treatment in sheep: effect of gender. Pediatr Res 1997;42:885–92. 126. Korhonen P, Tammela O, Koivisto A, et al. Frequency and risk factors in bronchopulmonary dysplasia in a cohort of very low birth weight infants. Early Hum Dev 1999;54:245–58. 127. Vrijlandt E, Gerritsen J, Boezen HM, et al. Gender differences in respiratory symptoms in 19-year-old adults born preterm. Respir Res 2005;6:117. 128. Fanaroff A, Korones S, Wright L, et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. Pediatr Inf Dis J 1998;17:593–98. 129. Nagy E, Kompagne H, Orvos H, et al. Gender-related differences in neonatal imitation. Infant Child Dev 2007;16:267–76. 130. Boatella-Costa E, Costas-Moragas C, Botet-Mussons F, et al. Behavioral gender differences in the neonatal period according to the Brazelton scale. Early Hum Dev 2007;83:91–97. 131. Lundqvist C, Sabel K-G. The Brazelton neonatal behavioral assessment scale detects differences among newborn infants of optimal health. J Pediatr Psychol 2000;25:577–82. 132. Guinsburg R, Peres C de A, Branco de Almeida MF, et al. Differences in pain expression between male and female newborn infants. Pain 2000;85:127–33. 133. Tommiska V, Heinonen K, Ikonen S, et al. A national shortterm follow-up of extremely low birth weight infants born in Finland in 1996–1997. Pediatrics 2001;107:1–9. 134. Borthwood M, Wolke D, Gamsu H, et al. Prognosis of the very low birth weight baby in relation to gender. Arch Dis Child 1986;61:559–64. 135. Hoffman E, Bennett F. Birth weight less than 800 grams: changing outcomes and influences of gender and gestation number. Pediatrics 1990;86:27–34. 136. Paz I, Gale R, Laor A, et al. The cognitive outcome of fullterm small for gestational age infants at late adolescence. Obstet Gynecol 1995;85:45245–46. 137. Laptook AR, O’Shea TM, Shankaran S, et al. NICHD Neonatal Network. Adverse neurodevelopmental outcomes among extremely low birth weight infants with a normal head ultrasound: prevalence and antecedents. Pediatrics 2005;115:673–80.
C h a p t e r 1 The Effects of Gender in Neonatal Medicine l
138. Hintz SR, Kendrick DE, Vohr BR, et al. Changes in neuro developmental outcomes at 18 to 22 months’ corrected age among infants of less than 25 weeks’ gestational age born in 1993–1999. Pediatrics 2005;115:1645–51. 139. Walsh MC, Morris BH, Wrage LA, et al. Extremely low birth weight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatrics 2005;146:798–804. 140. Hack M, Flannery DJ, Schluchter M, et al. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med 2002;346:149–57. 141. Wilson-Costello D, Friedman H, Minich N, et al. Improved neurodevelopmental outcomes for extremely low birth weight infants in 2000–2002. Pediatrics 2007;119:37–45. 142. Arnaud C, Daubisse-Marliac L, White-Koning M, et al. Prevalence and associated factors of minor neuromotor dysfunctions at age 5 years in prematurely born children: the EPIPAGE study. Arch Pediatr Adolesc Med 2007;161:1053–61. 143. Marlow N, Wolke D, Bracewell MA, et al. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005;352:9–19.
17
144. Hack M, Taylor HG, Klein N, et al. School-age outcomes in children with birth weights under 750 g. N Engl J Med 1994;331:753–59. 145. Tin W, Wariyar U, Hey E. Changing prognosis for babies of less than 28 weeks’ gestation in the north of England between 1983 and 1994. BMJ 1997;314:107–11. 146. Yliherva A, Olsen P, Mäki-Torkko E, et al. Linguistic and motor abilities of low-birth weight children as assessed by parents and teachers at 8 years of age. Acta Paediatr Scand 2001;90:1440–49. 147. Hack M, Taylor HG, Drotar D, et al. Poor predictive validity of the Bayley scales of infant development for cognitive function of extremely low birth weight children at school age. Pediatrics 2005;116:333–41. 148. Andrews H, Goldberg D, Wellen N, et al. Prediction of special education placement from birth certificate data. Am J Preventive Med 1995;11:55–61. 149. Msall M, Buck G, Rogers B, et al. Predictors of mortality, morbidity, and disability in a cohort of infants of 28 weeks gestation. Clin Pediatrics 1993;32:521–27.
C hapter
2
Sexual Development, Growth, and Puberty in Children Gaya S. Aranoff1, and Jennifer J. Bell2 1
Professor of Clinical Pediatrics, Columbia University College of Physicians and Surgeons, Department of Pediatrics, New York, NY, USA 2 Special Lecturer in Pediatrics, Columbia University College of Physicians and Surgeons, Department of Pediatrics, New York, NY, USA
Introduction
occurs with the onset of testicular Sertoli cell development, under the influence of a testis-determining locus on the Y chromosome (the SRY – Sex-determining Region of the Y locus).2 At about 7 weeks gestation, the Sertoli cells secrete anti-Müllerian hormone (AMH) which diffuses out of the testis to the adjacent Müllerian ducts, causing their dissolution by apoptosis. The Sertoli cells also induce the formation of Leydig cells, first identified at about the 8th week of gestation (60 days). Stimulated by both placental human chorionic gonadotropin (HCG) and, later in gestation, fetal pituitary luteinizing hormone (LH), the Leydig cells begin to synthesize testosterone by the 9th week of gestation. Testosterone diffuses out of each testis to the adjacent Wolffian duct, developing and maturing it into the vas deferens, epididymis, and seminal vesicle. In addition, testosterone is secreted into the bloodstream and circulates to the external genitalia where it is converted to dihydrotestosterone (DHT). DHT is the hormone responsible for the masculin ization of the external bipotential primordia, causing the fusion of the urethral folds into the male urethra, the development of the labioscrotal folds into the scrotum, and the transformation of the genital tubercle into the penis. This process of transformation is complete by the 13th week of gestation, at which point the fetus is anatomically identifiable as either male or female. Blood levels of testosterone peak to adult male levels by about 16 weeks gestation, then fall to early pubertal levels after the 24th week. Phallic growth, which is testosterone-dependent, continues to term. Many genes have been identified which are directly involved in the formation of testes and ovaries.2,3 Some (SRY and SOX9) stimulate testicular development; others (e.g. DAX1 and WNT-4) are believed to inhibit testicular development and may actively promote ovarian development. In the female, since the bipotential gonad has not been committed by SRY to become a testis, it will develop as an ovary (if germ cells are present). Ovarian development
Although gender/sex-specific events are multifactorial, the predominant underlying factor is the different hormonal milieu to which males and females are exposed. Pediatric endocrinology is concerned with the fetal determination and development of the two sexes, and the sex-specific hormonal environments experienced by each from fetal life through puberty and adolescence to adulthood. These differences include the testosterone-rich environment of the male fetus and neonate, the subtle hormonal differences between the two sexes during childhood, the differences in growth before and during sexual maturation, and variations in and implications of the timing of sexual maturation. The effects such childhood differences may have on adult gender-related disorders are as yet poorly understood.
Sexual development Normal Sexual Development1 In normal circumstances, a fetus’ sexual development is genetically determined in the process of conception, which has resulted in a fertilized egg with either XX or XY chromosomes. Until about the 6th week of gestation, organogenesis has resulted in a phenotypically indifferent, bipotential fetus with no apparent anatomic or metabolic distinction between male and female. In both sexes the gonad that has formed is bipotential, capable of becoming either a testis or an ovary. Both early male (Wolffian) and female (Müllerian) duct systems are present, and the external genitalia consist of a urogenital slit surrounded laterally by periurethral folds, more laterally by labioscrotal folds, and a genital tubercle. In the male, at about 6–7 weeks of gestation, the first step in the sexual differentiation of the bipotential gonad Principles of Gender-Specific Medicine
18
Copyright 2010, Elsevier Inc. All rights reserved.
C h a p t e r 2 Sexual Development, Growth, and Puberty in Children l
begins at about the 11th week of gestation. At that time primitive germ cells multiply and enlarge into oogonia. At about the 12th week of gestation the oogonia undergo meiosis into oocytes. The fetal ovary is relatively quiescent hormonally compared to the fetal testis. Very little estrogen is made in the fetal ovary, but estrogen is secreted in large quantities by the placenta in both sexes.4 In the absence of AMH secretion from a fetal testis, the Müllerian ducts develop into fallopian tubes, uterus, and the upper third of the vagina; the lower two-thirds of the vagina are formed from the urogenital sinus. The vagina acquires a perineal opening separate from the urethra. If the external genitalia have not been exposed to testosterone by the 13th week of gestation, the urethral folds do not fuse in midline but remain separate as the labia minora, and the labioscrotal folds form the bilateral labia majora. The small genital tubercle, now called the clitoris, grows little in the absence of circulating testosterone. Unlike the urethral and labioscrotal folds, the clitoris remains potentially responsive to testosterone throughout gestation.1
Disorders of Sexual Development When the sex of a newborn is unclear at birth, investigation must be undertaken to determine whether the genitalia are those of an incompletely virilized male or an inappropriately virilized female. Congenital disorders of sexual development (DSD) can be caused by chromosomal, hormonal, environmental, or developmental (anatomic) factors. DSD is now the accepted terminology to describe atypical sexual development, and replaces older stigmatizing terms like intersex and hermaphroditism (Table 2.1).5 In congenital DSD, the external genitalia of a newborn are not clearly identifiable as male or female. Inspection of the external genitalia may reveal: a phallic structure that may be a small, incompletely formed penis or an enlarged clitoris, a single perineal opening at the base of the phallus or on the penile shaft (which may represent either incomplete migration of the male urethra, or a female urethrovaginal orifice), and fused labioscrotal folds that may be either a poorly formed scrotum, or virilized labia.
●
●
●
Guiding principles in evaluating DSD are: 1. Male differentiation requires functioning testicular tissue; in the absence of this, ductal and external structures appear female. 2. Female differentiation does not require functioning ovarian tissue; in the absence of this, ductal and external structures will still appear female. 3. Internal genital structures are fixed by the 13th week of gestation. After that date, external genitalia can enlarge in response to hormonal stimulation, but their basic structure does not change.
19
Table 2.1 Revised nomenclature Previous
Current
Intersex Male pseudohermaphrodite Incompletely virilized or undervirilized male Female pseudohermaphrodite Virilized or masculinized female True hermaphrodite XX male or XX sex reversal XY sex reversal
DSD 46,XY DSD 46,XY DSD 46,XX DSD 46,XX DSD Ovotesticular DSD 46,XX testicular DSD 46,XY complete gonadal dysgenesis
Chromosomal Etiologies of DSD1 If in the first embryonic cell division one X chromosome is lost leaving all the cells with only one X chromosome, functioning ovarian tissue is absent (or deficient in 10%) but external genitalia are those of a normal female. This is true also if all of a Y chromosome is lost, again resulting in all cells with only one X chromosome. In this case the fetus has no functioning testicular tissue because the testis-determining gene of the Y chromosome is missing, and external genitalia are unambiguously female. This is known as XO gonadal dysgenesis or Turner syndrome. If, however, the Y chromosome loss occurs after the first cell division, causing an XO/XY mosaicism, then the phenotype can vary from a Turner phenotype to that of a normal male, depending on to what extent the XO or XY cell line predominates. This also determines whether testicular tissue is present and, if present, is normal or dysgenetic. The appearance of the external genitalia can be female, ambiguous, or male depending on how much functional testicular tissue is present. The same is true if all cells have XY chromosomes but the Y is incomplete, missing all or part of its long or short arms. Children with an ovotesticular disorder of sexual development have both testicular and ovarian tissue present, either as separate gonads or as a combined ovotestis. About half of these children have a 46,XX karyotype; a few of these will have the SRY locus of a Y chromosome translocated to one of the Xs. Others will have a 46,XY karyotype, or some form of sex chromosome mosaicism. The nature of the internal ductal structures will depend on the location and amount of testicular tissue. The side with testicular tissue present will be variably masculinized; the side without testicular tissue will develop female ducts. External genitalia are usually ambiguous. Hormonal Etiologies of DSD The adrenal cortex synthesizes three important classes of steroid hormones – glucocorticoids, mineralocorticoids, and androgens. Hormonal synthesis occurs through an orderly, stepwise enzymatic hydroxylation and dehydrogenation of cholesterol to produce the major glucocorticoid, cortisol, the major mineralocorticoid, aldosterone, and the adrenal
1
20
s e c t i o n 1 Gender and Normal Development l
androgens, dehydroepiandrosterone (DHEA) and androstenedione (A). The gonads share the same enzymatic conversion pathways of cholesterol to DHEA and A; in the testes (and to a lesser extent, the ovaries) these mild androgens are metabolized further to the potent androgen, testosterone. In the ovaries (and to a lesser extent, the testes) the testosterone is then aromatized to estradiol, the major estrogenic steroid. Disorders of Adrenal Steroid Biosynthesis6 Abnormalities in the steroidogenic enzymatic pathways of the adrenal cortex are grouped under a family of disorders known as congenital adrenal hyperplasia (CAH). The most common of these, a deficiency of the 21-hydroxylase enzyme (P450c21), results in cortisol and aldosterone deficiency, but, because 21-hydroxylation is not required for androgen biosynthesis, DHEA and A synthesis is intact. The low circulating cortisol level feeds back to the pituitary causing increased adrenocorticotropin hormone (ACTH) release. In response to the increased ACTH, the adrenal cortex becomes hyperplastic and produces increased amounts of DHEA and A, which are in turn converted to testosterone both in the adrenal cortex and peripherally. If the 21-hydroxylase enzyme deficiency is severe enough, and aldosterone synthesis is severely impaired, the affected infant will develop a life-threatening salt-losing condition soon after birth. In simple (aldosterone sufficient) or salt-losing (aldosterone insufficient) CAH, the excess adrenal androgens produced in the fetus result in virilization of the external genitalia. In the male fetus, this virilizing effect is obscured by the much stronger virilizing effect of testosterone from the testes. In the female fetus, the adrenal androgens cause clitoral hypertrophy and labioscrotal fusion to a greater or lesser degree, depending upon the levels of androgens. The second most common enzyme deficiency in CAH, 11-hydroxylase deficiency (P450c11ß), is also characterized by cortisol deficiency and, because of ACTH-induced hyperplasia, adrenal androgen excess. It is not a salt-losing condition because the synthesis of saltretaining desoxycorticosterone (DOC) is preserved. In this condition also, male genitalia appear normal at birth, and virilized female genitalia are ambiguous. Earlier blocks in adrenal steroid synthesis are much rarer. They affect both adrenal and gonadal androgen synthesis. These synthetic blocks (3-hydroxysteroid dehydrogenase (3HSD) deficiency; 17–hydroxylase/17,20-lyase (P450c17) deficiency), in contrast to the previously mentioned enzyme defects, cause defective adrenal androgen and gonadal testosterone and estrogen production. In 3HSD deficiency, DHEA levels are elevated sufficiently to virilize the female fetus. The male fetus, because of the lack of testosterone, is incompletely virilized by the DHEA. Both sexes are born with ambiguous genitalia in 3HSD deficiency. In P450c17 deficiency, all androgen and estrogen production is blocked. If P450c17 deficiency is complete, both sexes have external genitalia that appear female. If P450c17
deficiency is incomplete, external genitalia of a genetic male will appear ambiguous, and the genitalia of a genetic female will be unambiguously female. Disorders of Testosterone Biosynthesis7 Both isolated 17,20-lyase and 17-hydroxysteroid dehydrogenase type 3 deficiencies affect testosterone synthesis in the testis only. Adrenal cortical steroid biosynthesis is normal. The extent of the compromise of the male genitalia depends on how defective testosterone biosynthesis is. Placental Aromatase Deficiency8 In utero, fetal adrenal DHEA metabolites circulate to the placenta where a placental aromatase enzyme converts them to estrogens. If this metabolic pathway is blocked by placental aromatase deficiency, the accumulation of the mild androgen DHEA will cause virilization of the female fetus’ external genitalia. 5-Reductase Deficiency9 Testosterone does not act directly on the fetus’ external genitalia but is converted in the genital tissue into its active form, dihydrotestosterone, by the action of the enzyme 5reductase. Lack of this enzyme will cause ambiguity of the male genitalia. Defects of Androgen Receptor10 Mutations in or deletions of the gene encoding the androgen receptor cause resistance to the virilizing effect of testosterone. Abnormalities of the androgen receptor will block androgen action completely or incompletely. The resulting androgen insensitivity syndrome (AIS) can be complete or partial, depending upon whether the receptor is completely absent or is reduced in numbers or activity. The male fetus with complete AIS will be born with poorly developed internal Wolffian ducts and female external genitalia, sometimes with testes palpable in the labial structures. Male infants with partial AIS may have only partial masculinization of the external genitalia. Anatomic Etiologies of DSD1 Teratogenic abnormalities in the female fetus, such as a persistent cloaca, imperforate anus, and urinary tract abnormalities, are sometimes associated with malformations of the urethrovaginal orifices and thus disorders of development of the external genitalia. Similarly, males with penile agenesis and cloacal extrophy have often been given a female sex assignment. Less extreme examples of DSDs due to congenital anatomic abnormalities in males include perineal hypospadias and cryptorchidism. These conditions occur independent of any chromosomal, hormonal or receptor abnormalities of sexual differentiation.
C h a p t e r 2 Sexual Development, Growth, and Puberty in Children l
Environmental Etiologies of DSD1 Maternal ingestion of testosterone or of certain synthetic derivatives of 19-nortestosterone that have been used as progestational agents in threatened abortion or as part of hormonal treatments given with assisted fertilization, can cross the placenta and may cause virilization of the female fetus. Their effect depends on the time of ingestion as well as the androgen levels attained: if ingested before the 13th week of gestation the androgens may cause labial fusion and clitoral hypertrophy. After the 13th week only clitoral hypertrophy can occur. Maternal virilizing tumors (e.g. arrhenoblastoma) or cysts (luteomas) can also virilize a female fetus. Defining and Assigning Sex in DSD The first question invariably asked by the parents of a newborn infant is: Is it a boy or a girl? Normally, the answer to this question is straightforward, with a consistent response of male or female, no matter how one defines sex. The answer may be determined by inspection of external genitalia at the time of delivery, or prenatally by ultrasound (phenotypic sex), or by prenatal amniocentesis determination of the neonate’s chromosomal sex (46,XX karyotype for females, 46,XY for males). Even in infants born with DSDs, the sex of the baby and the appropriate sex of rearing can usually be determined reasonably quickly, after a thorough investigation is undertaken. In rare cases of infants born with DSDs, there are discrepancies between phenotypic, chromosomal, and gonadal sex (presence of ovaries in females, and testes in males). This may occur, for example, in the case of an infant with both ovarian and testicular tissue, or an infant with partial or complete androgen insensitivity syndrome.11,12 The sex of rearing must be assigned even though the ideal sex of rearing may remain unclear. Ideally, gender identity (how one identifies oneself, as male or female) should determine the sex of rearing, but since gender identity is not manifest in infancy, errors in neonatal sex assignment, though rare, are still possible. Psychosexual development progresses with time, and gender identity and subsequent sexual orientation (male or female partner preference) will take years to become clear. Sex assignment (or reassignment) should be done based on clinical and laboratory investigation obtained as quickly and thoroughly as possible, by an experienced medical team, comprised of specialists in pediatric endocrinology, urology, and psychiatry. The team should include the infant’s pediatrician, or family physician, and may benefit from involvement of social service and clergy as well. Clearly, the infant’s parents must be involved in, and supportive of the decision. In the last quarter of the twentieth century guidelines for determining sex of rearing in cases of infants born with what was then referred to as ‘ambiguous genitalia’ were based mainly on two factors: the potential for sexual function and the potential for fertility.13 These guidelines were based,
21
in part, on research that suggested that gender identity was determined by sex of rearing, as long as the sex of rearing was chosen early enough in life.14,15 Long-term follow-up of patients diagnosed with ‘ambiguous genitalia’ has highlighted discrepancies between sex of rearing and ultimate gender identity in some of these patients. It has called into question the wisdom of choosing sex of rearing without consideration of ‘brain sex’. There is increasing evidence to suggest that the brain is a sexual organ, and that it is paramount in determining human gender identity. It is clearly in the best interest of the patient that the sex of rearing be consistent with the patient’s gender identity. Unfortunately, we have no definitive diagnostic tools available to us at the time of birth to clarify the infant’s ultimate gender identity. Fetal exposure to testosterone has been found to be associated with male gender identity.16–18 During the second to fourth month of normal male fetal development, testosterone levels reach a peak as high as mature adult male levels (200–600 ng/dl).3 In 5-reductase deficiency, a 46,XY DSD, exposure of the brain to high intra-uterine levels of testosterone occurs. Despite having been raised unambiguously as girls from birth, many patients with this disorder spontaneously assume a male gender identity at puberty, when testosterone levels again rise.19 Spontaneous adoption of male gender identity in puberty has also been described in 17-hydroxysteroid dehydrogenase deficiency (46,XY DSD) patients, raised as girls from birth.20 The experience of these patients contradicts earlier theories about the primacy of sex of rearing on ultimate gender identity. From both of these populations we can learn that, if a society is accepting of the change, sex reassignment in order to make gender role consistent with gender identity is possible, even as late as puberty. Retrospective studies of women with virilizing CAH (associated with high intra-uterine testosterone levels) also suggest the importance of intra-uterine testosterone exposure on gender identity. Hines et al. found dissatisfaction with female gender identity and decreased heterosexual interest in adult CAH women who had a history of preferring typical male play as children.21 Another factor not adequately considered in the initial guidelines for sex assignment is the effect of genital surgery on genital sensation and its relation to sexual satisfaction.22–23 Although surgical technique has improved greatly over the last quarter century, some patients, now adult, who have undergone genital surgical procedures for correction of phenotypic genital ambiguity, are actively protesting against surgical intervention in cases where it is not considered medically essential for the health of the infant. They say that their ability to be sexually gratified has been impaired by lack of genital sensation due to surgery, and feel that ‘cosmetic’ genital surgery should be a decision
22
s e c t i o n 1 Gender and Normal Development l
made by the patient, and not the parents or doctors. The extent of dissatisfaction with the outcome of genital surgery is unknown, as retrospective studies are ethically difficult to carry out, given confidentiality issues.24 Until we are able to unequivocally diagnose gender identity at birth, assignment of sex of rearing may sometimes be an ethically challenging decision. It is a decision that must be made, as neonatal sex assignment of male or female remains socially essential in human society today. In addition to pediatric endocrinologists, specially trained pediatric psychiatrists should be involved in the long-term care of patients born with DSDs. Decisions about the necessity and timing of genital surgery should be made judiciously, taking into consideration the effect of genital surgery on sexual satisfaction in adulthood, as well as the need for phenotypic sex to match the sex of rearing.
Growth Normal Patterns in Boys and Girls Although for a large part of childhood boys and girls grow at the same rate, there are subtle sex differences in growth rates in utero and clear sex differences in growth patterns peripubertally. Boys grow slightly more than girls in utero and are born on average slightly longer than girls by about 0.8 cm. The prenatal difference in growth rates is lost soon after birth and although boys remain on average very slightly taller than girls, the growth rates of the two sexes are almost identical for most of childhood. The growth rate in both sexes is most rapid in the first year (average 25.4 cm), then decelerates over the next few years to an average rate of 5–6.5 cm from about 3 or 4 years until the onset of puberty. During childhood the two hormones most important for growth are growth hormone and thyroid hormone. At puberty, under the influence of the sex hormones estrogen and testosterone, the growth rate increases once more, to a peak annual rate of 8.3 cm in girls and 9.5 cm in boys.25 This increase is associated with an increase in growth hormone secretion correlated with estradiol levels in both sexes.26 The two sexes diverge in the timing of puberty; the pubertal growth spurt starts earlier in girls, usually between 10 and 11 years of age, and continues until the epiphyses of the bones fuse and growth ceases at an average age of 16. Boys start their growth spurt about 2 years later, at an average age of 12.5, at which point they are about 8 cm taller than girls were when their sexual development started. Boys stop growing at an average age of 18, and are on average 12.5 cm taller as adults than women.27 The action of the sex hormones, in particular estrogen, is required for epiphyseal fusion to occur and the potential for further growth to be lost in both boys and girls.
In addition to linear growth, children’s body proportions change as they age and mature. An infant is born with its head and trunk, the so-called ‘upper segment’, being almost twice as long as the lower extremities, the ‘lower segment’. An infant’s upper/lower segment ratio on average equals 1.7. As the child matures, the legs grow faster than the trunk, so that as the child approaches puberty the upper and lower segments are approximately equal (U/L segment ratio 1.0). Under the influence of the sex hormones, the extremities continue to grow faster than the trunk. In midadolescence the U/L segment ratio is about 0.9. The legs stop growing earlier than the trunk, so the adult U/L segment ratio, in both sexes, is again about 1.0.28 The epiphyses of the bones are mostly cartilaginous at birth. As a child matures, the epiphyses calcify. The degree and configuration of calcification change in relation to the shafts of the bones, and have a characteristic appearance at each age. At puberty, under the influence of estrogen in both sexes, the calcified epiphyses eventually fuse with the shafts of the bones. The cartilaginous zone of growth between the epiphysis and shaft disappears, and growth ceases at the end of puberty. As is true of the pattern of overall growth, the progression of epiphyseal changes is sex-specific and differs between boys and girls at any chronological age. The best-studied progression of bone maturation has been in the hands, and an x-ray of the child’s wrist and hand for a ‘bone age’ is the best objective marker we have for assessing the actual maturation of a child’s skeleton.29 Knowing this and the height of the child at the time the x-ray was taken, one can approximate the child’s growth potential and adult height (the ‘predicted adult height’).30–32
Abnormal Growth Patterns in Boys and Girls Charting children’s growth over time is the most efficient way of discerning deviation from normal patterns, and helps a practitioner decide when diagnostic and therapeutic intervention is indicated. Most pediatric clinics in the United States use growth curves provided by the National Center for Health Statistics (of the Centers for Disease Control and Prevention), which are based on cross-sectional data. The main limitations of these curves are that they do not provide norms for growth rates of children who fall below the 3rd or above the 97th percentiles, and they do not take the timing of puberty into consideration. In general, healthy children between the ages of 2 years and the onset of puberty should be growing on a given percentile or parallel to the curve. Crossing percentiles, or failing to grow parallel to the curve, warrants further investigation. Abnormal growth patterns can be the first manifestation of systemic disease unrelated to a hormonal or genetic etiology. A thorough history and physical examination, and appropriate laboratory investigation are indicated in all children who fail to grow normally. In this chapter, we will limit the discussion of pathological growth to genetic and hormonal etiologies, and briefly
C h a p t e r 2 Sexual Development, Growth, and Puberty in Children l
mention skeletal and environmental etiologies. Systemic disease resulting in poor growth will not be discussed. Genetic Etiologies of Short Stature Familial Short Stature and Constitutional Delay of Growth Evaluation of a child’s growth pattern must consider the parents’ heights and childhood growth patterns. Calculating the target height (mean parental height 6.5 cm for boys and 6.5 cm for girls) and comparing it to the child’s calculated predicted height (based on bone age) helps in the assessment. When the child’s growth pattern and potential are deviant from that of the parents and siblings, further evaluation is indicated. In both genetic and constitutional short stature, children are of normal size at birth, and grow at a normal velocity, but usually below the 3rd percentile (starting at about age 2 years). The child with genetic short stature will show a pubertal growth spurt at the expected age. In contrast, a child with constitutional delay will continue to grow at the usual prepubertal rate of growth and thus seem to fall below his or her usual growth curve until he or she begins the pubertal acceleration of growth at a later chronological age. The bone age is age appropriate in familial short stature, but retarded in constitutional delay. Final adult height is characterized by short stature in genetic short stature but may be normal in constitutional delay. In most cases of both constitutional delay and familial short stature, an extensive diagnostic evaluation and therapeutic intervention are not indicated. However, in cases where the height prediction is poor, or significantly below target height, laboratory investigation, and subsequent hormonal therapy may be indicated. In a few instances evaluation may document molecular genetic abnormalities or abnormalities in the growth hormone (GH)/insulin-like growth factors (IGF) receptor axis.25 Boys with constitutional delay of growth (and puberty) usually respond to treatment with oral oxandrolone or to a limited course of monthly testosterone injections with a rapid improvement in growth velocity, as well as improved self-esteem. Short courses of androgen therapy in boys are not thought to have an impact (positive or negative) on final height.33,34 Estrogen receptor blockers (aromatase inhibitors) are currently being investigated for use in boys to delay progression of bone age and to augment final heights.35 Although oxandrolone has been used successfully (in conjunction with growth hormone) to augment growth in girls with Turner syndrome,36 it has not been studied for treatment of constitutional short stature in otherwise normal girls. In girls with constitutional delay of growth, treatment with estrogen also is not used, mainly because of concerns about its effect on final height. Estrogen promotes epiphyseal closure (in males and females),37 and estrogen therapy may cause rapid bone age advancement and subsequent
23
shorter final heights. Estrogen receptor blockers are not being studied in females because of concerns about iatrogenic virilization due to elevated testosterone levels with inhibition of aromatase. Intra-uterine growth retardation may be caused by intrinsic abnormalities in the fetus, as seen in a number of genetic syndromes (e.g. Russell Silver syndrome, Seckel syndrome, Noonan syndrome, Cockayne syndrome, Bloom syndrome) or may be the result of maternal disorders or multiple gestation. No matter what the etiology, if these infants do not demonstrate adequate catch-up growth by age 3 years, they may benefit from treatment with growth hormone (Food and Drug Administration (FDA) approved for this purpose). Chromosomal Abnormalities In both boys and girls, when abnormal linear growth is accompanied by the presence of dysmorphic features, the possibility of a major chromosomal abnormality should be considered and a karyotype should be performed. Examples of major chromosomal abnormalities associated with short stature are trisomy 21 (Down syndrome), trisomy 18, and trisomy 13. In boys, trisomy of the sex chromosomes (47 XXY, Klinefelter syndrome) is associated with tall stature. Deletion of the X chromosome in girls (45,XO, Turner syndrome) is invariably characterized by short stature. All short girls with unexplained poor growth and short stature should have a karyotype to rule out Turner syndrome. Mosaicism for Turner syndrome also can be characterized by short stature, even without the presence of other dysmorphic features. Molecular genetic research has attributed the short stature seen in X chromosome deletions to haploinsufficiency of the short stature homeobox (SHOX) gene on the X chromosome. Treatment with growth hormone has been shown to increase growth velocity and final height in girls with Turner syndrome (and its mosaic forms), and is another FDA-approved indication for the use of growth hormone in children. As mentioned earlier, androgen therapy combined with growth hormone augments growth velocity as well as final height in girls with Turner syndrome. Although estrogen combined with growth hormone would be a more physiologic approach, there is concern that early estrogen replacement could cause more rapid epiphyseal maturation, and have a negative impact on final height. Recent studies have shown that when very low dose estrogen is administered systemically to young girls with Turner syndrome, height potential is preserved.38 Early estrogen therapy has also been shown to improve cognitive function.39 Prader–Willi syndrome, characterized by neonatal hypotonia, short stature, and obesity, is frequently associated with partial deletions or uniparental disomy of chromosome 15. Growth hormone therapy has been shown to improve growth as well as body composition in these children, and is also FDA approved for this purpose.
24
s e c t i o n 1 Gender and Normal Development l
Hormonal Etiologies of Short Stature Hypothyroidism Insufficient levels of thyroid hormone will cause inappropriately slow growth in children. This is true regardless of the etiology of thyroid hormone deficiency. In cases of congenital hypothyroidism, timely replacement therapy with thyroid hormone can prevent mental retardation and result in normal growth. Permanent brain damage can occur if thyroid hormone replacement is delayed. Acquired hypothyroidism, presenting later in childhood, is characterized by fatigue, constipation, dry skin, weight gain, and mental slowness, in addition to growth failure. The growth failure associated with hypothyroidism is almost always associated with a delay in bone age. Replacement therapy with thyroid hormone results in catch-up growth, restores the child to a normal growth pattern, and resolves the other signs and symptoms of hypothyroidism, including cognitive manifestations. Thyroid hormone deficiency will modify growth hormone response to provocative stimuli during testing for growth hormone deficiency, so it is important to rule out hypothyroidism prior to testing children for growth hormone deficiency.40 Cortisol Excess Excess cortisol, whether its source is endogenous or exogenous, will inhibit linear growth in children. Although endogenous oversecretion of cortisol (due to hypothalamic, pituitary or adrenal pathology) is rarely seen in pediatrics, exogenous, or iatrogenic Cushing’s syndrome is not uncommon. High dose glucocorticoids are an integral part of the therapeutic regimen for certain childhood diseases (some examples are: asthma, malignancies, autoimmune diseases, post-transplantation), and will cause Cushing’s syndrome. Replacement dose glucocorticoids used to treat adrenal insufficiency and congenital adrenal hyperplasia must be carefully adjusted to prevent overtreatment and subsequent iatrogenic growth suppression. Growth failure is common in children on high dose steroids. Poor linear growth also may be associated with excessive use of inhaled and topical steroids.41 Chronically elevated glucocorticoid levels, even when only slightly elevated, will interfere with the complex interactions between growth hormone (GH), insulin-like growth factors (IGFs), and bone metabolism. Normal growth patterns may resume when glucocorticoid levels are restored to the normal range, or when alternate day steroids are given. Growth hormone treatment has been reported to help normalize growth in children who must be kept on chronic steroids for treatment of their underlying disease.42 Growth Hormone Deficiency As pituitary growth hormone secretion depends on stimulatory hypothalamic releasing factors, deficiency of growth hormone can result from congenital malformations or destructive processes involving the hypothalamus or pituitary
(organic causes), or may be idiopathic. Both boys and girls with isolated growth hormone deficiency have proportional short stature, poor growth rates for their age and pubertal stage, delayed bone ages, abnormal body composition (increased body fat), and abnormally low growth hormone values during stimulation testing. The majority of children thought to be deficient in growth hormone (levels less than 10 ng/ml on pharmacologic stimulation testing) have no other pituitary hormone deficiencies and no abnormalities of the pituitary or hypothalamus on brain imaging. Children with GH deficiency by testing in childhood may have normal GH stimulation tests when repeat testing is done after years of exogenous GH therapy.43 As sex steroids play a role in GH responsiveness, some endocrinologists advocate priming prepubertal and early pubertal children with sex steroids prior to assessing their GH secretory ability. A majority of pediatric endocrinologists do not solely consider low GH levels post stimulation testing (with or without sex steroid priming) sufficient reason to treat a child with GH therapy. Poor growth velocity, poor predicted height, and low IGF-1 levels are also taken into consideration when deciding which children to treat.44 The congenital anomalies associated with growth hormone deficiency range from major malformations of the brain (e.g., holoprosencephaly) associated with multiple pituitary hormonal deficiencies, to minor malformations of the brain (e.g., isolated absence of the septum pellucidum) associated with only growth hormone deficiency. In congenital malformations causing growth hormone deficiency, where specific genetic mutations have been found, most are characterized by autosomal recessive inheritance, and are seen with equal frequency in both sexes.45 In cases of organic deficiency of growth hormone due to trauma, brain tumors, or brain irradiation, the incidence is similar for boys and girls, unless the underlying type of brain tumor is more commonly seen in one sex. Treatment of growth hormone deficiency with exogenous growth hormone results in improvement in growth velocity and final height. A preponderance of boys has been observed in most groups of patients treated with growth hormone, regardless of the etiology of the GH deficiency. It is likely that this reflects an ascertainment bias, as more boys than girls are referred for evaluation of short stature.46–48 When GH deficiency persists through adolescence into adulthood, ongoing lifelong therapy with GH is indicated to maintain bone health and body composition. The GH replacement dose is much lower in adults than in children; adult females may require higher replacement doses of GH than adult males.49 Growth Hormone Insensitivity Laron and colleagues first described peripheral resistance to growth hormone.50 Children with growth hormone insensitivity have the phenotypic appearance of growth hormone
C h a p t e r 2 Sexual Development, Growth, and Puberty in Children l
deficiency, but have normal or elevated levels of growth hormone when tested. A variety of GH receptor defects and IGF receptor defects have been found to cause GH insensitivity. Bioinactive GH as well as GH insensitivity caused by circulating antibodies to GH and its receptor also have been described. GH insensitivity has been an area of fertile molecular genetic research over the past decade. Children with insensitivity to GH do not respond to growth hormone therapy, but some will respond to treatment with IGF-1. In 2005, IGF-1 was approved by the FDA to treat children with short stature due to severe primary IGF-1 deficiency.51 Growth Failure Associated with Skeletal Disorders Genetic abnormalities in the formation of cartilage and bone (osteochondrodystrophies) result in profound compromise of stature associated with abnormal body proportions. The disproportion is readily apparent on physical examination, although the various osteochondrodystrophies may affect the growth of the limbs and trunk differently. Identification of the particular disorder causing the growth failure is based on radiological criteria and can be difficult. Only a few of the genetic mutations underlying these disorders have been identified. Of the many osteochondrodystrophies identified, achondroplasia is the most common. It is an autosomal dominant disorder involving a mutation in the gene for the fibroblast growth factor receptor 3 (FGFR3) on the short arm of chromosome 4. Although the growth of the limbs is characteristically affected, changes are seen also in the skull, vertebral column, and pelvis. Infants homozygous for the defect are very severely affected and usually die in infancy from respiratory compromise due to thoracic abnormalities. Heterozygous infants can appear quite normal at birth, and may not be identified for several months until the progressive growth disturbance becomes clear. There is severe short stature with shortening of the bones of the arms and legs proximally more than distally (rhizomelia), a short trunk and a significant lumbar lordosis due to vertebral abnormalities. The head is disproportionately large for the body; the involvement of the facial bones leads to a characteristically flat profile. The foramen magnum is small, which may lead to hydrocephalus, and vertebral compressions may cause significant nerve injuries. Growth charts for achondroplastic children are available. The average final height of achondroplastic males is 131 cm and females 124 cm.52 Growth Failure Secondary to Environmental Factors Internal Environment Normal growth requires a normal metabolism and adequate nutrition. Conditions associated with disturbances in metabolism or deficiencies of essential nutrients can lead to failure to thrive and stunted growth. Such disorders affect both sexes equally.
25
Chronic anoxia seen in some forms of congenital cyanotic heart disease is associated with impaired growth, due to an inadequate supply of the oxygen needed for normal energy metabolism, and also to the poor nutritional intake of these severely compromised children. Acidosis secondary to chronic renal failure leads to a significant and characteristic growth failure, associated with an increase in the IGF binding proteins resulting in less free IGF I available for local action on bone growth plates. Protein-calorie malnutrition is an alarming cause of stunted growth worldwide. Malabsorption syndromes like celiac disease or protein-losing enteropathies like regional ileitis lead to secondary growth failure. The various forms of rickets, either secondary to nutritional deficiency of vitamin D or to genetic disorders of vitamin D or calcium metabolism, will result in malformation of the long bones and stunting of their growth. Improving oxygenation, nutrition, and metabolism can improve growth in these children. Exogenous growth hormone has been shown to stimulate growth in children with chronic renal failure and is FDA approved for this indication. External Environment Profound failure to thrive with dramatic growth failure can be seen in both sexes, although more often in boys, in association with psychological stresses caused by an emotionally hostile psychosocial environment. This syndrome is known as psychosocial dwarfism or the emotional deprivation syndrome. In addition to growth failure, children with this syndrome sometimes have a set of bizarre behavioral disturbances, including hyperactivity, drinking out of toilet bowls, and eating garbage. A significant number of these children will test as growth hormone deficient when first seen, but GH secretion will normalize spontaneously and growth will start again when the children are removed from the hostile environment.53,54 Anorexia nervosa, a form of self-induced starvation, can be associated with growth failure and pubertal arrest. It occurs predominantly in girls at the time of puberty, but it is seen in boys also. Although GH may be normal, IGF-1 as well as follicle stimulating hormone (FSH) and LH are inappropriately low. Weight gain restores growth and hormone levels to normal, but resumption of pubertal progression may lag behind improvement in nutritional status for months or even years.
Puberty Puberty is the transitional period between the juvenile state and adulthood during which the adolescent growth spurt occurs, secondary sexual characteristics appear (resulting in the striking sexual dimorphism of mature individuals), fertility is achieved, and profound psychological changes take place. (M.M. Grumbach3)
26
s e c t i o n 1 Gender and Normal Development l
Normal Puberty The greatly increased secretion of gonadal hormones in puberty leads to dramatic physical, intellectual, and behavioral differences between the sexes. The adrenal cortex and the gonad are the major organs involved in sexual development. The maturation of the gonads is known as gonadarche, the maturation of the adrenal cortex as adrenarche. Puberty generally refers to the physical changes resulting from gonadarche. There is a marked sex difference in the timing of puberty. Girls enter puberty and complete it about two years earlier than boys. Adrenarche is the earliest pubertal phenomenon in both sexes. Beginning at a skeletal maturation of about 6 in girls and 7 in boys, the androgen-producing zona reticularis of the adrenal cortex increases in size and becomes increasingly sensitive to ACTH. In response to ACTH the adrenal cortex secretes increasing amounts of adrenal androgens, primarily dehydroepiandrosterone sulfate. The physical manifestations of adrenarche are oiliness of the skin, apocrine odor, axillary and pubic hair, and the pigmentation of perineum or scrotum and breast areolae. In girls, as puberty progresses the maturing ovary also secretes androgens, primarily androstenedione. In adult women low levels of testosterone are secreted by both the adrenal cortex and the ovary, but the major hormones responsible for sexual hair, odor, and sebaceous gland function in women are still the adrenal androgens. In pubertal and mature men the effects of the adrenal androgens, although present, are masked by the much stronger virilizing effects of the potent testicular androgen, testosterone. In both sexes, at the physiological levels seen in normal adrenarche, the adrenal androgens are too weak to cause a growth spurt or influence bone maturation. In puberty (gonadarche) the ovaries and testes mature, secrete characteristic hormones, estrogen and testosterone, and initiate the processes leading to fertility. The onset of puberty is marked by a maturation of and disinhibition of the central nervous system (CNS) hypothalamic–pituitary– gonadal (HPG) axis. This axis is also known as the gonadostat, a term reminiscent of a thermostat in recognition of the sensitive system of feedback regulation between the central hypothalamic and pituitary hormones (the furnace) and the gonadal sex steroids (the heat level). The gonadostat is in place early in gestation in both sexes. By the 16th week of gestation, pituitary FSH and LH levels reach postmeno pausal levels and the testis of the male fetus secretes high levels of testosterone comparable to those of adult men. The fetal ovary responds little, if at all, to the gonadotropins. Later in gestation, gonadotropin concentrations fall to low levels probably in response to placentally derived estrogen present in both sexes throughout gestation. After birth, the male infant, but not the female, has a 10fold surge of LH and an increase of testosterone in response to it.3 This surge subsides in a few days but a secondary
rise in LH and testosterone begins in the second week after birth and increases to a peak testosterone in the second month of life comparable to levels seen in early puberty. This so-called ‘minipuberty of infancy’55 is transient, and by 6 months of age LH and testosterone have fallen to the low levels seen throughout childhood. Female infants from the first week of life show a gradual rise in FSH and LH (and to a lesser extent estradiol) which peak in the 2nd month of life and then subside to low childhood levels. In both sexes, as inhibitory neural connections mature, the HPG axis is gradually suppressed and under normal circumstances remains almost fully suppressed from the age of 1–2 years throughout childhood (the so-called ‘juvenile pause’.). Inadequate neural maturation due to CNS disease can result in inadequate inhibition of the HPG axis and subsequent sexual precocity. Even during the ‘juvenile pause’ the HPG axis is not totally quiescent. Very small pulses of FSH and LH can be measured in both sexes. Although the frequency of pulses through childhood is the same in both sexes, the FSH pulse amplitude is slightly higher in girls and the consequent secretion of estrogen may explain the small but definite differences in body composition between prepubertal boys and girls.56 Neither the mechanism of suppression of the GnRH pulse generator at the beginning of the ‘juvenile pause’ nor the process of its disinhibition that heralds the onset of puberty is understood. Genetic and nutritional factors, chronic disease, and race influence the age of onset of puberty. Recent evidence suggests that the hormone leptin and, at least in girls, the percent of body fat, may have a permissive effect on the onset of puberty. Once triggered, the process of puberty starts with a marked increase in the amplitude of the pulses of gonadotropin-releasing hormone (GnRH) secreted by the hypothalamus into the hypothalamic-pituitary circulation, causing an increased synthesis and secretion of FSH and LH by the anterior pituitary. The first measurable phenomenon associated with puberty is a dramatic increase in the amplitude of the pulses of FSH and LH in the circulation. At first these large pulses are seen only at night associated with sleep. Later in puberty large pulses of gonadotropin can be measured approximately every two hours throughout the 24 hours, although still with a diurnal variation which persists until late puberty and adulthood. In response to the increased levels of FSH and LH, the ovaries and testes mature and secrete increasing amounts of hormone, in the case of ovaries primarily estrogen but also small amounts of testosterone, and in the case of testes primarily testosterone but also small amounts of estrogen. The increasing levels of estrogen and testosterone in turn cause characteristic secondary sexual changes and an increased velocity of linear growth (the pubertal growth spurt). The gonadal hormones are in large part responsible for the rapid growth of puberty, and in both sexes estrogen is necessary for the maturation and eventual fusion of the epiphyses of the bones, which marks the attainment of adult stature.37
C h a p t e r 2 Sexual Development, Growth, and Puberty in Children l
The first physical sign of puberty in girls is more often breast development than pubic hair, but adrenarche and gonadarche usually occur within 6–12 months of one another. Race influences the age of onset of puberty in girls. For black girls the average age of breast development and pubic hair is about 9½ years and for white girls 10–10½ years. The lower limit of the normal age for the onset of puberty in girls remains controversial. Although recent studies have suggested a significantly lower age for the normal onset of puberty in girls,57,58 the consensus is still that the lower limit of the normal onset of puberty in girls is 8 years.59,60 In developing girls, an increase in fat accumulation and its distribution to the hip and abdominal area result in the characteristic mature female contours. Estrogenization of the perineal area results in hypertrophy of the labia minora. Activation of the mucoid glands of the vagina mirrors maturation of the uterus and estrogenization of the uterine lining; a mucoid vaginal discharge presages the onset of menstruation (menarche). The average age of menarche is about 12 years 8 months in white girls, a few months earlier in black girls. Menarche normally occurs within 2–3 years of the onset of puberty. Regular menstrual cycles and consistent ovulation occurs usually within 1 year of menarche. The ‘secular trend’ refers to the observation that, in economically developed countries over the past 100–200 years, there has been a general trend to earlier sexual maturation and, to a lesser extent, an increase in the average adult size of both men and women. The age at menarche in Western countries had decreased until recently by an average of 3–4 months every decade since the 1850s. The major factors responsible for the secular trend are better nutrition and a lessening of disease. Once the optimal state of general nutrition in a society has been reached, the secular trend levels off. This has happened in the United States and the age at menarche has not changed significantly in a few decades.61 Soon after breast buds appear, girls start their pubertal growth spurt. Major growth is complete and bone fusion well under way by the time of menarche. Following menarche girls normally grow about 5 cm more before total bone fusion occurs and adult height is reached at about 16 years.62 In boys, the first physical sign of puberty is almost always testicular enlargement, which occurs at an average age of 11–12 (lower limit, 9 years) and is followed in a few months by the appearance of pubic hair. In response to the potent virilizing effects of increasing levels of testosterone, the scrotum thins and becomes pendulous and penile dimensions increase. Muscle mass and strength increase, particularly in the upper body, resulting in the characteristic ‘triangular’ male body contour dominated by shoulders and chest. Voice change and the appearance of facial hair occur later in puberty, at about age 15. Spermatogenesis begins at about 13½. The pubertal growth spurt starts also at about 13½ and reaches its maximum velocity at 14–15. Total bone fusion occurs and adult height is reached at
27
an average age of 18.63 Because they have more years of prepubertal growth and a longer and greater pubertal growth spurt, adult males are on average about 12.5 cm taller than adult females.57,61,64 The stage of pubertal development is described through the use of Tanner scoring for breast development in girls, testicular enlargement in boys, and the amount and distribution of pubic hair in both. Tanner I is prepubertal; Tanner II, early puberty; Tanner III, mid puberty; Tanner IV, late puberty; and Tanner V, adult. The breasts or testes, and the pubic hair, are scored separately because they reflect different aspects of sexual development – that is, the gonadarche and adrenarche respectively.62,63
Variants of Pubertal Development The question of abnormal puberty arises when the first signs of sexual development appear at too young or too old an age, when puberty progresses too rapidly or too slowly, when it is incomplete, or when there is evidence of heterosexual development. Because the timing, pace and quality of pubertal development vary greatly in normal children, deciding when to evaluate a child for possible pathologic variation can be challenging. The following clinical scenarios require investigation in boys: signs of puberty before the age of 9 years; no signs of puberty by age 14; heterosexual development at any age; incomplete pubertal development; abnormally slow or rapid progression through puberty. In girls, clinical scenarios requiring investigation are similar to those in boys. In girls, however, as mentioned earlier, there is some controversy about the lower limit of normal for the onset of puberty.57,58,65,66 Clinical investigation is always indicated in white girls when the onset of puberty is before age 7 years, or before age 6 years in black girls. Deciding whether clinical investigation should be undertaken when the onset of puberty is between the age of 7 and 8 in white girls, or 6 and 8 in black girls, requires careful clinical judgment. Relatively early pubertal onset can be a benign familial pattern; a detailed family history and physical exam are always indicated in such cases. Referral to a pediatric endocrinologist should be made when the clinician has any doubts about the possibility of a pathologic etiology. Investigation is also indicated in girls when there are no signs of puberty by age 13, when pubertal development is incomplete (e.g. absence of menarche despite adequate feminization), or if there are signs of heterosexual development (e.g. clitoromegaly, virilization) at any age. Premature Pubarche and Premature Adrenarche Premature pubarche is characterized by the appearance of pubic hair (and sometimes also axillary hair and odor) several years prior to the onset of true puberty. Premature adrenarche describes the biochemical and hormonal milieu characteristic of early puberty (Tanner II). In premature
28
s e c t i o n 1 Gender and Normal Development l
pubarche, pubertal levels of adrenal androgens (dehydroepiandrosterone and its sulfate) can often be demonstrated. Premature adrenarche is the most common cause of premature pubarche. Children with premature pubarche may have a mild growth spurt associated with bone age advancement of up to 2 years greater than chronological age. Despite the advancement in bone age, final height usually is not compromised in this condition, and true puberty (maturation of the HPG axis) occurs at the normal time. This condition occurs more frequently in girls than in boys, and also may be associated, in girls, with other endocrine abnormalities at a later age. Menstrual irregularities, hirsutism, glucose intolerance, insulin resistance, and obesity occur with increased frequency in women who have a history of premature adrenarche.67 Pathological conditions (e.g. late-onset congenital adrenal hyperplasia, polycystic ovary syndrome, virilization of any etiology) can present with premature adrenarche. Appropriate testing and therapeutic intervention are necessary when clinical signs are progressive. Premature Thelarche Premature thelarche is characterized by the appearance of breast development in girls before the onset of true puberty. It is unaccompanied by signs of androgen effect (i.e., neither pubic nor axillary hair is noted). When premature thelarche occurs in a female infant, it is usually transient. When it is first seen in the toddler years, it may regress or persist until the onset of true puberty. In most girls with premature thelarche, subtle elevations in baseline and stimulated levels of FSH and estrogen can be demonstrated, as well as an increased number of ovarian microcysts. LH levels remain prepubertal until the onset of true puberty. Despite these findings, bone maturation usually is not advanced, and adrenarche and menarche occur at a normal time. Girls with premature thelarche must be followed, as breast development may be the first sign of true precocious puberty or ovarian pathology. Pubertal Gynecomastia Pubertal gynecomastia occurs in almost half of normal boys during Tanner stages II to IV of pubertal development. It is seen more frequently in obese boys, and weight loss can sometimes ameliorate the condition. When gynecomastia occurs before the onset of puberty, or when it persists after the completion of puberty, a diagnostic evaluation is indicated. The etiologies of pre- and postpubertal gynecomastia are myriad, and include conditions that result in inadequate testosterone action (due to low active hormone levels or receptor abnormalities) or excessive estrogen action. Elevations in prolactin or HCG levels, drug reactions, exposure to exogenous estrogens or substances with estrogenic activity,68 hepatic insufficiency, and sex chromosome abnormalities (e.g. Klinefelter syndrome, 47,XXY) should be considered in the evaluation of non-pubertal
gynecomastia. Treatment of persistent or severe gynecomastia is usually surgical. Medical therapy with aromatase inhibitors usually is not effective.69 Constitutional Delay of Puberty Constitutional delay of puberty is characterized by late maturation of the HPG axis in an otherwise normal child. Constitutional delay is seen more often in boys than in girls. Approximately 1% of normal boys will have constitutional delay and will enter puberty spontaneously after 14 years of age. There is often a family history of late menarche in the child’s mother, or late puberty with growth continuing into the late teens or early twenties in the child’s father. Children with constitutional delay tend to be short for age and have delayed skeletal maturation, but growth velocity is in the normal prepubertal range and predicted heights are usually appropriate. When there are no signs of puberty in girls over age 13 years, and boys over age 14 years, an endocrine evaluation and appropriate intervention are indicated. It is sometimes difficult to differentiate between constitutional delay of puberty and true gonadotropin deficiency (hypogonadotrophic hypogonadism.) An 8:00 a.m. testosterone level greater than 20 ng/dl in a boy with a prepubertal physical exam predicts the onset of spontaneous puberty within a year in most cases.70 In boys with pubertal delay, a short course of monthly low dose IM testosterone may be helpful in differentiating constitutional delay from hypogonadotrophic hypogonadism. In constitutional delay, puberty often progresses when the IM testosterone is discontinued, and in hypogonadotrophic hypogonadism, it does not. In girls, measurement of gonadotropins and estradiol will help differentiate constitutional delay from primary ovarian failure, but not from true gonadotropin deficiency. GnRH stimulation testing may be helpful in both sexes. If a pubertal rise in LH is documented during testing, it is likely that clinical evidence of puberty will ensue.
Abnormal Puberty True (complete) Precocious Puberty in Boys True (complete) precocious puberty in boys is defined as the onset of maturation of the HPG axis before age 9. Clinically, this is characterized first by bilateral testicular growth, and the appearance of sexual hair. A morning testosterone level of 20 ng/dl is consistent with early puberty. Supporting laboratory evidence of early puberty includes a pubertal rise in gonadotropins after stimulation with GnRH. Idiopathic true precocious puberty is a diagnosis of exclusion in boys, as the majority presenting with true puberty before 9 years will be found to have a pathologic neurological etiology.71 Lesions causing increased intracranial pressure or lesions destructive to the posterior third ventricle interfere with the normal prepubertal inhibition of gonadotropin secretion and can cause sexual precocity. Because of this, the evaluation
C h a p t e r 2 Sexual Development, Growth, and Puberty in Children l
of true precocious puberty must be extensive and always include imaging of the brain. Hamartomas, gliomas, astrocytomas, ependymomas, germinomas, and choriocarcinomas are some tumors that can present with precocious puberty. Neurofibromas, granulomas, suprasellar or subarachnoid cystic lesions, congenital malformations of the brain, head trauma, and hydrocephalus all can result in disinhibition of the gonadostat, and the subsequent development of precocious puberty. Both boys and girls with neurodevelopmental disabilities and meningomyelocele are at increased risk for precocious pubertal development.72,73 Prepubertal boys exposed to androgen from any cause may develop precocious puberty due to premature disinhibition of the HPG axis. This can be seen clinically in boys with congenital adrenal hyperplasia, androgen-secreting tumors, or in boys who have received androgens for treatment of unrelated diseases. Once the underlying etiology is determined and addressed, treatment of true precocious puberty entails suppression of the HPG axis with potent GnRH analogs. Incomplete Precocious Puberty in Boys Incomplete precocious puberty in boys is characterized by clinical signs of virilization without maturation of the HPG axis. Testosterone levels are high for age, but pituitary gonadotropin response to GnRH is prepubertal (suppressed). In the absence of gonadotropin release, most boys with incomplete precocious puberty will not have testicular enlargement. An exception to this may be found in boys with CAH who often have asymmetric enlargement of testicular adrenal rests. Familial gonadotropin-independent sexual precocity (testotoxicosis) is a sex-limited autosomal recessive disorder, affecting only males, caused by an activating mutation of the LH receptor of the testis, and characterized by premature maturation of testicular Leydig cells, bilateral testicular hypertrophy, and testosterone secretion.74 Gonadotropin levels are suppressed to prepubertal levels, and treatment with GnRH analogs is ineffective. Drugs that interfere with testosterone synthesis and action (e.g., ketoconazole, testolactone, spironolactone) have been used effectively in treatment of this disorder.75,76 There are tumors that secrete HCG, the LH-like action of which will also stimulate testicular Leydig cell growth. The testes are bilaterally enlarged in this condition, but not as large as would be expected in normally progressing puberty or in testotoxicosis. HCG secretion has been described in a number of tumors, including hepatomas, hepatoblastomas, teratomas, chorioepitheliomas, and germinomas. Boys with inadequately treated congenital adrenal hyperplasia due to P450c21 or P450c11 deficiency have excessive adrenal androgen production from both the adrenal glands and any testicular adrenal rest cells, if present. The testicular adrenal rests can become quite large under ACTH stimulation, and result in bilateral irregular testicular enlargement. Treatment consists of adequate suppression of ACTH with
29
exogenous glucocorticoids, although once enlarged, testicular adrenal rests may become autonomous. If this condition progresses to true (gonadotropin dependent) precocious puberty, treatment with GnRH analog is indicated. Adrenal and testicular tumors can be virilizing or feminizing, and the clinical picture is determined by the hormones made by the tumor. In adrenal tumors characterized by masculinization, phallic enlargement is present without testicular growth. Testicular tumors cause unilateral, irregular testicular growth associated with virilization and phallic enlargement. The uninvolved testis remains prepubertal in size. The McCune–Albright syndrome was initially described as the clinical triad of polyostotic fibrous dysplasia, café au lait spots and precocious puberty.77 Other signs of autonomous endocrine dysfunction involving the pituitary, adrenal and thyroid glands have since been described in these patients. Activating somatic mutations in G-protein structure have recently been found to cause this unusual syndrome, which is more common in girls.78 Boys with precocious puberty due to McCune–Albright syndrome may initially have asymmetrically enlarged testes due to autonomous testicular function; maturation of the hypothalamic–pituitary axis and true precocious puberty with associated bilateral testicular enlargement can ensue. Treatment is with drugs that inhibit testosterone synthesis or action, or with GnRH analogs if indicated. Incomplete sexual precocity also can be caused by exposure to exogenous androgens, either orally, transdermally or parenterally. Testes are always prepubertal in size when virilization is due to exogenous androgens. Removal of the source of androgen will result in cessation of progression of virilization, unless the exposure was prolonged enough to result in maturation of the gonadostat, and cause true precocious puberty. True (complete) Precocious Puberty in Girls True (complete) precocious puberty in girls is defined as premature maturation of the HPG axis, with a characteristic pubertal rise in serum LH levels on stimulation testing with GnRH. The exact age at which puberty is considered to be premature in girls has been addressed earlier in this section, with the lower limit of normal ranging from 6 to 8 years. Unlike precocious puberty in boys, where underlying pathology is diagnosed in the majority of cases, over 95% of cases of true precocious puberty in girls are idiopathic, and no underlying pathology is found. Idiopathic true precocious puberty is seen with increased frequency in adopted children, possibly related to the nutritional changes in their new environment, and subsequent changes in body composition and leptin levels.79–80 When a pathologic etiology is found, it is usually neurologic, as in boys. Any intracranial condition can cause true precocious puberty by interfering with neurogenic inhibition of the HPG axis.81 Even though no pathologic etiology for precocious puberty is found in most girls, imaging of the
30
s e c t i o n 1 Gender and Normal Development l
brain is indicated as part of the evaluation because intracranial pathology may be present. Conditions associated with complete precocious puberty in girls include: hydrocephalus, cerebral palsy, congenital malformations of the brain, irradiation, and trauma. Although any intracranial mass can present with precocious puberty, optic gliomas (often seen in neurofibromatosis type I), hypothalamic hamartomas, and pineal tumors are most frequently associated with precocious puberty in girls. Premature hypersecretion of gonadotropins due to untreated primary hypothyroidism, or to primary ovarian failure, are rare causes of precocious puberty in girls.82–84 In girls as in boys, any condition (feminizing or virilizing) that accelerates somatic maturation (clinically demonstrable by significant bone age advancement), can result in true precocious puberty, even when the underlying condition is treated. Incomplete Precocious Puberty in Girls Incomplete precocious puberty in girls is characterized by premature appearance of either sexual hair or breast development, unaccompanied by laboratory evidence of maturation of the HPG axis. The LH response to GnRH stimulation testing is prepubertal. Most often, when nonprogressive isolated signs of estrogen or androgen effect are noted in girls, no pathology is found, and the diagnosis is premature thelarche or premature adrenarche, as discussed earlier. Benign ovarian cysts are the most common cause of progressive premature feminization in girls. Hormonally active solid tumors of the ovaries or the adrenals (e.g., granulosa, theca cell, Leydig–Sertoli cell, dysgerminomas, carcinomas) present with premature feminization or virilization, or a mixed picture. Progression of pubertal signs may be rapid. The treatment is usually surgical removal of the tumor. If the condition has caused marked bone age advancement and subsequent true precocious puberty, treatment with a GnRH agonist is also indicated. Gonadoblastomas are seen primarily in girls with dysgenetic gonads containing Ychromosome material. Girls with mixed gonadal dysgenesis or Turner syndrome mosaicism with a Y chromosome fragment should have bilateral gonadectomies, as the incidence of gonadoblastoma in these girls is high. McCune–Albright syndrome, described earlier, is seen predominantly in females.77 In this condition gonadotropinindependent ovarian cysts secrete estrogen, with resultant feminization and bone maturation. Initial treatment is with aromatase inhibitors. If true precocious puberty ensues, GnRH agonists may be required. Late onset congenital adrenal hyperplasia can present with premature signs of androgen effect (i.e. the appearance of axillary and or pubic hair). Frank virilization is usually not seen. The diagnosis is based on adrenal enzyme levels pre- and poststimulation with ACTH. Treatment depends on the severity and type of enzyme defect, and usually includes replacement with glucocorticoids.
Exogenous sources of estrogen or androgen must be considered in the differential diagnosis. Oral contraceptives, estrogen-containing creams, and foods and vitamins containing metabolically active hormones have all been implicated in the premature appearance of secondary sexual characteristics in children. Excessive ingestion of products containing phytoestrogens (soy products, ginseng) may also cause premature feminization.85–87 When isolated vaginal bleeding is present, without evidence of breast development or maturation of the labia minora, then sexual abuse, foreign body or genital tract tumors must be considered. Virilization of young children due to transdermal absorption of androgen gels prescribed for their parents has been reported.88 Sexual Infantilism in Boys Hypogonadotrophic Hypogonadism Permanent gonadotropin deficiency can result from congenital or acquired abnormalities of the central nervous system (CNS). In boys, the congenital etiologies are often associated with small genitalia and undescended testes, as well as with delayed puberty, because gonadotropin-stimulated testosterone secretion is required for normal intra-uterine genital development. Midline defects of the brain (e.g., septo-opticdysplasia) and congenital hypopituitarism can be associated with additional pituitary hormone deficiencies. In the past decade, extensive genetic research has expanded our knowledge of specific defects in patients with heritable gonadotropin deficiency. Kallman syndrome (gonadotropin deficiency and anosmia), five times more common in males than females, has been found to have an X-linked form.89 Congenital adrenal hypoplasia, associated with gonadotropin deficiency, is inherited as an X-linked recessive.90 Prader–Willi syndrome (previously discussed) and Biedl–Bardet syndrome (autosomal recessive) are both associated with pubertal delay and gonadotropin insufficiency. Additional rarer genetic defects associated with gonadotropin insufficiency have been described, but are beyond the scope of this chapter. Acquired abnormalities of the CNS resulting in permanent gonadotropin deficiency include midline and other tumors of the brain (e.g., craniopharyngiomas, prolactinomas, germinomas, astrocytomas, gliomas), infiltrative disease of the pituitary or hypothalamus (e.g., histiocytosis X, granulomatous disease, iron deposition in thalassemia major), irradiation, and trauma. Treatment of pubertal delay caused by gonadotropin deficiency is with testosterone replacement, or with HCG. Testicular Failure (Hypergonadotrophic Hypogonadism) Testicular failure (hypergonadotrophic hypogonadism) is characterized by pubertal delay associated with low testosterone levels and elevated gonadotropins. Klinefelter syndrome (47,XXY) is the most common cause of testicular insufficiency in males. Boys with this syndrome may have
C h a p t e r 2 Sexual Development, Growth, and Puberty in Children l
pubertal delay, or lack of normal progression of puberty. Testes are small and firm. Mumps orchitis can cause testicular damage, as can Coxsackievirus B, irradiation, chemotherapy, and trauma. Bilateral undescended testes may be damaged even when early orchiopexy is performed. Treatment of all causes of delayed puberty due to testicular failure is with testosterone replacement. Sexual Infantilism in Girls Hypogonadotrophic Hypogonadism As in boys, congenital gonadotropin deficiency can be seen in midline malformations of the brain, involving the pituitary and hypothalamus. Genetic syndromes associated with obesity (e.g., Laurence–Moon–Biedel, Prader–Willi) also are associated frequently with gonadotropin deficiency. Genetic mutations affecting leptin and its receptors can present with severe obesity and hypogonadism. Kallman syndrome, mentioned earlier, is more common in males than females, due to X-linked recessive inheritance in the majority of cases.89 Rarer genetic causes of gonadotropin deficiency have been reported and most are inherited in an autosomal recessive manner. Acquired gonadotropin deficiency due to brain tumors, irradiation, trauma, inflammatory disease, and chronic illness occur with the same frequency in males and females, unless the underlying disease (e.g., specific brain tumor type) does not. Prolactin levels should be monitored, as hyperprolactinemia, often seen in elevated intracranial pressure, may cause reversible gonadotropin deficiency. Anorexia nervosa, seen more commonly in girls, is also associated with reversible gonadotropin deficiency. Primary amenorrhea is characterized by lack of menstruation by 4½ years after the onset of puberty. Such a delay suggests structural abnormalities of the uterus or vagina, and appropriate studies should be undertaken. Primary amenorrhea is seen in healthy athletic girls with low total body fat; increasing fat intake usually results in menarche. Menarche is also delayed in girls with anorexia, and can be delayed for years even after normal weight is achieved.80 Ovarian Failure (Hypergonadotrophic Hypogonadism) In hypergonadotrophic hypogonadism, low sex hormone levels are accompanied by elevated gonadotropin levels. In girls with delayed puberty, if gonadotropin levels are elevated, the laboratory investigation must include a karyotype to rule out genetic disorders of gonadal development. Disorders of androgen synthesis in genetic males can present as delayed puberty in a phenotypic female. Genetic males who have complete androgen insensitivity can mature sexually in response to testicular estrogens and not infrequently present as a female with primary amenorrhea. Primary ovarian failure may be complete or partial. In this condition girls may start but not progress through
31
puberty, or they may present with complete sexual infantilism. The most common cause of primary ovarian failure in girls is gonadal dysgenesis (Turner syndrome) characterized by complete (45,X0) or partial deficiency of genes on the X chromosome (mosaicism for Turner syndrome is frequently found in these patients). Autoimmune oopheritis is characterized by primary or secondary amenorrhea, or premature menopause.91 These girls may have evidence of other autoimmune endocrinopathies which are seen more commonly in females than in males. Hemochromatosis due to recurrent transfusions or other causes of iron overload can result in failure or insufficiency of multiple endocrine glands (including the ovaries, testes and pituitary), and may present as lack of pubertal progression in both sexes.92 Depending on the degree of insufficiency of the glands involved, the hypogonadism may be hyper- or hypogonadotrophic. Ovarian damage due to radiation and chemotherapy given for treatment of childhood malignancies can result in primary ovarian failure, even though prepubertal ovaries are more resistant to the harmful effects of radiation and chemotherapy than mature ovaries. Treatment of both hyper- and hypogonadotrophic hypogonadism in girls consists of cyclic replacement of estrogen and progesterone in increasing doses so that pubertal development progresses as normally as possible. In well-estrogenized girls with primary amenorrhea (if pregnancy has been ruled out), a progesterone challenge may be indicated. Imaging studies can be done to rule out congenital malformations of the female genital tract (e.g., congenital absence of the uterus) and should be done if no menstrual bleeding occurs after progesterone administration. If signs of virilization are present in a girl with primary amenorrhea, the evaluation must include measurement of androgens, which, if elevated, can interfere with normal menstrual cycling. Polycystic ovary syndrome is the most common cause of amenorrhea in girls with normal pubertal development, oligo- or amenorrhea, and mild to moderate hyperandrogenism. When frank virilization or genital ambiguity is noted, an extensive investigation to rule out rare causes of hyperandrogenism (e.g., true hermaphroditism, or androgen-producing tumors) may be indicated.
Acknowledgments We are grateful to Sharon E. Oberfield, MD, for reviewing the manuscript.
References 1. Grumbach MM, Hughes IA, Conte FA. Disorders of sex differentiation. In: PR Larson, HM Kronenberg, S Melmed, KS Polonsky, eds. Williams Textbook of Endocrinology, 10th edn. Philadelphia, PA: W.B. Saunders; 2003:855–76, 2003:, 886–907, 934–5, 961–2.
32
s e c t i o n 1 Gender and Normal Development l
2. Barsoum I, Yao HH-C. The road to maleness: from testis to Wolffian duct. Trends Endocrinol Metab 2006;17:223–28. 3. Tilmann C, Capel B. Cellular and molecular pathways regulating mammalian sex determination. Recent Prog Horm Res 2002;57:1–18. 4. Grumbach MM. Sex begins in the womb. In: TM Wizemann, M-L Pardue, eds. Exploring the Biological Contributions to Human Health: Does Sex Matter?. Washington, DC: National Academy Press; 2001:45–72. 5. Lee PA, Houk CP, Ahmed SF, et al. Consensus statement on management of intersex disorders. International consensus conference on intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Pediatrics 2006;118(2): e488–500. 6. Donohoue PA, Panker K, Migeon CJ. Congenital adrenal hyperplasia. In: CR Scriver, AL Beaudet, WA Sly, D Vallee, eds. The Metabolic and Molecular Basis of Inherited Diseases, 8th edn. New York, NY: McGraw–Hill; 2001:4091–106. 7. Yanase T, Simpson ER, Waterman MR. 17 alpha-hydroxylase/17,20 lyase deficiency: from clinical investigation to molecular definition. Endocr Rev 1991;12:91–108. 8. Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999;84:4677–94. 9. Imperato-McGinley J, Peterson RE. Male pseudohermaphroditism: the complexities of male phenotypic development. Am J Med 1976;61:251–72. 10. Griffin JE, McPhaul M, Russel D, et al. The androgen resistance syndromes: 5 alpha reductase deficiency, testicular feminization and related disorders. In: CR Scriver, AL Beaudet, WA Sly, D Vallee, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th edn. New York, NY: McGraw–Hill; 1995:1919–44. 11. Deeb A, Mason C, Lee YS, et al. Correlation between geno type, phenotype and sex of rearing in 111 patients with partial androgen insensitivity syndrome. Clin Endocrinol 2005;63:56–62. 12. Diamond DA, Burns JP, Mitchell C, et al. Sex assignment for newborns with ambiguous genitalia and exposure to fetal testosterone: attitudes and practices of pediatric urologists. J Pediatr 2006;148:445–49. 13. Rappaport R, Forest MG. Disorders of sexual differentiation. In: J Bertrand, R Rappaport, PC Sizonenko, eds. Pediatric Endocrinology: Physiology, Pathophysiology, and Clinical Aspects. Baltimore, MD: Williams & Wilkins; 1993:447–70. 14. Money J, Devore H, Norman BF. Gender identity and gender transposition: longitudinal outcome study of 32 male hermaphrodites assigned as girls. J Sex Marital Ther 1986;12:165–81. 15. Money J, Norman BF. Gender identity and gender transposition: longitudinal outcome study of 24 male hermaphrodites assigned as boys. J Sex Marital Ther 1987;13:75–92. 16. Birnbacher R, Marberger M, Weissenbacher G, et al. Gender identity reversal in an adolescent with mixed gonadal dysgenesis. J Pediatr Endocrinol Metab 1999;12(5):687–90. 17. Reiner WG. Sex assignment in the neonate with intersex or inadequate genitalia. Arch Pediatr Adolesc Med 1997;151:1044–45.
18. Lerman SE, McAleerr IM, Kaplan GW. Sex assignment in cases of ambiguous genitalia and its outcome. Urology 2000;55:8–12. 19. Imperato-McGinley J, Peterson RE, Gautier T, et al. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency. N Engl J Med 1979;300:1233–37. 20. Rosler A. 17beta-hydroxysteroid dehydrogenase 3 deficiency in the Mediterranean population. Pediatr Endocr Rev 2006;3:455–61. 21. Hines M, Brook C, Conway GS. Androgen and psychosexual development: core gender identity, sexual orientation, and recalled childhood gender role behavior in women and men with congenital adrenal hyperplasia (CAH). J Sex Res 2004;41:75–81. 22. Jaaskelainen J, Tiitinen A, Voutilainen R. Sexual function and fertility in adult females and males with congenital adrenal hyperplasia. Horm Res 2001;56:73–80. 23. Meyer-Bahlburg HF. Gender and sexuality in classic congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001;30:155–71. 24. Sytsma S. Ethical dilemmas in retrospective studies on genital surgery in the treatment of intersexual infants. Camb Q Healthc Ethics 2004;13:394–403. 25. Tanner JM, Whitehead RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170–79. 26. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51–58. 27. Tanner JW, Davis PWS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985;107:317–29. 28. Hall JG, Froster-Iskenius UG, Allanson JE. Handbook of Normal Physical Measurements. New York, NY: Oxford University Press; 1989, 270–5. 29. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd edn. Stanford, CA: Stanford University Press; 1959. 30. Bayer LM, Bayley N. Growth Diagnosis. Chicago, IL: University of Chicago Press; 1959, 45–7. 31. Tanner JM, Whitehouse RH, Marshall WA, et al. Prediction of adult height from height, bone age and occurrence of menarche at ages 4–16 with allowance for mid-parental height. Arch Dis Child 1975;50:14. 32. Roche AF, Wainer H, Thissen D. The RWT method for the prediction of adult stature. Pediatrics 1975;56:1026. 33. Kaplowitz P. Delayed puberty in obese boys: comparison with constitutional delayed puberty and response to testosterone therapy. J Pediatr 1998;133(6):724–26. 34. Kaplowitz P. Commentary: Is growth hormone the best treatment for short stature in healthy peripubertal boys? Insights from the field of economics. Endocrinologist 2007;17(4):221–26. 35. Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases nearfinal height in boys with constitutional delay of puberty. Clin Endocrinol 2006;64:510–13. 36. Rosenfeld RG, Hintz RC, Johanson AJ, et al. Three-year results of a randomized prospective trial of methionyl human growth
C h a p t e r 2 Sexual Development, Growth, and Puberty in Children l
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51. 52. 53.
hormone and oxandrolone in Turner syndrome. J Pediatr 1986;121:45–55. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metabol 1995;80:3689–98. Rosenfeld RL, Devine N, Hunold JJ, et al. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metabol 2005;90(12):6424–30. Ross JL, Roeltgen D, Feuillan P, et al. Use of estrogen in young girls with Turner syndrome. Effects on memory. Neurology 2000;54:164–67. Sizonenko P, et al. Diagnosis and management of GH deficiency in childhood and adolescence. Growth Horm IGF Res 2001;11:137–65. Perry RJ, Findlay CA, Donaldson MDC. Cushing’s syndrome, growth impairment and occult adrenal suppression associated with intranasal steroids. Arch Dis Child 2002;87:45–48. Allen DB, Goldberg BD. Stimulation of collagen synthesis and linear growth by growth hormone in glucocorticoidtreated children. Pediatrics 1992;89(3):416–21. Radovick S, DiVall S. Approach to the growth hormone deficient child during transition to adulthood. J Clin Endocrinol Metabol 2007;92(4):1195–200. Hardin DS, Woo J, Butsch R, et al. Current prescribing practices and opinions about growth hormone therapy: results of a nationwide survey of paediatric endocrinologists. Clin Endocrinol 2007;66:85–94. Rosenfeld RG, Cohen P. Disorders of growth hormone/insulin-like growth factor secretion and action. In: MA Sperling, ed. Pediatric Endocrinology, 2nd edn. Philadelphia, PA: WB Saunders; 2002:247. Vanderschueren-Lodeweyckx M. Who is treated with growth hormone today? The executive scientific committee of the Kabi international growth study. Acta Paediatr Scand Suppl 1990;370:107–13. Root AW, Kemp SF, Rundle AC, et al. Effect of long term recombinant growth hormone therapy in 1985–1994. J Pediatr Endocrinol Metab 1998;11(3):403–12. August GP, Julius JR, Blethen SL. Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: the National Cooperative Growth Study experience. Pediatrics 1998;102:512–16. Attanasio AF, Shavrikova E, Blum WF, et al. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metabol 2004;89 (10):4857–62. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone – a new inborn error of metabolism. Isr J Med Sci 1966;2:152. FDA Center for Drug Evaluation and Research. Approval package for application number NDA 21-839. Horton WA, Rotter JI, Rimoin DL, et al. Standard growth curves for achondroplasia. J Pediatr 1978;93:435–38. Powell GF, Brasel JA, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism I: clinical evaluation of the syndrome. N Engl J Med 1967;276:1271–78.
33
54. Powell GF, Brasel JA, Raiti S, et al. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism II: endocrinologic evaluation of the syndrome. N Engl J Med 1967;276:1279–83. 55. Rosenfield R. The ovary and female sexual maturation. In: MA Sperling, ed. Pediatric Endocrinology, 2nd edn. Philadelphia, PA: W.B. Saunders; 2002;458:478–83. 56. He Q, Horlick M, Thornton J, et al. Sex and race differences in fat distribution among Asian, African-American and Caucasian prepubertal children. J Clin Endocrinol Metab 2002;87:2164–70. 57. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings Network. Pediatrics 1997;99:505–12. 58. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999;104(4 Pt1):936–41. 59. Parent AS, Teilmann G, Juul A, et al. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev 2003;24:668–93. 60. Rosenfield RL, Bachrach LK, Chernausek SD, et al. Current age of onset of puberty. Pediatrics 2000;106:622–23. 61. Grumbach MM, Styne DM. Puberty: Ontogeny, neuroendocrinology, physiology, and disorders. In: PR Larson, HM Kronenberg, S Melmed, KS Polonsky, eds. Williams Textbook of Endocrinology, 10th edn. Philadelphia, PA: W.B. Saunders; 2003:1115–70. 62. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303. 63. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23. 64. Styne DM. The testes: disorders of sexual differentiation and puberty. In: MA Sperling, ed. Pediatric Endocrinology, 2nd edn. Philadelphia, PA: WB Saunders; 2002:595–99. 65. Kaplowitz PB, Slora EJ, Wasserman RC, et al. Earlier onset of puberty in girls: relation to increased body mass index and race. Pediatrics 2001;108:347–53. 66. Papadimitriou A. Sex differences in the secular changes in pubertal maturation. Pediatrics 2001;108(4):E65. 67. Ibanez L, Potau N, Chacon P, et al. Hyperinsulinaemia, dyslipidaemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia 1998;41:1057. 68. Henley DV, Lipson N, Korach K, et al. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007;356:479–85. 69. Shulman DI, Francis GL, Palmert MR, et al. Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics 2008;121(4):e975–83. 70. Wu FC, Brown DC, Butler GE, et al. Early morning plasma testosterone is an accurate predictor of imminent pubertal development in prepubertal boys. J Clin Endocrinol Metabol 1993;76:26. 71. Sizonenko PC. Precocious puberty. In: J Bertrand, R Rappaport, PC Sizonenko, eds. Pediatric Endocrinology,
34
72.
73.
74. 75.
76.
77.
78.
79.
80.
81.
s e c t i o n 1 Gender and Normal Development l
Physiology, Pathophysiology and Clinical Aspects, 2nd edn. Baltimore, MD: Williams & Wilkins; 1993:387–403. Siddiqi SU, Van Dyke DC, Donohoue P, et al. Premature sexual development in individuals with neurodevelopmental disabilities. Dev Med Child Neurol 1999;41:392. Trollman R, Strehl E, Dorr HG. Precocious puberty in children with myelomeningocele. Treatment with gonadotropin-releasing hormone analogues. Dev Med Child Neurol 1998;40:38. Laue L, Cutler GBJ. Familial male precocious puberty. Curr Ther Endocrinol Metab 1994;5:296. Holland FJ, Fishman L, Bailey JD, et al. Ketoconazole in the management of precocious puberty not responsive to LHRHanalogue therapy. N Engl J Med 1985;312:1023. Laue L, Kenigsberg D, Pescovitz OH, et al. The treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med. 1989;320:496. McCune DJ, Bruch H. Osteodystrophia fibrosa: report of a case in which the condition was combined with true precocious puberty, pathologic pigmentation of the skin and hyperthyroidism, with a review of the literature. Am J Dis Child 1937;54:806. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688. Teilmann G, Pedersen CB, Skakkebaek NE, et al. Increased risk of precocious puberty in internationally adopted children in Denmark. Pediatrics 2006;118(2):391–99. Matkovic V, Ilich JZ, Skugor M, et al. Leptin is inversely related to age at menarche in human females. J Clin Endocrinol Metab 1997;82(10):3239–45. Junier M-P, Wolff A, Hoffman G, et al. Effect of hypothalamic lesions that induce precocious puberty on the morphological and functional maturation of the luteinizing hormone-releasing hormone neuronal system. Endocrinology 1992;131:787.
82. VanWyk J, Grumbach M. Syndrome of precocious menstruation and galactorrhea in juvenile hypothyroidism: an example of hormonal overlap in pituitary feedback. J Pediatr 1960;5:416. 83. Hemady ZS, Siler-Khodr TM, Najjar S. Precocious puberty in juvenile hypothyroidism. Pediatrics 1978;92:55. 84. Baer K. Premature ovarian failure and precocious puberty. Obstet Gynecol 1977;49:15s. 85. Saenz de Rodriguez CA, Bongiaovanni AM, Conde de Borrego L. An epidemic of precocious development in Puerto Rican children. J Pediatr 1985;107:393. 86. Setchell KD, Zimmer-Nechemias L, Cai J, et al. Exposure of infants to phyto-oestrogens from soy-based infant formula (see comments). Lancet 1997;350:23. 87. Hopkins MF, Androff L, Benninghoff AS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol 1988:121. 88. Kunz GJ, Klein KO, Clemons RD, et al. Virilization of young children after topical androgen use by their parents. Pediatrics 2004;114(1):282–84. 89. Maya-Nuanez G, Zenteno JC, Ulloa-Aguirre A, et al. A recurrent missense mutation in the KAL gene in patients with X-linked Kallmann’s syndrome. J Clin Endocrinol Metab 1998;83:1650. 90. Francke U, Harper JF, Darras BT, et al. Congenital adrenal hypoplasia, myopathy, and glycerol kinase deficiency: molecular genetic evidence for deletions. Am J Hum Genet 1987;40:212. 91. Betterle C, Rossi A, Pria S, et al. Premature ovarian failure: autoimmunity and natural history. Clin Endocrinol 1993;39:35. 92. Oerter KE, Kamp GA, Munson PJ, et al. Multiple hormone deficiencies in children with hemochromatosis. J Clin Endocrinol Metab 1993;76:357–61.
Chapter
3
Gender Differences in Pediatric Pulmonary Disease Beverley J. Sheares Associate Professor of Clinical Pediatrics, Columbia University, Pulmonary Division, Department of Pediatrics, New York, NY, USA
Introduction1
Developmental Respiratory Physiology Lung development and growth starts in the prenatal period and continues throughout early adulthood.9 Lung development proceeds through five distinct stages:10,11
There is increasing medical interest in differences between females and males in both normal lung development as well as in the incidence and expression of many pediatric lung disorders. The aim of this chapter is to highlight the influence of gender on the development, diagnosis, management, and outcomes of pulmonary diseases. While it is likely that biological, environmental, behavioral, and socio-cultural factors underlie the gender differences in respiratory disease, many of the pathophysiologic mechanisms are not well delineated. This chapter will review the anatomical, functional, and hormonal differences between the respiratory systems of females and males and delineate how changes occur from prenatal development through the adolescent years. Some common respiratory diseases with gender-specific differences will also be reviewed.
Between 3–4 weeks of gestation during the embryonic period, lung development commences as a ventral outpouching of the foregut and results in the formation of the trachea and two bronchial buds that eventually become the right and left mainstem bronchi.9,12 Airway and blood vessel branching and differentiation of epithelial cells into structures that will become submucosal glands, cartilage, and bronchial smooth muscle are the hallmarks of the pseudoglandular phase.9,12–14 Immature type II epithelial cells that will eventually produce surfactant also appear during this period. By 14 weeks gestation, 70% of the total airways that will be present at birth have formed and the entire conducting airway system is developed by the end of this phase.13 The canalicular period is heralded by the development of the pulmonary circulation and the further subdivision of distal airways. Progressive differentiation of epithelial cells into type I and type II pneumocytes occurs during this phase and by 24 weeks surfactant protein production has commenced.10,13 By the end of the canalicular phase gas exchange can be supported after birth; however, infants born during this phase are likely to have respiratory complications resulting
Prenatal lung growth Sex-related factors lead to alterations in the development and the mechanical properties of the lungs and may predispose to respiratory compromise or disease. These differences begin in the prenatal period.2–5 As early as 16–26 weeks in utero, the lungs of the female fetus are more matured.5 In the final stages of prenatal development, from approximately 26–36 weeks gestation, females have a further advantage in that surfactant production is enhanced and airway patency is increased leading to increased airflow rates in female newborns compared to males.6–8
Principles of Gender-Specific Medicine
Embryonic period (3–6 weeks post conception) Pseudoglandular period (6–16 weeks) Canalicular period (16–26 weeks) Saccular period (26–36 weeks) Alveolar period (36 weeks through adolescence)
35
Copyright 2010 20 , Elsevier Inc. All rights reserved.
s e c t i o n 1 Gender and Normal Development
36
l
from the lack of sufficient endogenous surfactant.11 The development of gas exchange units takes place predominantly during the saccular stage when terminal saccules are subdivided by ridges known as secondary crests.10,15 As the crests protrude into the saccules, capillaries are brought into close contact with the edges of the saccules in preparation for gas exchange. Maturation of type II pneumocytes occurs during this period with increased synthesis of surfactant proteins. Thereafter, in the alveolar stage, a further subdivision of the saccules into subsaccules occurs, leading to the eventual development of alveoli.15 Sex distinctions with regards to lung development and function occur during the pseudoglandular, canalicular, saccular, and alveolar periods (see Table 3.1).4–6,8 During the pseudoglandular and canalicular phases, differences between males and females with regards to fetal mouth movements and fetal breathing patterns that promote lung maturation have been detected.5,16 The canalicular and saccular periods are notable for sexual disparities in the biosynthesis and secretion of surfactant17–19 and for differing patterns of airway and alveoli development.15 Important gender differences also become apparent in the clinical manifestations of disease during the alveolar stage.
Fetal Breathing and Lung Maturation Breathing in the newborn is a result of many weeks or months of intra-uterine activity when the respiratory system transitions from moving fluid up the tracheobronchial tree to moving large amounts of air in and out of the alveoli. Given the efficiency with which changes in the lungs take place at birth, it is not likely that the respiratory system ‘attains such postnatal competence without prenatal practice.’16 Fetal breathing is also essential for lung growth Table 3.1 Stages of Lung Growth Stages of lung development
Time of Sex differences noted development during lung development
Embryonic 0–6 weeks Pseudoglandular 6–16 weeks
Canalicular
16–26 weeks
Saccular
26–36 weeks
Alveolar
36 weeks through adolescence
Fetal mouth movements and breathing advanced in females Hormonal differences are apparent and may enhance surfactant production in females Phospholipid profiles (surfactant production) of females more advanced than males by 1½ weeks Reduced risk of RDS in females Higher flow rates for a given lung volume in females infants
as well as pulmonary cellular differentiation required for functional development of the lung.20 During the intrauterine phase of development, the lungs have three distinct functions.20,21 1. A secretory role that contributes lung liquid to the intrauterine environment (amniotic fluid) in which the fetus grows. 2. Intra-uterine breathing movements that aid respiratory muscle development and pulmonary cellular differentiation. 3. Surfactant synthesis in preparation for postnatal breathing. Fetal respiratory movements were first described by Ahlfeld, a German obstetrician, in 1888, but his observations were largely ignored.3,16 In the 1940s other investigators observed fetal respiratory movements in animals at cesarean section, but attributed them to asphyxia and tactile stimulation.3,16 With the development of the A-scan ultrasound system in the early 1970s, Boddy et al. were able to detect chest wall movements in the fetus as early as 11 weeks gestation.3,16 The investigators used the technology to describe patterns of fetal breathing that delineated normal respiratory function for gestational age from fetal distress. During early fetal development, the breathing pattern is irregular and infrequent. By 24 weeks in utero breathing consists of clusters of breaths occurring periodically. A regular pattern of breathing does not usually appear until approximately 34 weeks gestation.16 When a normal pattern of breathing movements was observed 50% or more of the time, fetal distress and intrauterine or neonatal deaths were extremely rare.3,20,22 Thus, normal patterns of fetal respiratory movement suggest neonatal well-being. Decreased respiratory movement has been associated with the development of pulmonary hypoplasia.23,24 Fetal lung maturation is reflected also in fetal mouth movements. Hepper et al. demonstrated in serial sonograms taken at 16, 18, and 20 weeks gestation that fetal mouth movements increased with gestational age.5 Moreover, females had significantly more fetal mouth movements than males at each stage of development.5 Mouth movements are thought to reflect fetal breathing, a critical contributor to lung development and an indicator of fetal maturation.3,5,6 While this study made no causal inferences related to the subsequent development of lung disease in infants, it suggests that differences in pulmonary-related morbidity and mortality, as in respiratory distress syndrome (RDS) of the newborn, may be rooted in differences in lung maturation between females and males in the prenatal period.
Differences Between Males and Females in Surfactant Production In 1959, Avery and Mead reported that prematurely born infants with hyaline membrane disease had an abnormal surface tension at the air–liquid interface.25 They attributed this abnormality to a deficiency in pulmonary surfactant.
C h a p t e r 3 Gender Differences in Pediatric Pulmonary Disease l
Pulmonary surfactant, a combination of phospholipids and surface-associated proteins, produced in type II epithelial cells,26 is responsible for maintaining alveolar stability.27 Surfactant production is apparent by approximately 20 weeks gestation. By 22–24 weeks there are numerous lamellar inclusion bodies containing surfactant within the type II cells.28 Females have a more mature phospholipid profile by 26 weeks, indicating earlier production of surfactant.6,8 Although the lungs have an insignificant role in gas exchange during fetal development, they must produce enough surfactant during the prenatal period so that postnatal lung function is unencumbered. It is now well established that lung maturation as measured by surfactant protein production differs between females and males.8,29,30 As early as 1968, sex differences in the incidence and severity of RDS were recognized.18 Miller and Futrakul were the first to suggest that these differences in outcomes may be due to variations in surfactant metabolism.18 It was also postulated that male fetuses have a delay in surfactant synthesis during late gestation.6,29,31 These findings are supported by the fact that lung phospholipid profiles – lecithin/sphingomyelin (L/S) ratio, the percent of desaturated lecithin, phosphatidylglycerol (PG), and phosphatidylsitol, all markers of lung maturation – are reduced in males.6 During the saccular period of fetal lung development between 26 and 36 weeks of gestation, there is thinning of the respiratory epithelium, growth of lung acini, and the development of the capillary network necessary for gas exchange.28 Type II epithelial cells mature and biosynthesis of surfactant increases.28 Surfactant production is accelerated by a number of hormones, the best studied of which are glucocorticoids. Surfactant synthesis is controlled by complex cell-to-cell interactions between pulmonary fibroblasts and type II epithelial cells. When pulmonary fibroblasts are exposed to glucocorticoids they release fibroblast pneumocyte factor (FPF), an oligopeptide, which subsequently induces the type II cells to mature and rapidly synthesize and secrete surfactant.8,32 This is the basis for antepartum use of glucocorticoids to prevent or modulate RDS in premature infants.33 Additionally, estrogen, prolactin, ACTH, thyroxin, and catecholamines have been shown to augment pulmonary surfactant production.8,34–36 Earlier production of surfactant results in increased airway patency and flow rates in females and female newborns are less likely to develop transient tachypnea or RDS.37
The Role of Sex Hormones on Lung Physiology and the Development of RDS Hormonal differences are present in the fetus as early as 14–20 weeks.17,35 Estrogens and androgens have been examined as potential factors that affect fetal lung maturation. Animal studies reveal that following the administration of 17-estradiol, the lung lavage of newborn rabbits showed
37
increased levels of phosphatidylcholine production and an elevated phosphatidylcholine/sphingomyelin ratio, suggesting that estrogen may play a role in hastening fetal lung maturation and surfactant production.17,35,38 More extensive investigation has focused on the role of androgens. Circulating androgens, specifically dihydrotestosterone (DHT), inhibit the production of fetal surfactant at least in part by antagonism of glucocorticoid-induced fibroblast-epithelial cell interactions.8,39 When cortisol is added to fetal rat lung tissue culture it stimulates the synthesis of phosphatidylcholine via fibroblast-type II cell interaction mediated by FPF. However, when the cultures were pre-treated with DHT and then challenged with cortisol, there was no cortisol-stimulated phosphatidylcholine synthesis. This led investigators to conclude that androgens inhibit cortisol stimulated phosphatidylcholine production by interfering with the fibroblast-type II epithelial cell interaction, thereby reducing surfactant production.40 Additionally, maternal dexamethasone treatment in guinea pigs appears to increase the level of plasma cortisol in females, but decrease cortisol levels in males, indicating that the response to synthetic glucocorticoids might be sex-specific.41,42 The clinical significance of these findings is found in lower female morbidity and mortality in RDS.
Postnatal lung growth Early postnatal life is a period of rapid growth and development of the airways, alveoli, and vasculature. These structures have their own patterns of growth that are distinct with respect to number, size, and complexity.10,43,44 Differences in airway structure and function place males at greater risk of morbidity and death from respiratory dysfunction throughout early childhood.44–46 Although males have larger lung volumes compared to girls of the same height47 due to an increased total number of alveoli,48 females have higher sizecorrected flow rates,44–46,49,50 reduced resting airway tone,51 lower specific airway resistance (sRaw), and higher specific airway conductance (sGAW).2,4,42 When sex differences with regards to the degree of lung maturation are coupled with biochemical differences such as surfactant production during the gestational period, one begins to understand why the incidence, prevalence, and mortality of RDS are higher in boys.
Sex Differences in Alveolar and Airway Development A major development in the lungs at birth is a rapid increase in functional residual capacity (the amount of air left in the lungs at the end of a passive respiration) as a result of breathing air. This change is accomplished by an increase in the number of alveoli at birth. It has been estimated that there are 50 million alveoli present at birth21 (range 17–70 million)10,52 and they rapidly multiply during the first 2 years of life.48
38
s e c t i o n 1 Gender and Normal Development l
In 1982 Thurlbeck reported findings from the examination of 56 children (36 boys and 20 girls) aged 6 weeks to 14 years who died as a result of trauma or acute illnesses.48 Alveolar size and the number of alveoli per unit area did not differ between boys and girls of the same height. However, the lungs of girls were smaller than those of boys of the same stature. He concluded that this sex difference is explained by the larger total number of alveoli and larger surface area of alveoli in boys compared to girls.48 He also found that boys have more respiratory bronchioles than girls.48 The airways follow a different pattern of growth from the alveoli. Normally, bronchial formation, branching, and the ratio of large to small airways are complete by the end of the pseudo-glandular period (16 weeks gestation). Hence, the number of conducting airways is fixed at birth. Thereafter the airways increase in size and complexity. Conversely, alveolar formation does not commence until late in gestation during the saccular phase (26 weeks) and alveoli continue to increase in size, number, and complexity, resulting in a doubling of the lung volume in the first 6 months of life and tripling by 1 year of age.43 Females have proportionately larger airways relative to lung parenchyma size during early childhood.44,53 Sex-related differences in airway diameter, tone, and resistance are important risk factors for numerous respiratory diseases in childhood and they explain differences in prevalence and severity of a variety of pulmonary diseases.
Lung Function in Infancy and Childhood Lung growth in children occurs in a dysanaptic manner. Specifically, airways grow more slowly than does the lung parenchyma (dysanapsis).54 This phenomenon has been used to explain some of the differences between males and females in lung function during infancy and early childhood. In addition to the female advantage with respect to RDS in premature infants, sex also plays a role in airway function in healthy preterm infants. Stocks et al. measured forced expiratory flow rates in 56 preterm infants matched for birth weight, gestational age, postnatal age, weight, and length.50 The study results revealed that girls have a 20% higher maximal flow at functional residual capacity (VmaxFRC) and 10% lower respiratory system resistance (Rrs), although the difference failed to reach statistical significance due to small sample size.50 Increased flow rates and reduced resistance corrected for lung size in girls have been demonstrated in other studies.44,55 Taussig et al. obtained partial and maximal expiratory flow-volume curves on 47 healthy children between 3 and 13 years of age. The investigators demonstrated that girls had significantly higher size-corrected flows at VmaxFRC after deep inspiration.44 They concluded that these differences in the mechanical properties of the airways are related to the sex of the child and the degree of resting airway tone.44 In longitudinal studies of lung growth, Hibbert confirmed
findings of previous studies showing that girls generated higher absolute and size-corrected maximal expiratory flow rates, although by approximately 18 years of age there was a reversal in that males had higher volume-corrected flow rates.45 These studies show that while lung size is greater in boys, girls generate higher forced expiratory flow rates, suggesting they have larger airways. As children grow, lung function increases with height.4 During puberty, thoracic height increases twice as rapidly in boys.56 Additionally, thoracic width in boys increases during adolescence while no significant change is noted in girls.56 This pattern of thoracic growth results in approximately 25% greater lung function in males than in females of identical height during late adolescence.56
Lung disorders of childhood Asthma Asthma, the most common chronic disease of childhood, is a complex disorder characterized by acute and remitting exacerbations of wheeze, cough, shortness of breath, and chest tightness. These symptoms result from airway narrowing secondary to airway inflammation, bronchoconstriction, and airway hyperresponsiveness. The reason that some children develop asthma while others do not is under intensive investigation. Host or genetic susceptibility, environmental exposures both pre- and postnatally, as well as sex-related physiologic differences in the airways play significant roles. Host susceptibility may be greater in males than females before puberty.57 Asthma often begins in early childhood and male sex is a known risk factor.58 Males under the age of 6 years have a higher prevalence of asthma and wheeze.59–61 By some estimates young boys have 1.5–2.0 times the incidence of lower respiratory tract illnesses.62,63 The increased morbidity from lower respiratory tract disease in boys is in part due to narrower airways resulting from increased resting airway tone44 and dysanaptic lung growth. Boys have lower expiratory flow rates at any given lung volume.54 Between the ages of 6 and 15 years gender-related differences in the prevalence of asthma decrease and by late adolescence the incidence, prevalence, and morbidity associated with asthma begins to reverse and rise in females.64,65 Additionally, there is evidence that males have more airway hyperresponsiveness to methacholine in early childhood, with females having more hyperresponsiveness during adolescence.66,67 Young adult females report more asthma symptoms, have more hospitalizations, use more asthma medications, and describe an increased burden of disease.61,68,69 While many studies show that young boys wheeze more frequently than young girls and have lower expiratory flow rates (particularly mid maximal expiratory flow [MMEF] and forced expiratory flow at 75% of vital capacity [FEF75%]), Sennhauser and Kuhni revealed that even at
C h a p t e r 3 Gender Differences in Pediatric Pulmonary Disease l
ages when there were no significant differences between males and females in symptoms, boys were twice as likely to be diagnosed with asthma.61 This may be explained by: 1. Reporting bias on the part of parents, with symptoms in boys getting reported more frequently particularly if they are perceived to interfere with physical activity. 2. Variable or atypical presenting symptoms in girls (boys tend to have wheezing as a predominant presenting symptom while girls have more nonspecific symptoms). 3. Subconscious diagnostic bias on the part of physicians. There are several well-publicized studies examining the effect of gender on physicians’ diagnosing and managing acute and chronic diseases. In studies of coronary heart disease, investigators showed that the patient’s gender independently influenced physicians’ recommendations for cardiac catheterization even after controlling for symptoms.70,71 In Utero Tobacco Smoke Exposure and Asthma The phenotypic expression of asthma is determined by complex interactions between genes and the environment. Children who are exposed to tobacco smoke in utero are at increased risk of developing abnormal lung function.63,72–76 In a prospective cohort study of the environmental influences on the development of asthma, Young et al. demonstrated reduced maximal expiratory flows at functional residual capacity (VmaxFRC) in both males and females who were exposed to cigarette smoke in utero.63 Boys, however, had consistently lower lung function than girls.63 Li et al. confirmed that children with in utero exposure to maternal smoking independent of environmental tobacco smoke (ETS) exposure postnatally had abnormal lung function in infancy that persisted through adolescence.74,77 Moreover, boys who were exposed to in utero tobacco smoke showed significantly greater peak expiratory flow variability, suggesting increased airway hyperresponsiveness.78 Specific deficits in lung function associated with in utero exposure to tobacco smoke include reductions in small airway flow rates, namely MMEF and FEF75%. The lung function reduction that is related to in utero tobacco smoke exposure is substantially greater than the reductions seen when children are exposed to postnatal maternal or paternal smoking.73 The exact mechanism of the increased susceptibility in boys to in utero tobacco smoke is unknown. Childhood and Teen Smoking Cigarette smoking by children and teens remains prevalent79 and has been associated with new onset asthma in adolescents. Gilliland reported that among adolescents who reported smoking 300 or more cigarettes per year (regular smokers), the relative risk for the development of asthma was 3.9.80 Regular smokers who were also exposed to tobacco smoke in utero had the largest relative risk (8.8) for new onset asthma. Recent work reveals that the risk of recurrent
39
wheeze or asthma is greater in males who smoke compared to females.81 This finding was attributed to differences in airway lability between boys and girls. It was postulated that females with airway lability are less likely to smoke whereas males smoke irrespective of their level of airway lability.82 There is emerging evidence that early smoking confers an increased risk for the development of lung cancer independent of the number of years of smoking or number of packs per day.83,84 Sex-related differences in lung growth may play a role in the observation that males and females differ in their lung cancer risk for a given level of smoking.85 Females experience lung growth until approximately 18 years of age while males continue to have lung growth through their mid 20s. There is thought to be a critical period in which tobacco carcinogen exposure during the period of lung growth increases one’s susceptibility to lung cancer. It has been suggested that tobacco carcinogen exposure during pulmonary cellular proliferation can alter epithelial cells in the airway and later lead to the development of a malignancy.86 Because lung growth plateaus earlier in females than males, if the initiation of smoking occurs in late adolescence, it has been proposed that females may have a lower probability of inducing mutations that have malignant potential.85 Atopy The immunologic response of the body that results in IgE antibody production after exposure to allergens in one’s environment is termed atopy. IgE development has been shown to increase with age and several studies have shown that males have higher IgE levels and atopy rates than females.87 Male sex is associated with higher IgE levels at age 6 months and this higher level persists at age 2 and 4 years.87 However, the relationship between atopy, asthma, age, and sex is a complicated one with findings dependent on the window of time that these factors are examined. Prenatal and early life events are crucial in programming the infant’s immune system. The immune environment of a fetus is tilted toward the TH2 response, one that favors the development of atopy, allergy, and asthma resulting from the production of cytokines, IL-4 and IL-10, by the amnion and placenta.88 The TH2 tilt is maintained during early postnatal life, a time when chronic exposure to a number of antigens could result in consolidation of TH2 memory. Children who are at risk for the development of asthma and allergic disorders have delayed maturation in their capacity to develop TH1 cytokines such as interferon gamma (IFN).88 Studies indicate that T-lymphocytes in the cord blood of infants born to atopic mothers are capable of responding to allergens and aeroallergens.89 This finding suggests that fetal programming by the mother contributes to the increased prevalence of allergy and asthma in children born to mothers with allergies and asthma. It also explains why the history of maternal asthma has greater influence on the child’s outcomes than paternal asthma.
40
s e c t i o n 1 Gender and Normal Development l
The risk of developing asthma is related to the age of onset of atopy. Those who were atopic in early life are at a higher risk of developing respiratory disease than those who acquire atopy later.90 Examining the relationship between atopy and allergic sensitization and asthma has been the focus of a number of studies as a way of explaining the gender differences in the prevalence of asthma. In a populationbased birth cohort, investigators demonstrated that total IgE levels increased over the first 4 years of life in boys and girls. The increase was much higher in boys at both 2 years and 4 years of age even though there were no sex-specific differences noted in cord blood concentrations of IgE.87 Another birth cohort of 662 children in New Zealand was examined for the association between asthma in childhood and allergic sensitization demonstrated by skin prick testing to common aeroallergens.91 Boys and girls who were 13 years of age participated in the study. The proportion of boys with a diagnosis of asthma was 1.6 times higher than that of girls and the prevalence of having an asthma diagnosis increased with increasing numbers of positive skin tests.91 Boys were more likely to have a positive skin test.91 Other studies confirm a higher prevalence of atopic sensitization in boys.92 In a twin study examining the contribution of genetic susceptibility, environmental exposures, and the sex of the child to the development of asthma and other atopic diseases, Lichtenstein et al. demonstrated gender differences in disease manifestation with boys having two times the risk of being diagnosed with asthma and hay fever.93 On the other hand, girls were diagnosed with eczema more frequently. This has been seen in other studies.94 The different manifestations might be explained by differences in environmental exposures or differences in the types of physical activity. The fact that boys have more airway symptoms can be ascribed to physiologic differences in airway caliber, tone, and growth. Not all studies show an association between gender and atopy. Anderson et al. followed a birth cohort through age 23 years and showed similar ratios for the incidence of asthma with males 0–7 years of age having a ratio of 1.23 and rising to 1.48 between the ages of 12–16 years. The ratio reversed to 0.59 in the 17–23 year group. In this study reports of hay fever or eczema each increased the subsequent incidence of asthma with the highest incidence of asthma among those reporting both eczema and hay fever independent of gender. The investigators concluded that gender differences seen in the incidence of asthma vary by age and are not explained by differences in the occurrence of atopy.64 Hormonal Influences As children get older, there is a reversal in the male:female ratio of asthma, with a female predominance.64,95 Factors that influence changes in the prevalence of asthma are being investigated. One factor that could play a role in the reversal of prevalence of asthma between boys and girls is hormonal changes that occur during puberty and at the onset of
menstruation, although studies have yielded inconsistent results. Airway function is influenced by variations in sex hormone levels in relation to menses, the use of oral contraceptives, and pregnancy. In older women, menopause and postmenopausal hormonal changes affect ventilatory function.2 Premenstrual aggravation of asthma has been reported in many women. Using questionnaires and twice daily peak expiratory flow measurements to evaluate the effects of the menstrual cycle on asthma symptoms and flow rates in women with asthma, 40% reported premenstrual worsening of asthma symptoms confirmed by peak flow recordings.96 This finding was confirmed in a US study.97 To determine whether there is a relationship between phases of the menstrual cycle and asthma exacerbations resulting in emergency department visits, investigators surveyed 182 females, the youngest age of whom was 13 years. Information was collected regarding the asthma exacerbation, treatment, presenting peak expiratory flow rate, and the phase of the menstrual cycle. The investigators demonstrated that 46% of women coming to the ED with an asthma exacerbation were in the perimenstrual phase of the cycle and concluded that monthly variations in sex hormones levels associated with the premenstrual period may influence the severity of asthma in adult females.97 However, Zimmerman et al. found that women were more likely to present to the ED with an asthma exacerbation during the preovulatory phase and that few women cited menses as an important trigger of their asthma.98 The adverse effect of estradiol on asthma can be mitigated by the use of progesterone.99 When women with severe premenstrual exacerbations of asthma were treated with intramuscular progesterone, better control of asthma was achieved.99 Others have examined the link between asthma and estrogens in women, demonstrating that postmenopausal women who never used replacement hormone therapy had a significantly lower age-adjusted risk for developing asthma compared to premenopausal women.100 Among women who were current users of estrogens, there was a positive dose–response relationship between the daily dose of estrogens and the risk of developing asthma.100 Finally, the influence of the menstrual cycle on reactivity to skin-prick testing has been investigated. Preliminary results show that in both atopic and nonatopic women there is a significant increase in the size of the skin reaction on days of the menstrual cycle corresponding to peak estrogen levels associated with ovulation.101 These studies suggest that hormonal changes associated with the menstrual cycle can have an important impact on asthma symptoms, lung function, and skin reactivity and is an important area for future clinical and mechanistic research.
Cystic Fibrosis Cystic fibrosis (CF) is the most common life-threatening, autosomal recessive disease in North America and Europe.102 The disorder has variable phenotypic manifestations.103
C h a p t e r 3 Gender Differences in Pediatric Pulmonary Disease l
The CF gene, CF transmembrane conductance regulator (CFTR), is located on the long arm of chromosome 7 and codes for a cyclic adenosine monophosphate-dependent (cAMP) chloride channel found in membranes of cells that line the airways, pancreas, liver, intestines, reproductive tract, and skin. Defects in CFTR caused by CFTR gene mutation can lead to the clinical manifestations of CF. In the presence of impaired chloride transport, a milieu for bacter ial colonization emerges. In the case of CF, Staphylococcus aureus, Pseudomonas aeruginosa, and Burkholderia cepacia complex have been shown to be frequent and virulent colon izers. In severe cases, CF is characterized by progressive pulmonary disease and pancreatic insufficiency that leads to intestinal malabsorption.104 In the most recent report from the CF Foundation (CFF) Patient Registry, there are 24 511 patients receiving care at a CF foundation-accredited care center in the United States and of those, 52% are males.105 Morbidity and mortality vary with age at the time of diagnosis, genotype, nutritional status, fitness, colonizing organisms, co-morbid conditions, and severity and progression of lung disease resulting in loss of lung function.106–111 The median survival age for females is 3–4 years less than for males.107 According to the 2007 annual data report published by the CFF, the predicted median survival age has increased since 1985 from 25 years of age to 37.4 years in 2007.105 However despite the increase in life expectancy, mortality among females between the ages of 1 and 20 years consistently exceeds that of males.107,111 The fact that higher mortality rates for females are seen in this age group and then subsequently dissipate suggests that factors operating in early life result in earlier death of females. Although sex differences in mortality rates are well described, the reason for the survival advantage among males with this disease is not well understood. Factors Contributing to the Gender Gap in Cf Survival Age at Diagnosis Previous studies have shown that children who are diagnosed with CF at an early age have improved outcomes because of better maintenance of lung function and improved nutritional status.112 A 12-year review of the CF Foundation Registry examined the gender gap with respect to delayed diagnosis in females in the United States.110 Lai et al. reported that of the 11 275 newly diagnosed patients with CF between 1986 and 1998, 70% were identified on the basis of symptoms other than meconium ileus. The most common clinical presentations were combined respiratory and gastrointestinal symptoms (36%), predominantly respiratory symptoms (22%), and predominantly gastrointestinal symptoms (22%). Among these groups, females were diagnosed at significantly older ages (median age of 12.7 months) compared to males (median age 8.7 months). When respiratory symptoms were the predominant manifestation
41
of the disease, the gender gap was most striking with girls being diagnosed a median of 18 months later than boys.110 There was no statistically significant difference between girls and boys among factors that might impact survival such as genotype, acquisition of Pseudomonas aeruginosa, and radiographic findings. In a subsequent study of age at diagnosis in the United Kingdom, McCormick showed that while females who presented with respiratory symptoms alone were diagnosed significantly later (9 months) than boys, there were no differences in clinical outcomes between males and females.102 Given the prevalence of respiratory symptoms in boys in early childhood due to factors such as dysanaptic growth of the airways and airspaces discussed earlier in the chapter, physicians may be more aware of symptoms in boys and refer them for diagnostic evaluation earlier in the course of symptoms, resulting in earlier diagnosis for boys. There also may be sociocultural differences in the way parents perceive symptoms between boys and girls that lead them to seek care earlier for boys. Lai points out that it is unclear that the delay in diagnosis has a significant impact on survival.110 However, the delay occurs during the first year of life during a time when early intervention might have a more significant impact on disease course and survival.110 Pulmonary Function Given the male disadvantage with regards to morbidity from lung disease and diminished airway function particularly in the first 6 years of life, the fact that males have a survival advantage in CF is somewhat surprising. Chronic progressive, suppurative lung disease is the predominant cause of morbidity and death in CF. The rate of decline of lung function varies widely. To further investigate the rate of decline, Corey et al. studied 366 patients who had at least two measures of lung function, with at least one occurring prior to age 10 years. Females, patients who died before 15 years of age, and those with pancreatic insufficiency had significantly greater rates of lung function decline.113 In a subset of 197 who were genotyped, the rate of decline was greater in those who were homozygous for the F508 mutation. Patients who died before 15 years of age had a rate of decline in FEV1 of 9.16% predicted per year compared to 1.79% predicted per year for survivors.113,114 Of note, among those who died before 15 years of age, many had normal pulmonary function test in early childhood.113 A review of data from the CF registry revealed that girls have significantly lower FEV1 from age 6 to 15 years of life, similar FEV1 from 16 to 20 years, and better lung function thereafter compared to boys.115 The impact of early diagnosis on pulmonary function was studied in a cohort of children with CF who were diagnosed between 1982 and 1990 and who were categorized as either early asymptomatic or early symptomatic diagnosis if diagnosed before 6 weeks of
42
s e c t i o n 1 Gender and Normal Development l
life; or as later asymptomatic or later symptomatic diagnosis if the diagnosis was made from 6 weeks to 36 months. The study showed no differences in pulmonary function among the four groups, but children in the early asymptomatic group who were born in 1987 or later had higher FEV1 compared with the other groups, suggesting that children who were born more recently may have better pulmonary function throughout early childhood.116 Despite major improvements in lung health, the data show that the rate of decline in FEV1 has not changed significantly in recent decades. Future studies will be required to assess the impact of new therapies on lung function and survival in CF.
organism.121 Lewin et al. also demonstrated that patients with CF who become colonized with B. cepacia complex have higher mortality rates in the year after acquisition of the organism, with 30% of female patients dying compared to 21% of males.120 They also reported lower lung function in the three years prior to and two years following the date of first acquisition, with the impact on lung function in females being significantly greater than in males. In this study, it appears that only females colonized with B. cepacia complex had increased mortality compared with controls and compared with males who were colonized with the organism.120
Bacterial Colonization Another possible explanation for the increased mortality among females with CF is the significantly higher prevalence111 of Pseudomonas aeruginosa, a common colonizing organism in CF. This colonization in girls precedes colonization in boys. Once P. aeruginosa is repeatedly recovered in sputum from the lower respiratory tract, it is difficult to eradicate. The mucoid type of P. aeruginosa that is frequently associated with CF leads to poorer clinical status, worsening lung function, and poorer survival.117,118 Demko et al. demonstrated that the median age for the acquisition (initial positive culture) of mucoid P. aeruginosa was 7.4 years for girls and 8.4 years for boys. The median age of chronic colonization is 9.5 years for girls compared with 11.2 years for boys. Additionally, children under the age of 6 years who are chronically colonized with mucoid P. aeruginosa have worse chest radiographic scores and significantly higher mortality rates.117 In children older than 6 years of age, chronic colonization was associated with lower lung function. Colonization with mucoid P. aeruginosa is associated with significantly worse clinical outcomes, irrespective of gender. While this study showed that girls acquired and became chronically colonized with mucoid P. aeruginosa at an earlier age, this finding did not fully explain the gender gap in CF survival.117 Burkholderia cepacia complex is another colonizing organism found in patients with CF. Its clinical course is quite variable with early reports of rapid deterioration, particularly in females, after acquisition of the organism.119–122 Isles describes three outcomes after colonization with B. cepacia:
Dietary Intake, Nutritional Status, and Fitness It has been postulated that differences in dietary intake, nutritional status, and fitness between males and females could explain the gender differences in survival. Rosenfeld found that among young children, the height and weight percentiles were similar for both sexes. Females bettered males between the ages of 16 and 25 years, but this nutritional advantage did not translate into improved survival.111 Several authors report similar outcomes.117 When the level of fitness of patients has been examined as a possible factor to explain the mortality gap between males and females in CF, investigators have found that cardiovascular fitness predicted survival better that FEV1. Females achieved a lower peak work load relative to their male counterparts.123 When Nixon et al. used exercise testing to determine the relative risk of mortality from CF they found that patients with the highest levels of aerobic fitness (VO2 peak 82% predicted) had an 83% survival rate at 8 years, compared with those in the mid range (VO2 peak 59–81% predicted) with a 51% survival rate and those in the low range (VO2 peak 58% predicted) with a 28% 8-year survival rate.123 They concluded that patients with higher levels of fitness were three times more likely to survive compared with the group with low levels of fitness.123 Resting energy expenditure is increased by 4–33% in patients with CF.124 In a study of 25 prepubertal children, aged 5–10 years, with pancreatic insufficiency and an FEV1 60% predicted, Zemel et al. demonstrated that boys experienced a decline in growth status and pulmon ary function without a significant change in resting energy expenditure.124 Girls had an increase in resting energy expenditure, decline in growth status, but no change in pulmonary function. These findings suggest that measurement of pulmonary function may not be indicative of nutritional requirements and energy balance in girls. Pubertal growth spurt in children with CF is often delayed and attenuated.125 Although the degree of growth retardation that occurs in males is greater, it is not affected by the genotype. Girls who are homozygous for F508 experience later growth spurts compared to girls with one or more other CF mutations. Interestingly, while the timing
1. An unchanged clinical course following colonization with the organism. 2. A progressive decline in pulmonary status. 3. A rapid, fulminant clinical decline resulting in death. The investigators reported 7 deaths among 18 patients colonized with B. cepacia complex compared with 4 deaths among 67 patients with CF who had not acquired the organism.119 In a study closely matched on parameters that characterized disease severity, Tablan et al. found that 49% of patients died in the first year following acquisition of the
C h a p t e r 3 Gender Differences in Pediatric Pulmonary Disease l
of the growth spurt is affected by genotype, the final adult height of girls is less affected than in boys.125 Cystic Fibrosis-Related Diabetes (CFRD) Diabetes contributes significantly to CF-related morbidity and mortality126 and may play a substantial role in differences in CF survival.127 Cystic fibrosis-related diabetes affects 20–30% of patients with CF and is associated with exaggerated loss of lung function, decreased body mass index (BMI)128,129, and increased likelihood of acquiring Pseudomonas infection.129 There are reports indicating that females with CFRD have significantly lower survival compared to females without CFRD and males with CF regardless of CFRD status.130 A survival analysis of patients with CF performed to determine the impact of the development of CFRD on survival revealed that females with CFRD who had fasting hyperglycemia have a lifespan 17 years shorter than females with CF but without CFRD and all males with CF.127 Sims et al. reported that the FEV1 of females with established CFRD who were not colonized with Pseudomonas was 20% lower than sex-matched controls.131 This was not true in males, suggesting that CFRD in combination with female sex has an adverse impact on outcomes. In females with newly diagnosed CFRD, the decline in lung function does not occur in the first 12 months after CFRD diagnosis, suggesting that early intervention after CFRD diagnosis might reduce the decline in lung function.131 It has been postulated that an interaction between hormones and diabetes via an inflammatory mechanism may be responsible for these findings since sex differences in survival did not appear until after puberty. Whether estrogen contributes to reduced survival or testosterone is protective is unclear.127 Sex Hormones In animal models, sex hormones play a role in the expression of CFTR. Mutations in CFTR result in defective cAMP-mediated chloride secretion and increased sodium absorption, leading to abnormal airway surface liquid and reduced mucociliary clearance. This creates an environment conducive to bacterial infection. Sweezey et al. demonstrated that sex hormones, androgen and estrogen, differentially influence gene expression and functional activity of CFTR in rat lung models.132 Androgens increase,132 while estrogens decrease,132,133 the functional activity of the CFTR chloride channel. Others have shown that estrogens are responsible for cyclic changes during the menstrual cycle in the number of airway goblet cells, thereby affecting airway physiology in females with CF.134 Although the mechanisms by which sex hormones affect CFTR have not been fully delineated, it has been postulated that small changes in the functional activity of CFTR caused by androgen stimulation and/or estrogen inhibition may be sufficient to explain the survival difference between males and females with CF.
43
The gender gap in CF mortality is multifactorial. While age at diagnosis, rate of decline in pulmonary function, colonizing organisms, nutritional status, presence of co-morbid conditions such as CFRD, and level of fitness all play a role in determining CF survival, they do not fully account for the poorer survival among females. More studies are needed to better delineate the factors that may play a key role in CF survival.
Sleep Disorders Parasomnias Parasomnias are common sleep disorders in children. They are considered transient and often disappear during adolescence. Although not a medical condition per se, parasomnias can cause major disruption in sleep.135 Night terrors, leg restlessness, sleepwalking, somniloquy, enuresis, body rocking, and sleep bruxism are the most common parasomnias of childhood. It is estimated that over 75% of children between the ages of 3 and 13 years have had at least one parasomnia.136–138 A brief description of common parasomnias of childhood is listed below: Night terrors are disorders of arousal that occur early during the night and are associated with the feeling of extreme panic or fear, a loud piercing scream during sleep, and motor activities such as hitting objects.135 Leg restlessness has been considered a parasomnia of adulthood and there are currently no specific diagnostic criteria for children. Generally, it presents with insomnia and leg restlessness at bedtime. Symptoms are described as worsening with rest and temporary improvement is noted with activity.137 During a sleepwalking episode, the child performs a series of complex behaviors that can result in wandering aimlessly during sleep. Behaviors can range from sitting up in bed to going outdoors.137,138 Somniloquy consists of talking during sleep. It is the most frequent parasomnia in children. Enuresis (bedwetting) is characterized by the presence of involuntary micturition during sleep in children with normal bladder control when awake. Enuresis is diagnosed as an abnormal condition when persistent bedwetting occurs after 5 years of age.137 Nocturnal body rocking represents rhythmic movements of the axial muscles in the back and forth or right and left motion occurring mostly during the transition from wakefulness to sleep.137 Sleep bruxism is characterized by grinding or clenching of the teeth during sleep. In a longitudinal cohort study of dyssomnias and parasomnias, Petit et al. report that at age 6 years, boys were significantly more likely than girls to experience sleepwalking and enuresis.138 Although the peak occurrence for sleep walking is 11–12 years of age, there are reports emerging
44
s e c t i o n 1 Gender and Normal Development l
of increased incidence in younger children.139 Differences between males and females in the prevalence of enuresis among 5- and 6-year-olds are well established.1,137,140,141 A longitudinal study of children ages 6–16 years demonstrated that girls at age 11 years experienced leg restlessness significantly more than boys (p 0.05), boys were three times more likely to have enuresis compared to girls (p 0.001), and significantly more boys were somniloquists (p 0.05).137 The reasons for the gender differences noted in parasomnias are unclear. Obstructive Sleep Apnea Hypoventilation Syndrome Obstructive sleep apnea hypoventilation syndrome (OSAHS) is a relatively common disorder characterized by recurrent episodes of upper airway narrowing and/or collapse resulting in either complete or partial airflow obstruction. The physiologic response to OSAHS is hypoxemia, hypercapnia, recurrent arousals, and sleep disruptions.142 It is estimated that 2–24% of the adult population is affected by OSAHS, and as such, it is a significant public health problem.143–146 Gender differences in the prevalence of OSAHS have been well characterized in the adult population, with women having overall lower prevalence rates (2–9%) than men (4–24%).147 The initial studies of OSAHS reported that few women, approximately 4–12% of the cases, were affected by the disorder.148 Other studies indicated that the male to female ratio for the disorder varied from as high as 60:1 to 8:1.149–151 More recent rigorous studies reveal that the male and female ratio may be closer to 2:1 with a prevalence in women of 2% and 4% in men.152,153 The wide range of prevalence rates as well as lower than expected ratio of men to women in some studies raises the question of whether the increased prevalence in men that has been widely reported is due to underreporting of symptoms by women, differences in clinical presentation leading to fewer referrals for formal evaluation and polysomnography testing in women, or subconscious selection bias on the part of physicians because they perceive that there is a much higher prevalence of the disorder in males and are more likely to refer males for evaluation. As shown in other chronic disorders such as asthma61,154 and cardiovascular disease,70,71 females may present with nonspecific symptoms that do not get recognized, may not report symptoms at the same rate as males and may, in fact, have symptoms that go untreated for a longer duration than males. To determine if women with sleep apnea have unique symptoms or complaints compared to men, Redline et al. examined two groups: a clinical sample of 36 patients (31 males, 5 females) who had been referred for polysomnography with confirmed OSAHS; and a community sample of 65 patients (41 males, 24 females) who were the friends and family members of the clinical sample found to also have OSAHS. In the clinical sample classical symptoms usually associated with OSAHS (snoring, gasping, daytime somnolence, and apnea that was witnessed)
were equally present in both men and women. In the community sample, however, men were 2–3 times more likely to report the symptoms than women.155 Other studies have confirmed these findings.156 To further test the hypothesis that the male prevalence of OSAHS was due to under-reporting of symptoms by women, Young et al. undertook the Wisconsin Sleep Cohort Study, a community-based study of the natural history of sleep apnea involving 551 men and 388 women.153 Data were obtained via interviews regarding typical sleep apnea symptoms and the degree of sleepdisordered breathing was determined from the frequency of apneic and hypopneic events during sleep as recorded by polysomnography in the laboratory during a full night of sleep. Young et al. showed that women with OSAHS did not report symptoms that differed significantly from those reported by men with the same levels of OSAHS.153 Snoring was the best and most sensitive predictor of OSAHS. The authors concluded that there must be reasons other than differences in the symptoms reported that explain the gender disparity in OSAHS. A closer look at the data reveals that women in the study reported daytime fatigue, morning headaches, anxiety, insomnia, and other signs of depression more frequently than men. These complaints as well as the misguided notion that OSAHS is a ‘male disorder’ could lead clinicians to diagnose depression in women and delay the evaluation and subsequent diagnosis of OSAHS. Pathogenesis Anatomy and Patency of the Upper Airway During Sleep Investigators have focused on sex-related differences in the anatomy and patency of the upper airway, particularly during sleep, as possible explanations for gender differences in the prevalence of OSAHS. Maintenance of upper airway patency depends on a dynamic interaction between pharyngeal muscle activity and airway structure. It has been postulated that despite females having structurally smaller airways, heightened activity of the genioglossus muscle in females could result in better upper airway stability and less likelihood of upper airway collapse during sleep.157 This has not been a consistent finding.158,159 Another study concluded that differences in airway anatomy account for the gender disparities.158,159 Malhotra et al. report that pharyngeal airway length, soft palate area, and pharyngeal volume are greater in men. These findings indicate that the male airway is significantly more collapsible based solely on anatomical differences.158,159 Obesity and Body Fat Distribution Obesity has been clearly shown to be associated with the development of OSAHS. Obesity alone, however, is neither necessary nor sufficient to cause the physiologic abnormalities associated with OSAHS. Female patients with OSAHS are more obese than males147,148,153 and the evidence shows that obesity is a characteristic of young, premenopausal
C h a p t e r 3 Gender Differences in Pediatric Pulmonary Disease l
women with OSAHS. This is not to say that obesity is not a characteristic of males with OSAHS. Body fat distribution in males tends to play a larger role. Upper body obesity, particularly with fat accumulation in the neck, leads to narrowing of the airway and increases the likelihood of airway closure during sleep. Childhood OSAHS While OSAHS in adults has received increasing attention over the past 2–3 decades, it is still an under-recognized and underdiagnosed disorder in children. The prevalence and risk factors for OSAHS in children have not been well studied. It is not clear how the findings in adult-onset OSAHS relate to childhood sleep-disordered breathing. It has been estimated that habitual snoring occurs in 7–12% of children and, as in adults, snoring is the most common presentation of OSAHS in children.160,161 However, not all children who snore have OSAHS with physiologic abnormalities such as hypoxemia, hypercapnia, sleep disruption, and daytime somnolence. Ali et al. estimated that 0.7% of the general childhood population has significant sleep-related breathing disorders,160 although in another study OSAHS was found in 2.9% of children 6 months to 6 years of age.161 To determine the prevalence of OSAHS and the signs and symptoms that could lead to early diagnosis of OSAHS, Chay et al. undertook a three-phase study of Singapore schoolchildren (age 1–18 years). Initially 3671 children referred for obesity were screened by questionnaire. From the initial 3671 children, those who had a percent ideal body weight 180 and those reporting symptoms that were suggestive of OSAHS were recalled for further evaluation. A total of 146 children underwent polysomnography and 26 of the 146 had abnormalities on sleep study. Chay concluded that the prevalence in the general population of OSAHS was 0.7%, similar to findings in the Ali study.162 Risk Factors The major risk factors in adults for OSAHS include male sex (on the basis of both anatomical and physiologic differences), obesity, aging, alcohol use, craniomandibular anomalies, familial predisposition, menopause, and chronic rhinitis. In children, adenotonsillar hypertrophy, nasal obstruction, craniofacial anomalies, neuromuscular disease, and genetic disorders such as Down syndrome are risk factors for OSAHS.163 These findings are taken from a population of children referred for evaluation of daytime somnolence, behavioral problems, or right heart failure. In adults, obesity as measured by body mass index, neck circumference, and skinfold thickness are strongly related to OSAHS.147 To determine the role of obesity in childhood OSAHS, several investigators undertook small studies with conflicting results. In a 1989 study, Mallory et al. enrolled 41 morbidly obese (mean percent of ideal body weight was 208 42.2) children and adolescents (mean age was
45
10.3 4.4 (SD) years) with a history consistent with sleepdisordered breathing. All of the patients reported snoring; 32% reported apnea. All 41 underwent polysomnography and 37% (15/41) had abnormalities such as apnea, hypopnea, excessive arousals, hypoxemia or hypercapnia. No significant association between gender and any of the physiologic measures on the sleep study was found. The authors concluded that obesity may play a role in OSAHS in childhood, and although the polysomnography abnormalities were mild, they were significant enough to require intervention.164 Similar results were reported in the Singapore study.162 Of the children with polysomnographic evidence of OSAHS, 13.3% were obese.162 Other investigators in 1992 reviewed the charts of 93 patients (18 months to 12 years of age) who had symptoms suggestive of OSAHS. All 93 underwent polysomnography with a similar percentage (36%) of children meeting the polysomnography criteria for OSAHS. No significant differences in age, sex or symptoms were found between the children who were positive for OSAHS by sleep study and the children with normal studies. Surprisingly, obesity was not significantly associated with OSAHS.165 Rosen also showed that the association of OSAHS with obesity in childhood was weak relative to the adult population.142 Unlike in the adult population, the major risk factor for OSAHS in children is adenotonsillar hypertrophy. While many children without OSAHS have enlarged adenoids and tonsils, relatively few of them develop sleep disordered breathing. Tonsillar hypertrophy reduces upper airway caliber, thereby increasing the risk of airway obstruction during sleep. In general, once the child undergoes adenotonsillectomy, many of the symptoms of OSAHS improve or completely resolve. Another important difference between adult and childhood OSAHS is that gender differences in the pediatric population are not as apparent. Girls are as likely to have OSAHS as boys. In a study of 326 children between the ages of 1 and 12 years, Rosen reported that the gender distribution of the children referred to the sleep laboratory and those who were subsequently diagnosed with OSAHS was nearly equal.142 This is consistent with findings from other studies showing no difference in the prevalence of snoring between girls and boys161 and that sex does not significantly impact risk of developing sleep-disordered breathing.166 In a study examining sex-dependent differences in the craniofacial morphology of children with OSAHS, Kawashima showed that boys with OSAHS had larger anterior lower facial height and a more anterior hyoid bone position than girls with sleep disordered breathing, but girls with OSAHS had a sagittally narrower pharyngeal airway space than affected boys. The study suggested that craniofacial skeletal differences in boys with OSAHS placed them at increased risk for sleep disordered breathing problems whereas narrower airways was a risk factor in girls with OSAHS.167 The increased risk of OSAHS later in life in men may start with skeletal differences in
46
s e c t i o n 1 Gender and Normal Development l
childhood. This study was limited by small sample size so it is difficult to draw inferences from the data regarding the role of gender in the development of OSAHS in children. The reason that there is such a clear gender-related difference in the prevalence of OSAHS in adults and not in children has not been delineated. It has been suggested that hormonal factors affecting body fat distribution may play a significant role. More studies are needed.
References 1. Touchette E, Petit D, Paquet J, et al. Bed-wetting and its association with developmental milestones in early childhood. Arch Pediatr Adolesc Med 2005;159(12):1129–34. 2. Becklake MR, Kauffmann F. Gender differences in airway behaviour over the human life span. Thorax 1999;54(12):1119–38. 3. Boddy K. Fetal breathing: its physiologic and clinical implications. Hosp Pract 1979;14(2):89–96. 4. Boezen HM, Jansen DF, Postma DS. Sex and gender differences in lung development and their clinical significance. Clin Chest Med. 2004;25(2):237–45. 5. Hepper PG, Shannon EA, Dornan JC. Sex differences in fetal mouth movements. Lancet 1997;350(9094):1820. 6. Fleisher B, Kulovich MV, Hallman M, et al. Lung profile: sex differences in normal pregnancy. Obstet Gynecol. 1985;66(3):327–30. 7. Holt PG, Macaubas C, Cooper D, et al. Th-1/Th-2 switch regulation in immune responses to inhaled antigens. Role of dendritic cells in the aetiology of allergic respiratory disease. Adv Exp Med Biol. 1997;417:301–6. 8. Torday JS, Nielsen HC. The sex difference in fetal lung surfactant production. Exp Lung Res 1987;12(1):1–19. 9. Joshi S, Kotecha S. Lung growth and development. Early Hum Dev 2007;83(12):789–94. 10. Merkus PJ, ten Have-Opbroek AA, Quanjer PH. Human lung growth: a review. Pediatr Pulmonol 1996;21(6):383–97. 11. Whitsett J, Wert S. Molecular determinants of lung morphogenesis. In: V Chernick, T Boat, R Wilmott, A Bush, eds. Kendig’s Disorders of the Respiratory Tract in Children, 7th edn. Philadelphia, PA: Saunders Elsevier; 2006:1–16. 12. Jeffrey PK. The development of large and small airways. Am J Respir Crit Care Med 1998;157(5 Pt 2):S174–80. 13. Kotecha S. Lung growth for beginners. Paediatr Respir Rev 2000;1(4):308–13. 14. Kotecha S. Lung growth: implications for the newborn infant. Arch Dis Child Fetal Neonatal Ed 2000;82(1):F69–74. 15. Thurlbeck W. Pre- and postnatal organ development. In: V Chernick, R Mellins, eds. Basic Mechanisms of Pediatric Respiratory Disease: Cellular and Integrative. Philadelphia, PA: BC Decker; 1991:23–35. 16. Boddy K, Dawes GS. Fetal breathing. Br Med Bull 1975;31(1):3–7. 17. Khosla SS, Rooney SA. Stimulation of fetal lung surfactant production by administration of 17beta-estradiol to the maternal rabbit. Am J Obstet Gynecol 1979;133(2):213–16. 18. Miller HC, Futrakul P. Birth weight, gestational age, and sex as determining factors in the incidence of respiratory distress syndrome of prematurely born infants. J Pediatr 1968;72(5):628–35.
19. Torday JS. The sex difference in type II cell surfactant synthesis originates in the fibroblast in vitro. Exp Lung Res 1984;7(3-4):187–94. 20. Inanlou MR, Baguma-Nibasheka M, Kablar B. The role of fetal breathing-like movements in lung organogenesis. Histol Histopathol 2005;20(4):1261–66. 21. Murray J. Prenatal growth and development of the lung. The Normal Lung. Philadelphia, PA: WB Saunders; 1986, 1–21. 22. Platt LD, Manning FA, Lemay M, et al. Human fetal breathing: relationship to fetal condition. Am J Obstet Gynecol. 1978;132(5):514–18. 23. Inanlou MR, Kablar B. Abnormal development of the diaphragm in mdx:MyoD-/-(9th) embryos leads to pulmonary hypoplasia. Int J Dev Biol 2003;47(5):363–71. 24. Tseng BS, Cavin ST, Booth FW, et al. Pulmonary hypoplasia in the myogenin null mouse embryo. Am J Respir Cell Mol Biol 2000;22(3):304–15. 25. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child 1959;97(5, Part 1):517–23. 26. Yee WF, Scarpelli EM. Surfactant replacement therapy. Pediatr Pulmonol 1991;11(1):65–80. 27. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999;13(6):1455–76. 28. Kirkpatrick B, Mueller D. Respiratory disorders in the newborn. In: V Chernick, T Boat, eds. Kendig’s Disorders of the Respiratory Tract in Children. Philadelphia, PA: WB Saunders; 1998:328–64. 29. Nielsen HC, Torday JS. Sex differences in fetal rabbit pulmonary surfactant production. Pediatr Res 1981;15(9):1245–47. 30. Torday JS, Dow KE. Synergistic effect of triiodothyronine and dexamethasone on male and female fetal rat lung surfactant synthesis. Dev Pharmacol Ther 1984;7(2):133–39. 31. Nielsen HC, Kirk WO, Sweezey N, et al. Coordination of growth and differentiation in the fetal lung. Exp Cell Res 1990;188(1):89–96. 32. Smith B. Fibroblast-pneumonocyte factor. Intercellular mediator of glucocorticoid effect on fetal lung. In: L Stern, W Oh, B Friis-Hansen, eds. Neonatal Intensive Care. New York: Masson; 1978:25–32. 33. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50(4):515–25. 34. Hitchcock KR. Hormones and the lung. I. Thyroid hormones and glucocorticoids in lung development. Anat Rec 1979;194(1):15–39. 35. Khosla SS, Gobran LI, Rooney SA. Stimulation of phosphatidylcholine synthesis by 17 beta-estradiol in fetal rabbit lung. Biochim Biophys Acta 1980;617(2):282–90. 36. Mendelson CR, Johnston JM, MacDonald PC, et al. Multihormonal regulation of surfactant synthesis by human fetal lung in vitro. J Clin Endocrinol Metab 1981;53(2): 307–17. 37. Dani C, Reali MF, Bertini G, et al. Risk factors for the development of respiratory distress syndrome and transient tachypnoea in newborn infants. Italian Group of Neonatal Pneumology. Eur Respir J 1999;14(1):155–59. 38. Khosla SS, Smith GJ, Parks PA, et al. Effects of estrogen on fetal rabbit lung maturation: morphological and biochemical studies. Pediatr Res 1981;15(9):1274–81.
C h a p t e r 3 Gender Differences in Pediatric Pulmonary Disease l
39. Torday J. Dihydrotestosterone (DHT) uncouples cell interactions in developing lung. Prog Clin Biol Res 1986;217B: 425–28. 40. Torday JS. Dihydrotestosterone inhibits fibroblast-pneumonocyte factor-mediated synthesis of saturated phosphatidylcholine by fetal rat lung cells. Biochim Biophys Acta 1985;835(1):23–28. 41. Dean F, Matthews SG. Maternal dexamethasone treatment in late gestation alters glucocorticoid and mineralocorticoid receptor mRNA in the fetal guinea pig brain. Brain Res 1999;846(2):253–59. 42. Pollak A, Birnbacher R. Preterm male infants need more initial respiratory support than female infants. Acta Paediatr 2004;93(4):447–48. 43. Dezateux C, Stocks J. Lung development and early origins of childhood respiratory illness. Br Med Bull 1997;53(1):40–57. 44. Taussig LM, Cota K, Kaltenborn W. Different mechanical properties of the lung in boys and girls. Am Rev Respir Dis 1981;123(6):640–43. 45. Hibbert M, Lannigan A, Raven J, et al. Gender differences in lung growth. Pediatr Pulmonol 1995;19(2):129–34. 46. Schwartz J, Katz SA, Fegley RW, et al. Sex and race differences in the development of lung function. Am Rev Respir Dis 1988;138(6):1415–21. 47. Hsu KH, Jenkins DE, Hsi BP, et al. Ventilatory functions of normal children and young adults – Mexican-American, white, and black. I. Spirometry. J Pediatr 1979;95(1):14–23. 48. Thurlbeck WM. Postnatal human lung growth. Thorax 1982;37(8):564–71. 49. Leeder SR, Swan AV, Peat JK, et al. Maximum expiratory flow-volume curves in children: changes with growth and individual variability. Bull Eur Physiopathol Respir 1977;13(2):249–60. 50. Stocks J, Henschen M, Hoo AF, et al. Influence of ethnicity and gender on airway function in preterm infants. Am J Respir Crit Care Med 1997;156(6):1855–62. 51. Landau LI, Morgan W, McCoy KS, et al. Gender related differences in airway tone in children. Pediatr Pulmonol 1993;16(1):31–35. 52. Dunnill MS. The problem of lung growth. Thorax 1982;37 (8) :561–63. 53. Tepper RS, Morgan WJ, Cota K, et al. Physiologic growth and development of the lung during the first year of life. Am Rev Respir Dis 1986;134(3):513–19. 54. Green M, Mead J, Turner JM. Variability of maximum expiratory flow-volume curves. J Appl Physiol 1974;37(1):67–74. 55. Pagtakhan RD, Bjelland JC, Landau LI, et al. Sex differences in growth patterns of the airways and lung parenchyma in children. J Appl Physiol. 1984;56(5):1204–10. 56. DeGroodt EG, van Pelt W, Borsboom GJ, et al. Growth of lung and thorax dimensions during the pubertal growth spurt. Eur Respir J 1988;1(2):102–8. 57. Postma DS. Gender differences in asthma development and progression. Gend Med 2007;4(Suppl B):S133–46. 58. Schaubel D, Johansen H, Dutta M, et al. Neonatal characteristics as risk factors for preschool asthma. J Asthma 1996;33(4):255–64. 59. Dodge RR, Burrows B. The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 1980;122(4):567–75.
47
60. Gissler M, Jarvelin MR, Louhiala P, et al. Boys have more health problems in childhood than girls: follow-up of the 1987 Finnish birth cohort. Acta Paediatr 1999;88(3):310–14. 61. Sennhauser FH, Kuhni CE. Prevalence of respiratory symp toms in Swiss children: is bronchial asthma really more prevalent in boys? Pediatr Pulmonol 1995;19(3):161–66. 62. Redline S, Gold D. Challenges in interpreting gender differences in asthma. Am J Respir Crit Care Med 1994;150(5 Pt 1):1219–21. 63. Young S, Sherrill DL, Arnott J, et al. Parental factors affecting respiratory function during the first year of life. Pediatr Pulmonol 2000;29(5):331–40. 64. Anderson HR, Pottier AC, Strachan DP. Asthma from birth to age 23: incidence and relation to prior and concurrent atopic disease. Thorax 1992;47(7):537–42. 65. Sweeting H, West P. Sex differences in health at ages 11, 13 and 15. Soc Sci Med 2003;56(1):31–39. 66. Le Souef PN, Sears MR, Sherrill D. The effect of size and age of subject on airway responsiveness in children. Am J Respir Crit Care Med 1995;152(2):576–79. 67. Paoletti P, Carrozzi L, Viegi G, et al. Distribution of bronchial responsiveness in a general population: effect of sex, age, smoking, and level of pulmonary function. Am J Respir Crit Care Med 1995;151(6):1770–77. 68. Gold DR, Rotnitzky A, Damokosh AI, et al. Race and gender differences in respiratory illness prevalence and their relationship to environmental exposures in children 7 to 14 years of age. Am Rev Respir Dis 1993;148(1):10–18. 69. Schatz M, Clark S, Camargo CA Jr. Sex differences in the presentation and course of asthma hospitalizations. Chest 2006;129(1):50–55. 70. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians’ recommendations for cardiac catheterization. N Engl J Med 1999;340(8):618–26. 71. Steingart RM, Packer M, Hamm P, et al. Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med. 1991;325(4):226–30. 72. Cunningham J, Dockery DW, Gold DR, et al. Racial differences in the association between maternal smoking during pregnancy and lung function in children. Am J Respir Crit Care Med 1995;152(2):565–69. 73. Gilliland FD, Berhane K, McConnell R, et al. Maternal smoking during pregnancy, environmental tobacco smoke exposure and childhood lung function. Thorax 2000;55(4):271–76. 74. Li YF, Gilliland FD, Berhane K, et al. Effects of in utero and environmental tobacco smoke exposure on lung function in boys and girls with and without asthma. Am J Respir Crit Care Med 2000;162(6):2097–104. 75. Lux AL, Henderson AJ, Pocock SJ. Wheeze associated with prenatal tobacco smoke exposure: a prospective, longitudinal study. ALSPAC Study Team. Arch Dis Child 2000;83(4):307–12. 76. O’Connor GT, Sparrow D, Demolles D, et al. Maximal and partial expiratory flow rates in a population sample of 10to 11-year-old schoolchildren. Effect of volume history and relation to asthma and maternal smoking. Am J Respir Crit Care Med, 2000;162(2 Pt 1):436–39. 77. Cunningham J, O’Connor GT, Dockery DW, et al. Environmental tobacco smoke, wheezing, and asthma in children in 24 communities. Am J Respir Crit Care Med 1996;153(1):218–24.
48
s e c t i o n 1 Gender and Normal Development l
78. Kuehr J, Frischer T, Karmaus W, et al. Cotinine excretion as a predictor of peak flow variability. Am J Respir Crit Care Med 1998;158(1):60–64. 79. Prevention CfDCa. Tobacco use among high school students – United States, 1997. MMWR 1998;47:229–33. 80. Gilliland FD, Islam T, Berhane K, et al. Regular smoking and asthma incidence in adolescents. Am J Respir Crit Care Med 2006;174(10):1094–100. 81. Strachan DP, Cook DG. Health effects of passive smoking. 6. Parental smoking and childhood asthma: longitudinal and case-control studies. Thorax 1998;53(3):204–12. 82. Rasmussen F, Siersted HC, Lambrechtsen J, et al. Impact of airway lability, atopy, and tobacco smoking on the development of asthma-like symptoms in asymptomatic teenagers. Chest 2000;117(5):1330–35. 83. Doll R, Peto R. Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health 1978;32(4):303–13. 84. Moolgavkar SH, Dewanji A, Luebeck G. Cigarette smoking and lung cancer: reanalysis of the British doctors’ data. J Natl Cancer Inst 1989;81(6):415–20. 85. Wiencke JK, Kelsey KT. Teen smoking, field cancerization, and a ‘critical period’ hypothesis for lung cancer susceptibility. Environ Health Perspect 2002;110(6):555–58. 86. Gold DR, Wang X, Wypij D, et al. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996;335(13):931–37. 87. Johnson CC, Peterson EL, Ownby DR. Gender differences in total and allergen-specific immunoglobulin E (IgE) concentrations in a population-based cohort from birth to age four years. Am J Epidemiol 1998;147(12):1145–52. 88. Holt PG, Sly PD. Allergic respiratory disease: strategic targets for primary prevention during childhood. Thorax 1997;52(1):1–4. 89. Miles EA, Warner JA, Jones AC, Colwell BM, Bryant TN, Warner JO. Peripheral blood mononuclear cell proliferative responses in the first year of life in babies born to allergic parents. Clin Exp Allergy 1996;26(7):780–88. 90. Xuan W, Marks GB, Toelle BG, et al. Risk factors for onset and remission of atopy, wheeze, and airway hyperresponsiveness. Thorax 2002;57(2):104–9. 91. Sears MR, Burrows B, Flannery EM, Herbison GP, Holdaway MD. Atopy in childhood. I. Gender and allergen related risks for development of hay fever and asthma. Clin Exp Allergy 1993;23(11):941–48. 92. Arshad SH, Tariq SM, Matthews S, Hakim E. Sensitization to common allergens and its association with allergic disorders at age 4 years: a whole population birth cohort study. Pediatrics 2001;108(2):E33. 93. Lichtenstein P, Svartengren M. Genes, environments, and sex: factors of importance in atopic diseases in 7-9-year-old Swedish twins. Allergy 1997;52(11):1079–86. 94. Wieringa MH, Weyler JJ, Van Bever HP, Nelen VJ, Vermeire PA. Gender differences in respiratory, nasal and skin symptoms: 6-7 versus 13-14-year-old children. Acta Paediatr 1999;88(2):147–49. 95. Schachter J, Higgins MW. Median age at onset of asthma and allergic rhinitis in Tecumseh, Michigan. J Allergy Clin Immunol 1976;57(4):342–51.
96. Gibbs CJ, Coutts II, Lock R, Finnegan OC, White RJ. Premenstrual exacerbation of asthma. Thorax 1984;39(11): 833–36. 97. Skobeloff EM, Spivey WH, Silverman R, et al. The effect of the menstrual cycle on asthma presentations in the emergency department. Arch Intern Med 1996;156(16): 1837–40. 98. Zimmerman JL, Woodruff PG, Clark S, et al. Relation between phase of menstrual cycle and emergency department visits for acute asthma. Am J Respir Crit Care Med 2000;162(2 Pt 1):512–15. 99. Beynon HL, Garbett ND, Barnes PJ. Severe premenstrual exacerbations of asthma: effect of intramuscular progesterone. Lancet 1988;2(8607):370–72. 100. Troisi RJ, Speizer FE, Willett WC, et al. Menopause, postmenopausal estrogen preparations, and the risk of adultonset asthma. A prospective cohort study. Am J Respir Crit Care Med 1995;152(4 Pt 1):1183–88. 101. Kalogeromitros D, Katsarou A, Armenaka M, et al. Influence of the menstrual cycle on skin-prick test reactions to histamine, morphine and allergen. Clin Exp Allergy 1995;25(5):461–66. 102. McCormick J, Sims EJ, Mehta A. Delayed diagnosis of females with respiratory presentation of cystic fibrosis did not segregate with poorer clinical outcome. J Clin Epidemiol 2006;59(3):315–22. 103. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996;154(5):1229–56. 104. Wood RE, Boat TF, Doershuk CF. Cystic fibrosis. Am Rev Respir Dis 1976;113(6):833–78. 105. Cystic Fibrosis Foundation, Patient Registry 2006 Annual Report. Bethesda, MD; 2006. 106. Britton JR. Effects of social class, sex, and region of residence on age at death from cystic fibrosis. BMJ 1989;298(6672): 483–87. 107. Davis PB. The gender gap in cystic fibrosis survival. J Gend Specif Med 1999;2(2):47–51. 108. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122(1):1–9. 109. Hudson I, Phelan PD. Are sex, age at diagnosis, or mode of presentation prognostic factors for cystic fibrosis? Pediatr Pulmonol 1987;3(5):288–97. 110. Lai HC, Kosorok MR, Laxova A, et al. Delayed diagnosis of US females with cystic fibrosis. Am J Epidemiol 2002;156(2):165–73. 111. Rosenfeld M, Davis R, FitzSimmons S, et al. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145(9): 794–803. 112. Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997;337(14):963–69. 113. Corey M, Edwards L, Levison H, et al. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131(6):809–14. 114. Davis PB. The decline and fall of pulmonary function in cystic fibrosis: new models, new lessons. J Pediatr 1997;131(6): 789–90. 115. Cystic Fibrosis Foundation, Patient Registry 2001 Annual Report. Bethesda, MD; 2002.
C h a p t e r 3 Gender Differences in Pediatric Pulmonary Disease l
116. Wang SS, O’Leary LA, Fitzsimmons SC, et al. The impact of early cystic fibrosis diagnosis on pulmonary function in children. J Pediatr 2002;141(6):804–10. 117. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48(8):1041–49. 118. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12(3):158–61. 119. Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984;104(2):206–10. 120. Lewin LO, Byard PJ, Davis PB. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 1990;43(2): 125–31. 121. Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985;107(3):382–87. 122. Thomassen MJ, Demko CA, Klinger JD, et al. Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis 1985;131(5):791–96. 123. Nixon PA, Orenstein DM, Kelsey SF, et al. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med. 1992;327(25):1785–86. 124. Zemel BS, Kawchak DA, Cnaan A, et al. Prospective evaluation of resting energy expenditure, nutritional status, pulmonary function, and genotype in children with cystic fibrosis. Pediatr Res 1996;40(4):578–86. 125. Byard PJ. The adolescent growth spurt in children with cystic fibrosis. Ann Hum Biol 1994;21(3):229–40. 126. Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988;112(3): 373–77. 127. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005; 28(9):2141–44. 128. Lanng S. Diabetes mellitus in cystic fibrosis. Eur J Gastroenterol Hepatol 1996;8(8):744–47. 129. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162(3 Pt 1):891–95. 130. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998;113(5):1230–34. 131. Sims EJ, Green MW, Mehta A. Decreased lung function in female but not male subjects with established cystic fibrosisrelated diabetes. Diabetes Care 2005;28(7):1581–87. 132. Sweezey NB, Ghibu F, Gagnon S. Sex hormones regulate CFTR in developing fetal rat lung epithelial cells. Am J Physiol May 1997;272(5 Pt 1):L844–51. 133. Singh AK, Schultz BD, Katzenellenbogen JA, et al. Estrogen inhibition of cystic fibrosis transmembrane conductance regulator-mediated chloride secretion. J Pharmacol Exp Ther Oct 2000;295(1):195–204. 134. Taussig L. Cystic Fibrosis. New York: Thieme-Stratton Inc; 1984.
49
135. Sharma S. Parasomnias. eMedicine 2007, Available at http://emedicine.medscape.com/article/291931-overview. Accessed May 25, 2009. 136. Kales JD, Kales A, Soldatos CR, et al. Night terrors. Clinical characteristics and personality patterns. Arch Gen Psychiatry 1980;37(12):1413–17. 137. Laberge L, Tremblay RE, Vitaro F, et al. Development of parasomnias from childhood to early adolescence. Pediatrics 2000;106(1 Pt 1):67–74. 138. Petit D, Touchette E, Tremblay RE, et al. Dyssomnias and parasomnias in early childhood. Pediatrics 2007;119(5):e1016–25. 139. Klackenberg G. Somnambulism in childhood – prevalence, course and behavioral correlations. A prospective longitudinal study (6–16 years). Acta Paediatr Scand. 1982;71(3):495–99. 140. Byrd RS, Weitzman M, Lanphear NE, et al. Bed-wetting in US children: epidemiology and related behavior problems. Pediatrics 1996;98(3 Pt 1):414–19. 141. Stein MA, Mendelsohn J, Obermeyer WH, et al. Sleep and behavior problems in school-aged children. Pediatrics 2001;107(4):E60. 142. Rosen CL. Clinical features of obstructive sleep apnea hypoventilation syndrome in otherwise healthy children. Pediatr Pulmonol 1999;27(6):403–9. 143. Mohsenin V. Gender differences in the expression of sleepdisordered breathing: role of upper airway dimensions. Chest 2001;120(5):1442–47. 144. Schwab J. Sex differences and sleep apnoea. Thorax 1999;54(4):284–85. 145. Strollo PJ Jr, Rogers RM. Obstructive sleep apnea. N Engl J Med. 1996;334(2):99–104. 146. Young T, Finn L. Epidemiological insights into the public health burden of sleep disordered breathing: sex differences in survival among sleep clinic patients. Thorax 1998;53 (Suppl 3):S16–9. 147. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328(17):1230–35. 148. Guilleminault C, Quera-Salva MA, Partinen M, et al. Women and the obstructive sleep apnea syndrome. Chest 1988;93(1):104–9. 149. Block AJ, Boysen PG, Wynne JW, et al. Sleep apnea, hypopnea and oxygen desaturation in normal subjects. A strong male predominance. N Engl J Med. 1979;300(10):513–17. 150. Chaudhary BA, Speir WA Jr. Sleep apnea syndromes. South Med J 1982;75(1):39–45. 151. Guilleminault C, Stoohs R, Kim YD, et al. Upper airway sleep-disordered breathing in women. Ann Intern Med. 1995;122(7):493–501. 152. Gislason T, Benediktsdottir B, Bjornsson JK, et al. Snoring, hypertension, and the sleep apnea syndrome. An epidemiologic survey of middle-aged women. Chest 1993;103(4):1147–51. 153. Young T, Hutton R, Finn L, et al. The gender bias in sleep apnea diagnosis. Are women missed because they have different symptoms? Arch Intern Med. 1996;156(21):2445–51. 154. Kuhni CE, Sennhauser FH. The Yentl syndrome in childhood asthma: risk factors for undertreatment in Swiss children. Pediatr Pulmonol 1995;19(3):156–60.
50
s e c t i o n 1 Gender and Normal Development l
155. Redline S, Kump K, Tishler PV, et al. Gender differences in sleep disordered breathing in a community-based sample. Am J Respir Crit Care Med 1994;149(3 Pt 1):722–26. 156. Ambrogetti A, Olson LG, Saunders NA. Differences in the symptoms of men and women with obstructive sleep apnoea. Aust N Z J Med 1991;21(6):863–66. 157. Popovic RM, White DP. Influence of gender on waking genioglossal electromyogram and upper airway resistance. Am J Respir Crit Care Med 1995;152(2):725–31. 158. Malhotra A, Huang Y, Fogel RB, et al. The male predisposition to pharyngeal collapse: importance of airway length. Am J Respir Crit Care Med. 2002;166(10):1388–95. 159. Pillar G, Malhotra A, Fogel R, et al. Airway mechanics and ventilation in response to resistive loading during sleep: influence of gender. Am J Respir Crit Care Med 2000;162(5):1627–32. 160. Ali NJ, Pitson DJ, Stradling JR. Snoring, sleep disturbance, and behaviour in 4-5 year olds. Arch Dis Child 1993;68(3):360–66. 161. Gislason T, Benediktsdottir B. Snoring, apneic episodes, and nocturnal hypoxemia among children 6 months to 6 years old. An epidemiologic study of lower limit of prevalence. Chest 1995;107(4):963–66.
162. Chay OM, Goh A, Abisheganaden J, et al. Obstructive sleep apnea syndrome in obese Singapore children. Pediatr Pulmonol. Apr 2000;29(4):284–90. 163. Brouilette R, Hanson D, David R, et al. A diagnostic approach to suspected obstructive sleep apnea in children. J Pediatr. Jul 1984;105(1):10–14. 164. Mallory GB Jr, Fiser DH, Jackson R. Sleep-associated breathing disorders in morbidly obese children and adolescents. J Pediatr 1989;115(6):892–97. 165. Leach J, Olson J, Hermann J, et al. Polysomnographic and clinical findings in children with obstructive sleep apnea. Arch Otolaryngol Head Neck Surg 1992;118(7):741–44. 166. Redline S, Tishler PV, Schluchter M, et al. Risk factors for sleep-disordered breathing in children. Associations with obesity, race, and respiratory problems. Am J Respir Crit Care Med 1999;159(5 Pt 1):1527–32. 167. Kawashima S. Sex-dependent differences in the craniofacial morphology of children with a sleep-related breathing disorder. Oral Surg Oral Med Oral Pathol Oral Radiol Endod Aug 2002;94(2):167–74.
Chapter
4
Gender-Specific Aspects of Pediatric Hematology and Oncology James H. Garvin, Jr Professor of Clinical Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY, USA
Introduction
the hemoglobin level continues to rise throughout puberty to higher levels characteristic of adult men. Thus, the mean hemoglobin level in healthy white children age 11–14 years is 14.0 g/dl in boys and 13.5 g/dl in girls, with the same lower limit (95% range) of 12.0 g/dl (Table 4.1).1 For older adolescents age 15–19 years, the mean hemoglobin level in boys is 15.0 g/dl (lower limit 13.0 g/dl), whereas in girls it remains 13.5 g/dl (lower limit 12.0 g/dl). The difference results from the stimulatory effect of androgen secretion. Indeed, androgenic steroids are used therapeutically in certain bone marrow failure states, notably Fanconi anemia. Because of the difference in hemoglobin levels, the packed cell volume (PCV) will also be higher in adolescent males than females. However, the mean corpuscular volume (MCV) varies only with age, with average values of 85 fL (lower limit 77 fL) in boys and girls age 11–14, and 88 fL (lower limit 79 fL) in boys and girls age 15–19. The blood
While normal developmental changes in fetal and postnatal hematopoiesis are identical in males and females, genderrelated differences in red blood cell production are noted in adolescence and persist throughout adult life. Iron deficiency anemia is particularly common in adolescent girls. Although white blood cell and platelet counts do not differ between males and females, and coagulation factor levels are normally identical, certain disorders of neutrophil function and clotting such as chronic granulomatous disease and hemophilia are X-linked and therefore occur overwhelmingly in males. Sickle cell anemia affects males and females equally but morbidity appears to be increased in males. Childhood cancer is more common in males than females, particularly hematological cancers such as acute lympho blastic leukemia and non-Hodgkin’s lymphoma. Gender differences in survival and patterns of late effects are reported for certain diagnoses. An appreciation of genderspecific aspects of hematologic and oncologic disorders of childhood has resulted in the application of risk-adapted therapeutic strategies, and raises questions about gender differences in disease susceptibility and treatment response. More research is required to understand the molecular and pharmacogenetic basis for these differences.
Table 4.1 Normal values for hemoglobin and mean corpuscular volume Age (yr)
0.5–4 5–10 11–14
Normal hematopoiesis
15–19
Hemoglobin levels are identical in male and female infants and gradually rise at the same rate during childhood. Gender-related differences in hemoglobin concentration begin to emerge in adolescence. In females, the hemoglobin level reaches a plateau during early puberty, while in males Principles of Gender-Specific Medicine
20–44
Gender
M/F M/F F M F M F M
Hemoglobin (g/dl)
MCV (fl)
Mean
Lower limit
Mean
Lower limit
12.5 13.0 13.5 14.0 13.5 15.0 13.5 15.5
11.0 11.5 12.0 12.0 12.0 13.0 12.0 13.5
80 83 85 85 88 88 90 90
72 75 77 77 79 79 80 80
Lower limit of normal is 95% range. From Dallman and Slimes, 19791
51
Copyright 2010 20 , Elsevier Inc. All rights reserved.
52
s e c t i on 1 Gender and Normal Development l
volume depends on weight, averaging 75–77 ml/kg in children and adults of both genders. Bone marrow cellularity and differential cell count are comparable in males and females. However, subtle genderrelated differences have been noted, such as the more pronounced age-related decline in alkaline-phosphataseexpressing colony forming units (CFU-AP) seen in women compared to men,2 which could be relevant to gender differences in bone loss and osteoporosis. Recent research on determinants of hematopoietic and mesenchymal stem cell differentiation in healthy subjects and patients with osteoarthritis and rheumatoid arthritis reveals age-related increases in RANKL and PPAR-gamma levels (osteoclast and adipocyte determinants) and DRAK1 expression (apoptosis-related gene) in females but not males.3 Peripheral blood white cell count, platelet count, and coagulation factor levels are all independent of gender, but there may be functional differences. For example, an influence of the menstrual cycle on monocyte cytokine release in response to lipopolysaccharide stimulation has been demonstrated.4 Studies of the immune response to hemorrhagic shock have shown enhanced immune function and lower mortality from subsequent sepsis in females compared to males.5 In a murine model, interleukin-10 treatment restored depressed immune responses (splenocyte proliferation, interferon-gamma, and interleukin 1-) preferentially in male animals, without further enhancing immune function in female animals, suggesting a potential relative deficit or inhibition of IL-10 in males.
Iron deficiency anemia Iron deficiency in American children occurs mainly in older infants and adolescents. Rapidly growing infants are subject to inadequate dietary intake of iron and possible intestinal blood loss due to sensitivity to cow’s milk protein; male and female infants are equally at risk. Among adolescents, rapid growth with the expansion of the total blood volume and lean body mass may also lead to iron deficiency, and there are additional gender-specific factors. In males, there is a more substantial increase in hemoglobin level due to androgen secretion, with corresponding greater need for iron, while females begin to experience menstrual blood loss and may deplete iron stores. Overall iron requirements increase from a preadolescent level of 0.7–0.9 mg of iron per day to as much as 2.2 mg per day or more in heavily menstruating young women.6 Based on the third National Health and Nutrition Examination Survey (1988–1994), the prevalence of iron deficiency in the United States is estimated to be 9% among toddlers aged 1–2 years, and 9–11% among adolescent girls and women of child-bearing age.7 The corresponding prevalence of iron deficiency anemia was 3% among toddlers and 2–5% among adolescent girls and young women. Iron deficiency was found in no more
than 1% of adolescent boys and young men. Among adolescents in Japan, mild hypochromic anemia was detected in 5% of girls compared to 2% of boys, and it was suggested that the difference might be due in part to dieting.8 Iron deficiency anemia is a much greater problem in the developing world. The World Health Organization estimates that 46% of the world’s children aged 5–14 years are anemic. Assessment of iron bioavailability from dietary sources in both developing and industrialized countries suggests that a negative iron balance is likely in many female adolescent populations. Other nutritional anemias are more likely to be related to underlying disease states rather than gender.
Glucose-6-phosphate dehydrogenase deficiency G6PD deficiency is relatively common, with sex-linked recessive inheritance because the G6PD locus is on the X chromosome. G6PD deficiency affects more than 1% of males in Mediterranean and Middle Eastern regions, 5% of Chinese males, and 10% of black males. Clinical manifestations of episodic acute hemolysis following infection or ingestion of certain drugs will be seen either in affected males or rare female homozygotes. Female heterozygotes are usually unaffected, but may have excess enzyme deficient cells due to random X chromosome inactivation and can potentially be symptomatic. Definitive diagnosis is by quantitative enzyme assay in red cell lysates, but screening tests are available for identification of susceptible individuals. The standard fluorescent spot test reliably detects hemizygous totally G6PD-deficient males but fails to detect heterozygous partially G6PD-deficient females. Newer fully quantitative screening tests will detect the latter individuals.
Sickle cell disease Sickle cell disease is an inherited chronic hemolytic anemia primarily affecting children of black ancestry. The most common forms are sickle cell anemia, sickle -thalassemia, and sickle hemoglobin C disease. All occur equally in males and females. However, there may be gender-related differences in some of the acute and chronic complications of this disease. For example, hyper-hemolytic crisis is associated with red cell G6PD deficiency, and therefore considerably more likely in boys than girls. Gender differences in morbidity and mortality are reported in adults with sickle cell disease. The Cooperative Study of Sickle Cell Disease reported a median age of death of 42 years for men and 48 years for women, a greater difference than in black control subjects.9 There is a striking increase in veno-occlusive crisis after age 15 years, with a greater rate of pain attacks in males than females.10 Female patients have slightly greater fetal hemoglobin
C h a p t e r 4 Gender-Specific Aspects of Pediatric Hematology and Oncology l
levels, which may be protective. The basis for these differences could lie in the observation that nitric oxide bioavailability and responsiveness are reduced in males but not females with sickle cell disease.11 Nitric oxide is thought to be important in maintaining vasomotor tone, limiting platelet aggregation, inhibiting ischemia-reperfusion injury, and modulating endothelial adhesion molecule expression. Sickle cell-related vascular phenomena of increased shear stress and compensatory responses to chronic vascular injury normally promote increased endothelial nitric oxide production, but this system is impaired in males. Estrogens facilitate nitric oxide production and limit its consumption. Moreover, nitric oxide has been linked to transcriptional control of fetal hemoglobin and could therefore contribute to gender differences in fetal hemoglobin expression.12 Therapies that restore nitric oxide bioactivity or reduce its consumption (or enhance non-nitric oxide induced vasodilatation) could be particularly beneficial in male patients with sickle cell anemia. The onset of puberty may be delayed by several years in both boys and girls with sickle cell disease. Various nutritional abnormalities have been reported. A study of adolescents and young adults in Nigeria found that, compared to controls, male patients had a significantly lower mean weight, body mass index, mid-arm circumference, and triceps and subscapular skinfold thickness, whereas these differences from controls were not noted in female patients. This was not due to any difference in intake of calories and micronutrients (when corrected for body weight), and suggested a gender-related difference in somatic growth.
Chronic granulomatous disease (cgd) CGD is a neutrophil function defect inherited predominantly in an X-linked manner, and therefore affects mainly boys. In CGD, the oxidative reactions required for bacterial killing by neutrophils are impaired, resulting in recurrent infection. There is an autosomal recessive form of CGD, affecting girls as well as boys, but the genetic abnormality is different. The X-linked disorder involves absence of membrane cytochrome b558, a heterodimer with 91 and 22 kilodalton subunits, due to a defect in the gene encoding the 91 kD protein. In the autosomal recessive form, there is lack of a neutrophil cytosolic oxidase protein.13
Coagulation defects Classic hemophilia (hemophilia A; factor VIII deficiency) is the most common hereditary deficiency of a coagulation factor with clinically severe manifestations. The disease is transmitted by females as a sex-linked recessive trait, and the estimated incidence is 1 per 10 000 white male births
53
in the United States. Severely affected males generally have factor VIII levels below 1% of normal, while levels between 1 and 5% are associated with moderate disease severity. Female carriers are usually asymptomatic, but the majority have subnormal levels of factor VIII activity in the range of 30–50%. Because factor VIII is bound to von Willebrand factor (VWF) in the circulation, carriers can be suspected based on low ratio of factor VIII activity to VWF antigen, and the carrier state can be confirmed by molecular genetic testing using DNA probes. von Willebrand disease is considerably more common than factor VIII deficiency, but affects males and females equally. Most often VWD is inherited as an autosomal dominant trait with mild to moderate bleeding tendency. The autosomal recessive form of VWD is associated with more severe bleeding. Factor IX deficiency (hemophilia B; Christmas disease) is sex-linked and accounts for about 12% of hemophilia. Factor IX deficiency is clinically indistinguishable from hemophilia A; female carriers may have subnormal levels of factor IX, and carrier status can be confirmed by molecular genetic testing. The remaining clotting factor deficiencies are not sexlinked, but in at least one case, that of factor VII, gender related differences in concentration (determined by monoclonal antibody) and pro-coagulant activity (determined by clotting assay) have been described in healthy adolescents and adults.14 There appears to be a gender dependent effect of factor VII gene polymorphisms on plasma levels of factor VII.15 The clinical significance of these differences is uncertain.
Childhood cancer Incidence Childhood cancer, the leading cause of non-accidental deaths below age 15 years, is more frequent in males than females. For the period 1990–7, the incidence of cancer in all children in the United States under age 15 years was 141 per million, or 1 in 7000.16 The incidence in males was 152 per million, compared to 130 per million females (male: female ratio 1.2). Similarly, the overall incidence for adolescents age 15–19 years was 207 per million, or 1 in 4800, but the incidence in males was 212 per million compared to 201 per million in females (male:female ratio 1.1). Cancer incidence in young persons increased between 1975 and 2000, with disproportionate increases among males in the age groups 0–1 year, 10–14 years, and 15–19 years. Data for the year 2004 continue to show an excess incidence as well as excess mortality in males (Table 4.2). The age-adjusted cancer incidence rates for males and females age 0–19 years were 176 and 157 per million, respectively, while the age-adjusted mortality rates for males and females
s e c t i on 1 Gender and Normal Development
54
l
Table 4.2 Age-adjusted invasive cancer incidence rates for ages 0–19 by International Classification of Childhood Cancer Subgroup, United States, all races, 2004 Diagnosis
All diagnoses Lymphoid leukemia Acute myeloid leukemia Hodgkin’s disease Burkitt’s lymphoma Other non-Hodgkin’s lymphoma Ependymoma/choroid plexus Astrocytoma CNS embryonal tumor Other glioma Other specified CNS tumor Neuroblastoma Retinoblastoma Nephroblastoma Renal cell carcinoma Hepatoblastoma Hepatocellular carcinoma Osteosarcoma Chondrosarcoma Ewing’s sarcoma Rhabdomyosarcoma Fibrosarcoma Other specified soft tissue sarcoma CNS germ cell tumor Gonadal germ cell tumor Extragonadal germ cell tumor Thyroid carcinoma Nasopharyngeal carcinoma Malignant melanoma
Incidence rates M
Fe
M:F
176.2 36.4 9.0 11.8 3.5 10.4 2.8 14.6 7.2 4.7 0.8 8.2 3.0 5.5 0.5 1.9 0.6 5.0 0.7 2.7 4.8 1.1 5.0 2.4 9.9 1.1 2.4 0.7 5.7
157.2 27.3 7.0 11.3 1.1 6.2 2.5 14.5 5.7 4.6 0.6 7.6 3.1 5.8 0.5 1.6 0.5 5.1
1.1 1.3 1.3 1.0 3.2 1.7 1.1 1.0 1.3 1.0 1.3 1.1 1.0 0.9 1.0 1.2 1.2 1.0
2.4 3.6 1.5 4.8 1.1 4.6 1.4 11.0
1.1 1.3 0.7 1.0 2.2 2.2 0.8 0.2
6.8
0.8
Rates are per 1 000 000 and are age-adjusted to the 2000 US standard population. Source: US Cancer Statistics Working Group42
were 30 and 24 per million, respectively. There is a striking male preponderance for non-Hodgkin’s lymphoma (male:female ratio 3.2 for Burkitt’s lymphoma and 1.7 for other non-Hodgkin’s lymphoma). Other pediatric cancers showing a 1.2-fold or higher male predominance are acute lymphoblastic leukemia (the commonest type of childhood cancer), acute myeloid leukemia, central nervous system embryonal and germ cell tumors, hepatoblastoma, hepatocellular carcinoma, rhabdomyosarcoma, and gonadal germ cell tumors. Langerhans cell histiocytosis, a monoclonal neoplastic disorder with variable clinical manifestations, is also more common in males than females. Remarkably, thyroid cancer is five times more frequent in females than males. Other cancers with a female predominance are fibrosarcoma and extragonadal non-CNS germ cell tumors. Of note, the incidence of malignant melanoma,
which affects 20% more girls than boys, is rising faster than that of any other cancer in the United States. Data from other countries confirm the general finding that childhood cancer is more common in males than females. Registry data for 53 countries show male:female ratios ranging from 1.09 to 2.05.17 The greatest excess of males in childhood cancer registrations tends to be reported from developing countries, and may reflect socioeconomic factors as well as underlying disease incidence.
Risk Factors Gender-specific risk factors for cancer in children include cryptorchidism (testicular germ cell tumors) and X-linked immunodeficiencies such as Wiscott–Aldrich syndrome and X-linked lymphoproliferative disorder (non-Hodgkin’s lymphoma). Phenotypic females with all or part of a Y chromosome are at risk for development of gonadoblastoma in the streak gonads.18 Included in this group are girls with androgen resistance syndromes, gonadal dysgenesis, and Turner syndrome with mosaicism (45X,46XY). Gonadoblastoma in these conditions has been linked to the TSPY gene on the Y chromosome.19 Prophylactic removal of the gonads (which are generally nonfunctional) is recommended because the risk of gonadoblastoma can be as high as 25%. Males with Klinefelter syndrome (47XXY) appear to have an increased risk of dysgerminomas20 and extra-gonadal germ cell tumors21 as well as breast cancer,22 but probably not leukemia23 as previously thought. Beckwith–Wiedemann syndrome is associated with an increased risk of Wilms tumor and hepatoblastoma, and although independent of the patient’s gender, this syndrome can be traced specifically to the child’s mother or father. For example, the autosomal dominant form of BWS (linked to chromosome 11p15) is more likely to be inherited from the mother,24 while a sporadic form may result from inheritance of two copies of a paternal chromosome 11,25 an example of genomic imprinting. The excess of males with acute lymphoblastic leukemia is more pronounced among pubertal children, but a role for sex hormones has not been conclusively demonstrated. There is some evidence for an impact of genetic polymorphisms. One study found a protective effect for girls having a particular cytochrome P-450 allele.26 Another study found an increased risk for boys who were HLA-DRB4*01 and had a certain mutation in the hereditary hemochromatosis gene.27 The male predominance in ALL is also particularly evident in the T cell subtype of the disease.28 A nonrandom chromosomal translocation, t(11;14)(p13;q11), involving the T cell receptor, is associated with T cell phenotype, male gender, high white blood count, and extramedullary disease. Another clonal chromosomal aberration in ALL, del(6q), is also more frequent in males than females, whereas t(1:19) in ALL and del(5q) in myelodysplastic syndrome is more common in females than males.29
C h a p t e r 4 Gender-Specific Aspects of Pediatric Hematology and Oncology l
The male predominance in pediatric CNS tumors results from the excess of males with medulloblastoma (the commonest malignant brain tumor) and CNS germ cell tumors. The biologic basis for gender differences in CNS tumor incidence is unclear. The larger head size in boys compared to girls has been attributed to the relatively larger posterior fossa CSF spaces in males, allowing higher peak pressure in the lateral ventricles during fetal development;30 restriction of posterior fossa growth in girls has been hypothesized to explain the higher incidence of spina bifida in girls, but as yet there is no corresponding hypothesis to account for differential incidence of posterior fossa medulloblastoma. Germ cell tumors of the pineal region are up to nine times more common in males than females, whereas suprasellar germ cell tumors and pineal parenchymal tumors (pineoblastomas) affect males and females equally. Wilms tumor is slightly more frequent in girls than boys. Interestingly, the male:female ratio is 0.92:1 for unilateral tumors, and 0.60:1 for bilateral cases.31 The mean age of presentation is 3–5 months earlier for boys. Wilms tumor is associated with pseudohermaphroditism (Denys–Drash syndrome, associated in turn with mutations in chromosome 11p).32 An impact of gender is noted in renal cell carcinoma, which affects mainly adults but also adolescents.33 Males have an excess incidence of renal cell carcinoma, and present with larger, higher stage, and higher grade tumors. Since obesity is a risk factor, it has been suggested that adipocytokines such as leptin may be implicated in tumor growth;34 gender differences in adipocytokines are noted during pubertal progression, related to changing serum androgen levels.35 Both hepatoblastoma and hepatocellular carcinoma are more common in boys than girls. Although likely multifactorial, this difference could be due in part to gender disparities in inflammatory cytokine production and prevailing levels in the tumor microenvironment.36 Pediatric germ cell tumors occur predominantly in the 15–19 year age group, with a male:female ratio of 2.4:1. Testicular germ cell tumors in adolescent males and ovarian germ cell tumors in adolescent females have common features of aneuploidy and isochrome 12p, and appear to arise in premeiotic germ cells37,38 with progression following puberty, implicating hormonal factors. Additional histologies seen in ovarian germ cell tumors include mature and immature teratoma, suggesting possible clonal evolution in females. The development of an aneuploid endodermal sinus tumor with i(12p) within a diploid ovarian immature teratoma lacking i(12p) has been described.39 Clinically, ovarian teratomas may be associated with peritoneal implants of mature glial tissue (gliomatosis peritonei), while testicular germ cell tumors can be accompanied by neoplasia in situ in adjacent seminiferous tubules (intra tubular germ cell neoplasia). Pediatric thyroid carcinoma occurs predominantly in adolescent females. Radiation is known to be causative,
55
but without gender-specificity; the male:female ratio for papillary thyroid carcinoma in children of the Republic of Belarus exposed after the Chernobyl nuclear reactor accident was 1.0:1.2. Gender differences in thyroid cancer incidence are more likely due to genetic and immunologic factors. For example, papillary and follicular thyroid cancers have been reported in children with Hashimoto’s thyroiditis, which has a marked predilection for females and may be associated with altered immune surveillance. An influence of sex hormones on the immune system is suggested by studies in mice showing that estrogen treatment induces polyclonal B cell activation with increased expression of autoantibodies characteristic of autoimmune disease.40 While few cancers in children and adolescents can be directly attributed to environmental exposures, one genderspecific example is clear cell adenocarcinoma of the vagina or uterine cervix in teenage girls whose mothers took diethylstilbestrol (DES) prenatally.41 A case-control interview study of maternal hormone and fertility drug use and its possible association with neuroblastoma (the commonest cancer of infancy) in offspring found no consistent increased risk, but suggested an increased risk only for males after exposure to oral contraceptives or clomiphene.42
Survival Outcome Overall survival rates for children with cancer have improved substantially. Five-year survival was only 28% in the 1960s, but increased to 75% by the 1990s. Age-adjusted cancer death rates in children and adolescents age 0–19 years decreased from 34.2 per million in 1990 to 27.3 in 2004.43 The death rate in males decreased from 37.8 to 30.1 per million, while the death rate in females decreased from 30.4 to 24.3 per million. Gender-specific differences in survival outcome are apparent in several childhood cancers. The prognosis for girls with ALL is consistently better than for boys.44 This has been attributed to the increased frequency of T cell ALL in boys, with associated shorter remission duration, but a survival advantage for girls has been noted in both T cell and pre-B cell ALL.45,46 Boys also have an additional risk of relapse in the testicles; with recent advances in therapy this risk is now approximately 5%. The testes may be a sanctuary site for occult disease due to limited access of systemic chemotherapy, but evidence for involvement of the ‘blood–testis barrier’ is inconclusive. Moreover, male gender has been a significant predictor of late relapse even when adjusted for isolated testicular relapse.47 Ovarian relapse is evidently rare.48 The survival advantage for females with ALL is likely due to additional unidentified genetic, endocrine, and metabolic differences. Like other prognostic variables, the influence of gender may be treatment-dependent and change with therapeutic advances, as in recent Children’s Cancer Group trials.49 Interestingly,
56
s e c t i on 1 Gender and Normal Development l
gender differences in survival and mortality are not seen in children with acute myelocytic leukemia. Because girls have had superior survival in ALL, treatment duration is often shorter than for boys. Typically, girls may be treated for two years, compared to three years for boys. One study found that 1.5 years of treatment was sufficient for girls, but not boys.50 Less is known about the possible influence of gender on survival from solid tumor malignancies. Females have superior survival outcome in primary cutaneous melanoma,51 which could be due to earlier detection, but also in metastatic melanoma, which may be explained by differential effects of female and male hormones on tumor cell invasiveness.52 A prospective study of adults with colorectal cancer found significantly longer disease-free and overall survival in women compared to men following curative rectal cancer resection,53 suggesting possible differences in the immunological response to surgery. A tumor registry study of non-small cell lung carcinoma in adults found that men had significantly shorter median survival than women, independent of disease stage, and also lost significantly more weight over the course of the disease,54 suggesting possible gender determinants of cancer cachexia. The possible relevance of these observations to pediatric solid tumors such as neuroblastoma remains to be determined. Gender differences have been noted in interval from symptom onset to diagnosis of certain pediatric solid tumors. Compared to boys, girls had increased lag time to diagnosis of non-Hodgkin’s lymphoma but shorter lag time to diagnosis of Ewing sarcoma.55 However, age, gender, and race together accounted for only 16% of variance in lag time, which ranged from 21 days for neuroblastoma to 72 days for Ewing sarcoma.
Acute and Late Effects of Treatment Gender-related differences in susceptibility of children to the toxic effects of cancer chemotherapy are illustrated by doxorubicin-induced cardiomyopathy. The incidence of cardiac abnormalities at any cumulative dose of doxorubicin is higher in girls than boys,56 and female gender, together with young age and high cumulative dose, is a major risk factor for late-onset cardiotoxicity which may be life-threatening.57 Because of relatively more body fat, girls may have decreased clearance of anthracycline drugs, prolonging exposure. Myocardial damage may be more critical in girls than boys because of smaller ventricular mass and wall thickness relative to body size. Late-onset cardiomyopathy may also be provoked by pregnancy.58 Doxorubicin therapy is a risk factor for excess mortality in long-term survivors of childhood cancer.59 Cardioprotective agent, dexrazoxane, has been shown to be efficacious in children.60 There may be gender differences in the severity of other acute toxicities of treatment. For example, a review of infections occurring in children being treated for cancer found
what appeared to be an excess of girls among children dying of Gram-negative sepsis.61 Girls may be more susceptible to chemotherapy-induced nausea and vomiting, and tend to use different coping strategies compared to boys.62 A major concern of patients and families is gonadal toxicity of treatment for childhood cancer. Radiation therapy and alkylating agents such as cyclophosphamide can cause infertility and endocrine dysfunction. Although these effects are age- and dose-dependent in both males and females, there are gender differences in the pattern of toxicity. Infertility is more common in male than female survivors of childhood cancer. Relatively low doses of radiation and moderate doses of certain chemotherapy agents cause permanent azoospermia in males, whereas Leydig cell dysfunction is seen only with higher radiation doses and may remain subclinical after chemotherapy if compensated (low normal testosterone with elevated LH). Permanent azoospermia was found after radiation therapy for Hodgkin’s disease with testicular exposures of 140–300 cGy,63 and 8 of 10 survivors of Wilms tumor treated before puberty with abdominal irradiation (testicular exposure 268–983 cGy) had oligospermia or azoospermia.64 Leydig cell function was preserved following fractionated doses up to 1200 cGy in prepubertal boys,65 while decreased testosterone levels are seen in boys treated with 2400 cGy for testicular leukemia,66 and doses exceeding 3000 cGy cause Leydig cell failure in at least half of patients.67 Chemotherapy with mechlorethamine, vincristine, prednisone, and procarbazine (MOPP) for Hodgkin’s disease caused permanent azoospermia in 80%,68 while the alternative regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) caused azoospermia in only 38%, reversible in all.69 Small testes are reported following prepubertal treatment with MOPP for Hodgkin’s disease,70 nitrosoureas for brain tumors,71 and cyclophosphamide for paratesticular rhabdomyosarcoma.72 Compensated Leydig failure may be found at diagnosis or following MOPP chemotherapy for Hodgkin’s disease,68,73 but Leydig cell function is preserved following chemotherapy for ALL.74 In females, adverse effects of cancer treatment on fertility and ovarian endocrine function tend to occur in parallel. Radiation doses of 400–700 cGy caused irreversible ovarian failure in adult women,75 but not necessarily in prepubertal or adolescent girls, in whom exposure of one or both ovaries to doses of 90–1000 cGy caused ovarian failure in only 23%.76 However, total body irradiation in a single fraction of 1000 cGy caused primary amenorrhea in most young girls, and premature menopause has also been reported.77 MOPP chemotherapy for Hodgkin’s disease in young women resulted in amenorrhea in 30% of cases,78 a substantially lower incidence of infertility than in males. Even after six cycles of alkylator-based chemotherapy, ovarian function was preserved in at least 80% of females.79 Ovarian failure was transient in prepubertal girls receiving MOPP,80 and chemotherapy for ALL caused no gonadal dysfunction.
C h a p t e r 4 Gender-Specific Aspects of Pediatric Hematology and Oncology l
For males, sperm banking prior to treatment may be recommended, and normal children have been born following artificial insemination with patients’ cryopreserved sperm.81 For females, cryopreservation of ova prior to treatment remains investigational,82 but a successful term pregnancy has been achieved following ovarian cryopreservation in a woman treated for Hodgkin’s disease.83 Suppression of ovarian function with oral contraceptives may reduce the risk of ovarian damage during cancer treatment; a gonadotropin-releasing hormone agonist was protective in young women with lymphoma.84 Surgical oophoropexy to transfer ovaries out of the radiation field has afforded preservation of ovarian function in female patients requiring abdominal and pelvic irradiation.85 Although chemotherapy is likely to be teratogenic in the first trimester of pregnancy, children of cancer survivors who completed intensive chemotherapy (including myeloablative chemotherapy with bone marrow transplant) prior to pregnancy tend to be normal.86 In a survey of more than 6000 pregnancies in couples one of whom was a childhood cancer survivor, no excess adverse outcomes were attributed to chemotherapy with the possible exception of procarbazine received by males.87 Neurocognitive and Psychological Outcomes Neurocognitive deficits following radiotherapy for medulloblastoma and ALL are more frequent in girls than boys;88,89 girls’ intellectual performance was also worse than boys’ following ALL treatment in which prophylactic irradiation was abandoned in favor of more intensive systemic and intrathecal chemotherapy.90 Hormonal factors appear to interact with both radiation and chemotherapy in the developing brain, accounting for differential genderrelated treatment toxicity. Long-term survivors of childhood leukemia, Hodgkin’s disease, and non-Hodgkin’s lymphoma, although generally psychologically healthy, were 1.6–1.7 times more likely than siblings to report depressive symptoms and somatic distress.91 The relative risk for women was significantly higher than for men among survivors, but also among sibling controls. Further research is necessary to determine if female survivors experience more depression and somatic distress than male survivors, or whether the test measures used are simply more sensitive to females’ expression of their psychological status. Regardless, female gender may compound other risk factors for adverse psychological outcome. Recent research on childhood brain tumor survivors found greater risk of depression in girls than boys, particularly in girls with more limited social skills or lower selfconfidence.92 Even girls with high social skills but low self-worth scores reported significant depression. Among boys, risk of depressive symptoms was increased only in those with low scores for both attributes. Girls may be more vulnerable to low self-worth following diagnosis of a brain tumor, or may simply be better than boys at expressing their negative feelings.
57
Second Malignant Neoplasms The most serious late effect of cancer treatment is the development of a second malignant neoplasm. Females are almost twice as likely as males to develop a second cancer after treatment for Hodgkin’s disease in childhood.93 The actuarial risk at 20 years was 9.7% for males and 16.8% for females. The difference in females was due to a 9.2% risk of breast cancer, and subsequent studies have confirmed that the risk of breast cancer is uniquely high in females treated below age 19 years for Hodgkin’s disease.94 The risk of breast cancer may approach 35% by age 40 years, with the majority of the breast cancers occurring within radiation fields.95 Awareness of gender-specific toxicities of cancer therapy has prompted new strategies to reduce late effects, involving risk-adapted treatment with different regimens for male and female patients. The best example is Hodgkin’s disease, where high cure rates can be achieved with several different radiation and chemotherapy combinations. Thus, in males, who have an excess of infertility with MOPP chemotherapy, the alternative regimen of ABVD may be preferred, with or without radiation therapy according to other risk factors. In females, who have a substantial risk of radiation-induced breast cancer, chemotherapy may be intensified to minimize the need for radiation therapy. It is anticipated that riskadapted therapy for Hodgkin’s disease with gender-specific chemotherapy and low-dose radiotherapy will be associated with a reduction in secondary breast cancer and male infertility, but prospective trials are required to confirm that cure rates will be preserved. Bone Marrow Transplant Bone marrow transplant and the related techniques of peripheral blood stem cell transplant and placental cord blood transplant are potentially curative for a variety of malignant and non-malignant conditions in childhood. Major indications for bone marrow transplant include acute leukemia and lymphoma, advanced neuroblastoma, severe aplastic anemia, and severe combined immunodeficiency disease. Among these disorders, there is a male predominance in acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, and congenital immunodeficiency. Taking into account this biological difference in disease incidence, there is no male bias in referral for stem cell transplant, in contrast to renal transplantation, where a bias against females has been documented.96 A serious complication of allogeneic bone marrow transplant is graft versus host disease. Although GVHD occurs equally in males and females, there is a greater risk of acute GVHD when the donor is female, and gender mismatch between donor and recipient tends to increase the risk of chronic GVHD.97 GVHD is a major contributor to transplant-related mortality (TRM) at day 100; female to male transplant for pediatric leukemia was associated with
58
s e c t i on 1 Gender and Normal Development l
increased risk of TRM, particularly if there was HLA mismatch.98 An earlier study found that female donor gender was associated with increased severity of acute GVHD, particularly with female donors of older age compared to recipient.99 This could not be attributed to gender-related differences in the marrow content of immunoreactive cells. Increasing parity in female donors further increases the risk of acute GVHD, suggesting some female donors have been presensitized to their respective recipients by prior pregnancies. It is known that sex chromosome-linked minor histocompatibility determinants are important in acute GVHD, and it had been assumed that this was simply due to female donor cell recognition of recipient male HY antigens as foreign. Studies in mice indicate that reaction against recipient female HX antigen is also possible, and suggest that sex chromosome-linked minor histocompatibility determinants may be polymorphic and capable of multiple allelic expression.100
Chronic Pain An important feature of childhood cancer and certain hematologic disorders such as sickle cell disease is chronic pain-related to the underlying disease, as well as acute pain related to diagnostic and therapeutic procedures. Genderrelated differences in pain tolerance and coping strategies are widely reported in adults, but less is known about children. Tools such as the Pain Experience Interview provide insight into the experience of acute, recurrent, and chronic pain by children at different ages and developmental stages.106 Using such methodology, investigators are conducting exploratory analyses of age- and gender-related differences in children’s pain experience.
Suggestions for further investigations Gender-specific determinants of somatic growth and vaso-occlusive crisis pain in sickle cell anemia. Potential gender differences in tumor immunity, tumor invasiveness, immune response to surgery, and susceptibility to immunotherapy, as may be revealed from gene expression profiling. Risk-adapted treatment of childhood cancers with the goal of reducing gender-specific late effects, using the model of Hodgkin’s disease.
●
●
Pharmacokinetics and Drug Toxicity Potential gender-related differences in drug metabolism and toxicity are increasingly appreciated. Among the drugs implicated are some which are important in cancer treatment and supportive care. Gender differences in drug metabolism and elimination are mainly related to steroid hormone levels. Cytochrome P450 isozyme CYP3A4, which is responsible for the metabolism of the majority of therapeutic drugs, is reported to exhibit higher activity in females than males.101 Conversely, the activity of other cytochrome P450 isozymes (CYP2C19, CYP2D6, and CYP2E1), as well as glucuronidation activity, may be higher in males than females. Among the newer immunosuppressive agents used to prevent GVHD following bone marrow transplant, sirolimus may be more potent in adult males than females, based on inhibition of lymphocyte proliferation in vitro.102 Gender-related differences in adverse reactions to antibiotics and other drugs have been noted in adults.103 The extent of gender differences, if any, in drug metabolism, efficacy, and toxicity in the pediatric age group is beginning to be investigated. A study of pediatric ALL patients receiving high-dose methotrexate found a genderspecific impact of a particular adenosine triphosphate-binding cassette class transporter polymorphism (-24T allele); girls carrying at least one -24T allele had two-fold higher mean plasma methotrexate area under the curve compared to all other patients,104 and were substantially more likely to require intensified folinic acid rescue. An early review of experience with investigational cancer chemotherapy trials in children found no significant gender differences in response, disease progression, or death on study,105 but with new classes of agents entering phase I trials, further study of gender influences on drug metabolism is warranted.
●
References 1. Dallman PR, Slimes MA. Percentile curves for hemoglobin and red-cell volume in infancy and childhood. J Pediatr 1979;94:26. 2. Muschler GF, Nitto H, Boehm CA, et al. Age- and genderrelated changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res 2001;19:117–25. 3. Jiang Y, Mishima H, Sakai S, et al. Gene expression analysis of major lineage-defining factors in human bone marrow cells: effect of aging, gender, and age-related disorders. J Orthop Res Feb 2008;26, (epub ahead of print). 4. Schwarz E, Schafer C, Bode JC, et al. Influence of the menstrual cycle on the LPS-induced cytokine response of monocytes. Cytokine 2000;12:413–16. 5. Kahlke V, Dohm C, Brotzmann K, et al. Gender-related therapy: early IL-10 administration after hemorrhage restores immune function in males but not in females. Shock 2000;14:354–59. 6. Beard JL. Iron requirements in adolescent females. J Nutr 2000;130:440S–442S. 7. Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. JAMA 1997;277:973–976. 8. Maeda M, Yamamoto M, Yamauchi K. Prevalence of anemia in Japanese adolescents: 30 years’ experience in screening for anemia. Int J Hematol 1999;69:75–80. 9. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994;330:1639–1644.
C h a p t e r 4 Gender-Specific Aspects of Pediatric Hematology and Oncology l
10. Baum KF, Dunn DT, Maude GH, et al. The painful crisis of homozygous sickle cell disease: a study of the risk factors. Arch Intern Med 1987;147:1231–1234. 11. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003;107:271–278. 12. Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclasecGMP-dependent protein kinase pathway. Proc Natl Acad Sci USA 2001;98:1847–1852. 13. Curnutte JT, Scott PJ, Babior BM. Functional defect in neutrophil cytosols from two patients with autosomal recessive cytochrome-positive chronic granulomatous disease. J Clin Invest 1989;83:1236. 14. Albrecht S, Kotzsch M, Siegert G, et al. Detection of circulating tissue factor and factor VII in a normal population. Thromb Haemost 1996;75:772–777. 15. DiCastelnuovo A, D’Orazio A, Amore C, et al. Genetic modulation of coagulation factor VII plasma levels: contribution of different polymorphisms and gender-related effects. Thromb Haemost 1998;80:592–597. 16. Ries LAG, Smith MA, Gurney JG, eds. Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. National Cancer Institute, SEER Program, NIH Pub No 99-4649. Bethesda, MD, 1999. 17. Pearce MS, Parker L. Childhood cancer registrations in the developing world: still more boys than girls. Int J Cancer 2001;91:402–406. 18. Manuel M, Katayama PK, Jones HW Jr. The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. Am J Obstet Gynecol 1976;124:293–300. 19. Lau YF. Gonadoblastoma, testicular and prostate cancers, and the TSPY gene. Am J Hum Genet 1999;64:921–927. 20. Chaussain JL, Lemerle J, Roger M, et al. Klinefelter syndrome, tumor, and sexual precocity. J Pediatr 1980;97:609–611. 21. Bussey KJ, Lawce HJ, Olson SB, et al. Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences – a Children’s Cancer Group study. Genes Chromosomes Cancer 1999;25:134–146. 22. Hultborn R, Hanson C, Köpf I, et al. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res 1997;17:4293–4297. 23. Horsman DE, Pantzar JT, Dill FJ, et al. Klinefelter’s syndrome and acute leukemia. Cancer Genet Cytogenet 1987;26:375–376. 24. Viljoen D, Ramesar R. Evidence for paternal imprinting in familial Beckwith–Wiedemann syndrome. J Med Genet 1992;29:221–225. 25. Slatter RE, Elliott M, Welham K, et al. Mosaic uniparental disomy in Beckwith–Wiedemann syndrome. J Med Genet 1994;31:749–753. 26. Krajinovic M, Labuda D, Richer C, et al. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999;93:1496–1501. 27. Dorak MT, Burnett AK, Worwood M, et al. The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia [Letter; comment]. Blood 1999;94:3957.
59
28. Neglia JP, Robison LL. Epidemiology of the childhood acute leukemias. Pediatr Clin North Am 1988;35:675–692. 29. Mertens F, Johansson B, Mitelman F. Age- and gender-related heterogeneity of cancer chromosome aberrations. Cancer Genet Cytogenet 1993;70:6–11. 30. Williams H. Gender, head size and disease: a hypothesis related to posterior fossa growth. Med Hypotheses 2008, doi:10.1016/j.mehy.2007.10.015. 31. Breslow N, Olshan A, Beckwith JB, et al. Epidemiology of Wilms tumor. Med Pediatr Oncol 1993;21:172–181. 32. Coppes MJ, Huff V, Pelletier J. Denys–Drash syndrome: relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1. J Pediatr 1993;123:673–678. 33. Aron M, Nguyen MM, Stein RJ, et al. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 2007, doi:10.1016/j.eururo.2007.12.001. 34. Murai M. Editorial comment on: Impact of gender in renal cell cardinoma: an analysis of the SEER database. Eur Urol 2007, doi10.1016/j.eururo.2007.12.002. 35. Böttner A, Kratzxch J, Muller G, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004;89:4053–4061. 36. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121–124. 37. Inoue M, Fujita M, Azuma C, et al. Histogenetic analysis of ovarian germ cell tumors by DNA fingerprinting. Cancer Res 1992;52:6823. 38. Jorgensen N, Rajpert-De Meyts E, Graem N, et al. Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells. Lab Invest 1995;72:223. 39. Speleman F, DePotter C, Dal Cin P, et al. i(12p) in a malignant ovarian tumor. Cancer Genet Cytogenet 1990;45:49. 40. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol 2001;1:983–993. 41. Melnick S, Cole P, Anderson D, et al. Rates and risks of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix: an update. N Engl J Med 1987; 316:514–519. 42. Olshan AF, Smith J, Cook MN, et al. Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. Am J Epidemiol 1999;150:930–938. 43. US Cancer Statistics Working Group: United States cancer statistics: 1999–2004 incidence and mortality Webbased report. Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2007. Available at www.cdc. gov/uscs. 44. Pui CH, Boyett JM, Relling MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 1999;17:818–824. 45. Imbach P, Fuchs A, Berchtold W, et al. Boys but not girls with T-lineage acute lymphocytic leukemia (ALL) are different from children with B-progenitor ALL. Population-based data results of initial prognostic factors and long-term eventfree survival. Swiss Pediatric Oncology Group. J Pediatr Hematol Oncol 1995;17:346–949.
60
s e c t i on 1 Gender and Normal Development l
46. Shuster JJ, Wacker P, Pullen J, et al. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1998;16:2854–2863. 47. Baum E, Sather H, Nachman J, et al. Relapse rates following cessation of chemotherapy during complete remission of acute lymphoblastic leukemia. Med Pediatr Oncol 1979;7:25–34. 48. Heaton DC, Duff GB. Ovarian relapse in a young woman with acute lymphoblastic leukemia. Am J Hematol 1989;30:42–43. 49. Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognosis features: randomized controlled trial from the Children’s Cancer Group. Cancer 1998;82:600–612. 50. Medical Council Working Party on Leukemia in Childhood. Duration of chemotherapy in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1982;10:511. 51. Lasithiotakis K, Leiter U, Meier F, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer Feb 2008;27, epub ahead of print. 52. Richardson B, Price A, Wagner M, et al. Investigation of female survival benefit in metastatic melanoma. Br J Cancer 1999;80:2025–2033. 53. Wichmann MW, Muller C, Hornung HM, et al. Gender differences in long-term survival of patients with colorectal cancer. Br J Surg 2001;88:1092–1098. 54. Palomares MR, Sayre JW, Shekar KC, et al. Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. Cancer 1996;78:2119–2126. 55. Pollock BH, Krischer JP, Vietti TJ. Interval between symptom onset and diagnosis of pediatric solid tumors. J Pediatr 1991;119:725–732. 56. Silber JH, Jakacki RI, Larsen RI, et al. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993;21:477–479. 57. Lipschultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738–1743. 58. Katz A, Goldenberg I, Maoz C, et al. Peripartum cardiomyopathy occurring in a patient previously treated with doxorubicin. Am J Med Sci 1997;314:399–400. 59. Green DM, Hyland A, Chung CS, et al. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol 1999;17:3207–3215. 60. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996;14:362–372. 61. Auletta JJ, O’Riordan MA, Nieder ML. Infections in children with cancer: a continued need for the comprehensive physical examination. J Pediatr Hematol Oncol 1999;21:501–508. 62. Tye VL, Mulhern RK, Jayawardene D, et al. Chemotherapyinduced nausea and emesis in pediatric cancer patients: an analysis of coping strategies. J Pain Symptom Manage 1995;10:338–347. 63. Speiser B, Rubin P, Casarett G. Aspermia following lower truncal irradiation in Hodgkin’s disease. Cancer 1973;32:692. 64. Shalet SM, Beardwell CG, Jacobs HS, et al. Testicular function following irradiation of the human prepubertal testes. Clin Endocrinol 1978;9:483.
65. Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol 1999;33:2. 66. Brauner R, Czernichow P, Cramer P, et al. Leydig-cell function in children after direct testicular irradiation for acute lymphoblastic leukemia. N Engl J Med 1983;309:25. 67. Izard MA. Leydig cell function and radiation: a review of the literature. Radiother Oncol 1995;34:1. 68. Sherins RJ, Olweny CLM, Ziegler JL. Gynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin’s disease. N Engl J Med 1978;299:12. 69. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987;5:27. 70. Green DM, Brecher ML, Lindsay AN, et al. Gonadal function in pediatric patients following treatment of Hodgkin’s disease. Med Pediatr Oncol 1981;9:235. 71. Ahmed SR, Shalet SM, Campbell RHA, et al. Primary gonadal damage following treatment of brain tumors in childhood. J Pediatr 1983;103:562. 72. Heyn R, Raney RB, Hayes DM, et al. Late effects of therapy in patients with paratesticular rhabdomyosarcoma. J Clin Oncol 1992;10:614. 73. Chapman RM, Sutcliffe SB, Malpas JS. Male gonadal dysfunction in Hodgkin’s disease: a prospective study. JAMA 1981;245:1323. 74. Blatt J, Poplack DG, Sherins RJ. Testicular function in boys after chemotherapy for acute lymphoblastic leukemia. N Engl J Med 1981;304:1121. 75. Lushbaugh CC, Casarett GW. The effect of gonadal irradiation in clinical radiation therapy; a review. Cancer 1976;37:1111. 76. Ortin TTS, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 1990;19:873. 77. Liesner RJ, Leiper AD, Hann IM, et al. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 1994;12:916. 78. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in women with Hodgkin’s disease. JAMA 1979;242:1877. 79. Horning SJ, Hoppe RT, Kaplan HS, et al. Female reproductive potential after treatment for Hodgkin’s disease. N Engl J Med 1981;304:1377–1382. 80. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer 1985;55:2364. 81. Scammell GE, White N, Stedionska J, et al. Cryopreservation of semen in men with testicular tumors or Hodgkin’s disease: results of artificial insemination of their partners. Lancet 1985;1:31. 82. Grundy R, Gosden RG, Hewitt M, et al. Fertility preservation for children treated for cancer (1): scientific advances and research dilemmas. Arch Dis Child 2001;84:355–359. 83. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405–1410. 84. Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women
C h a p t e r 4 Gender-Specific Aspects of Pediatric Hematology and Oncology l
85.
86. 87.
88.
89.
90.
91.
92.
93.
94.
95.
with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996;11: 1620–1626. Le Floch O, Donaldson SS, Kaplan HS. Pregnancy following oophoropexy in total nodal irradiation in women with Hodgkin’s disease. Cancer 1976;38:2263. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol 1999;33:29. Green DM, Fiorello A, Zovan MA. Birth defects and childhood cancer in offspring of survivors of childhood cancer. Arch Pediatr Adolesc Med 1997;151:379–383. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. J Clin Oncol 2001;19:3470–3476. Waber DP, Tarbell NJ, Kahn CM. The relationship of sex and treatment modality to neuropsychological outcome in childhood acute lymphoblastic leukemia. J Clin Oncol 1992;10:810–817. Von der Weid N, Mosimann I, Hirt A, et al. Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sexrelated differences. Eur J Cancer 2003;39:359–365. Zebrack BJ, Zeltzer LK, Whitton J, et al. Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin’s disease, and non-Hodgkin’s lymphoma: a report from the Childhood Cancer Survivor Study. Pediatrics 2002;110:42–52. Barrera M, Schulte F, Spiegler B. Factors influencing depressive symptoms of children treated for a brain tumor. J Psychosoc Oncol 2008;26:1–16. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin’s disease. J Clin Oncol 1998;16:536–544. Aisenberg AC, Finkelstein DM, Doppke KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin’s disease. Cancer 1997;79:1203–1210. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second malignant neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996;334:745–751.
61
96. Mehta P, Pollock BH, Nugent M, et al. Access to stem cell transplantation: do women fare as well as men? Am J Hematol 2003;72:99–102. 97. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995;15:663–668. 98. Gustafsson Jernberg Å, Remberger M, Ringdén O, et al. Risk factors in pediatric stem cell transplantation for leukemia. Pediatr Transplant 2004;8:464–474. 99. Atkinson K, Farrell C, Chapman G, et al. Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol 1986;63:231–239. 100. O’Kunewick JP, Kociban DL, Machen LL, et al. Effect of donor and recipient gender disparities on fatal graft-vs.-host disease in a mouse model for major histocompatibility complex-matched unrelated-donor bone marrow transplantation. Exp Hematol 1993;21:1514–1516. 101. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharmacol Ther 1999;24:339–346. 102. Ferron GM, Pyszczynski NA, Jusko WJ. Gender-related assessment of cyclosporine/prednisone/sirolimus interactions in three human lymphocyte proliferation assays. Transplantation 1998;15:1203–1209. 103. Tran C, Knowles SR, Liu BA, et al. Gender differences in adverse drug reactions. J Clin Pharmacol 1998;38:1003–1009. 104. McGrath PA, Speechley KN, Seifert CE, et al. A survey of children’s acute, recurrent, and chronic pain: validation of the pain experience interview. Pain 2000;87:59–73. 105. Rau T, Erney B, Göres R, et al. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 2006;80:468–476. 106. Weitman S, Ochoa S, Sullivan J, et al. Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 1997;19:187–191.
C hapter
5
Gender Differences in Neurological Conditions of Children David M. Kaufman Assistant Clinical Professor of Pediatrics and Neurology, Mount Sinai School of Medicine, Department of Pediatric Neurology, New York, NY, USA
This chapter discusses some of the differences between the brains of boys and girls, in terms of early brain growth, normal development, and in some specific neurological conditions. It is not meant to be a comprehensive review, but rather an overview. At the end of the chapter there is a listing of several other neurological conditions/diseases in which there is a gender predilection. The reader is invited to delve further into areas of interest.
greater in the male because a greater number of neurons are present, preventing some of the functional losses. This, of course, does not imply that one is ‘better’ than the other. Some functions may benefit from the presence of more cells, while others may be enhanced because of the larger number of connections.1 The human brain develops early in prenatal life, three weeks after conception. The brain develops throughout the pregnancy, and continues to develop throughout infancy and childhood, into adult life. Genes and environment interact as the brain develops, but they play very different roles. Generally, genes are responsible for the basic anatomical substrate of the brain – forming the neurons and connections between the different regions of the brain. Experience is responsible for fine-tuning the connections and allowing children to adapt to their particular environment.2 By 3 months of age, the brains of boys and girls react differently to the sound of the human voice. These differences are presumably due to the presence of sex chromosomes, or hormonal influences, or both. As early as 7 weeks of gestation, testosterone levels rise in the male fetus and this affects the growth and development of neurons in many areas of the brain. Female sex hormones may also play a role, but their function is currently not well understood. By most measures of cognitive and sensory development, young girls are slightly more advanced. Vision, hearing, memory, and smell are all more acute in female than in male infants. Girl babies are also somewhat more attuned socially than their male counterparts, and they usually lead boys in terms of their fine motor and language skills. By age 3, however, boys generally catch up, and they will be superior to girls on tests of visual-spatial integration (involving puzzles, and certain types of eye–hand coordination tasks). Recently, scientists at UCLA Medical Center studied the brains of normal boys and girls between the ages of 3
Introduction Boys and girls have distinctly different brains. This becomes apparent right from birth. A newborn’s brain is only about one-quarter the size of an adult’s. It will grow to about 80% of adult size by 3 years of age, and 90% by age 5. The average head circumference in the full term, newborn female is 34 cm, while in the male it is 35 cm. This is unrelated to birthweight or body size. The average adult male head circumference is almost 56 cm, while that of the average adult female is 55 cm. The average weight of the male newborn brain is about 370 g, while that of the average female newborn brain is somewhat less (about 300 g). For men 21–25 years of age, 1400 g is considered average brain weight, and for women, 1250 g (Volpe). Men also have more neurons in the cerebral cortex while women have more neuropils, which contain the processes that promote cell communication. The cerebral cortex is responsible for voluntary movements, sensory perception, memory, language, reasoning, and learning. Research has shown that women are more prone to dementing illnesses than men. Although a man and a woman might lose the same number of neurons, the woman’s functional loss may be greater because the lost cells are more densely connected to other neurons. Conversely, the functional reserve may be Principles of Gender-Specific Medicine
62
Copyright 2010 20 , Elsevier Inc. All rights reserved.
C h a p t e r 5 Gender Differences in Neurological Conditions of Children l
and 15 years, using magnetic resonance imaging (MRI) technology.3 They discovered a massive growth spurt from ages 3 to 6 in the frontal regions of the brain. These areas are involved in organizing and planning new behaviors, and during these ages, children are learning a wide variety of new behaviors. They also found that brain areas involved in learning language skills grew extremely rapidly from 6 until puberty in both boys and girls. These areas then experience a dramatic slow-down in growth between the ages of 11–15 years. This coincides with the period during which children no longer learn new languages. No differences were noted between boys and girls. With norms now established, these researchers will start to look at abnormal growth patterns and study conditions such as autism, attention deficit hyperactivity disorder, Tourette’s syndrome, and childhood onset schizophrenia, among others.
Attention deficit hyperactivity disorder (ADHD) Although there are some who doubt the validity of the diagnosis of ADHD, most clinicians agree that this is a legitimate condition that affects many children and adults. ADHD is thought to affect 3–5% of children, or as many as 2 million school-age children in the United States.4 The criteria for diagnosis will not be reiterated here, as they are readily available in many other sources. It has long been held that the male:female ratio of ADHD is 4:1, and may be as high as 6:1. Recent studies suggest that the true incidence is probably closer to 2:1. Attention deficit disorder (ADD) in girls is more subtle because there is a lower incidence of hyperactivity; affected girls are more often diagnosed with the inattentive type of ADD rather than the hyperactive type. Dr Judith Rapoport, Director of Child Psychiatry at the National Institute of Mental Health, has been tracking long-term changes in brain anatomy in children with or without neurological or psychiatric conditions. Among many other findings, Dr Rapoport has reported that children with ADHD have smaller brains, differences in the frontal regions, basal ganglia, and cerebellar vermis (these latter two regions control movement and planning, while the frontal lobes are involved in ‘executive functioning,’ all areas of dysfunction in children with ADHD). These changes are non-progressive, and suggest that they may have been present since birth, have biologic underpinnings, and help explain some of the symptoms seen in these children.5 Another study, carried out by Mostofsky et al.6 at the Kennedy Krieger Institute at Johns Hopkins, found smaller prefrontal and premotor brain volumes in boys with ADHD, which may also help to explain why the symptoms of ADHD are more pronounced in boys. Girls with ADHD are less likely to have an associated learning disability,
63
but are more likely to have lower IQ scores, impaired social and family functioning, and co-morbid conduct, mood, and anxiety disorders. Interestingly, the response to stimulant medication is the same in boys and girls, suggesting that although there may be anatomic differences in their brains, the neurotransmitter deficiencies are the same.7
Tourette’s syndrome (TS) Tourette’s syndrome is a neurobiological condition characterized by vocal and motor tics that change over time, and wax and wane in severity. Tourette’s syndrome is part of a spectrum of tic disorders, including transient tic disorder (tics lasting less than one year) and chronic tic disorder (motor or vocal tics lasting more than one year). As many as 10–20% of all school-age children have transient motor tics, and less commonly, vocal tics, lasting less than one year. This is more common in boys than girls. In 3–4% of these children, motor or vocal tics, but not both, will persist for more than one year. Again, this is more common in boys. TS (motor and vocal tics of more than a year’s duration) is said to be present in 1% of school-age boys, and 0.1% of school-age girls.8 Several studies have reported an increased risk for TS of 11.5% of brothers and 4.8% of sisters of children with TS (Tourette Syndrome International Consortium for Genetics). Most researchers also have found a high incidence of obsessive– compulsive disorder and ADHD in people with TS. It appears that this is a spectrum of expressions of the same underlying genetic disorder. An autosomal dominant model with sex-specific penetrance, accounting for the higher incidence in boys, has been postulated.9
Epilepsy In most population-based studies, the incidence of epilepsy is higher in males than in females. The consistency of the male–female difference suggests that males are at higher risk to develop epilepsy and unprovoked seizures.10 This suggests that gender factors are important for epileptogenesis, and may lead to different treatment regimens for boys and girls. The overall incidence of epilepsy in the United States (based on population studies done in Rochester, Minnesota) is 49 per 100 000 person-years in males, and 41 per 100 000 person-years in females.11 During the first five years of life, however, females have a slightly higher incidence, especially of generalized seizures. Among specific seizure types, the incidence for all categories of partial seizures (simple, complex, and secondarily generalized), and for generalized tonic-clonic seizures is greater in males. The incidence of absence seizures is slightly higher in females. Among some of the childhood epilepsy
64
s e c t i o n 1 Gender and Normal Development l
syndromes, childhood absence and photosensitive epilepsy are more prevalent in males. The incidence of a first unprovoked seizure is somewhat greater in males than females (68 vs. 56 per 100 000 person-years). However, there is no gender difference in the risk of recurrence within two years.12,13 Epilepsy is also seen in Aicardi syndrome and in Rett syndrome, both of which occur almost exclusively in females. Aicardi syndrome is characterized by agenesis of the corpus callosum, lacunar retinopathy, and infantile spasms. This is an X-linked condition, which is believed to be lethal to males, as there is a high incidence of spontaneous abortion of male fetuses in mothers of affected girls. Presumably, girls are affected by a new X-linked dominant spontaneous mutation that is lethal to a male fetus. Affected girls are mentally retarded, and continue to have refractory seizures. Rett’s syndrome is a progressive encephalopathy characterized by autism, hand-wringing motions, and an acquired microcephaly. Rett’s syndrome is also felt to represent new mutations of a gene on the X chromosome, lethal to males.
Duchenne muscular dystrophy Duchenne muscular dystrophy (DMD), a sex-linked recessive disorder, affects 1 in 3500 live born males, most of whom have not had, nor will have another case in their families. Since the affected males virtually never survive into their reproductive years, a DMD mutation usually lasts for only one generation. Boys affected by DMD develop calf hypertrophy and gait disturbance as toddlers, usually require wheelchairs by the end of the first decade, and succumb by the end of the second decade. In Becker muscular dystrophy (BMD), onset and progression is slower, and most affected boys will survive into middle age. For women, the most common clinical problem posed by DMD or BMD is the birth of an affected son. Female carriers are usually asymptomatic, although there have been reports of girls with a Duchenne phenotype, usually with a negative X-chromatin pattern, XO/XX mosaicism, or a structurally abnormal X chromosome. DMD in females has also been reported in several girls with X chromosome translocations, and these have been helpful in identifying the DMD gene.12,14 DMD and BMD are caused by defects in the same gene. DMD patients produce virtually no dystrophin, a protein found in the muscle cell membrane, while BMD patients produce an abnormal but partially functional protein. The role of dystrophin is poorly understood, although it may be involved in the maintenance of the membrane in muscular contractions and/or in transmembrane ion fluxes. Approximately 70% of female carriers for DMD have an elevated level of creatine kinase in their serum. Affected males have high levels of creatine kinase detectable from birth. Presently, demonstration of absent dystrophin and/or deletion in the DMD gene is required for definitive diagnosis.
Fragile x syndrome More males are mentally retarded than females. Much of this disproportion may result from mutations of an as yet unspecified number of genes located on the X chromosome. This gives rise to phenotypes that behave as X-linked recessives, with no detectable abnormality in women. In a few of these disorders, however, there is some phenotypic expression in females, usually quite minor compared to that of hemizygous males. Fragile X syndrome is the most common form of inherited mental retardation. The Fragile X syndrome is most appropriately classified as an X-linked dominant condition with reduced penetrance in females. Fragile X results from a defect in the X chromosome (the FMR1 gene), which cannot manufacture a protein (FMRP) which it normally makes. FMRP is believed to be a regulatory protein essential for normal brain functioning. The genetic code for the FMR1 gene usually contains a limited number of CGG sequences (usually 5–50 repeats). When the number of CGG repeats is between 50 and 200, the individual is a carrier and has a premutation of Fragile X syndrome. When the number of repeats exceeds 200, this disrupts the code, prevents the production of the FMR protein, and these individuals have the full mutation and are affected by Fragile X syndrome.15 Males and females who possess the intermediate length permutation are often phenotypically normal, but there may be subtle facial dysmorphisms in males, or lowering of the IQ scores in both males and females. Fragile X affects 1 in 2000 boys and 1 in 4000 girls. One in 260 women are believed to be carriers.16 Carriers are not usually affected by Fragile X syndrome, but they are at risk of having affected children. 90% of Fragile X patients have autistic features, and 6% of autistic individuals have Fragile X. The effects of Fragile X are seen more frequently and with more severity in males. Each child of a carrier woman has a 50% chance of inheriting the gene. The Fragile X permutation can be passed silently through generations in a family before a child will be affected by the syndrome.
Pelizaeus–merzbacher disease (PMD) PMD begins in infancy (as early as 8 days of age, and usually before 3 months), is seen predominately in males, and is very slowly progressive (patients may live into middle age). The initial symptoms are pendular eye movements, head shaking, hypotonia, choreoathetosis, and pyramidal signs. Three types of PMD have been recognized. The classic type, with onset in infancy and death in late adolescence or early adulthood, is characterized by nystagmoid eye movements, jerking, and rolling head movements, or head tremor. The nystagmus disappears, and as the patient matures, ataxia, spasticity, and involuntary movements become apparent.
C h a p t e r 5 Gender Differences in Neurological Conditions of Children l
Optic atrophy, microcephaly, and failure to thrive may also be features of this type. A second type will present with rapid progression and is fatal in infancy or childhood. The third type is a transitional or intermediate form, and may present with stridor early in life. Some heterozygous females may show symptoms as well. PMD has been determined to be a result of a mutation in the gene encoding proteolipid protein-1 (PLP1) which is located in the proximal long arm of the X chromosome (Xq22).14 The resulting leukodys trophy is limited to the central nervous system. There are a number of other X-linked neurodegenerative disorders that mostly affect boys, which will be listed here, but not further discussed. These include adrenoleukodystrophy, adrenomyeloneuropathy, ornithine transcarbamylase deficiency, X-linked spastic paraplegia, X-linked aqueductal stenosis with hydrocephalus, Menkes kinky-hair disease, Lesch–Nyhan syndrome, Hunter syndrome (mucopolysaccharidosis II), incontinentia pigmenti, X-linked lissencephaly, and Lowe oculocerebrorenal syndrome. This is by no means a complete list, but merely meant to allow the reader to look further, if interested.
Conclusion Neurologic disease can present in very different ways in children and adults, and also differs in boys and girls. Diseases may be specific to a certain developmental period (autism, Rett’s syndrome, absence seizures) or they may affect the physical development of the brain (neuronal migration disorders). In some conditions, only children are affected due to shortened lifespan. In others life expectancy is normal and disease may be diagnosed in childhood and continue into adulthood (Tourette’s syndrome). Children also may experience the same disease as adults, but with different symptomatology (migraines). With increasingly precise understanding of many genetic disorders, early diagnosis in childhood will permit appropriate genetic and prognostic counseling for families.
References 1. De Courten-Myers G. Gender-Specific Differences Found in Human Brain. American Academy of Neurology 51st Annual Meeting. Toronto; April 17–24, 1999. 2. Peterson BS. Neuroimaging Studies of Sex, Maturation, and Impulse Control: NYU Child Study Center Grand Rounds; 15 September, 2000. 3. Sowell ER, Thompson PM, Tessner KD, et al. Mapping continued brain growth and gray matter density reduction in dorsal frontal cortex: inverse relationships during postadolescent brain maturation. J Neurosci 2001;22:8819–29. 4. Szymanski ML, Zolotor A. Attention-deficit/hyperactivity disorder: management. Family Phys 2001;64(8):1355–62. 5. DeFrancesco L. Watching how the brain grows. The Scientist 2002;16:27.
65
6. Mostofsky S, Cooper K, Kates WR, et al. Smaller prefrontal and premotor volumes in boys with attention-deficit/hyper activity disorder. Biol Psychiatry 2002;52:785–94. 7. Bukstein OG, Lerner MA. The changing face of AD/HD: a clinical practice update. Clin Cour 2002;20:1–4. 8. Schapiro NA. ‘Dude, you don’t have Tourette’s’: Tourette’s syndrome, beyond the tics. Pediatr Nurs 2002;28(3):243–46, 249-53. 9. Alsobrook JP, Pauls DL. The genetics of Tourette syndrome. Neurol Clin North Am 1997;15:381–93. 10. Kotagal P, Luders HO, eds. The Epilepsies: Etiologies and Prevention. San Diego, CA: Academic Press; 1999. 11. Irizarry MC. Epilepsy. In: ME Cudkowicz, MC Irizarry, eds. Neurologic Disorders in Women. Newton, MA: Butterworth– Heinemann; 1997:1–16. 12. Aicardi J. Diseases of the Nervous System in Childhood. London: MacKeith Press; 1998. 13. Wyllie E. The Treatment of Epilepsy: Principles and Practice. Philadelphia, PA: Lea & Febiger; 1993. 14. Hurko O. Genetic disorders. In: PW Kaplan, ed. Neurologic Disease in Women. New York, NY: Demos Medical Publishing; 1998:53–83. 15. Hagerman RJ, Lampe ME. Fragile X syndrome. In: S Goldstein, CR Reynolds, eds. Handbook of Neurodevelopmental and Genetic Disorders in Children. New York, NY: The Guilford Press; 1999:298–316. 16. Turner G, Webb T, Wake S, et al. Prevalence of the fragile X syndrome. Am J Med Genet 1966;64:196–97.
Further reading Alves FE. Do women fare worse: a meta-analysis of gender differences in traumatic brain injury outcome. J Neurosurg 2001;93:862–64. Anon. New study shows prevalence of ADHD may be underestimated. Brown Univ Child Adolesc Behav Lett 2002;18:1–4. Aylward EH, Minshew NJ, Field K, et al. Effects of age on brain volume and head circumference in autism. Neurology 2002;59:175–83. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002;159:36–42. Briellmann RS, Berkovic SF, Jackson GD. Men may be more vulnerable to seizure-associated brain damage. Neurology 2000;55(10):1479–85. Brown RT, Ievers CE. Gilles de la Tourette syndrome. In: S Goldstein, CR Reynolds, eds. Handbook of Neurodevelopmental and Genetic Disorders in Children. New York, NY: The Guilford Press; 1999:185–215. Bukstein OG, Lerner MA. The changing face of AD/HD: case studies. Clin Cour 20 April, 2002. Carey JC, McMahon WM. Neurobehavioral disorders and medical genetics. In: S Goldstein, CR Reynolds, eds. Handbook of Neurodevelopmental and Genetic Disorders in Children. New York, NY: The Guilford Press; 1999. Elliott H. Attention deficit hyperactivity disorder in adults: a guide for the primary care physician. South Med J 2002;95:736–42. Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention deficit/hyperactivity disorder in children and adolescents. JAMA 1998;279:1100–7.
66
s e c t i o n 1 Gender and Normal Development l
Goldstein S. Attention deficit/hyperactivity disorder. In: S Goldstein, CR Reynolds, eds. Handbook of Neurodevelopmental and Genetic Disorders in Children. New York, NY: The Guilford Press; 1999:154–84. Hindmarsh GJ, O’Callaghan MJ, Mohay HA, et al. Gender differences in cognitive abilities in extremely low birth weight infants. Early Hum Dev 2000;60:115–22. Hong KE, Ock SM, Kang MH, et al. The segmented regional volumes of the cerebrum and cerebellum in boys with Tourette syndrome. J Korean Med Sci 2002;17:530–36. Jankovic J. Tourette’s syndrome. N Engl J Med 2001;35:1184–92. Kadesjo B, Gillberg C. Tourette’s disorder: epidemiology and comorbidity in primary school children. J Acad Child Adolesc Psychiatry 2000;39:548–55. Korn ML. Understanding and treating obsessive–compulsive disorder. US Psychiatr Ment Health Congr 2001. Kreeger KY. X and Y chromosomes concern more than reproduction. The Scientist 2002;16:25. Kurlan R. New treatments for tics. Neurology 2001;56:580–81. Mejias-Aponte CA, Jimenez-Rivera CA, Segarra AC. Sex differences in models of temporal lobe epilepsy: role of testosterone. Brain Res 2002;944:210–18. Mink JW, McKinstry RC. Volumetric MRI in autism: can hightech craniometry provide neurobiological insights?. Neurology 2002;59:158–59. Parraga HC, Parraga MI, Spinner LR, et al. Clinical differences between subjects with familial and non-familial Tourette’s syndrome: a case series. Int J Psychiatry Med 1998;28:341–51. Pary R, Lewis S, Arnpl C, et al. Attention-deficit/hyperactivity disorder: an update. South Med J 2002;95:743–49. Peterson BS, Pine DS, Cohen P, et al. Prospective, longitudinal study of tic, obsessive-compulsive and attention-deficit/hyperactivity
disorders in an epidemiological sample. J Am Acad Child Adolesc Psychiatry 2001;40:685–95. Plenge RM, Stevenson RA, Lubs HA, et al. Skewed X-inactivation is common in carriers of X-linked mental retardation (XLMR). Am J Hum Genet 2002;71:168–73. Resnick SM, Maki PM. Sex differences in regional brain structure and function. In: PW Kaplan, ed. Neurologic Disease in Women. New York, NY: Demos Medical Publishing; 1998:3–10. Roberts JE, Bell MA. The effects of age and sex on mental rotation performance, verbal performance, and brain electrical activity. Develop Psychobiol 2002;40:391–407. Rutledge SL, Mussell HG. Neurologic disease in girls. In: PW Kaplan, ed. Neurologic Disease in Women. New York, NY: Demos Medical Publishing; 1998:97–114. Scudder L. Recognition and management of attention deficit disorders. National Conference for Nurse Practitioners. 2001. Singer HS, Naidu SB. Rett syndrome: ‘We’ll keep the genes on for you’. Neurology 2001;56:582–85. Tourette Syndrome Association International Consortium for Genetics (TSAICG). A complete genome screen in sib pairs affected by Gilles de la Tourette syndrome. Am J Hum Genet 1999;65:1428–1436. Tsai EC, Santoreneos S, Rutka JT. Tumors of the skull base in children: review of tumor types and management strategies. Neurosurg Focus 2002;12(5):e1. Volpe J. Neurology of the Newborn. Philadelphia, PA: WB Saunders; 1987. Zohar AH, Apter A, et al. Epidemiological studies. In: JF Leckman, DJ Cohen, eds. Tourette’s Syndrome – Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. New York, NY: Wiley & Sons; 1999:177–92.
Chapter
6
Gender and Sports: Past, Present, and Future Jordan D. Metzl Co-Founder, The Sports Medicine Institute for Young Athletes, Hospital for Special Surgery, New York, NY
Introduction
sex. Since this included all school-sponsored extracurricu lar activities, sports teams were affected. Although Title IX does not mandate equal funding for male and female sport ing teams in practice, it does mandate that the ratio of male to female athletes be equal to the ratio of males to females at the institution. Following on the heels of Title IX was the Amateur Sports Act of 1978, which extended the policy of nondiscrimination to amateur sports. This increased opportu nities for women to participate in amateur events like the Olympics and other international sporting events. Before Title IX, it is estimated that about 1 in 27 American high school girls participated in varsity sports. In 1999 it was estimated to be 1 in 3, closely approximat ing the 1 in 2 American high school boys participating in varsity sports. The increase in participation has spawned a revolution in female athletics, and has opened new direc tions of research in Sports Medicine. Women and men clearly occupy different niches in sports, with areas of overlap and areas of divergence. Differences in performance between male and female ath letes can partly be explained by physiology. Separating these differences from those caused by cultural and societal expectations, environment, upbringing, coaching, and train ing is difficult.
The demographics of sports participation have changed considerably over the past 20 years. Sports participation used to be restricted to high level male athletes competing in high school, collegiate, and professional sports. With the advent of Title IX in 1972, the landscape of the sports world changed considerably. As of 2008, there are record numbers of female athletes participating in sports both in the United States and around the world. In the high school age group, the numbers of male and female participants are nearly equal. This has changed the very nature of the term ‘athlete.’ In today’s culture, sports participants are equally likely to be female as male. There are significant differences between female and male athletes. These differences include physiologic abil ity to achieve maximum potential, injury patterns related to gender, and specific medical issues related to sports partici pation. This chapter will explore the differences between male and female athletes.
Sports in america: a changing demographic The demographics of sports and physical activity have changed dramatically over the past 40 years in the United States. Whereas sports participation and viewing was once dominated by males, female participation has increased more than 500% in the past 20 years. There are several important reasons for these changes. Title IX of the Education Amendments of 1972 prohi bited institutions receiving federal funds from discriminating in admissions, access, and treatment of students based on
Principles of Gender-Specific Medicine
Physiology Size There are numerous physiologic differences between men and women that contribute to differences in sports perform ance and experience. The first and most obvious is the fact
67
Copyright 2010 20 , Elsevier Inc. All rights reserved.
68
s e c t i o n 1 Gender and Normal Development l
that men are usually taller and weigh more than women. As a corollary, men have longer limbs, especially advanta geous in sporting activities where the arms or legs are used for lever-like motions. Men also have greater muscle mass, with a greater area of muscle fibers. Until the age of 10–11 years, boys and girls are roughly similar in size and sports ability. Females experience puberty first, and have their growth spurt around 12 years of age. Boys have their growth spurt later, around 13 years of age, but grow more during their period of rapid growth than females. Girls usually attain skeletal maturity at 18 years of age, while boys attain skeletal maturity at about 21 years of age.
Body Proportions Until roughly the age of 11, the ratio of sitting height to standing height is similar for boys and girls. After age 11, this ratio increases in girls and remains higher in adult females than adult males. Even if they are the same height, women will have shorter legs than men, giving them a rela tively lower center of gravity. Men also have broader shoulders as compared to their hips, whereas women usually have wider hips as compared to their shoulders. This has been demonstrated by measuring the ratio between the biacromial breadths. This ratio remains relatively constant in males between the ages of 9 and 18 years, while in females during this time it steadily decreases.
Composition Females consistently have an increased percentage of body fat compared to males. The percentage body fat in females on average is about 22–26%, while in males it ranges from 13 to 16%. The distribution of this fat is also different. Women tend to store more fat in the lower half of the body, concen trating on the thighs and buttocks, while men tend to concen trate more fat in the upper half of the body in the abdomen. Basal metabolic rate is 6–10% lower in non-pregnant females than in males; females need fewer calories to maintain the same level of activity as males.
Cardiorespiratory System The cardiovascular and respiratory systems also show sig nificant differences between men and women. Men have larger hearts, with increased pumping force and increased stroke volume. At rest, women have a slightly faster heart rate than men, but this is not enough to equalize cardiac output. Women also have a smaller blood volume than men and a lower hemoglobin concentration. For the respiratory system, men have larger chest wall size, larger lung vol umes, larger vital capacity, and larger residual volumes. Maximal oxygen uptake, or VO2max as expressed in l/min, is the best measure of overall functional capacity. VO2 is similar in boys and girls before puberty. In adults, however,
VO2max is 40% greater in males than females. When this is adjusted for body weight, VO2max is about 20% greater in males than females. When adjusted for lean body mass to take into account the greater percentage of body fat in females, the VO2 is still around 8–10% greater in males than females.
Other Differences There are many other factors to consider when assess ing physical and functional differences between male and female athletes. Women have an increased carrying angle of the arm at the elbow and thighs that slant more inward toward the knees. These differences affect the biomechanics of motion differently for different activities. Bone mineral density is an important issue for females, with osteoporosis more prevalent in the female population in general. No sig nificant differences have been demonstrated in temperature regulation and gender. There exists an entire realm of societal and cultural influences to study when comparing male and female ath letic performance. In addition to body habitus, sportsrelated skills also determine level of athletic performance. Traditionally, women have not received the same amount of encouragement, training or coaching as men. With changes in demographics of participants, this is changing.
SpecifIc issues of gender and sport The issues of gender and sport are of paramount importance to both improving performance and preventing injury. As has been previously mentioned, there are fixed physiologi cal differences that affect performance in male and female athletes. In terms of injury prevention, there are specific injury patterns that are unique to both genders. These are important when considering safe and healthy participation. This section will explore these issues in terms of gender.
Female Athlete The Female Athlete Triad One of the issues specific to the female athlete which is receiving a great deal of attention is the female athlete triad of disordered eating, amenorrhea (absence of menses), and osteoporosis (low bone density). The risk in terms of the athletic population is that women with low bone density are particularly prone to stress fractures, injuries to the bone from repetitive use. Disordered eating in female athletes can manifest in different ways. Restrictive eating patterns and compulsive exercise habits contribute to a total energy and caloric defi cit. Athletes most at risk for disordered eating are those who participate in sports that emphasize thinness for either mechanical or aesthetic reasons, such as gymnastics, ballet,
C h a p t e r 6 Gender and Sports: Past, Present, and Future l
figure skating, and cross-country running. Most of these athletes maintain body weight through restriction of calo ries, but others do engage in activities such as binge eating, purging, and laxative use. The DSM-IV manual describes the clinical criteria for eating disorders. Poor nutrition and inadequate caloric intake can result in hormonal changes in the athlete, most important of which is loss of the luteinizing hormone (LH) surge. Normal men strual function is dependent on having normal levels of estrogen and normal LH pulsatility. LH pulsatility, how ever, is dependent on energy availability. Without adequate caloric intake, the LH surge is absent or reduced, and men struation is impaired. Women athletes have a high incidence of primary amenorrhea (absence of menses by the age of 16 years), secondary amenorrhea (absence of 3–6 menstrual cycles in a menstruating woman), and oligomenorrhea as compared to controls. Amenorrhea and associated low levels of estrogen con tribute to osteoporosis. Estrogen slows bone resorption and contributes to the maintenance of strong and functional bone architecture. Bone mineral density tests demonstrate that adolescents with amenorrhea or oligomenorrhea may lose up to 2% of bone mass per year as opposed to the normal annual gain of 3%. Some of this bone loss may not be completely recoverable despite the resumption of normal menses. Women with lower bone density, either osteopenia (greater than one standard deviation from normal values) or osteoporosis (greater than two standard deviations from nor mal), are more prone to bone-related injuries such as stress fracture from overuse. Athletes with stress fractures can be recognized by having gradually worsening pain associated with a particular activity. Physical exam is usually remark able for a point of tenderness in the bone, difficulty bear ing weight, and sometimes mild swelling. Although plain radiographs are usually the first test of choice in evaluation, they are often unremarkable, and radiographic findings can lag behind clinical findings by weeks. Common findings are mild lucencies in the compact bone, and the gray cortex sign in focal areas of stress injury. MRI and sometimes bone scan are often used to confirm the diagnosis of a stress fracture. Treatment of stress fractures generally does not require surgery; most injuries heal within 4–6 weeks with rest, ice, and non-steroidal anti-inflammatory (ibuprofen) as needed. Once stress fractures are healed, prevention of recurrence is important. Ensuring proper foot biomechanics through the use of orthotics and promoting adequate muscle strength to lessen the load on the affected area are both useful. Good rehabilitation and the maintenance of strong muscles can help to prevent future injuries. Awareness of the female athlete triad is extremely impor tant. The physician, coach, or parents should inquire about nutritional practices, with a concentration on eating pat terns, caloric intake and any purging activities. Prevention of the female athlete triad lies in a careful history and good anticipatory guidance.
69
Ligamentous Injury Since the increase in women’s participation in sports, the prevalence of injuries has risen. Over the past 15 years it has been noted that female athletes in sports such as soc cer and basketball are at least four times as likely as males to suffer injury to the anterior cruciate ligament (ACL), the major stabilizing ligament in the knee. These injuries are significant and usually require surgery and 7 months of rehabilitation before return to activity. Several theories have been proposed to explain this gender difference. Women in general have greater ligamentous laxity than men, although men’s and women’s measurements overlap. It was thought earlier that this increased laxity could predis pose women to ACL injuries. Ligaments do have estrogen receptor sites, although the significance of these receptors is not known. Some studies have shown increased ligamen tous laxity associated with higher estrogen levels and have postulated that athletes may be at more risk for injury dur ing certain periods of the menstrual cycle. This theory has recently fallen from favor. More recently, joint proprioception has been studied as a factor in ACL injury. Detection of joint movement is critical to determining the position of the knee and its risk for injury from intrinsic or extrinsic forces. Some experiments have shown decreased joint proprioception in females as com pared to males. One interesting study showed that although female proprioception was inferior, females demonstrated superior balancing ability and a greater activity of the lateral hamstring muscles when landing from a jump. This could possibly represent a compensatory mechanism for decreased proprioception and increased ligamentous laxity. With females at higher risk of ACL injury and with more women participating in twisting and pivoting sports such as soccer and basketball, it is no wonder that ACL injuries have increased considerably, both in absolute number and as a percentage of sports injuries. Effective prevention programs can reduce the risk of ACL injury in female athletes. Prevention is important, not only for the immediate complications of ACL injury, but also for the long-term consequences. The post-ACL injured knee is at high risk for arthritic degeneration with or with out surgical treatment. ACL injury prevention programs are available both over the Internet and in person. They gen erally combine hip strengthening, plyometric jump, and landing exercises, and screening for at-risk athletes. These programs should be the hallmark of pre-sports preparation for female athletes over the age of 12 and are starting to be implemented at the junior high and high school level. Nutrition Female athletes have special metabolic and nutritional needs. One of the primary issues facing female athletes is finding the healthy balance between caloric intake and expenditure. Thinness is desired by many women, especially
70
s e c t i o n 1 Gender and Normal Development l
those involved in athletics. In any sport or training program, it is essential to consume enough energy to cover the basic energy costs of building and repairing muscle mass. Many women, and frequently women and girl ath letes, express a desire to lose weight. Some attempt to lose weight through food restriction and exercise, which can result in a negative energy balance. Some sports empha size a thin physique, and female athletes often feel pres sure to create a negative energy balance. Long term energy restriction can contribute to fatigue, poor concentration, increased risk for injury, and prolonged recovery time after an injury. Concentration on thinness also can contribute to the increased prevalence of eating disorders among certain athletes. If an athlete does need to lose weight, aerobic and strength exercise should be judiciously combined with mild to moderate decreases in energy intake. Training should be increased in intensity by small amounts only, with adequate periods of rest for building and repairing muscle. Special care must be shown to consume a diet with appropriate bal ance of carbohydrate, protein and fat. A sports nutritionist is often a helpful ally in creating a healthy diet. In the adolescent female athlete, these issues are espe cially important. Adolescent female athletes not only have to consume enough energy to meet basic metabolic and nutritional demands, but also need substrates with which to grow. Female adolescents who engage in strenuous activ ity may need to consume up to 2400–2600 kcal to allow for optimal growth and prevent muscle breakdown. Healthy nutrition also requires the proper amounts of vitamins and minerals such as calcium, iron, and vitamin B. These nutrients are essential for enzyme function, energy production, heme (blood) synthesis, and the maintenance of appropriate bone mineral density. These issues are particu larly important to the female adolescent athlete whose body is undergoing rapid growth and development. Calcium is deficient in the diet of most Americans. For women between 9 and 18 years, the recommended daily intake (RDI) is 1500 mg/day, while for adult women the RDI is 1000 mg/day. On average, the calcium intake for adult women in the United States is about 770 mg/day. Calcium is necessary for the maintenance of healthy bones and for the prevention of stress fractures. In order to absorb adequate calcium, female athletes also must maintain ade quate vitamin D and estrogen levels. Clinically, poor bone health evidenced by a stress frac ture in a young female athlete should prompt concern regarding possible osteopenia as a causative factor. In addi tion to a good menstrual and dietary history, DEXA scan ning has become the standard of care as a screening tool for low bone density. This test should be utilized to screen any athlete suspected to have low bone density. If osteopenia or osteoporosis is present, effective nutritional counseling with respect to calcium and vitamin D is indicated. Iron deficiency is also common in female athletes. Many limit meat intake and have increased iron losses through
menstruation, sweat, and urine. Many iron-fortified foods have low bioavailability and must be consumed in great quantities to achieve positive iron balance. Iron is necessary for heme synthesis and also for effective energy metabolism. Female athletes tend to be mildly deficient in most of the B complex vitamins, especially folate and vitamin B12. It is critically important for women of childbearing age to be in a positive folate balance to prevent neural tube defects in children. Even with the increased requirements of exercise, female athletes should be able to consume their daily recommended vitamins and minerals through a healthy, well-balanced diet. Anticipatory guidance through preventive counseling and education programs can help athletes better understand the importance of nutrition.
Specific Issues of Male Athletes Ergogenic Aids Ergogenic aids are substances used by athletes to enhance ath letic performance. Although ergogenic aids are used by both male and female athletes, they traditionally have been more of a problem in the male population. Anabolic-androgenic steroids are the most serious of the compounds commonly used by athletes; studies estimate a 5–10% user rate in the adolescent male population. Anabolic steroids are testoster one derivatives that are taken orally or injected. In 1990, the United States Congress passed the Anabolic Steroids Control Act, which added these compounds to Schedule III (non-narcotic substances) of the Controlled Substances Act. Some steroid precursors such as androstenedione are pack aged as nutritional supplements and are legal in some sports. The Food and Drug Administration does not regulate these so-called nutritional supplements. The effects sought from steroid-based compounds are anabolic: increased skeletal muscle mass, decreased catab olism, increased aggressiveness, and decreased fatigue. Many different synthetic steroids have been formulated in an attempt to maximize the perceived benefits of anabolicandrogenic steroids and minimize the undesirable side effects, with varying degrees of success. Steroid use does increase muscle mass and decrease catabolism. The effects are most pronounced in athletes combining steroid use with strength training. Side effects are due to the androgenic properties of the steroids. Side effects that are relatively reversible include decreased sperm production, infertility, male pattern bald ness, gynecomastia, acne, and increased rates of hepatic cancer. Anabolic steroids have been implicated in altering lipoprotein profiles, with increased low-density lipoprotein (LDL) levels and decreased high-density lipoprotein (HDL) levels, thus increasing the risk of atherogenic changes and cardiovascular heart disease. Anabolic steroids can also increase both systolic and diastolic blood pressures, espe cially at high serum concentrations. Finally, these substances
C h a p t e r 6 Gender and Sports: Past, Present, and Future l
are mind-altering. Psychiatric changes sometimes associated with anabolic steroid use include depression, aggression, hostility, and paranoia. These are often referred to as the ‘steroid rage.’ Estimating the prevalence of steroid use as an ergogenic aid is difficult, due to its illegal status and the stigma associ ated with its use. Some sporting associations have stringent drug testing and zero tolerance policies, while others are pur ported to turn a blind eye to rampant use. The level of com petition is an important factor in determining the pressure on an athlete to use supplemental steroids, as is the prevalence of use by peers. Dissatisfaction with body image and weight, perfectionism, and a drive to win at all costs are characteris tics attributed to many anabolic-androgenic steroid users. Most alarming are the data collected from different anony mous adolescent surveys, including the Youth Risk and Behavior Surveillance System data collected by the Centers for Disease Control and Prevention. These studies consist ently show that approximately 6% of adolescent males and 1% of adolescent females admit to using illegal steroids. Exogenous androgens can lead to premature fusion of the epiphyses, termination of growth, and ultimate short stature. Other ergogenic aids are used and discussed more freely because they are legal and exist under the nebulous category of ‘dietary supplements.’ Creatine, a compound made up of three amino acids, has received a great deal of publicity due to its use by high-profile elite athletes. Creatine taken orally in powder form can increase muscle stores of phos phocreatine, which is thought to facilitate faster regenera tion of muscle adenosine triphosphate (ATP) and decrease muscle fatigue. This would be especially useful for activi ties requiring a high intensity of energy over a short period of time, like swinging a baseball bat. The major side effects are abdominal bloating, weight gain, muscle cramps, and mild hypertension. Several reports of renal failure in patients with underlying renal disease make creatine a sub stance to be used with caution and discouraged in adoles cent athletes. No study has tested the safety of creatine in subjects less than 18 years of age. The number of nutritional supplements on the market continues to increase exponentially, making it impossible for anyone to maintain a comprehensive body of knowl edge about the safety and side effects of these products. It is imperative to keep in mind that for most of the dietary supplements used as ergogenic aids, the Food and Drug Administration has no legislative control over the efficacy or even the content of the products sold. The concentration of the desired substance has been shown to vary widely from package to package, often with unknown and poten tially harmful ingredients mixed in for added effect. Until there is strict regulation of the use and abuse of all of these substances, the incentive to achieve and maintain a com petitive edge at all costs will perpetuate the use of ergo genic aids. The physician, parent, or coach must be vigilant to the possibility of the use of ergogenic aids and must be
71
able to provide a non-judgmental environment to facilitate candid discussions and counseling about the risks of these products. Males, Sports, and Violence Aggression, often necessary for winning, is acceptable and indeed encouraged in many sports. Sports provide a con trolled and acceptable venue for physical aggression. Occasionally sports violence on and off the field is excessive and harmful. These episodes can be defined as ‘aggression outside of the rules of acceptable competition with the intent to harm another person.’ Stories of exces sive sports violence often receive significant attention in the media, sending an unsatisfactory message to the general community that unchecked violence is condoned. These violent actions are almost exclusively perpe trated by male athletes. Behavior that is clearly unaccept able in general society may be tolerated or even rewarded in the sporting arena. A disproportionate number of athletes are accused of sexual assault or domestic violence against women. Children are sensitive to media messages and the most aggressive athletes, as defined by their physicality and will ingness to risk serious injury, may be glorified. Sports cov erage often shows ‘highlights’ of fights occurring during a game, reinforcing the concept that fights are expected and acceptable. In American culture men face societal expectations of being strong and aggressive. They are encouraged to play sports at an early age, often bonding with fathers or other older male figures through athletic endeavors. While they are likely to receive encouragement, support, and better coaching and training, boys face more pressure to succeed in physical and athletic arenas than do girls. Studies show that among American athletes, aggression and violence is best associated with lower socioeconomic status. A structured and supportive family unit provides some protection against violence. Sports can also provide an acceptable vehicle for physical aggression without crossing the line into violence. Athletics in general promote socializa tion and young athletes learn to relate to each other in a com petitive environment. It is tremendously important, however, for those supervising male athletes, including parents and coaches, to ensure that the healthiest message is presented. This includes teaching the value of fair competition and demanding appropriate behavior both on and off the field.
Conclusion This chapter has examined the issue of sports participa tion and gender. Overall, sports participation is a favorable lifestyle choice that encourages fitness and activity. The number one cause of mortality for men and women con tinues to be related to obesity and cardiovascular disease.
72
s e c t i o n 1 Gender and Normal Development l
Physical activity and a healthy diet reduce the incidence of many common diseases that contribute to this mortality. Sports participation continues to increase for male and female athletes and is an important part of the American lifestyle and culture. Physical activity has many benefits and participation should be strongly encouraged. Although some medical issues of the athlete are similar for men and women, there are many differences in physiology, psychology, and culture to be addressed. Greater awareness of the specific issues concerning male and female athletes will encourage important preventive health measures in the future.
Further Reading Abdal-Haqq I. Violence in Sports: ERIC Digest, American Association of Colleges for Teacher Education; 1989. Ahrendt DM. Ergogenic aids: counseling the athlete. Am Fam Phys 2001;63(5):913–22. American Academy of Pediatrics. Medical concerns of the female athlete. Committeee on sports medicine and fitness. Pediatrics 2000;106(3):610–13. Blue JG, Lombardo JA. Nutritional aspects of exercise: steroids and steroid-like compounds. Clin Sports Med 1999;18(3): 667–89. Callahan L. Stress fractures in women. Clin Sports Med 2000;19(2):303–14. Centers for Disease Control and Prevention. www.cdc.gov; 2002. Children Now. Boys to men, sports media – message about mas culinity. www.childrennow.org. (accessed October 2007). Garrett WE, Kirkendall DT, eds. Exercise and Sport Science. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
Harmon KG, Ireland ML. Gender differences in noncon tact anterior cruciate ligament injuries. Clin Sports Med 2000;19(2):287–302. Hewett TA. Predisposition to ACL injuries in female athletes ver sus male athletes. Orthopedics 2008;31(1):26–28. Hobart JA, Smucker DR. The female athlete triad. Am Fam Phys 2000;61(11). Humara M. The relationship between athletics, hispanics, and aggression. Athletic Insight 2002;1(1), online. Lopiano DA. Modern history of women in sports. Clin Sports Med 2000;19(2):163–73. Loud KJ, Gordon CM, Micheli LJ, et al. Correlates of stress fractures among preadolescent and adolescent girls. Pediatrics 2005;115(4):e399–406. Manore MM. Nutritional aspects of exercise: nutritional needs of the female athlete. Clin Sports Med 1999;18(3):549–63. Micheli L. The Sports Medicine Bible. New York, NY: HarperCollins; 1995. Renstrom P, Ljungqvist A, Arendt E, et al. Non-contact ACL inju ries in female athletes: an international olympic committee cur rent concepts statement. Br J Sports Med 2008;42(6):394–412. Rozzi SL, Lephart SM, Gear WS, et al. Knee joint laxity and neu romuscular characteristics of male and female soccer and bas ketball players. Am J Sports Med 1999;27(3):312–19. Shangold M, Mirkin G. Women and Exercise: Physiology and Sports Medicine, 2nd edn.. Philadelphia, PA: FA Davis; 1994. Shangold M, Rebar RW, Wentz AC, et al. Evaluation and management of menstrual dysfunction in athletes. JAMA 1990;263(12):1665. Sullivan JA, Anderson SA. Care of the Young Athlete. Rosemont, IL: American Academy of Pediatrics and the American Academy of Orthopedic Surgeons; 2000.
Section 2
Gender and the Nervous System
74
s e c t i o n 2 Gender and the Nervous System l
Introduction William Byne
Men and women differ in their vulnerabilities to particular neurological and psychiatric disorders, as well as in the particular manifestations of those disorders, their clinical course, and response to therapy. Such differences are not surprising considering that each cell within the central nervous system differs chromosomally and genetically between the sexes, with women having perhaps as many as 130 more active genes per cell than men. Moreover, genetic and endocrine factors interact in early development to produce brains that are sexually dimorphic in their rates of development and senescence as well as in their structural and functional organization. Added to the contribution of these biological differences is the medical impact of social, cultural, and economic factors associated with living in a particular gender role. The goal of gender-specific medicine is to take all of these factors into account in order to optimize the healthcare of all patients, regardless of gender. Particularly when the brain is involved, however, gender-specific medical research carries the risk of contributing to gender-based social discrimination by widening the perception of gender inequalities. That risk cannot be denied and we must take steps to mitigate it. We should not, however, be deterred by it. The potential benefits of a gender-specific approach to healthcare are too great. I thank the authors who have contributed to this section for the superb job they have done in providing the most current information available in their respective specialties.
Gur et al. provide a comprehensive overview of sex differences in the structural and functional organization of the brain. Drawing largely on animal work, McCarthy provides a state of the art review of the cellular mechanisms that underlie sex differences in brain structure and function, emphasizing how these mechanisms are brain regionspecific. My own chapter then addresses parallel research in humans where much less is known. Amatniek et al. provide a comprehensive review of the gender-specific incidence rates of neurological disorders and explain how these are a necessary first step toward development of gender-specific interventions. Gottesman and Hillis describe gender differences in the epidemiology and mechanisms of stroke as well as in stroke symptoms and recovery. Seeman reviews gender differences in psychiatric disorders that present during childhood, adulthood, or old age in order to draw inferences pertaining to possible etiological mechanisms. Finally, Sano et al. review clinical trials of a gender-specific intervention, postmenopausal hormonal replacement therapy. Cognitive data in adulthood and aging through the menopause are reviewed as are the effects of hormone replacement therapy on cognitive functions. Given the complexity of the CNS and the disorders that affect it, many important issues could not be accommodated within the pages of this section. Nevertheless, we hope that we have drawn attention to the importance of a genderspecific approach to disorders of the CNS and to current gaps in our knowledge. Above all, it is hoped that an appreciation of those gaps will encourage gender-specific research that will culminate in improved healthcare for all.
Chapter
7
Gender Differences in the Functional Organization of the Brain Ruben C. GUR 1, Tamara Bockow 2, and Raquel E. Gur3 1
Professor of Psychology, University of Pennsylvania Medical Center, Department of Psychiatry, Radiology and Neurology, and the Philadelphia Veterans Administration Medical Center, Philadelphia, Pennsylvania, PA, USA 2 Medical Student, University of Pennsylvania Medical School, Philadelphia, PA, USA 3 Professor of Psychiatry, Neurology, and Radiology, University of Pennsylvania Medical Center, Pennsylvania, PA, USA
Introduction
objections are based on the notions that when there is a dif ference between two groups then one must be ‘better,’ and that biology is destiny and, therefore, that differences are not malleable. Of course, these are misconceptions. Apples and oranges are different without one being inherently bet ter, and genetic predisposition for high cholesterol can be countered by diet and other means. Thus, the discovery of a biological basis for sex differences should not imply dif ferential treatment, social or individual, nor should it entail acceptance and inaction. It should be studied in a way that can improve understanding of brain behavior relation and enhance patient care.
Converging lines of research suggest that sex differences may modulate healthy behavior across the lifespan1,2 as well as brain structure3–5 and function.6,7 Sex differences are evident in the presentation and course of a range of mental disorders,8–10 other brain disorders,11–13 and autoim mune disorders.13 The growth of divergent methodologies has reached the level of maturity necessary for integrative research that can help advance understanding of such sex differences. It is important to keep in mind that sex differ ences exist against a background of fundamental similari ties, and that aspects of behavioral differences between men and women vary across cultures. However, there is increas ing evidence for neurobiological substrates. Animal and human studies have suggested that reproductive hormones play a significant neuroregulatory role in brain develop ment and sexual dimorphism.14–19 The existence of sex dif ferences in brain anatomy and physiology has implications for understanding the neural organization of behavior in healthy people, and its disruption in illness. The purpose of this chapter is to review the available evidence for sex dif ferences in behavior that may relate to differences in brain anatomy and physiology. While the implications of these sex differences are still unclear, we will attempt to outline some general directions that may help improve patient care. One issue merits mention prior to examining specific evidence. Reporting the discovery of sex differences in neu robiology requires sensitivity to potentially strong social and public reactions. Investigators who have been studying such differences since the late 1970s have experienced the intensity of both positive and negative reactions. The main
Principles of Gender-Specific Medicine
Sex differences in behavioral measures While behavioral measures do not provide direct evidence for neurobiological substrates, linkage between behavioral domains and regional brain function can help guide hypo theses on brain dysfunction. A comprehensive review of this literature is beyond our scope, but we will highlight the main findings in the area of sex differences in cognitive and emotion processing that can be linked to neurobiology.
Cognitive Processing Sex differences in cognition have been well documented with standardized measures. Women perform better on some verbal and memory tasks, whereas men excel in spatial tasks.1,2,20,21 These differences were attributed to variation in hemispheric specialization of cortical function. While
75
Copyright 2010 20 , Elsevier Inc. All rights reserved.
s e c t i o n 2 Gender and the Nervous System
76
l
the left hemisphere is generally dominant in verbal and the right in spatial processing,22 some neuropsychological studies have suggested less hemispheric specialization in women compared to men.23,24,25 Gender-related differences in behavior have been observed across species and are increasingly being linked to sex differences in neurobiologic substrates. The dimen sion of processing capacity has not been systematically disentangled from that of memory, although there are some indications that these factors have an additive influence, and perhaps interact. For example, evidence for better verbal memory in women is stronger than for other verbal process ing tasks,26 and while better performance has been consist ently shown for men on spatial tasks,21 there is evidence for equal performance on episodic memory for geometric designs.27,28 0.5 0.4
Sex differences in cognition need evaluation from a devel opmental perspective.14,19,26 Studies in children with Turner’s syndrome dramatize the pivotal role played by gonadal hor mones in shaping sex differences in cognitive functions.16 In a sample of healthy young adults (age 18–45), consisting of 124 men and 117 premenopausal women, we have observed sex differences in 3 of 8 behavioral domains (Figure 7.1a). Women had better verbal memory, and men performed better on spatial and motor tasks. In examining compo nents of domains that show sex differences, we find that the verbal memory advantage for women is accounted for pri marily by performance on the California Verbal Learning Test29 whereas the advantage for men in spatial abilities is accounted for by performance on Benton’s Line Orientation Test.30 Some sex differences are manifested not in the pro file of abilities, but in the effects of healthy aging within 0.6
Men 124 0.4
Women 117
0.3
Z-Score
P .01
0.2
0.2
P .05
0.1
r
0 −0.1
0 P .05 P .01
−0.2
−0.2 −0.3
−0.4
−0.4 −0.5
(a)
ABF ATT
VMEM SMEM
LAN
SPA
SEN
MOT
ATT
VMEM SMEM
LAN
SPA
SEN
MOT
Neuropsychological function
CNT Men CNT Women
0.5 z-Accuracy
ABF
(b)
Neuropsychological function 1
−0.6
0 −0.5 −1 1
z-Speed
0.5 0 −0.5 −1
ABF
ATT
VMEM FMEM SMEM
LAN
SPA
SM
Memory
(c)
Neurocognitive domain
Figure 7.1 Sex differences in neurocognitive profile (a) and age effects (b) on performance in the traditional neuropsychological bat tery and on the computerized battery (c) for accuracy (top panel) and speed (bottom panel) in healthy men and women. Reproduced from Gur, Ragland, Moberg, et al., 2001.31
C h a p t e r 7 Gender Differences in the Functional Organization of the Brain l
the range of young adulthood. In our sample, age range of 18–45, no significant correlations were observed between age and any of the behavioral measures in women. For men, however, increased age was associated with decrease in per formance on attention, verbal memory, spatial memory, and spatial abilities (Figure 7.1b). To enhance efficiency, we have developed a computerized battery.31 The pattern of sex differences seen with this computerized battery duplicates that obtained with traditional paper and pencil batteries, but adds the finding that women do better in facial memory, not available in the traditional battery (Figure 7.1c). Efforts to relate gender differences in cognition to neuro biologic substrates have followed three main avenues: cor relation of cognitive performance with hormonal state, examination of neuroanatomic measures in structural imag ing and post-mortem studies, and examination of neuro physiologic measures using functional imaging. While this area is relatively early in development, and there are several inconsistent reports, some convergence does seem to emerge. Both animal and human research on gonadal hormones indicates that they play a neuroregulatory role in early CNS organization, and modulate the activity of mature neural pathways.16,17 Estradiol, the major estrogen in premenopausal women, affects neurotransmitters in brain regions presumably involved in memory.32 The relation of hormones and human behavior has been examined by stud ies of hormone levels and cognition. In premenopausal women fluctuation in hormone levels during the menstrual cycle has been associated with performance on cognitive and motor tasks. Better performance in verbal fluency33 and memory34 has been reported during the high-estrogen and low-progesterone phase of the cycle, relative to improved spatial performance during menses, the low estrogen and progesterone phase.35–37 On the other hand, Janowsky et al.18 found negative correlations between estradiol levels and ver bal performance and positive correlations with spatial per formance for women studied during the mid-luteal phase as well as for men. They propose that in addition to the well-established effects of sex hormones during develop ment, ‘testosterone continues to play a modulatory role in the function of the prefrontal cortex, particularly working memory, throughout life’ (p. 410). The mechanism for such effects could include receptor androgen genomics or aroma tization of testosterone to estrogen with downstream effects on estrogen receptors or synaptic morphology or function.
Emotion Processing In the constellation of factors affecting sex differences in cognition, the role of emotion has received relatively limi ted attention. Dysphoric mood has been associated with the onset of menses in healthy women38 and the effects of mood on cognitive performance have been demonstrated in sev eral studies,39,40 but few links have been established between menstruation-related mood changes and performance. Memory and emotion have not been separated in most studies.
77
Attempts to dissect these components suggest that emotional stimuli may enhance or impair recognition memory. Perceiving, experiencing, and expressing emotions seem essential capacities, and more recently the study of emotion has benefited from converging methodologies in animals and humans.41,42 The face has been the main target of study in humans, and methods were applied to quantify expression of emotion with cross-cultural consistency.43–45 Standardized tools have been developed for measuring emotion discrimination,46 mood induction,47,48 affective valence, and arousal.49 Emotional displays that can be reli ably coded in the face are happiness, sadness, anger, fear, and disgust, while surprise is more controversial. There is also increased agreement that emotion processing is not restricted to the ‘limbic system’ and involves cortical regions, where it seems to be organized, perhaps paral lel to the ‘cognitive’ system, along laterality and anterior– posterior dimensions.50,51 There is controversy about whether emotional expression is lateralized, although a meta-analysis by Borod et al.52 seems to confirm that nega tive emotions are expressed more intensely on the left side of the face whereas the opposite may hold for positive emo tions.53 There is more agreement, though less data, that receptive, experiential, and expressive aspects of emotion processing can be mapped to frontal, temporal, and pari eto-occipital involvement, respectively. This interaction between the emotion and cognitive systems, particularly as it applies to memory, is an issue of current interest. Sex differences were observed in affect and emotion processing.54,55 Women perform better in speeded emotion recognition tasks56 and in tasks requiring facial expression of emotions.54 In a study of facial recognition, we reported sex differences in sensitivity to happy and sad expressions depending on the poser’s sex. Women were more sensi tive to opposite than to same-sex expressions, whereas men were differentially poor at detecting sadness in female faces.46 Regarding emotional experience, women are more prone to clinical depression.8 Mood fluctuations associated with phases of the menstrual cycle have been documented, and such phase associated hormonal changes may relate to cognitive performance.33–37 There is increased evidence that men and women may differ in their emotional memory. Cahill and colleagues found gender-related hemispheric asymmetry of amygdala function related to emotional memory. Memory of emo tional material seems to involve mostly the right hemisphere of the amygdala in males and mostly the left hemisphere of the amygdala in females.57,58 Using this evidence, and the hypothesis that the brain has a bias for processing holistic information on the right and detail information on the left, Cahill and colleagues tested sex differences in the effects of a beta-adrenergic receptor antagonist, propranolol, on longterm memory of an emotionally arousing story. Although the propranolol was given systemically, it was expected to disrupt the memory-modulating function only of the hemisphere containing the amygdala most involved in the
78
s e c t i o n 2 Gender and the Nervous System l
emotional learning situation (amygdala in the left hemi sphere of women, in the right hemisphere of men). Indeed with propranolol, which is expected to deactivate the limbic system bilaterally, men were impaired in remembering glo bal aspects of the story, while women showed the opposite effect, impairment with the story details but not the cen tral information.58 This experiment supports both the role of sexually dimorphic lateralization in the amygdala and the information processing biases in the two hemispheres. This work on gender differences in memory and emotions has implications for understanding clinical disorders such as posttraumatic stress disorder (PTSD). The incidence of PTSD is approximately twice as high in women as in men, and neural mechanisms may underlie some of these gender differences.58 More recently, sex differences have been reported in the way men and women perceive and anticipate rewards. Dreher et al. showed that gonadal steroid hormones, such as estrogen and progesterone, can influence the human reward system. Using functional MRI, they found that when anticipating a reward, women activate the orbitofrontal cortex and amygdala during the midfollicular phase (days 4–8 after onset of menses when estrogen is unopposed by progesterone). These cortical areas are crucially involved with emotion, arousal, and autonomic and endocrine func tion. In contrast, during the luteal phase (days 6–10 after luteinizing hormone surge) women showed the greatest activation in the midbrain, striatum, and left frontopolar cortex. Thus, women showed activation in different regions depending on their levels of sex hormones. On the other hand, men activated the ventral putamen more than women during anticipation of reward. Such evidence that sex-related ovarian steroids modulate the neural activity associated with receiving rewards may have implications for understanding sex differences in mood disorders, neuro psychiatric diseases, and susceptibility to drug abuse.59
Psychological Stress Response According to Mary Seeman, women are twice as likely to suffer mood and anxiety disorders as men, while men are more likely to experience alcohol abuse disorders (see Chapter 12). While environmental factors certainly play a role, this may, in part, reflect sex differences in biological responses to stress. Men and women likely differ in their response to stress. The human stress response has been characterized as ‘fight-or-flight.’ This makes sense for males who, evolutionarily, confront a stressor either by aggres sive fighting or fleeing. Females’ response to stress may fit a dimension of ‘tend-and-befriend’.60 In that perspective, tending involves nurturing and protecting one’s self and offspring while befriending relates to creating social net works to aid in protection and maximize survival. There is neuroendocrine evidence to suggest that oxytocin may be critical in this response.60
Wang and his colleagues investigated the gender-specific neural circuitry of psychological stress in male and female brains using fMRI. Stress in men was associated with cere bral blood flow (CBF) increase in the right prefrontal cortex (RPFC) and CBF reduction in the left orbitofrontal cortex (LOrF). In contrast, stress in women primarily activated the limbic system, including the ventral striatum, putamen, insula and cingulate cortex.61 This is consistent with the ‘fightor-flight’ and ‘tend-and-befriend’ models. ‘Fight-or-flight’ requires increased focus, alertness, and fear. The RPFC is important for vigilance, awareness, and negative emotion. In contrast, the limbic system is involved with emotion regula tion, and the areas activated in the female response to stress are rich in receptors for oxytocin, vasopressin, dopamine, and endorphin. This indicates a consistency with the ‘tendand-befriend’ model.61 Other hormones are also modulated in the stress response. The hypothalamic–pituitary–adrenal (HPA) axis is one of the major systems involved in responses to stress. Corticotropin-releasing hormone (CRH) neurons project into the brain and stimulate the secretion of adrenocortico tropic hormone (ACTH) from the anterior pituitary. ACTH then travels through the blood and triggers the secretion of glucocorticoids such as cortisol from the adrenal glands. It is hypothesized that this release of glucocorticoids is activated in depression and induces symptoms (Seeman, Chapter 12 this volume). There is evidence that this system is influenced by ovar ian hormones.62 Animal studies show that the corticosterone response to stress differs in male and female rats. Female rats demonstrate a greater overall response, a faster onset of corticosterone secretion, and a faster rate of rise of cor ticosterone.62 Additionally, chronic administration of estro gen enhances the corticosterone response to stress. While conclusions are more difficult to draw in human studies, depressed premenopausal women show greater increases in baseline cortisol levels than postmenopausal depressed women and depressed men.62 These gender differences in response to stress may play a role in risk factors for genderspecific health problems.
Sex differences in neuroanatomic measures Animal studies on sex differences in neuroanatomy have reported dimorphism in regions involved in gonadal hor mone regulation such as the bed nucleus of the stria ter minalis.63 This finding was replicated in humans with post mortem data, which demonstrated that the sex differences in this structure emerged only during adulthood.64 Most human neuroanatomic studies on sex differences have focused on measures related to hemispheric specialization of func tion.65 A neuroanatomic basis for functional asymmetry has been suggested, with larger volumes of left cortical regions
C h a p t e r 7 Gender Differences in the Functional Organization of the Brain l
implicated in language.66 However, evidence for sex differ ences in this asymmetry is inconsistent. Furthermore, some of the neuroanatomic differences may reflect the confound of lower cranial volume in women.67 It would seem impor tant to link the neuroanatomic parameters with performance measures, as was done by Davatzikos and Resnick.68 They used an innovative image analysis technique, which allows investigation of local variability in brain morphology, in magnetic resonance images (MRI) from 114 individuals. There was a robust sex difference in the splenium of the corpus callosum, suggesting greater interhemispheric con nectivity in women. Furthermore, size of the splenium ‘cor related with better cognitive performance in women than in men, indicating that the degree of interhemispheric connec tivity has different implications for men and women.’ MRI studies enable volumetric three-dimensional meas ures of brain parenchyma and cerebral spinal fluid (CSF). Studies of healthy people across the lifespan have provided valuable data regarding normal brain development against which changes associated with diverse brain disorders can be examined. Sex differences emerge as an important mode rating variable for whole brain and regional volumes.
Whole Brain Sex differences in brain anatomy have been increasingly documented with methods for morphometric analysis of MRI data.3,4,67–74 Quantitative MRI studies using algo rithms for tissue segmentation suggested that men have
55 %Volume
higher white matter (WM) volumes than women.5,74 Using algorithms for automated tissue segmentation of MRI, we examined sex differences in the volume, hemispheric asym metry, and distribution of intracranial compartments related to cytoarchitecture and connectivity: gray matter (GM), white matter (WM), and CSF. Higher percent GM in left subregions relative to the right and higher percent GM in women than men were observed.3 Because GM largely con sists of the somatodendritic compartment of neurons (cell body and dendrites) while WM contains the axonal com partment (myelinated fibers), verbal functions may require substrates that facilitate processing within regions whereas spatial performance is optimized by transfer across regions. Indeed, women had a higher percent GM whereas men had higher percent WM and percent CSF (Figure 7.2). The find ing that women have higher percent GM than men repli cates earlier studies with the 133Xenon clearance method.75 Our finding of lower overall proportion of WM in women seems to contrast with reports of higher volumes of corpus callosum,76,77 which is a white matter structure. While the corpus callosum findings have been challenged as an artifact of smaller cranial volume,78 investigators have reported that sex differences in the callosum have sustained corrections for cranial volume.68,76 Conceivably, men and women differ in the relative amount of inter- and intrahemispheric communi cation. This possibility can be tested more specifically using neurobehavioral and functional imaging methods. The sex difference in intracranial tissue composition may reflect adaptation to the smaller cranial volumes of
Men
a
Women
10
45
5
35 0.5
0 0.5
Laterality (L–R)
c
b
d
0
−0.5
79
0
GM
WM
−0.5
CSF
Figure 7.2 Sex differences in the percent of gray matter (GM), white matter (WM), and cerebrospinal fluid (CSF) in healthy people. The top row shows percent of volume out of the entire cranial supertentorial volume and the bottom shows laterality (left minus right) of volume. Reproduced from Gur, Turetsky, Matsui, et al., 1999.3
80
s e c t i o n 2 Gender and the Nervous System l
women. Sexual anatomic dimorphism has been comparable at least since the Middle Pleistocene hominids.79 Because GM is the somatodendritic compartment, where computa tion is done, while WM is the myelinated connecting tis sue needed for information transfer across distant regions, higher percent GM in women increases the proportion of tissue available for computational processes. This is a rea sonable evolutionary strategy, as smaller crania require shorter distances for information transfer, hence there could be relatively less need for WM. The higher percent GM is bilateral in women, with lat erality effects – higher left hemispheric percent GM and right hemispheric percent CSF – evident only in men. This is consistent with some behavioral and neurobiologic data suggesting less hemispheric asymmetry in women.24 In a functional MRI (fMRI) study, Shaywitz et al.6 reported that for phonological tasks men showed left lateralized inferior frontal gyrus activation whereas women showed more bilat eral activation in this region. The results were considered consistent with the hypothesis that men are more highly lateralized for language functions. On the other hand, it is noteworthy that the hemispheric asymmetries for our whole brain measures were small relative to the sex differences in compartmental percentages. Thus, while men have rela tively higher percent GM in the left, they still have lower percent GM than women in either hemisphere. This may differ for smaller structures.
in men.82 Although two MRI studies that measured the orbital frontal cortex failed to note a similar effect, neither of these studies statistically adjusted the regional volumes for intracranial volume.67,83 The behavioral implications of women’s relatively larger orbital frontal regions warrant further investigation in light of evidence for the critical role of the orbital frontal cortex in social behavior, emotional functioning and higher order cognitive skills, such as rea soning and decision making.84 Indeed, reduced frontal volume has been associated with greater tendency toward psychopathy in men who were screened for psychiatric dis orders in themselves and first-degree relatives85 and in anti social personality disorder.86 The frontal lobes are involved in decision-making, as several lesion studies have con firmed that decision-making is impaired with frontal lobe lesions. However, most of these studies have involved only men and lesions on the right side. Notably, in 2005, Tranel et al. reported that right hemisphere lesions impair men, but not women. Additionally, left-sided lesions alter women’s decision making but do not impair men.87 The significance of larger orbital volumes can be interpreted relative to the volume of the amygdala, whose output is modu lated by this region.41,42,89–93 We found that women, correcting for cranial volume, have equal volumes to men in temporolimbic regions (Figure 7.3). Thus, the increased orbital volume relative to amygdala volume in women compared to men sup ports the hypothesis that women have greater tissue volume available for modulating amygdala action. In addition, several
Regional Volumes 10 9 8 Lateral orbital gray/Amygdala
Volumetric MRI studies of specific regions have also sug gested sex differences.73,80,81 Regional sex differences may shed light on the neurobiologic substrates of behavioral sex differences in healthy people and may provide insight into sex differences in behavior and hence the prevalence and severity of certain neurobehavioral disorders. There is evidence that the hippocampus, a part of the brain associated with learning and memory, is significantly differ ent in men and women.116 In his review of sex differences, Cahill concludes that imaging studies consistently find that the hippocampus is larger in women compared to men when adjusted for brain size. Additionally, when comparing female and male rats raised in an enriched environment, females tend to generate dendritic spines with more branching com pared to males. This may have implications for learning and memory. For example, the estrus cycle may influence maze learning tactics in rats; it seems that sex hormones alter the balance of hippocampal and striatal learning strategies in female rats.57 However, there is also evidence that, within the hippocampus, the CA1 region is larger in male compared to female rats. How gender influences hippocampal function in humans is not yet well understood, but given the evidence in rats, this area of study merits further investigation. In humans, following adjustment for intracranial volume, we observed sex differences in the frontal lobes, where orbital frontal regions were relatively larger in women than
7 6 5 4 3 2 1 Men
Women
Figure 7.3 The ratio of orbital frontal to amygdala volume in healthy men and women. Reproduced from Gur, Gunning-Dixon, Bilker, and Gur, 2002.82
C h a p t e r 7 Gender Differences in the Functional Organization of the Brain l
imaging studies have found differences in hemispheric lateral ization of the amygdala with regard to memory of emotional material. Cahill et al. reported that women show preferential involvement of the left amygdala for memory of emotional material, while the same material involves mostly right amyg dala activation in men.88 These findings may contribute to gender differences in emotional memory and emotional behav ior, particularly aggression. The sex difference in the ratio of orbital to amygdala volume is quite marked. It is noteworthy that only five men had values in the range recorded in over half the women, and conversely only a handful of women had ratios as low as seen in about half the men. It is likely that such a neuro anatomic difference will have functional significance. While environmental and cultural factors undoubtedly contribute to sex differences in aggression, the existence of such marked neuroanatomic differences in brain structure related to emo tion regulation warrants systematic effort to link emotional behavior to neural substrates. These anatomic differences also need to be considered when interpreting functional neuroimaging studies. Finally, animal studies may help determine whether these sex differences exist in other spe cies and relate to differences in emotional behavior.
Sex differences in neurophysiologic measures The feasibility of studying neural substrates of behavior is enhanced by functional imaging methods for measuring regional brain activity. Both resting metabolism and activa tion patterns are linked to performance on neurobehavioral tasks requiring verbal, spatial, attention, memory and facial processing. Unlike neuroanatomic studies that have consist ently examined sex differences and age effects, there is a paucity of neurophysiologic studies that have examined these factors.
Cerebral Blood Flow Women have higher rates of basal cerebral blood flow (CBF) than men75,94–96 and equal rates of cerebral glucose metabolism.97 There is no evidence for sex differences in the laterality of regional brain activity. In early studies, with the 133Xenon CBF method, we reported that women have higher rates of cortical CBF75 and this finding was repli cated and extended to other methods that measure CBF for the entire cranium.94–96 We found about equal rate of ageassociated reduction in CBF in men and women98 and this too has been reported in other studies,99 although samples were usually small in the elderly range. Functional MRI (fMRI) has been increasingly used for measuring regional brain activation. The method has several potential advantages: higher spatial and temporal resolu tion, noninvasiveness and lack of ionizing radiation, direct
81
correlation with anatomical imaging, greater repeatability, and economy. Disadvantages of fMRI techniques include loud background noise generated by the gradients, difficul ties in presenting stimuli and performing tasks in the magnet bore, claustrophobia, low signal-to-noise for most methods in high susceptibility areas and lack of quantitation in physi ologic units for most methods. Among the various fMRI methods, blood oxygenation level-dependent (BOLD) imag ing has been most widely applied. This technique relies on magnetic susceptibility effects of deoxyhemoglobin, which cause regional decreases in signal in imaging sequences sensitive to susceptibility (e.g. echoplanar). With regional brain activation studies a net increase in signal intensity is observed in regions known to be activated by the task. The increase in image intensity corresponds to a local decrease in deoxyhemoglobin. This is attributed to an increase in regional blood flow compared to regional oxygen consump tion. A typical response is a 1–25% increase in regional image intensity, which develops over 3–8 sec following task initiation. Susceptibility effects are field-dependent so, using the 4T magnet available to us, an initial decrease in signal intensity is detectable in the first 1–2 sec following stimu lation, corresponding to a focal increase in deoxyhemo globin. When combined with ultrafast echoplanar imaging (100 msec per slice), the time course of signal change in response to individual stimuli can thus be observed. Shaywitz et al.6 reported a CBF activation study with fMRI where women showed more bilateral activation dur ing a phonemic task. We reported an fMRI study examining CBF changes during the performance of a verbal analogies and a spatial line orientation task.7 Task difficulty effects were tested by dividing conditions into easy and hard. Complementing Shaywitz et al.’s results for the phonemic task, men showed more bilateral activation for the spa tial task. When activation was examined for target regions of interest, the planum temporale and the inferior parietal lobe, both men and women showed equally left lateral ized activation for the verbal task. However, whereas men activated the right hemisphere for the spatial task, women showed left hemispheric activation for the easy spatial prob lems and bilateral activation for the hard problems. Thus, it appears that spatial processing requires, for harder tasks, greater reliance on visual association cortex with minimal activation of other areas. Poorer performance in women may relate to continued reliance on supplementary strate gies, perhaps verbal, which is ineffective for the success on the harder spatial items. We also have evidence from posi tron emission tomography (PET) that better verbal memory in women is associated with higher mid-temporal resting CBF, and positive correlations with left lateralized CBF in mid-temporal and temporal pole regions.94 Such studies may help elucidate neural substrates of sex differences in cognitive strategies for problem solving. There is evidence that neurobiologic processes triggered by the hormonal changes exert influence by affecting neu rotransmitter availability, cerebral perfusion, and perhaps
82
s e c t i o n 2 Gender and the Nervous System l
by eliminating neuroprotective effects of estrogen.100,101 Matteis et al.,102 using transcranial Doppler ultrasonogra phy, found, as we did, higher flow estimates in women than men overall. However, a subgroup of 15 postmenopausal women aged 48–53 had lower flow values than 15 premen opausal women of the same age, or any other group.
Cerebral Metabolism Unlike CBF, where women consistently show higher val ues, there are no sex differences in whole brain rates of glu cose metabolism. Basal metabolic rates for glucose were measured in 37 men and 24 women.97 Average metabolism, calculated from whole-brain counts, did not differ between men (4.66 or 0 97 ml/100 g/min) and women (4.62 or 1.09). However, regional differences were notable. The groups had identical metabolism in all non-limbic frontal, parietal, and occipital regions, but sex differences were prevalent in temporal-limbic regions, basal ganglia, brain stem, and cerebellum. Men had higher relative metabolism in all lateral and ventromedial aspects of temporal lobe regions, including occipito-temporal, superior, middle, and inferior temporal cortices, the temporal pole, parahippo campal, and entorhinal regions, hippocampus, amygdala, insula, fusiform and rectal gyri, and orbital-frontal cortex. They did not differ from women in relative activity of the anterior cingulate, but had lower relative metabolism in the middle and posterior cingulate gyrus. It is noteworthy that while asymmetries in metabolic rates were ubiquitous, there were largely similar in men and women. The findings indicate sex differences in the regional topography of resting cerebral metabolic activity and sys tematic asymmetries in regional metabolism that are largely shared by men and women. The higher relative metabo lism in men in the entire temporo-limbic system, and the reversal of this difference for the middle and posterior cin gulate gyrus, where women had higher metabolism, reflect a different baseline activity. This could help explain sexrelated differences in emotional processing. The cingulate is cytoarchitecturally one of the most complex components of the limbic system. Since behavior evolves from instru mental to increasingly symbolic modes of processing, we may speculate that the higher metabolic activity of men in phylogenetically older limbic regions relates to their greater proclivity toward instrumental expression of emotion, such as through violence. Similarly, higher activity in the cingu late may explain why women seem to have better access to emotional expression through symbolic mediation, such as vocal and gestural means.
Neuroreceptors In humans, dopamine (DA) neural transmission participates in the mediation of motor and cognitive tasks, and its pharma cological or pathophysiological depletion is associated with
performance decrements, independent of age-associated loss of neural tissue.103,104 Estrogen regulates DA transmission,105–107 perhaps in an antidopaminergic fashion in women.108 Estrogen receptors are found in cortical and subcortical areas, includ ing the DA-rich caudate and putamen.15,16,100,101 The DA transporter is a primary regulator of intra-synaptic DA lev els109 and its concentration reflects the homeostatic tone of the dopaminergic system.110 Behavioral studies have demon strated that women perform better than men on verbal learning tasks.111,112 In addition, verbal learning performance deterio rates with age and is adversely affected by menopause.113,114 Taken together, these findings suggest sex differences in the neuromodulatory effects of DA on behavior. However, stud ies of the coupling between DA and behavior in humans have been lacking because of the scarcity of reliable ligands for measuring dopamine transporter availability. In a singlephoton emission computed tomography (SPECT) study with TRODAT, a technetium-99m-labeled dopamine transporter imaging agent, 32 healthy men and 36 healthy women were examined.115 Coupling between dopamine transporter avail ability and learning was noted. Women and younger partici pants had higher dopamine availability in the caudate nucleus, and this was associated with their stronger performance scores on verbal learning tasks. Additionally, studies suggest that there are neurochemi cal differences within the hippocampus, a major region involved in learning and memory. Neurotransmitter systems within the hippocampus, such as the serotonergic, adrener gic, cholinergic, glucocorticoid, benzodiazepine, and chole cystokinin systems, may differ with regard to their receptor affinity and cell excitability in males and females. Such dif ferences may have implications for learning and memory. For example, Shors et al. showed that in rats, exposure to stressful learning situations (brief tail shocks) increases the number of dendritic spines in males but decreases the den sity of dendritic spines in females. This finding was similar with Pavlovian conditioning; stress enhanced performance for male rats but impaired performance in female rats.116 Such gender differences in neuroreceptors and receptor activity may contribute to difference in learning, and how men and women deal with stress.
Implications for sex differences in functional brain organization The extent and nature of sex differences in brain function indicates that men and women differ in important aspects of functional brain organization. These differences are likely to manifest in behavior throughout the developmental span. While very little is known about sex differences in brain maturation, tools are available to link known differences in the rate of behavioral development to the underlying cere bral processes. With regard to functional organization, the neurobiological data suggest several areas where men and
C h a p t e r 7 Gender Differences in the Functional Organization of the Brain l
women may differ. Perhaps the most conspicuous differ ences in anatomy indicate that women have a higher percent of gray matter tissue and correspondingly lower volume of white matter. At the same time women seem to have rela tively larger posterior corpus callosum, which is the largest body of white matter fibers in the brain. The combined pat tern of lower overall white matter with increased callosal volume suggests a fundamental difference in the direction of optimizing interhemispheric connectivity in women, rela tive to connectivity within the hemisphere. Thus, we would expect to find sex differences in behavior where different amounts of interhemispheric communication – relative to intrahemispheric connectivity – is required. Although we have focused on findings in healthy people, the effects have implications for brain disorders where gen der differences have been observed across the lifespan. For example, neurodevelopmental disorders such as attention deficit and learning disabilities are more common in boys, schizophrenia is more severe in young men, autism is more prevalent in men, while depression is more common in women. Similarly, effects of acquired brain disorders such as stroke, traumatic brain injury, Parkinson disease and Alzheimer’s disease, differ in men and women. For exam ple, occlusive stroke is more frequent in men while hemor rhagic stroke is more frequent in women, and Alzheimer’s disease has greater prevalence and severity in women even when corrected for longevity. Notably, in reviewing avail able studies in neurological populations, Amatniek and col leagues (Chapter 10) found a higher overall incidence for females in vascular dementia, multiple sclerosis, migraine and tension headache, pseudotumor cerebri, Bell palsy, meningioma, and myasthenia gravis. For males, the studies showed a greater incidence of epilepsy, amyotrophic lateral sclerosis, Parkinson disease, and Guillain–Barré syndrome. Considering sex differences in brain function can advance understanding of the neural basis of these disorders. The clinical implications of these findings need to be examined in relation to disease presentation and course.8–13 In view of the greater vulnerability of males in prefrontal regions, one would expect brain disorders affecting these regions to be more severe in men and perhaps requiring multimodal therapeutic interventions. For females, with improved understanding of regional brain activity during emotion processing, we may be in a position to explain the neuro biology of increased vulnerability to depression.
Questions for future An impediment for understanding the effects of sex differ ences on brain function is the lack of data on the relationship between neurobiologic and behavioral measures. Available studies have suggested tantalizing parallels between sex dif ferences in behavioral measures and sex differences in neuro anatomy and neurophysiology. However, very few studies
83
have actually correlated behavior with biologic parameters of such differences. Once we have a better appreciation of the nature and magnitude of these correlations, we will be able to answer several questions regarding the etiology and consequences of sex differences in health and disease. Can we capitalize on these sex differences to help amel iorate disease processes? For example, would gonadal hormones help in disorders that are less frequent or less severe in one sex or the other? Could strategies be devised in a manner that would be more gender-specific for detection, prevention, and treat ment of brain disorders? Can we gain further insights on sex differences in brain behavior relations by incorporating genomic strategies?
●
●
●
Acknowledgment Supported by NIH grants MH-60722 and MH-64045.
References 1. Halpern DF. Sex Differences in Cognitive Abilities. Hillsdale, NJ: Lawrence Erlbaum Associates; 1992. 2. Caplan PJ, Crawford M, Hyde JS, et al. Gender Differences in Human Cognition. New York, NY: Oxford University Press; 1997. 3. Gur RC, Turetsky BI, Matsui M, et al. Sex differences in brain gray and white matter in healthy young adults: correlations with cognitive performance. J Neurosci 1999;19:4065–72. 4. Coffey CE, Lucke JF, Saxton JA, et al. Sex differences in brain aging: a quantitative magnetic resonance imaging study. Arch Neurol 1998;55:169–79. 5. Passe TJ, Rajagopalan P, Tupler LA, et al. Age and sex effects on brain morphology. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:1231–37. 6. Shaywitz B, Shaywitz SE, Pugh KR, et al. Sex differences in the functional organization of the brain for language. Nature 1995;373:607–9. 7. Gur RC, Alsop D, Glahn D, et al. An fMRI study of sex dif ferences in regional activation to a verbal and a spatial task. Brain Lang 2000;74:157–70. 8. Hartung CM, Widiger TA. Gender differences in the diagno sis of mental disorders: conclusions and controversies of the DSM-IV. Psychol Bull 1998;123:260–78. 9. Gur RE, Petty RG, Turetsky BI, et al. Schizophrenia through out life: sex differences in severity and profile of symptoms. Schizophr Res 1996;21:1–12. 10. Gaub M, Carlson CL. Gender differences in ADHD: metaanalysis and critical review. J Am Acad Child Adolesc Psychiatry 1997;36:1036–45. 11. Gao S, Hendrie HC, Hall KS, et al. The relationships between age, sex, and the incidence of dementia and Alzheimer dis ease: a meta-analysis. Arch Gen Psychiatry 1998;55:809–15. 12. Savic I, Engel J Jr. Sex differences in patients with mesial temporal lobe epilepsy. J Neurol Neurosurg Psychiatry 2009;65:910–12.
84
s e c t i o n 2 Gender and the Nervous System l
13. Whitacre CC, Ereingold SC, O’Looney PA, et al. A gender gap in autoimmunity. Science 1999;283:1277–78. 14. Collaer ML, Hines ML. Human behavioral sex differences: a role for gonadal hormones during early development? Psychol Bull 1995;118:55–107. 15. McEwen BS. Steroid hormone actions on the brain: when is the genome involved? Horm Behav 1994;28:396–405. 16. McEwen BS, Woolley CS. Estradiol and progesterone regu late neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol 1994;29:431–36. 17. Woolley CS, Weiland NG, McEwen BS, et al. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci 1997;17:1848–59. 18. Janowsky JS, Chavez B, Zamboni BD, et al. The cognitive neuropsychology of sex hormones in men and women. Dev Neuropsychol 1998;14:421–40. 19. Berenbaum SA. Gonadal hormones and sex differences in behavior. Dev Neuropsychol 1998;14:175–96. 20. McGivern RF, Huston JP, Byrd D, et al. Sex differences in visual recognition memory: support for a sex-related dif ference in attention in adults and children. Brain Cogn 1997;34:323–36. 21. Voyer D, Voyer S, Bryden MP. Magnitude of sex differences in spatial abilities: a meta-analysis and consideration of criti cal variables. Psychol Bull 1995;117:250–70. 22. Springer SP, Deutsch G. Left Brain, Right Brain: Perspectives from Cognitive Neuroscience, 5th edn. New York, NY: W. H. Freeman & Co.; 1998. 23. Witelson DF. Sex and the single hemisphere: specializa tion of the right hemisphere for spatial processing. Science 1976;193:425–27. 24. Hiscock M, Israelian M, Inch R, et al. Is there a sex differ ence in human laterality? II. An exhaustive survey of visual laterality studies from six neuropsychology journals. J Clin Exper Neuropsychol 1995;17:590–610. 25. Herlitz A, Nilsson LG, Backman L. Gender differences in episodic memory. Mem Cognit 1997;25:801–11. 26. Kramer JH, Delis DC, Kaplan E, et al. Developmental sex differences in verbal learning. Neuropsychology 1997;11:577–84. 27. Saykin AJ, Gur RC, Gur RE, et al. Normative neuropsy cholgical test performance: effects of age, education, gender and ethnicity. Appl Neuropsychol 1995;2:79–88. 28. Gur RE, Gur RC. Gender differences in aging: cognition, emotions and neuroimaging studies. Dialogues Clin Neurosci 2002;4:197–207. 29. Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test: Adult Version. San Antonio, TX: Psychological Corporation; 1987. 30. Benton AL, Varney NR, Hamsher KdeS. Judgment of Line Orientation. Iowa City: Form V. University of Iowa Hospitals; 1975. 31. Gur RC, Ragland JD, Moberg PJ, et al. Computerized neuro cognitive scanning: I. Methodology and validation in healthy people. Neuropsychopharmacology 2001;25:766–76. 32. Woolley CS, Weiland NG, McEwen BS, et al. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci 1997;17:1848–59.
33. Hampson E. Variations in sex-related cognitive abilities across the menstrual cycle. Brain Cogn 1990;14:26–43. 34. Phillips S, Sherwin BB. Effects of estrogen on memory func tion in surgically menopausal women. Psychoneuroendocrinol 1991;17:485–95. 35. Hampson E. Estrogen-related variations in human spa tial and articulatory-motor skills. Psychoneuroendocrinol 1990;15:97–111. 36. Silverman I, Phillips K, Silverman LK. Homogeneity of effect sizes for sex across spatial tests and cultures: implica tions for hormonal theories. Brain Cogn 1996;31:90–94. 37. Saucier DM, Kimura D. Intrapersonal motor but not extraper sonal targeting skill is enhanced during the midlutel phase of the menstrual cycle. Dev Neuropsychol 1998;14:385–98. 38. Freeman EW, Rickels K, Schweizer E, et al. Relationships between age and symptom severity among women seeking medical treatment for premenstrual symptoms. Psychol Med 1995;25:309–15. 39. Papousek I, Schulter G, Lang B. Effects of emotionally con tagious films on changes in hemisphere-specific cognitive performance. Emotion 2009;9:510–19. 40. Levine LJ, Burgess SL. Beyond general arousal: effects of spe cific emotions on memory. Social Cognition 1997;15:157–81. 41. LeDoux JE. Emotion: clues from the brain. Ann Rev Psychol 1995;46:209–35. 42. Rolls ET. A theory of emotion and its application to understand ing the neural basis of emotion. Cogn Emotion 1990;4:161–90. 43. Ekman P, Rosenberg EL. What the Face Reveals. New York, NY: Oxford University Press; 1997. 44. Ekman P. Strong evidence for universals in facial expres sions: a reply to Russell’s mistaken critique. Psychol Bull 1994;115:268–87. 45. Izard CE. Innate and universal facial expressions: evidence from developmental and cross-cultural research. Psychol Bull 1994;115:288–99. 46. Erwin RJ, Gur RC, Gur RE, et al. Facial emotion discrimina tion: I. Task construction and behavioral findings in normal subjects. Psychiatry Res 1992;42:231–40. 47. Velten E Jr. A laboratory task for induction of mood states. Behav Res Ther 1968;106:473–82. 48. Schneider F, Gur RC, Gur RE, et al. Standardized mood induction with happy and sad facial expressions. Psychiatry Res 2004;51:19–31. 49. Watson D, Clark LA, Tellegen A. Development and valida tion of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988;54:1063–70. 50. Heilman KH. The neurobiology of emotional experience. J Neuropsychiatry Clin Neurosci 1997;9:439–48. 51. Cancelliere AE, Kertesz A. Lesion localization in acquired deficits of emotional expression and comprehension. Brain Cogn 1990;13:133–47. 52. Borod J, Haywood JC, Santschi C, et al. Neuropsychological aspects of facial asymmetry during emotional expression: a review of the normal adult literature. Neuropsychol Rev 1997;7:41–60. 53. Sackeim HA, Gur RC, Saucy MC. Emotions are expressed more intensely on the left side of the face. Science 1978;202:434–36. 54. Kring AM, Gordon AH. Sex differences in emotion: expres sion, experience, and physiology. J Pers Soc Psychol 1998;74:686–703.
C h a p t e r 7 Gender Differences in the Functional Organization of the Brain l
55. Bettencourt AB, Miller N. Gender differences in aggression as a function of provocation: a meta analysis. Psychol Bull 1996;119:422–47. 56. Natale M, Gur RE, Gur RC. Hemispheric asymmetries in processing emotional expressions. Neuropsychologia 1983;21:555–65. 57. Cahill L. Why sex matters for neuroscience. Nat Rev Neurosci 2006, Online publication. 58. Cahill L. Sex related influences on neurobiology of emotion ally influenced memory. Ann NY Acad Sci 2003;985:163–73. 59. Dreher JC, Schmidt PJ, Kohn P, et al. Menstrual cycle phase modulates reward-related neural function in women. Proc Natl Acad Sci U S A 2007;104(7):2465–70. 60. Taylor S, Klein L, Lewis B, et al. Biobehavioral responses to stress in females: tend-and-befriend, not fight-or-flight. Psychol Rev 2000;107(3):411–29. 61. Wang J, Korczykowski M, Rso H, et al. Gender difference in neural response to psychological stress. Soc Cogn Affect Neurosci 2007;24(3):227–39. 62. Young EA, Altemus M. Puberty, ovarian steroids, and stress. Ann N Y Acad Sci 2004;1021:124–33. 63. Allen LS, Gorski RA. Sex difference in the bed nucleus of the stria terminalis of the human brain. J Comp Neurol 1990;22:697–706. 64. Chung WC, De Vries GJ, Swaab DF. Sexual differentiation of the bed nucleus of the stria terminalis in humans may extend to adulthood. J Neurosci 2002;22:1027–33. 65. Witelson SF, Glezer II, Kigar DL. Women have greater den sity of neurons in posterior temporal cortex. J Neurosci 1995;15:3418–28. 66. Harasty J, Double KL, Halliday GM, et al. Language-associated cortical regions are proportionally larger in the female brain. Arch Neurol 1997;54:171–76. 67. Gur RC, Mozley PD, Resnick SM, et al. Gender differences in age effect on brain atrophy measured by magnetic reso nance imaging. Proc Natl Acad Sci U S A 1991;88:2845–49. 68. Davatzikos C, Resnick SM. Sex differences in anatomic measures of interhemispheric connectivity: correla tions with cognition in women but not men. Cereb Cortex 1998;8:635–40. 69. Courchesne E, Chisum HJ, Townsend J, et al. Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers. Radiology 2000;216:672–82. 70. De Bellis MD, Keshavan MS, Beers SR, et al. Sex differences in brain maturation during childhood and adolescence. Cereb Cortex 2001;11:552–57. 71. Goldstein JM, Seidman LJ, Horton NJ, et al. Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging. Cereb Cortex 2001;11:490–97. 72. Nopoulos P, Flaum M, O’Leary D, et al. Sexual dimorphism in the human brain: evaluation of tissue volume, tissue com position and surface anatomy using magnetic resonance imaging. Psychiatry Res 2000;98:1–13. 73. Raz N, Gunning FM, Head D, et al. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Cereb Cortex 1997;7:268–82. 74. Filipek PA, Richelme C, Kennedy DN, et al. The young adult human brain: an MRI-based morphometric analysis. Cereb Cortex 1994;4:344–60.
85
75. Gur RC, Gur RE, Obrist WD, et al. Sex and handedness differences in cerebral blood flow during rest and cognitive activity. Science 1982;217:659–61. 76. Steinmetz H, Staiger JF, Schlaug G, et al. Corpus callosum and brain volume in women and men. Neuroreport 1995;6:1002–4. 77. Witelson SF. Hand and sex differences in the isthmus and genu of the human corpus callosum. A postmortem morpho logical study. Brain 1989;112:799–835. 78. Jäncke L, Staiger J, Schlaug G, et al. The relationship between corpus callosum size and forebrain volume. Cereb Cortex 1997;7:48–56. 79. Arsuaga JL, Carretero JM, Lorenzo C, et al. Size variations in middle pleistocene humans. Science 1997;277:1086–88. 80. Cowell PE, Turetsky BI, Gur RC, et al. Sex differences in aging of the human frontal and temporal lobe. J Neurosci 1994;14:4748–55. 81. Schlaepfer TE, Harris GJ, Tien AY, et al. Structural differ ences in the cerebral cortex of healthy female and male sub jects: a magnetic resonance imaging study. Psychiatry Res 1995;61:129–35. 82. Gur RC, Gunning-Dixon F, Bilker WB, et al. Sex differ ences in temporo-limbic and frontal brain volumes of healthy adults. Cerebral Cortex 2002;12:998–1003. 83. Szeszko PR, Robinson D, Alvir JM, et al. Orbital frontal and amygdala volume reductions in obsessive–compulsive disor der. Arch Gen Psychiatry 1999;56:913–19. 84. Fuster JM. The prefrontal cortex and its relation to behavior. In: G Holstege, ed. Progress in Brain Rresearch. New York, NY: Elsevier Science; 1996:318–66. 85. Matsui M, Gur RC, Turetsky BI, et al. The relation between tendency for psychopathology and reduced frontal brain vol ume in healthy people. Neuropsychiat Neuropsychol Behav Neurol 2000;13:155–62. 86. Raine A, Lencz T, Bihrle S, et al. Reduced prefrontal gray matter volume and reduced autonomic activity in antisocial personality disorder. Arch Gen Psychiat 2000;57:119–27. 87. Tranel D, Damasio H, Denburg NL, et al. Does gender play a role in functional asymmetry of ventromedial prefrontal cor tex? Brain 2005;128:2872–81. 88. Cahill L, Haier RJ, White NS, et al. Sex-related difference in amygdala activity during emotionally influenced memory storage. Neurobiol Learn Mem 2001;75:1–9. 89. Davidson RJ, Putnam KM, Larson CL. Dysfunction in the neural circuitry of emotion regulation – a possible prelude to violence. Science 2000;289:591–94. 90. Damasio AR. Towards a neuropathology of emotion and mood. Nature 1997;386:769–70. 91. LeDoux JE. Emotion circuits in the brain. Annu Rev Neurosci 2000;23:155–84. 92. Price JL. Prefrontal cortical networks related to visceral func tion and mood. Ann N Y Acad Sci 1999;877:383–96. 93. Rolls ET. The Brain and Emotion. New York, NY: Oxford University Press; 1999. 94. Ragland JD, Coleman AR, Gur RC, et al. Sex differences in behavior relationships between verbal episodic memory and resting regional cerebral blood flow. Neuropsychologia 2000;38:451–61. 95. Esposito G, Van Horn JD, Weinberger DR, et al. Gender dif ferences in cerebral blood flow as a function of cognitive state with PET. J Nucl Med 1996;37:559–64.
86
s e c t i o n 2 Gender and the Nervous System l
96. Kastrup A, Li TQ, Glover GH, et al. Gender differences in cerebral blood flow and oxygenation response during focal physiologic neural activity. J Cereb Blood Flow Metab 1999;19:1066–71. 97. Gur RC, Mozley LH, Mozley PD, et al. Sex differences in regional cerebral glucose metabolism during a resting state. Science 1995;267:528–31. 98. Gur RC, Gur RE, Obrist WD, et al. Age and regional cer ebral blood flow at rest and during cognitive activity. Arch Gen Psychiatry 1987;44:617–21. 99. Madden DJ, Turkington TG, Coleman RE, et al. Adult age differences in regional cerebral blood flow during visual world identification: evidence from H215O PET. Neuroimage 1996;3:127–42. 100. McEwen BS. Possible mechanisms for atrophy of the human hippocampus. Mol Psychiatry 1997;2:255–62. 101. McEwen BS, Alves SE, Bulloch K, et al. Ovarian ster oids and the brain: implications for cognition and aging. Neurology 2007;48:S8–S15. 102. Matteis M, Troisi E, Monaldo BC, et al. Age and sex dif ferences in cerebral hemodynamics: a transcranial Doppler study. Stroke 1998;29:963–67. 103. Volkow ND, Wang GJ, Fowler JS, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998;44:143–47. 104. Volkow ND, Gur RC, Wang GJ, et al. Association between decline in brain dopamine activity with age and cogni tive and motor impairment in healthy individuals. Am J Psychiatry 1998;155:344–49. 105. Halbreich U. Role of estrogen in postmenopausal depres sion. Neurol 1997;48:S16–20.
106. Lindamer LA, Lohr JB, Harris MJ, et al. Gender, estrogen, and schizophrenia. Psychopharm Bull 1997;33:221–28. 107. Nordström A-L, Olsson H, Halldin C. A PET study of D2 dopamine receptor density at different phases of the men strual cycle. Psychiatry Res Neuroimaging 1998;83:1–6. 108. Pohjalainen T, Rinne JO, Någren K, et al. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 1998;155:768–73. 109. Jaber M, Jones S, Giros B, et al. The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997;29:633. 110. Jones SR, Gainetdinov RR, Jaber M, et al. Profound neu ronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A 1998;95:4029–34. 111. Kramer JH, Delis DC, Kaplan E, et al. Developmental sex differences in verbal learning. Neuropsychol 1997; 11:577–84. 112. Reite M, Cullum CM, Stocker J, et al. Neuropsychological test performance and MEG-based brain lateralization: sex differences. Brain Res Bull 1993;32:325–28. 113. Chalfonte BL, Johnson MK. Feature memory and binding in young and older adults. Mem Cognit 1996;24:403–16. 114. Craik FI, McDowd JM. Age differences in recall and rec ognition. J Exp Psychol Learning, Memory, Cognition 1987;13:474–79. 115. Mozley LH, Gur RC, Mozley PD, et al. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 2001;158:1492–99. 116. Shors T, Chua C, Falduto J. Sex differences and opposite effects of stress on dendritic spine density in the male versus female hippocampus. J Neurosci 2001;16:6292–97.
Chapter
8
Sexual Differentiation of Brain Structure and Function Margaret M. McCarthy Professor of Physiology, University of Maryland Baltimore School of Medicine, Department of Physiology, Baltimore, MD, USA
Introduction
sets the stage for sex differentiation, the process whereby the body and the brain become differentiated between males and females. Hormones synthesized and released by the gonads, predominantly androgens and anti-Müllerian hormone by the testis, will direct the formation of the gonadal duct system, genitalia, and secondary sex characteristics, as well as sex differences in the brain. However, unlike the differentiation of the Wolffian ducts into the vas deferens or the formation of a penis and scrotum instead of a vagina and uterus, processes which are absolute and irreversible, the differentiation of the brain is regionally specific, highly variable and often a matter of degree. Moreover, despite 50 years of research, our understanding of sexual differentiation of the brain remains rudimentary, with considerable controversy surrounding such core questions as whether there are separate neural circuitries controlling male versus female sex behavior, the nature of the critical hormones and their receptors, the timing of specific events and the precise cellular mechanisms mediating neuronal differentiation, and lastly, whether the changes induced are permanent or merely enduring. Finally, central to understanding sexual differentiation of the brain is identifying what it is not. All sex differences in brain and behavior are not necessarily the result of differentiation. Multiple factors can result in sex differences that are temporary due to changes in reproductive status, previous experience or chronological age.3 For example, the threshold for long-term potentiation (LTP) in the hippocampus, a phenomenon considered a physiological manifestation of learning, varies in females across stages of the estrus cycle and encompasses a range that includes the relatively constant threshold for LTP observed in males. Thus, at some points in the estrus cycle there is a sex difference in threshold, but the direction of the sex difference reverses, and at other times there is no sex difference at all. Although important, this is not an
Gender is the first and most salient attribute we integrate into our perception of other individuals, being signaled to us via multiple modalities that include dress, tone of voice, odors, and even name. Animals also readily signal their own sex and immediately perceive it in conspecifics. But how do these external manifestations of sex or gender reflect the phenotype of the brain? Is there a male brain and a female brain? Or, are our brains relatively gender-neutral but limited in range of function by the physical attributes associated with the sex of the body they happen to inhabit? The goal of this chapter is to review the current state-of-the-art in the study of sex differences in the brain and to put forward the argument that the answer to the above questions lies somewhere in the middle. It is a gross oversimplification to suggest that the entire brain, in all its complexity and diverse functionality, is ubiquitously male or female. But it is equally egregious to ignore sex and gender as variables in brain function, or to assume that these differences are only relevant to reproduction. As our understanding of the origins of sex differences in the brain becomes more sophisticated, we will better succeed at understanding what is nature, what is nurture, what are their interactions, and what is of value to the practitioner of gender-specific medicine. Sex begins with the chromosomes, specifically the Sry gene on the Y chromosome which codes for tdf, the testis determining factor. In response to expression of this single gene, the bipotential gonadal rudiment will be directed toward development as a testis. In the absence of this gene, regardless of whether an individual is XX or XY, the gonad will develop along its default pathway, which is to become an ovary.1,2 This process occurs early in embryogenesis and is referred to as sex determination. Sex determination then
Principles of Gender-Specific Medicine
87
Copyright 2010 20 , Elsevier Inc. All rights reserved.
88
s e c t i o n 2 Gender and the Nervous System l
endpoint that is subject to sexual differentiation and therefore mechanistically and functionally distinct from those endpoints that are differentiated. Tremendous advances are being made in identifying gender differences and their relevance to the human brain, much of it reviewed in this volume. Equally important advances are being made with the more empirical approach afforded by animal models. Gender is a uniquely human construct, as it involves both self-identification as a member of a particular gender category, and the societal and cultural factors that are associated with gender. Animals, however, have only sex. This both simplifies and limits the study of sexual differentiation of the brain. Moreover, one overarching rationale for understanding the nature of the variables and cellular mechanisms mediating sex differences in the brain is to gain insight into basis of gender biases in neurological and mental health disorders. Males are at higher risk for autism, dyslexia, stuttering, early-onset schizophrenia, and attention deficit and hyperactivity disorders, whereas females are at greater risk for being diagnosed with disorders of mood and affect. Thus males suffer disproportionately from disorders with origins in early development, whereas females are more likely to suffer adult onset disease.4 The variables contributing to this difference are surely complex, including societal, cultural, and biological components. The study of animal models is an important contributor to achieving the goal of understanding, but is limited by our inability to truly model complex and uniquely human conditions such as autism or schizophrenia.
Historical overview The origins of the study of sexual differentiation of the brain are generally attributed to a single iconic paper published by Phoenix, Goy, Gerall, and Young in 19595 on the impact of hormonal treatment of pregnant guinea pigs on the adult sexual behavior of their offspring. In a remarkably insightful synthesis of converging evidence, the authors proposed for the first time the notion that differences in hormone exposure to the developing male and female brain permanently organized the neural substrate such that it was then selectively activated in adulthood to induce the appropriate behavioral repertoire. Now codified as the Organizational/Activational Hypothesis, this postulate has stood the test of time and trial exceedingly well and provided a constructive framework from which to begin the investigation of the origins of sex difference.6,7 The guinea pig quickly proved to not be the optimal species for such studies as the majority of its brain sex differentiation occurs in utero, thereby complicating manipulation with exogenous steroids. The rat, by contrast, is readily sex reversed (at least to a first approximation) with neonatal castration of males or treatment of females with androgens during the
first few days of life. A sensitive period was identified that is operationally defined as the onset of testicular androgen synthesis in the late-gestational male and the postnatal day at which females become refractory to the masculinizing effect of exogenous hormone administration. The timing of the offset of the sensitive period varies with the endpoint under study, but the window of opportunity has usually closed by postnatal day 10, although recent evidence supports the existence of a second sensitive period associated with the hormonal changes of puberty8 (Figure 8.1). During the course of studies exploring the dose and duration of androgen exposure required to differentiate the brain of a female into a male, investigators detected an unexpected anomaly. A hormone that was used as a control, estradiol, was found to be even more effective than testosterone at masculinizing sex behavior. Several pieces of evidence converged to coalesce as the Aromatization Hypothesis.9,10 These included the fact that estradiol is a byproduct of testosterone produced by the aromatization of its A-ring, that the aromatase enzyme is found at high levels in neurons in sexually dimorphic brain regions, particularly during the sensitive period, and that estrogen receptors are also found at high levels in these same brain regions. The final piece of the puzzle was the discovery that fetal and neonatal rat blood carries alpha-fetoprotein, a steroid binding globulin with high affinity for estradiol but none for testosterone (in the rodent). This allows for sequestering of maternal estrogens in the fetal blood, permitting testosterone to enter into neurons where it is locally converted to estradiol which then masculinizes the neural substrate.11 This counter-intuitive observation, that a hormone largely identified with the ovary and considered to be a ‘female hormone’, estradiol, is the masculinizing hormone in brain development, does not extend to the primate brain. Both naturally occurring endocrine variations in humans and exhaustive empirical studies in captive primates indicate that in primates, in contrast to rodents, androgens are the masculinizing hormones, not estrogens. What role, if any, estradiol plays in primate brain development remains to be discovered. Around the same chronological time that the role of aromatization in brain masculinization was identified, the first replicable reports of major neuroanatomical sex differences were confirmed in animals, substantiating the view that male and female animals brains are different and fueling speculation regarding differences between the brain of men and women. Cleverly noting that male canaries sing a complex and alluring song, while females do not, Nottebohm and Arnold surmised there must be a brain difference controlling the behavioral difference.12 We now know there is an entire song control circuit that is highly sexually dimorphic and many of the guiding principles establishing this difference are still being determined.13 In response to the report in birds, mammalian researchers took a closer look at the rodent brain and made the startling discovery of a small
C h a p t e r 8 Sexual Differentiation of Brain Structure and Function l
89
Figure 8.1 Hormonally induced sexual differentiation of the brain occurs during a restricted sensitive period. In rodents, a perinatal sensitive period for sexual differentiation of the brain is operationally defined as the onset of testosterone synthesis by the fetal gonad beginning around embryonic day (E) 18, followed by a second surge in testosterone levels on the day of birth (PN 0), and the loss of sensitivity of females to exogenous steroid administration, which is usually around postnatal day (PN) 10. The Organizational/ Activational Hypothesis of steroid action postulated in 1959 that steroids exert distinct effects during two different life phases. During the sensitive period, steroid actions are referred to as organizational because they are largely permanent, altering multiple aspects of brain development including cell birth, death, migration, and differentiation. The organized neural substrate is then acted upon by adult circulating steroid hormones to mediate the expression of sexually dimorphic behaviors, such as sexual behavior. In primates, including humans, the sensitive period appears to be entirely prenatal with the critical period for fetal steroid exposure being at the end of the second and beginning of the third trimester.
dense sub-nucleus in the preoptic area that was 5–7 times larger in males than females, aptly naming it the sexually dimorphic nucleus of the preoptic area or SDN-POA.14 The fact that the preoptic area is a major brain region controlling male sexual behavior in animals had not escaped their notice and voluminous follow up studies have sought to identify the etiology and function of the SDN-POA, an effort that continues to this day.15 The discovery of the SDN-POA in the rat also prompted interest in similar neuro anatomical sex differences in humans.16 Recent advances in in vivo neuroimaging techniques have pushed the frontier in the study of sex differences in the human brain.17,18 In addition, the tragic consequences of the AIDS epidemic in the 1990s provided an abundance of tissue from men of known sexual orientation which allowed investigators to test the hypothesis that sexual orientation is dependent on the sexually differentiated state of the brain. More recently the field has seen advances on both conceptual and mechanistic fronts. The advent of transgenic mice has produced a wide-ranging array of sexual pheno types and renewed interest in both the steroid hormone receptors and their effectors that mediate differentiation. Sorting out the genuine from the artifact in genetic mutants will be a long but essential process. But the genetic facileness of mice has also brought to light a new principle, that genes associated with the X and Y chromosomes might importantly contribute to sex differences in brain and behavior.19 Lastly, there has been a drive to re-examine our old biases and assumptions about both the importance and purpose of sex differences in the brain. Paradoxically, some of the neuroanatomical differences we observe may in fact be for the purpose of converging the behavior of the two sexes
toward a common goal when one sex is deprived of the endocrine state that would normally induce the behavior.20 A clear example is parenting. Only females experience the hormonal milieu associated with pregnancy, parturition, and lactation, but it is often in the male’s vested interest to provide paternal care for his offspring. Compensatory changes exclusive to the male brain appear to drive this behavior and represent a circumstance where a sex difference in the brain eliminates a sex difference in behavior.21
Sex differences in neuroanatomy There are three fundamental ways in which male and female brain anatomy can differ: (1) size (usually but not always a function of cell number); (2) pattern of synaptic connectivity; and (3) neurochemical phenotype. While each of these refers to a distinct quantifiable endpoint, they are not necessarily separate. For example, the number and nature of the synapses evident in a particular nucleus might be a function of the size of the afferent projection it receives, which may in turn differ in the dominant neurotransmitter involved in males versus females. Examples of all varieties of sex differences have been identified and continue to be reported. The great challenge ahead is to characterize and understand functional neural circuits that differ in meaningful ways in males versus females.
Volumetric Sex Differences The size of a region, nucleus, projection or individual cell can be larger or smaller in either sex. Examples of all have
90
s e c t i o n 2 Gender and the Nervous System l
been noted, beginning with the overall larger male brain, an effect which is diminished but not eliminated when corrected for body size. As a general rule, structures tend to be larger in male brains, and considerable attention is given to those instances in which the opposite is reported. There are limited ways in which a brain region, nucleus or projection can be larger in one sex. Essentially there can be the same number of cells but they are larger and/or more widely spaced in one sex than the other. Alternatively, there can be more cells coalesced to constitute a particular region, such as is the case for the SDN-POA in the rat. Here, the density and size of the neurons is the same in males and females; however, there are simply more neurons in males, thereby occupying a larger volume. The SDN-POA is probably the most famous brain sex difference, if such a moniker can be applied to a small collection of Nissl dense cells embedded within a large and complex brain region, the preoptic area. The attention given the sex difference in the size of the SDN-POA is in part a function of its magnitude, which is substantial as it is 5–7 times larger in males, and in part a function of its simplicity. The sex difference is entirely due to the actions of a single hormone, estradiol, acting during a restricted perinatal period to influence cell survival.22 The functional impact of this nucleus being larger in males remains elusive but of continuing interest. A projection can be larger in one sex because more cells contribute axons to the pathway, and this has been documented for the posterior portion of the bed nucleus of the stria terminalis (pBNST) in rats which projects to the anteroventroperiventricular nucleus (AVPV) of the preoptic area, together constituting a component of a synaptic circuit regulating gonadotropin secretion.23 Alternatively, a projection can be larger as a function of the degree of myelination of the axons, as has been speculated for the corpus callosum, one of the more controversial and direction-changing of sex differences in the human brain. The corpus callosum is the major projection between the cortical hemispheres. The callosum, or various of its subregions, have variously been reported to be larger in females, larger in males or the same size in both sexes depending on the laboratory doing the measurements as well as the particular subregion examined and the species in which it was examined.24,25 The reversing fortunes of the corpus callosum provides a cautionary tale in the study of sex differences. Precisely why there have been so many conflicting reports is unclear, but a desire to provide a structural underpinning to the perception that the two hemispheres of male brains function more asymmetrically than those of females may have generated inappropriate enthusiasm. That is, the underlying assumption of many studies has been that female brains function more symmetrically and should, therefore, have more or larger fibers interconnecting the two hemispheres. There are numerous other volumetric sex differences reported in the mammalian brain, but none matches those observed in the song-control nuclei of the avian brain, with
the exception of the spinal nucleus of the bulbocavernosus which consists of motor neurons that control the penis. In humans, volumetric sex differences have been described but generally of a smaller magnitude than seen in our animal models and varying substantially across the lifespan,26–29 highlighting the ever-changing nature of the brain.
Synaptic Patterning Sex Differences Synapses come in two flavors, excitatory and inhibitory. Synaptic patterning refers to the number and/or density of excitatory versus inhibitory synapses found within a particular brain region, meaning a specific nucleus or a particular cell layer in a larger brain region such as the hypothalamus or hippocampus. To truly identify a synapse as excitatory or inhibitory requires electron microscopy to distinguish the shape, location, and nature of the vesicles. Fortunately, where a synapse is located on a neuron is a pretty good indicator of the type, with inhibitory synapses generally being on the soma (cell body) and excitatory synapses found on the dendrites. Even more fortunately, specialized protuberances on dendrites, called dendritic spines, are almost exclusively excitatory and can be easily quantified with the use of Golgi cox impregnation or proxy markers such as the protein, spinophilin.30 Early and heroic EM studies from the laboratory of Arai in Japan, exhaustively characterized the synaptic profiles in sexually dimorphic brain regions such as the ventromedial and arcuate nuclei of the hypothalamus,31 revealing that the proportion of presumptively excitatory versus inhibitory synapses in these regions is profoundly different between male and female rats and is sex reversed by hormone treatment of neonatal females. The same has subsequently been confirmed for the preoptic area and subregions of the amygdala. Interestingly, despite the overwhelming perception to the contrary, no such sex difference has been identified for the hippocampus or cortex. And more importantly, sex differences in synaptic profiles have not been explored in the primate, leaving a major gap in our knowledge of the nature of sex differences in the human. In the continuing effort to understand how sex differences in synaptic profile impact on physiology and behavior, it is essential to place the findings in the context of a circuit. For example, in the preoptic area, males have a twoto three-fold greater density of dendritic spine synapses, whereas in the ventromedial nucleus, males have a two- to three-fold greater number of dendritic spines.32 The difference between the two brain regions is the nature of the dendrites themselves, which are similar in the sexes in the preoptic area, but are longer and branch more frequently in the male ventromedial nucleus than the female (Figure 8.2). How this changes the response to afferent stimuli is unclear, but the consequences for behavior are profound. The male pattern of synapses in either brain region is essential for the normal expression of male sexual behavior in adulthood, a topic discussed in greater detail below.
C h a p t e r 8 Sexual Differentiation of Brain Structure and Function l
Figure 8.2 Sex differences in dendritic spine synapses can be in number or density. One of the more profound sex differences in the brain is the pattern of synaptic connections. Dendritic spines are the primary site of excitatory synapses. In the preoptic area, a major brain region controlling male sexual behavior, the dendrites of males have twoto three fold greater density of spine synapses, revealing a higher level of excitatory input onto these neurons. In the ventromedial nucleus, a major brain region controlling female sexual behavior, the dendrites of males are longer and branch more frequently, resulting in overall more dendritic spine synapses and suggesting a broader array of afferent inputs to this region in males, although this remains to be determined.
Neurochemical Sex Differences The third major neuroanatomical sex difference possible is the neurochemical phenotype of a set of neurons, which may differ in abundance and/or projections.33 Quantifying sex differences in neurons of a particular phenotype often provides the advantage of being one step closer to the functional significance of any observed differences. For example, a collection of galanin-positive neurons in the brainstem project to motor neurons of the spinal cord and have been identified as the ejaculation center.34 Not surprisingly, there are few if any of these galanin-positive neurons in the female brainstem. In this case the female lacks the peripheral structures involved in the behavioral response, making the connection between neuroanatomy and functional output relatively unambiguous. However, this is not always the case. There is a marked male bias in the density of vasopressin innervation of the septum in both rats and other rodents, including voles.35 Vasopressin, similar to the closely related oxytocin, is strongly associated with the control of affiliative behaviors such as parenting and pair bonding.36,37 The denser vasopressin innervation in males is speculated to provide the neurological underpinnings for inducing males to provide parental care of their offspring,38 an endpoint achieved in females by the hormonal milieu of pregnancy, parturition, and lactation.39,40 A sex difference in the number of vasopressin-positive neurons in the human pBNST is of unknown significance but notable in that it is not apparent until puberty.41 There is also a sex difference in the number of dopamine synthesizing neurons of the AVPV and this again seems to be directly tied to reproduction in that this nucleus plays a critical role in the control of the GnRH neurons that regulate the release of gonadotropins
91
from the anterior pituitary.42 So in three different instances there is a direct connection between sex differences in defined populations of neurochemically identified neurons and a reproduction-related output. When the discussion of sex differences in neuroanatomy and function strays outside of the immediate realm of reproduction in laboratory animals, such direct connections have not been established, and perhaps may not exist. For example, the sexual neuroanatomical dimorphisms in the particular circuits that regulate gonadotropin secretion in rats are unlikely to have counterparts in primates, including humans, since the function they mediate is sexually dimorphic in rats but not in a primate that has been studied to date.
Cellular mechanisms establishing sex differences in brain A Critical Role for Naturally Occurring Cell Death After confirming that a particular brain region or structure is larger in one sex versus the other, and that the difference is due to the number of neurons and not cell size or spacing, the next critical question is how does this sex difference come about? There are three fundamental strategies by which the size of a collection of neurons, meaning a nucleus, can be altered: (1) more cells are born, (2) more cells migrate into the region, or (3) more cells die. There is also the potential for cells to be larger or have more associated neuropil in one sex versus the other, but this would impact cell density, not cell number, which is the basis of most volumetric sex differences. Estimates are that 50% of the cells generated in the nervous system are ultimately fated to die during early periods of development. Analyses of numerous volumetric sex differences, including the song control nuclei of birds, the SDN-POA of rats and the AVPV and SNB of mice and rats, consistently conclude that volumetric sex differences are established when males and females begin with the same number of neurons but that differential hormonal exposure results in sex differences in cell death. The identification of apoptosis as a mechanism for establishing sex differences in the vertebrate nervous system was made over 20 years ago,43,44 but has been investigated mechanistically only recently. The greatest advances have been made in the study of the SNB, which consists of motor neurons that innervate the penis. The size of the SNB is, not surprisingly, substantially larger in males. Ciliary neurotrophic factor (CNTF) is upregulated by androgens in the bulbocavernosus muscle, which is innervated by the SNB motor neurons, and then retrogradely transported to act on the CNTF receptors on the motor neurons, promoting their survival. Mutant mice lacking receptors for CNTF have no sex difference in the size of the SNB. CNTF administered to females rescues the motor neurons, and treating males with antagonists to CNTF receptor reduces
92
s e c t i o n 2 Gender and the Nervous System l
the number of motor neurons.45 Thus, testosterone regulates cell death in a specific CNS region because it has evolved control of a well-established neurotrophic mechanism that controls apoptosis in numerous neural tissues. Developmentally restricted sex differences in cell death leading to adult volumetric dimorphisms have been well characterized, and well reviewed for several other brain regions, most notably the SNB and SDN-POA of rats, the AVPV of mice and rats and the song control nuclei of birds.22,44,46 In each case there is a temporal disconnect of days between hormone exposure and maximum cell death, suggesting an initiation of a long-term cellular process by estradiol or testosterone, perhaps involving afferent input or efferent connections. The delay in dying further complicates attempts at identifying the mechanism of hormone action, which can vary from neuroprotection (SDN-POA, SNB, song nuclei) to death promoting (AVPV). Mice with a null mutation in the Bcl-2 gene, a potent inhibitor of cell death, or in Bax, a promoter of cell death, have been usefully exploited to advance our understanding. Sex differences in the SNB and AVPV were eliminated in Bax / mice, indicating Bax is required for sexually dimorphic cell death in the mouse forebrain and spinal cord. Interestingly, Bax is involved in death that is increased by estradiol (in the AVPV) as well as that decreased by testosterone (in the SNB). One advantage of this approach is that the number of neurons observed in Bax / adults represents the original number generated in each sex, whereas the difference in cell number between Bax / and Bax / adults reveals the total number of neurons lost ‘integrated over the entire developmental cell death period’,45 further supporting the notion that sex differences in cell death contribute to volume differences in multiple brain regions. However, it would be simplistic to suggest that this is the only basis for volumetric sex differences. Brain nuclei are defined by a combination of their histological appearance, the neurochemical phenotype of the cells and the function attributed to that group of cells. They are not monomorphic collections of identical neuronal phenotypes. The ability of steroids to distinguish the phenotype of neurons, and perhaps even to determine the fate of precursor cells as neurons versus glia, is an important and still relatively poorly understood mechanism for distinguishing male from female brains.
An Emerging Role for Cell Genesis and/or Cell Differentiation The importance of cell death in sculpting the differential size of specific nuclei in males and females is clear, but an emerging view is that this is not the sole mechanism either establishing, or even maintaining volumetric sex differences. When brain regions are examined for sex differences in cell genesis during the developmental peak of cell birth (usually prenatally), there has been no good evidence for sex differences in the number of cells born. However, the
tremendous interest in neurogenesis in the adult brain has also brought attention to the possibility of important cell genesis in the early postnatal brain. In rats the hippocampus is larger in males than females, but both the magnitude and reliability of the difference is small (reviewed in McCarthy and Konkle3). Nonetheless, more new cells are detected in the one-week-old male rat hippocampus than the female hippocampus, particularly in the CA1 region of Ammons horn.47 Treatment of females with either testosterone or estradiol increases the number of new cells to that of males, but the hormonal modulation appears to be complex and multifactorial, as there are differential effects on neurons versus glia and androgens versus estrogens. This evolving story is further complicated by the difficulty in resolving whether more new cells are born or more cells simply survive in the hippocampus of males compared to females. However, the phenomenon seems relatively specific since there is no difference in the number of new cells detected in the hypothalamus of the same animals at the same developmental time point. Similar questions are being asked in regard to a profound sex difference in vasopressin positive neurons in the rat and vole brain.48 Again, the issue of differential birth versus survival arises, with the latter being importantly impacted by differentiation. New cells that do not differentiate into either neurons or glia are destined to die. Stimuli that promote movement along a dedicated differentiation pathway increase survival. Steroids are very likely to regulate, if not determine, cell fate but to date this has not been definitively demonstrated. In the arena of areas to watch, the importance of sex differences in cell genesis and differentiation is at the top of the list.
Importance of Cell-to-Cell Communication Sexual differentiation of neuroanatomy is determined by neonatal steroid action. Steroids act via receptors that are transcription factors and induce gene expression followed by protein synthesis. The steroid receptors of greatest interest are the estrogen receptor (ER), which has two isoforms, ER and ER, and androgen receptors (AR), which bind both testosterone and dihydrotestosterone (DHT). The distribution of steroid receptors in the brain is characterized by receptor autoradiography, immunocytochemistry or in situ hybridization for detection of the mRNA,49–52 all of which allow for identification of individual cells. The limits of sensitivity of each not withstanding, a consistent conclusion is that some brain regions, such as the POA or VMN of the mediobasal hypothalamus, have dense collections of neurons that express ER and/or AR, whereas others do not. This pattern seems to hold across species and is seen also in humans. However, even within those regions where this is a high level of steroid receptor expression, not every neuron is presumed to express the receptor, and evidence for steroid receptors in non-neuronal astrocytes is notably
C h a p t e r 8 Sexual Differentiation of Brain Structure and Function l
lacking. Thus, a natural corollary of a restricted expression of ER and AR is that estradiol- or androgen-induced differentiation would be restricted to those cells possessing the receptor. In other words, steroid-mediated differentiation of neuroanatomy would be expected to be cell autologous, with only those neurons expressing ER or AR changing morphology in response to steroids. But contrary to this prediction, the data suggest otherwise. Quantification of morphometric endpoints, such as dendritic length, branching and density of dendritic spines within a particular nucleus (i.e. medial pre optic nucleus, VMN, arcuate), consistently indicate that the entire population of neurons has shifted its phenotype in response to steroid stimulation.30 The key to understanding this apparently contradictory observation is the importance of cell-to-cell communication in transmitting the signal to change. Gaba in the Arcuate Nucleus of the Hypothalamus The arcuate nucleus is located at the ventral border of the hypothalamus in close proximity to the median eminence through which it exerts influence over the anterior pituitary gland. A variety of neuropeptide releasing factor expressing neurons and GABA interneurons are interspersed with protoplasmic astrocytes distinguished by their early maturation in relation to other hypothalamic nuclei. Neurons of the arcuate nucleus are sexually dimorphic, with males having fewer dendritic spine synapses than females.53,54 The astrocytes of the arcuate nucleus are also sexually dimorphic, with males having more stellate-shaped glia that have longer and more highly branched processes than females.55 In an effort to understand the relationship between neuronal and glial morphology, Mong and colleagues determined that in developing males, estradiol (aromatized from testicular androgens) induces expression of the rate-limiting enzyme in GABA synthesis, GAD, thereby increasing levels of GABA which is made exclusively in neurons. Astrocytes do not make GABA, therefore limiting the primary site of steroid action to the neuron, but astrocytes do respond to GABA with increased process growth and branching.56 In the adult, astrocytes of the arcuate nucleus regulate the synaptic profile of immediately adjacent neurons57 and a similar phenomenon is presumed to occur during development. Thus a neuron-to-astrocyte-to-neuron loop is established in which steroids, i.e. estradiol, act first in the neuron and then indirectly modify the morphology of neighboring astrocytes which in turn modify the neuron (Figure 8.3). Prostaglandins in the Preoptic Area An analogous yet distinct process occurs in the preoptic area. In this brain region males have a greater density of dendritic spines, but surprisingly they also have more stellate and complex astrocytes compared to females.58,59 The astrocytes of the preoptic area are similar to the arcuate in that they are also highly mature at birth as evidenced by
93
Figure 8.3 GABA mediates neuronal-astrocytic communication to induce sex differences in the arcuate nucleus. An emerging principle in the organizational actions of steroids is the importance of cell-to-cell communication. In some regions, astrocytes are a critical component of this communication. The arcuate nucleus of the rat exhibits sexually dimorphic synaptic patterning and this is established by estradiol (E2) binding to its receptor (ER) primarily within neurons to increase expression of the rate-limiting enzyme in GABA synthesis, GAD (glutamic acid decarboxylase), which is then released from neurons to act on the neighboring astrocytes to induce them to differentiate into a more complex stellate morphology. This increased complexity of the astrocytes is correlated with a reduction in the density of dendritic spine synapses in this brain region.
dense expression of glial fibrillary acid protein (GFAP), yet the relationship between astrocyte morphology and dendritic morphology is the opposite in the POA compared to the arcuate nucleus. Neuron-to-astrocyte-to-neuron communication also plays a critical role in establishing the sexually dimorphic neuroanatomy of the preoptic area, but the nature of the signaling molecules is profoundly and surprisingly different. Rather than a classic neurotransmitter, the initiating event in the cellular cascade leading to changes in astrocytic and neuronal morphology is increased synthesis of the prostaglandin E2 (PGE2). The synthesis of all the prostanoids begins with the oxygenative cyclization of arachidonic acid by cyclooxygenase. The inducible isoform of cyclooxygenase, COX-2, is an immediate early gene responsive to a variety of stimuli including infection, injury, and stimuli associated with neuronal plasticity.60–62 As early as the day of birth, COX-2 mRNA and protein are significantly higher in the POA of males than females and treating females with estradiol increases COX levels to that of males. Increased COX-2 is directly correlated with increased PGE2 production and treating newborn females with estradiol increases PGE2 levels in the POA almost seven-fold. Most importantly, administrating PGE2 to newborn females induces a permanent two- to threefold increase in dendritic spines on neurons in the preoptic
94
s e c t i o n 2 Gender and the Nervous System l
area, but not the ventromedial nucleus or the hippocampus. Conversely, blocking PGE2 synthesis temporarily in newborn males by inhibiting the COX enzymes, significantly reduces POA dendritic spines to the level seen in normal females.58,63 The neighboring astrocytes also change their morphology in response to PGE2, with increased process length and branching, although the magnitude of the response is about half that seen with estradiol treatment. The COX enzymes, COX-1 and COX-2, are present in neurons of the POA, and the receptors for PGE2 (EP1-4) can be found in this brain region as well, including on astrocytes. One established effect of PGE2 on astrocytes is the induction of glutamate release,64 and this appears to be true in the POA as well. Moreover, the induction of dendritic spines on POA neurons by PGE2 requires at least in part the activation of the AMPA-type glutamate receptor. Taken together, these data present a working model in which estradiol upregulates the expression of COX-1 mRNA and protein in neurons and thereby markedly increases the production of PGE2. The prostanoid is released by neurons to act on neighboring astrocytes, causing them to release glutamate which in turn acts back on the neurons inducing the formation of dendritic spines (Figure 8.4). Thus once again there is presumptive neuron-to-astrocyte-to-neuron communication that coordinates the induction of morphological changes over an entire, but limited, region of the brain. The preoptic area is the critical brain region controlling male sexual behavior, and the importance of these morphological changes for behavior will be discussed below. Glutamate in the Ventromedial Nucleus of the Hypothalamus In rats, the ventromedial nucleus (VMN) is to female sexual behavior what the preoptic area is to male sexual behavior, a critical node in a complex circuit and a central site of steroid-induced sexual dimorphism. Dendrites on neurons of the VMN have more branches, and as a consequence more dendritic spines in males than females,65,66 and just like the POA and the arcuate, this sex difference is mediated by estradiol (derived from testicular androgen) during the first few days of life. However, in contrast to the POA and arcuate nucleus, the astrocytes of the developing VMN are notably immature and appear to play no role in the process of sexual differentiation. This does not mean there is no role for cell-to-cell communication, however. In this brain region, estradiol acts in one neuron to induce changes in another neuron. What makes the situation even more unique in this brain region is the mechanism of estradiol action, which is non-genomic. As discussed above, steroids act via transcription factors to directly alter gene expression and protein synthesis. An emerging concept in steroid action has been the direct activation of signaling molecules at the membrane, in particular membrane-bound kinases such as MAP kinase or PI3 kinase.67–71 These interactions are generally rapid and transient, but can have long-term
Figure 8.4 PGE2 mediates neuronal-astrocytic communication to induce sex differences in the preoptic area. Astrocytes of the preoptic area (POA) are also sexually dimorphic, with males having more complex cells that have longer processes which branch more frequently. In this brain region, estradiol (E2) again binds to its receptor (ER) and upregulates the expression of the cyclooxygenase enzyme, COX-2, which is a principle enzyme in the production of the prostaglandin, PGE2. Astrocytes respond to PGE2 by releasing glutamate, and glutamate acting at AMPA receptors induces the formation of dendritic spine synapses. In this way, neuronal-to-astrocyte-to-neuronal communication establishes a sexually dimorphic pattern of dendritic spine synapse density.
consequences for the cell by secondarily inducing gene transcription via changes in intracellular calcium or other signaling molecules.72 Because these effects are rapid, however, it was generally assumed that they would not be involved in the process of sexual differentiation of the brain since it is a process that permanently alters brain structure. But the data remind us why we should never make assumptions. In the developing mediobasal hypothalamus, estradiol activates PI3 kinase within one hour and this leads to increased release of glutamate from presynaptic terminals. The released glutamate acts on postsynaptic NMDA receptors and induces the formation of dendritic spine excitatory synapses. There is no direct role for estradiol in the post-synaptic neuron.65 Thus, the primary event in the sexual differentiation of synaptic patterning in the VMN is non-genomic, rapid, and requires cell-to-cell communication (Figure 8.5).
Sex differences in physiology and behavior The term ‘sexually dimorphic’ is frequently used to describe any observed sex difference and as a result has lost its true meaning. To be dimorphic means to be of two forms, and most sex differences in brain and behavior, including gender differences in psychiatric and neurological disorders, are not dimorphic, they are allomorphic, meaning of one form but differing in incidence or degree. For example, both
C h a p t e r 8 Sexual Differentiation of Brain Structure and Function l
Figure 8.5 Estradiol induces glutamate release from hypothalamic neurons to induce sex differences in the ventromedial nucleus. A different form of cell-to-cell communication occurs in the ventromedial nucleus of the hypothalamus, and in this brain region there is no identified role for astrocytes. Instead, estradiol (E2) acts primarily in one neuron to non-genomically activate PI3 kinase which induces the release of the neurotransmitter glutamate (through mechanisms that are not understood). The released glutamate then acts on neighboring neurons to activate AMPA and NMDA receptors, leading to calcium influx and activation of MAP kinases and the construction of dendritic spines. Experimental evidence confirms that estradiol acts only in the presynaptic neuron to induce organizational effects on the synaptic profile of the post-synaptic neuron. Via this mechanism, the actions of estradiol are extended beyond the principle neuron that expresses estrogen receptor.
males and females exhibit aggression, but males do so more frequently and generally at a higher intensity, depending in part on the provocation. There are, however, two genuinely sexually dimorphic endpoints: (1) the control of gonadotropin secretion from the anterior pituitary in rodents and (2) sexual behavior, including the propensity to become sexually aroused by members of the same or opposite sex. Early studies of sexual differentiation were unambiguous in their focus on these two dimorphic endpoints which were assessed in the context of the Organizational/Activational Hypothesis. These remain useful today as valuable tools for elucidating the cellular mechanisms mediating sex differences in the brain, as illustrated above, and it can be argued that we have the greatest traction in identifying mechanisms of differentiation when using behavior as the endpoint. Therefore we will further exploit this model system for purposes of discussion.
Sexual Behavior as a Readout of Brain Differentiation Sexual behavior in males is commonly regarded as opportunistic and readily expressed when a receptive female is present, provided there is an absence of other more salient stimuli such as an approaching predator. In most species studied female sexual behavior is physiologically constrained
95
to be expressed only in proximity to ovulation. A fascinating but mechanistically unexplained distinction in male and female sexual behavior is the impact of experience. Males improve with practice and if testosterone is removed (via castration), will continue to exhibit high levels of copulatory behavior that only gradually extinguishes over a period of months. In contrast, the female receptive posture, lordosis, does not require practice but will only be displayed under the proper hormonal umbrella. If steroids are eliminated, so is the behavior. In terms of ultimate causation, the adaptive basis for the distinction is obvious, there is no benefit and possible cost to females mating outside the window of opportunity for conception, whereas in species in which males make little parental investment, males maximize their evolutionary fitness by never missing an opportunity to reproduce. This is not true in humans where copulations outside the period of fertility are believed to play an important role in maintaining the pair bond. Proximately, however, this dichotomy in the nature of the plasticity attendant to both behaviors is suggestive of distinct and separate neuronal circuitries, be they physically or merely functionally so. A useful framework for investigating mechanistic questions of sexual differentiation is the operationally defined and distinct processes of masculinization, feminization, and defeminization. Masculinization refers to an active developmental process initiated by gonadal steroids during the perinatal sensitive period followed by expression of normal male copulatory behavior in adulthood. Feminization is essentially what happens in the absence of masculinization, meaning it is the default pathway leading to expression of lordosis under the proper hormonal conditions in adulthood. Defeminization is distinct from but normally occurs in tandem with masculinization and refers to the process whereby the ability to express female sexual behavior is lost. In rats the neural circuitry controlling male sexual behavior has been mapped by lesion studies and expression of the immediate early gene, c-fos. Olfactory input is received via the main and accessory olfactory bulbs and transferred to the sub-nuclei of the amygdala before converging on the POA. From there the information is sent down to the midbrain and critical spinal cord nuclei for the control of the penis and suppression of micturition.73–75 The POA serves as a critical nodal point for the integration of sensory cues and is a principle site for steroid hormone action. As discussed above, in the rat there are two major sex differences in the POA, one is the overall size of the SDN-POA, and the other is the density of dendritic spine synapses. To date, there has been no clear relationship between the volume of the SDN-POA and a behavioral output, and the size of the SDN-POA has been distinctly dissociated from male sexual behavior in that females masculinized by PGE2 have a small female-sized SDN-POA but show robust male sex behavior while males treated neonatally with an inhibitor of PGE2 synthesis have a normal male-sized SDN-POA but exhibit almost no male sex behavior.76 This does not preclude the possibility that the rat
96
s e c t i o n 2 Gender and the Nervous System l
SDN-POA is a neuroanatomical substrate for the process of defeminization, as has been suggested by others, however a growing body of evidence suggests the SDN-POA may be important to partner preference. This is best exemplified in recent studies of a naturally occurring animal variant of same sex preference, male sheep preferring domestic rams. In at least two different herds of domestic sheep, approximately 8% of rams prefer to mount other males. These animals also have a smaller SDN-POA that contains fewer aromatase-expressing neurons, suggesting they may have been exposed to lower levels of endogenous estradiol early in development.15,77 The preoptic area and the anterior hypothalamus have also been implicated in influencing the sex of the conspecifics toward which one displays sexual interest in rodents, ferrets, and humans,16,78,79 but this remains a controversial and poorly developed research area. Considerably more progress has been made in associating the changes in the synaptic profile and behavioral output. There is a direct correlation between the presence of a high density of dendritic spines on POA neurons and the expression of male sexual behavior in adulthood.63 This does not preclude the expression of female sexual behavior, which appears to be under distinct control from a separate neural circuitry.76 Thus, neonatal females treated with PGE2 in order to induce the organization of a male dendritic profile, will exhibit robust male sexual behavior as adults if provided with exogenous testosterone and a sexually receptive female. These same masculinized females will also show robust female sexual receptivity (i.e. lordosis) if provided with exogenous estradiol and progesterone and a sexually experienced male. Similar plasticity in sexual behavior was recently reported in mice lacking a functional form of the Trp2c channel in the vomeronasal organ, only in this instance the behavioral changes were independent of gonadal hormone.80 Both of these sets of studies reflect how much we have to learn regarding the biological basis of sex behavior and how it differs in males and females.
Sex Differences in Aggression Sex differences in aggression are best illustrated in seasonally breeding animals, in which testosterone levels fluctuate widely and male-to-male aggressive interactions increase dramatically as males compete for mates, territory or other limiting resources relevant to reproductive success, and then drop precipitously with falling testosterone levels. But it is somewhat disingenuous to call this a sex difference in aggression since the entire constellation of variables dictating a species-specific mating strategy confines the behavioral repertoire of males and females such that it is advantageous for males to compete and females not to. Similarly, maternal aggression, a particularly vicious form of aggression, occurs only in females, only in response to certain threats, and only during a restricted postpartum period when offspring are vulnerable. This can hardly be considered a sex difference
in aggression since only females give birth, and it clearly illustrates that the capacity exists for females to exhibit high levels of aggression. Displays of aggression are further constrained by variables extrinsic to the individual such as the social structure, availability of resources, artificial conditions associated with laboratory settings, etc. Despite the many variables influencing expression of aggressive behavior, questions can still be asked regarding organizational versus activational hormonal control. Unlike sexual behavior which involves distinct motor patterns in males versus females, aggression is expressed in the same way by both sexes, but it is the frequency and intensity of the expression that varies. A naturally occurring source of variability in prenatal exposure to gonadal steroids provides some of the best evidence that at least some components of adult expressions of aggression are organized during early life. Species with large litter sizes, such as rats and mice, have a bifurcated uterus that allows for fetuses to be packed in as peas in a pod. Because of the copious quantities of androgens produced by late gestation male fetuses, a female fetus that finds herself sandwiched between two males in the uterine horn experiences a distinctly different endocrine environment from a female that develops between two sisters. By delivering the rat or mice pups via Caesarean section, the relative position of a fetus in relation to other fetuses can be noted, the individual marked and then development monitored. Modest changes in the external genitalia of females developing between males confirms that hormonal exposure has been different. When animals are monitored through to adulthood, it is apparent that females that developed between male littermates are more likely to exhibit aggression, and their responsiveness to the effects of androgen treatment on inducing aggression is also greater.81 This phenomenon is referred to as the intra-uterine position effect or IUP, and has also been used to explain subtle individual variability in sexual and social behaviors.82 But in many ways what the IUP effect is best at illustrating is the tremendous sensitivity of the developing brain to even subtle perturbations in the hormonal milieu. While there is good evidence for organizational effects of hormones on adult expression of aggression, there is equally good evidence that it is a relatively weak effect. This stems in part from observations of the importance of adult circulating hormone levels, which are tightly linked to fluctuating aggression in seasonal breeders, but can also be associated with changes in the perception of and response to a social threat in non-seasonal breeders, including rodents and humans. Anabolic steroids lower the threshold to respond to provocation in a laboratory setting, and cortical regions associated with aggression and impulsivity disorders show greater activation in females treated with testosterone compared to placebo.83,84 But the hegemony of testosterone begins to break down when one tries to correlate individual serum levels with behavior. This is in part because, as with all steroids, testosterone levels vary throughout the day, and
C h a p t e r 8 Sexual Differentiation of Brain Structure and Function l
relative levels of free to bound hormone can impact access to the brain, something we still cannot assess accurately. Perhaps more importantly, behavior itself has an enormous influence on circulating androgen levels. Individuals who experience victory in a competitive situation will show a significant and sustained increase in serum testosterone, while those experiencing defeat show a decrease. Remarkably, even just observing one’s favorite sports team win or lose can alter hormonal profiles as demonstrated by tracking salivary steroid content in fans watching a World Cup soccer match.85 Even winning a contest that is purely a matter of chance and involves only a small reward ($5) will increase serum testosterone in young men.86 Women do not respond to chance victories with an increase in serum testosterone, suggesting an interesting sex difference in parameters associated with reward value, dominance and obtainment and defense of resources. Children as young as 5 years old exhibit sex differences in aggression, and while these do not neatly correlate with androgens, there is an effect in each sex, with androstenedione being a better predictor of provocation in males and testosterone of affectivity in females.87 A second major variable dissociating early organization actions of androgens and adult aggressive behavior is the importance of genetics. The notion that genetic differences originating with the X or Y chromosome might contribute to sex differences in behavior is a relatively new one,88,89 but the empirical evidence that genetics is important to variability in aggression is long standing and unquestioned.90 Interestingly, much of the attention on genetic variation is on how it influences an individual’s sensitivity to steroids, in particular androgens and estrogens. In summary, aggression is a sexually dimorphic trait not because it takes a different form in males versus females, but rather because it is expressed at different levels of intensity and frequency and can be evoked in response to distinct stimuli. Normally docile, or at least civil, females can become viciously aggressive when under the hormonal grip of early postpartum and lactation, but only when the perceived threat is toward their young, not themselves. Males are on average more likely to be aggressive than females, and this is a product of both early exposure to androgens during a perinatal sensitive period and the impact of testosterone on reactive thresholds as an adult. But prior experience, both immediate and long term, combined with genetic predispositions, can introduce far more variability in responsiveness than hormone levels. Thus, sex differences in aggression are not so easily attacked from a mechanistic standpoint as those seen for reproductive behavior.
Sex Differences in Stress and Anxiety Sex differences in stress and anxiety are less clear and far more complicated than sex differences in aggression. Animal models reveal that in adult animals, females are generally more sensitive to any given stressor and take longer to
97
recover from stress when quantified as the duration of time required for corticosterone to return to basal levels.91 This sex difference is in part organized by perinatal hormones and in part a function of adult circulating steroids, with estrogens generally exacerbating stress responding while androgens temper the response to stress. However, any simple conclusions regarding sex differences in stress and anxiety are precluded by the major confounding impacts of early life experience, adult hormonal milieu, nature of the stressor, and endpoint being measured. In classic eye blink conditioning studies, males respond positively to stress with both an increase in dendritic spine synapses on hippocampal neurons and improved learning, whereas females show the opposite, reduced dendritic spine synapses and impaired learning.92 But in studies using spatial learning as the endpoint and restraint as a mild stressor, females show improved performance post-stressor while males are impaired.93 A systematic comparison of the impact of very early to adolescent stress on anxiety responses in adulthood in rats revealed multiple sex differences.94 Some have speculated that stress responding in males is relatively uniform across the lifespan whereas females possess an early resilience that is compromised with increasing age,93 although others suggest females are particularly sensitive to stressors during the adolescent period.95 A meta-analyses of human studies focusing on major life stressors indicates females subjectively experience more stress than males and report more symptoms of depression, anxiety, and psychosomatic problems,96 but this accounts for only a small percentage of the variance in life events. Thus any meaningful discussion of sex differences in stress and anxiety must include consideration of the life history of the individual, including extrinsic factors that can introduce gender bias independent of biology.
Suggestions for future investigations This is an exciting time for the study of sex differences in brain and behavior and the impact of gender on disorders that affect the nervous system. There has never been more attention on the topic and the level of discourse has moved beyond the merely descriptive. We are now making genuine strides in understanding the sources of the variables contributing to sex differences, with appropriate weight given to hormones, genes and environment. We are also making progress, albeit slowly, in elucidating the cellular mechanisms leading to the establishment and maintenance of sex differences in the brain. Some may question why this is an important thing to understand. For this investigator there are a number of reasons why it is essential to explore mechanism. One important reason is that the study of sex differences is a model system that can provide unique insights into both male and female brain development. This is evident in the discovery that prostaglandins play a role
98
s e c t i o n 2 Gender and the Nervous System l
in masculinization of the brain, something that might not have been discovered in the absence of comparing males and females. Moreover, all of the processes fundamental to brain development; neurogenesis, apoptosis, synaptogenesis, myelination, axonal and dendritic growth, and phenotypic differentiation are regulated by gonadal steroids and many times are different in males and females. By establishing the mechanisms of hormone action we can increase our knowledge of these pivotal events. Clinically, the need to understand the origins of sex differences in the brain is self-evident in the profound impact of gender on the relative risk of various mental health and neurological disorders. As reviewed elsewhere in this volume, males are at greater risk of disorders that originate early in development, whereas females are at greater risk of adult onset disorders. By understanding the basics of brain development in males versus females we can hope to gain insight into the biological underpinnings of this gender bias. Likewise, males frequently suffer worse outcomes to pediatric brain damage, and the source of this vulnerability is largely unknown. Finally, there is increasing evidence of compounds in our environment that either mimic or disrupt the actions of steroids. Neonates are among the highest risk group for exposure due to transfer from the mother’s milk, ingestion directly from the environment, and indirect exposure via the plastics used in many modern day baby products. Evaluating the true nature of the risk involved requires that we understand how both these artificial and natural steroidal compounds act on the developing brain. Lastly, as important as understanding sex differences is to the practice of gender-specific medicine, it is equally important that we recognize that few gender differences in the brain and its functions are simple sexual dimorphisms, most are statistical differences between the sexes in the distribution of particular measures. Group statistics apply to groups and do not predict the behavior of their individual members. This is particularly relevant in areas of cognition and emotionality where presumptions of greater skill in one sex versus the other become a restrictive principle that limits individual growth due to either internal perceptions or external pressures.
References 1. Harley V, Goodfellow P. The biochemical role of SRY in sex determination. Mol Reprod Dev